{"data":[{"slug":"15d","canonical_uri":"https://healtheconomics.wiki/concept/15d","name":"15D","short_definition":"A generic, multi-attribute quality of life instrument measuring fifteen health dimensions, each scored on five levels, combined into a single utility index.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.199Z"},{"slug":"340b-program","canonical_uri":"https://healtheconomics.wiki/concept/340b-program","name":"340B Drug Pricing Program","short_definition":"A US federal programme requiring manufacturers to provide outpatient drugs to eligible organisations serving low-income populations at reduced prices.","category":"Health Policy","category_path":"Health Systems › Health Policy › Drug Pricing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-13T23:32:14.369Z"},{"slug":"abbreviated-new-drug-application","canonical_uri":"https://healtheconomics.wiki/concept/abbreviated-new-drug-application","name":"Abbreviated New Drug Application","short_definition":"A streamlined US regulatory application letting a generic manufacturer gain approval by demonstrating bioequivalence to an approved reference drug, without repeating full trials.","category":"Health Policy","category_path":"Health Systems › Health Policy › Generic Competition","level_1":"Health Systems","level_2":"Health Policy","level_3":"Generic Competition","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.185Z"},{"slug":"absenteeism","canonical_uri":"https://healtheconomics.wiki/concept/absenteeism","name":"Absenteeism","short_definition":"Time lost from work due to illness, injury, or caregiving responsibilities, resulting in a direct, measurable cost to employers through lost productivity.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Productivity Measurement","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Productivity Measurement","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-13T22:27:36.428Z"},{"slug":"absolute-risk","canonical_uri":"https://healtheconomics.wiki/concept/absolute-risk","name":"Absolute Risk","short_definition":"The probability that an individual in a defined population will experience a specific outcome over a given period, without reference to a comparison.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.243Z"},{"slug":"absolute-risk-reduction","canonical_uri":"https://healtheconomics.wiki/concept/absolute-risk-reduction","name":"Absolute Risk Reduction","short_definition":"Absolute risk reduction (ARR) is the control group's risk of an outcome minus the treated group's risk over the same period, so ARR equals CER minus EER.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.6","status":"PUBLISHED","published_at":"2026-10-17T20:34:52.296Z"},{"slug":"absolute-shortfall","canonical_uri":"https://healtheconomics.wiki/concept/absolute-shortfall","name":"Absolute Shortfall","short_definition":"Absolute shortfall is the future QALYs lost with a condition under current care versus the age- and sex-matched population, used by NICE to judge severity.","category":"Decision Rules","category_path":"Health Economics › Economic Evaluation › Cost-Utility Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Utility Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-14T22:25:41.638Z"},{"slug":"absorbing-state","canonical_uri":"https://healtheconomics.wiki/concept/absorbing-state","name":"Absorbing State","short_definition":"An absorbing state is a state in a Markov model that patients cannot leave once they enter it, usually death, so the whole cohort eventually ends there.","category":"Model Structures","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-10T15:29:43.180Z"},{"slug":"academic-detailing","canonical_uri":"https://healtheconomics.wiki/concept/academic-detailing","name":"Academic Detailing","short_definition":"Academic detailing is educational outreach in which trained clinicians visit prescribers to give independent, evidence-based advice about medicines.","category":"Health Economics","category_path":"Health Systems › Health Policy › Systems Strengthening","level_1":"Health Systems","level_2":"Health Policy","level_3":"Systems Strengthening","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:53.900Z"},{"slug":"accelerated-approval","canonical_uri":"https://healtheconomics.wiki/concept/accelerated-approval","name":"Accelerated Approval","short_definition":"Accelerated approval is an FDA pathway that approves medicines for serious conditions on a surrogate endpoint, with confirmatory trials to verify benefit.","category":"Regulatory Concepts","category_path":"Health Economics › Pharmacoeconomics › Drug Development","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Drug Development","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:56:02.360Z"},{"slug":"accelerated-failure-time","canonical_uri":"https://healtheconomics.wiki/concept/accelerated-failure-time","name":"Accelerated Failure Time Model","short_definition":"An accelerated failure time (AFT) model is a survival model in which treatment or another factor stretches or shrinks time to an event by a time ratio.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T15:29:43.373Z"},{"slug":"acceptability","canonical_uri":"https://healtheconomics.wiki/concept/acceptability","name":"Acceptability of Healthcare","short_definition":"Acceptability is the dimension of access concerned with whether people find health services culturally, socially and personally appropriate enough to use.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.281Z"},{"slug":"access-barrier","canonical_uri":"https://healtheconomics.wiki/concept/access-barrier","name":"Access Barrier","short_definition":"An access barrier is any obstacle, such as cost, distance, waiting lists or discrimination, that prevents or delays a person obtaining needed healthcare.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:56.130Z"},{"slug":"access-negotiation","canonical_uri":"https://healtheconomics.wiki/concept/access-negotiation","name":"Access Negotiation","short_definition":"Access negotiation is the process in which a health technology supplier and a payer agree the price, eligibility and other conditions for patient access.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Drug Pricing","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T00:10:15.778Z"},{"slug":"access-policy","canonical_uri":"https://healtheconomics.wiki/concept/access-policy","name":"Access Policy","short_definition":"Access policy is the set of government or health system measures, such as coverage, user charges and waiting time rules, that shape access to healthcare.","category":"Regulatory Concepts","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-13T23:32:14.711Z"},{"slug":"access-to-care","canonical_uri":"https://healtheconomics.wiki/concept/access-to-care","name":"Access to Care","short_definition":"Access to care is the opportunity to obtain appropriate healthcare when needed, given the availability, location, cost and acceptability of services.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:53.975Z"},{"slug":"accountability-for-reasonableness","canonical_uri":"https://healtheconomics.wiki/concept/accountability-for-reasonableness","name":"Accountability for Reasonableness","short_definition":"Accountability for reasonableness (A4R) is a fair-process framework for health priority setting: publicity, relevance, revisability and enforcement.","category":"Decision Rules","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:07.725Z"},{"slug":"accountable-care-organization","canonical_uri":"https://healtheconomics.wiki/concept/accountable-care-organization","name":"Accountable Care Organization","short_definition":"An accountable care organization (ACO) is a provider group that shares in savings if its patients' spending beats a benchmark and quality targets are met.","category":"Health Economics","category_path":"Health Systems › Health Policy › Integrated Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Integrated Care","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.159Z"},{"slug":"acquired-resistance","canonical_uri":"https://healtheconomics.wiki/concept/acquired-resistance","name":"Acquired Treatment Resistance","short_definition":"Acquired treatment resistance is the loss of a cancer treatment's effect after initial response or disease control, as the tumour adapts and progresses.","category":"Health Economics","category_path":"Health Economics › Pharmacoeconomics › Oncology Outcomes","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology Outcomes","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.272Z"},{"slug":"acquisition-cost","canonical_uri":"https://healtheconomics.wiki/concept/acquisition-cost","name":"Acquisition Cost","short_definition":"Acquisition cost is what a payer spends to buy a drug, at the price actually paid after any discounts, excluding administration and monitoring costs.","category":"Parameters","category_path":"Health Systems › Drug Costs › Drug Acquisition and Administration","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Drug Acquisition and Administration","evidence_level":"high","version":"1.0.6","status":"PUBLISHED","published_at":"2026-10-21T00:55:07.849Z"},{"slug":"action-research","canonical_uri":"https://healtheconomics.wiki/concept/action-research","name":"Action Research","short_definition":"Action research is a cyclical approach where researchers and staff plan, act, observe and reflect together to change health care while studying the change.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Governance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Governance","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.014Z"},{"slug":"active-choice","canonical_uri":"https://healtheconomics.wiki/concept/active-choice","name":"Active Choice","short_definition":"Active choice is a choice architecture design that asks people to state a decision, such as on organ donation or vaccination, instead of setting a default.","category":"Health Economics","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.472Z"},{"slug":"active-comparator","canonical_uri":"https://healtheconomics.wiki/concept/active-comparator","name":"Active Comparator","short_definition":"An active comparator is an existing treatment, rather than placebo, that a new health technology is compared with in HTA and economic evaluation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:07.910Z"},{"slug":"active-control-trial","canonical_uri":"https://healtheconomics.wiki/concept/active-control-trial","name":"Active Control Trial","short_definition":"An active control trial is a randomised trial testing a new treatment against a known effective treatment, not placebo, for superiority or non-inferiority.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:07.973Z"},{"slug":"active-life-expectancy","canonical_uri":"https://healtheconomics.wiki/concept/active-life-expectancy","name":"Active Life Expectancy","short_definition":"Active life expectancy (ALE) is the average number of years a person of a given age can expect to live free of dependency in activities of daily living.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.305Z"},{"slug":"activities-of-daily-living","canonical_uri":"https://healtheconomics.wiki/concept/activities-of-daily-living","name":"Activities of Daily Living","short_definition":"Activities of daily living (ADL) are basic self-care tasks, such as bathing, dressing, toileting and eating, used to measure dependence and need for care.","category":"Outcome Measures","category_path":"Health Systems › Health Policy › Population Health Outcomes","level_1":"Health Systems","level_2":"Health Policy","level_3":"Population Health Outcomes","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.037Z"},{"slug":"activity-limitation","canonical_uri":"https://healtheconomics.wiki/concept/activity-limitation","name":"Activity Limitation","short_definition":"Activity limitation is a difficulty a person has in carrying out a task or action, such as walking, washing or communicating, as defined in the WHO ICF.","category":"Outcome Measures","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.225Z"},{"slug":"activity-based-budget","canonical_uri":"https://healtheconomics.wiki/concept/activity-based-budget","name":"Activity-Based Budgeting","short_definition":"Activity-based budgeting (ABB) builds a health service budget from forecast service volumes, the activities each needs and each activity's cost per unit.","category":"Economic Methods","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.549Z"},{"slug":"activity-based-costing","canonical_uri":"https://healtheconomics.wiki/concept/activity-based-costing","name":"Activity-Based Costing","short_definition":"Activity-based costing (ABC) is a method that assigns resource costs to activities, then to patients or services in proportion to the activities they use.","category":"Economic Methods","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.100Z"},{"slug":"activity-based-funding","canonical_uri":"https://healtheconomics.wiki/concept/activity-based-funding","name":"Activity-Based Funding","short_definition":"Activity-based funding (ABF) pays hospitals a preset, case-mix-weighted price for each episode of care, so income follows patient numbers and complexity.","category":"Health Economics","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.162Z"},{"slug":"actuarial-analysis","canonical_uri":"https://healtheconomics.wiki/concept/actuarial-analysis","name":"Actuarial Analysis","short_definition":"Actuarial analysis uses probability and statistics to estimate expected health insurance claims for pricing premiums or contributions and holding reserves.","category":"Statistical Methods","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-14T23:51:56.274Z"},{"slug":"actuarial-projection","canonical_uri":"https://healtheconomics.wiki/concept/actuarial-projection","name":"Actuarial Projection","short_definition":"Actuarial projection estimates future health spending, insurance claims or fund balances for a population from assumptions on demography, costs and policy.","category":"Statistical Methods","category_path":"Health Economics › Economic Evaluation › Economic Policy","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Policy","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.588Z"},{"slug":"actuarial-value","canonical_uri":"https://healtheconomics.wiki/concept/actuarial-value","name":"Actuarial Value","short_definition":"Actuarial value (AV) is the share of the total allowed cost of covered care that a health plan is expected to pay for a standard population.","category":"Parameters","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.378Z"},{"slug":"adaptive-trial-design","canonical_uri":"https://healtheconomics.wiki/concept/adaptive-trial-design","name":"Adaptive Trial Design","short_definition":"Adaptive trial design is a trial plan whose prespecified rules let interim data change the trial, such as stopping early, while keeping inference valid.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.6","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.288Z"},{"slug":"adaptive-voi","canonical_uri":"https://healtheconomics.wiki/concept/adaptive-voi","name":"Adaptive Value of Information","short_definition":"Adaptive value of information applies VOI analysis to staged research, re-valuing further data at each interim look to decide whether to continue.","category":"Economic Methods","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-10T16:03:49.413Z"},{"slug":"added-therapeutic-value","canonical_uri":"https://healtheconomics.wiki/concept/added-therapeutic-value","name":"Added Therapeutic Value","short_definition":"Added therapeutic value is the extra patient-relevant benefit a new medicine gives over existing care, as graded by HTA bodies such as HAS and G-BA.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.350Z"},{"slug":"addiction-treatment-economics","canonical_uri":"https://healtheconomics.wiki/concept/addiction-treatment-economics","name":"Addiction Treatment Economics","short_definition":"Addiction treatment economics is the economic evaluation of treatments for substance use disorders, weighing their costs against health and crime outcomes.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Mental Health","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Mental Health","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.412Z"},{"slug":"additive-scale","canonical_uri":"https://healtheconomics.wiki/concept/additive-scale","name":"Additive Interaction Scale","short_definition":"The additive interaction scale judges two exposures to interact when their joint risk difference departs from the sum of their separate risk differences.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.474Z"},{"slug":"adherence","canonical_uri":"https://healtheconomics.wiki/concept/adherence","name":"Adherence","short_definition":"Adherence is how far a person's behaviour, such as taking medicines or following diet or lifestyle advice, matches recommendations agreed with a clinician.","category":"Parameters","category_path":"Pharmacy Practice › Pharmaceutical Care › Adherence Support","level_1":"Pharmacy Practice","level_2":"Pharmaceutical Care","level_3":"Adherence Support","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-13T23:32:15.410Z"},{"slug":"adme-studies","canonical_uri":"https://healtheconomics.wiki/concept/adme-studies","name":"ADME Studies","short_definition":"ADME studies measure how a drug is absorbed, distributed, metabolised and excreted, informing dose adjustments for organ impairment and drug interactions.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Drug Development","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Drug Development","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.536Z"},{"slug":"administrative-barrier","canonical_uri":"https://healtheconomics.wiki/concept/administrative-barrier","name":"Administrative Barrier","short_definition":"An administrative barrier is a paperwork, enrolment, renewal or approval requirement that deters or delays use of healthcare.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.344Z"},{"slug":"administrative-censoring","canonical_uri":"https://healtheconomics.wiki/concept/administrative-censoring","name":"Administrative Censoring","short_definition":"Administrative censoring is right censoring that occurs when a trial's planned end of follow-up or data cut-off arrives before a patient has the event.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.7","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.521Z"},{"slug":"administrative-cost-ratio","canonical_uri":"https://healtheconomics.wiki/concept/administrative-cost-ratio","name":"Administrative Cost Ratio","short_definition":"Administrative cost ratio is the share of an insurer's premium income, or a health system's spending, used for administration rather than claims or care.","category":"Outcome Measures","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-14T22:25:41.678Z"},{"slug":"administrative-data","canonical_uri":"https://healtheconomics.wiki/concept/administrative-data","name":"Administrative Data","short_definition":"Administrative data are records made to run or pay for care, such as claims, hospital admissions and prescriptions, reused to measure costs and outcomes.","category":"Data Sources","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":"high","version":"1.0.7","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.660Z"},{"slug":"administrative-feasibility","canonical_uri":"https://healtheconomics.wiki/concept/administrative-feasibility","name":"Administrative Feasibility","short_definition":"Administrative feasibility is whether the agencies that would run a health policy have the staff, systems and mandate to deliver it as designed.","category":"Health Policy","category_path":"Health Systems › Health Policy › Policy Analysis","level_1":"Health Systems","level_2":"Health Policy","level_3":"Policy Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.184Z"},{"slug":"administrative-simplification","canonical_uri":"https://healtheconomics.wiki/concept/administrative-simplification","name":"Administrative Simplification","short_definition":"Administrative simplification is policy to cut the cost of health system paperwork, such as claims, eligibility checks and prior authorisation.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Delivery","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.415Z"},{"slug":"administrative-waste","canonical_uri":"https://healtheconomics.wiki/concept/administrative-waste","name":"Administrative Waste","short_definition":"Administrative waste is health care administrative spending that adds no value or costs more than needed, such as duplicate reporting or complex billing.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-14T22:25:44.213Z"},{"slug":"advance-care-planning","canonical_uri":"https://healtheconomics.wiki/concept/advance-care-planning","name":"Advance Care Planning","short_definition":"Advance care planning (ACP) is a process in which people discuss and record their goals and preferences for future medical care with family and clinicians.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Delivery","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.486Z"},{"slug":"advanced-therapy","canonical_uri":"https://healtheconomics.wiki/concept/advanced-therapy","name":"Advanced Therapy Medicinal Product","short_definition":"An advanced therapy medicinal product (ATMP) is an EU-regulated gene, cell or tissue-based medicine, often given once, whose lasting value HTA must judge.","category":"Regulatory Concepts","category_path":"Health Economics › Pharmacoeconomics › Advanced Therapies","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Advanced Therapies","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.782Z"},{"slug":"adverse-drug-event","canonical_uri":"https://healtheconomics.wiki/concept/adverse-drug-event","name":"Adverse Drug Event","short_definition":"An adverse drug event (ADE) is harm to a patient from a medicine, whether caused by a medication error or by a reaction despite correct use.","category":"Pharmaceutical Care","category_path":"Pharmacy Practice › Pharmaceutical Care › Medication Safety","level_1":"Pharmacy Practice","level_2":"Pharmaceutical Care","level_3":"Medication Safety","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T16:03:50.358Z"},{"slug":"adverse-drug-reaction","canonical_uri":"https://healtheconomics.wiki/concept/adverse-drug-reaction","name":"Adverse Drug Reaction","short_definition":"An adverse drug reaction (ADR) is a noxious, unintended response to a medicine, where a causal link to the drug is at least a reasonable possibility.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Real-World Evidence","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Real-World Evidence","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-14T21:24:07.204Z"},{"slug":"adverse-event","canonical_uri":"https://healtheconomics.wiki/concept/adverse-event","name":"Adverse Event","short_definition":"An adverse event (AE) is any unfavourable medical occurrence after treatment, caused by it or not; in patient safety, an injury caused by medical care.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.787Z"},{"slug":"adverse-event-rate","canonical_uri":"https://healtheconomics.wiki/concept/adverse-event-rate","name":"Adverse Event Rate","short_definition":"Adverse event rate (AE rate) is the count of adverse events, or of patients with one, divided by the patients or person-time at risk in a stated period.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.6","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.849Z"},{"slug":"adverse-event-reporting","canonical_uri":"https://healtheconomics.wiki/concept/adverse-event-reporting","name":"Adverse Event Reporting","short_definition":"Adverse event reporting sends suspected drug reactions and safety incidents to regulators or national systems, giving safety signals but not event rates.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T00:10:15.932Z"},{"slug":"adverse-selection","canonical_uri":"https://healtheconomics.wiki/concept/adverse-selection","name":"Adverse Selection","short_definition":"Adverse selection occurs when people who know they are higher risk buy more health or life insurance, which can raise premiums and drive out lower risks.","category":"Health Economics","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.13","status":"PUBLISHED","published_at":"2026-10-14T23:51:56.557Z"},{"slug":"affordability","canonical_uri":"https://healtheconomics.wiki/concept/affordability","name":"Affordability","short_definition":"Affordability is whether a payer or household can meet the cost of health care from available resources without displacing other care or causing hardship.","category":"Health Economics","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.240Z"},{"slug":"affordability-threshold","canonical_uri":"https://healtheconomics.wiki/concept/affordability-threshold","name":"Affordability Threshold","short_definition":"An affordability threshold is the budget impact level above which a payer flags a new technology for special handling, even if it is cost-effective.","category":"Decision Rules","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-26T23:14:42.809Z"},{"slug":"age-rating","canonical_uri":"https://healtheconomics.wiki/concept/age-rating","name":"Age Rating","short_definition":"Age rating is setting health insurance premiums by the buyer's age, as expected costs rise with age; some laws cap it, such as the US 3:1 adult limit.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.558Z"},{"slug":"age-weighting","canonical_uri":"https://healtheconomics.wiki/concept/age-weighting","name":"Age Weighting","short_definition":"Age weighting values a year of healthy life by the age at which it is lived, as in the original GBD DALY, which gave years in young adulthood most weight.","category":"Economic Methods","category_path":"Health Economics › Economic Evaluation › Discounting","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Discounting","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:18:39.963Z"},{"slug":"agent-based-model","canonical_uri":"https://healtheconomics.wiki/concept/agent-based-model","name":"Agent-Based Model","short_definition":"An agent-based model (ABM) simulates individuals as agents that follow rules and interact, so outcomes such as infections, costs and QALYs emerge.","category":"Model Structures","category_path":"Health Economics › Economic Modelling › Agent-Based Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Agent-Based Modelling","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.912Z"},{"slug":"aggregate-data-meta-analysis","canonical_uri":"https://healtheconomics.wiki/concept/aggregate-data-meta-analysis","name":"Aggregate Data Meta-Analysis","short_definition":"Aggregate data meta-analysis pools study-level summary results, such as effect estimates and standard errors, from several studies into one estimate.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.975Z"},{"slug":"aggregate-stop-loss","canonical_uri":"https://healtheconomics.wiki/concept/aggregate-stop-loss","name":"Aggregate Stop-Loss","short_definition":"Aggregate stop-loss is insurance that reimburses a self-funded employer for total health claims above an agreed attachment point in a plan year.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-13T23:32:16.100Z"},{"slug":"aging-driven-cost-growth","canonical_uri":"https://healtheconomics.wiki/concept/aging-driven-cost-growth","name":"Aging-Driven Cost Growth","short_definition":"Aging-driven cost growth is the share of health spending growth due to an older population, usually smaller than growth from rising incomes and technology.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.702Z"},{"slug":"ai-diagnostic-value","canonical_uri":"https://healtheconomics.wiki/concept/ai-diagnostic-value","name":"AI Diagnostic Value","short_definition":"AI diagnostic value is the assessment of an AI diagnostic tool's net health and cost effect in a care pathway, judged on outcomes, not accuracy alone.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Therapeutic Innovation","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Therapeutic Innovation","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:16.163Z"},{"slug":"akaike-information-criterion","canonical_uri":"https://healtheconomics.wiki/concept/akaike-information-criterion","name":"Akaike Information Criterion","short_definition":"Akaike information criterion (AIC) is a statistic ranking models fitted to the same data, such as survival curves in HTA, by fit penalised per parameter.","category":"Statistical Methods","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.037Z"},{"slug":"alcohol-policy","canonical_uri":"https://healtheconomics.wiki/concept/alcohol-policy","name":"Alcohol Policy","short_definition":"Alcohol policy is the set of public measures, such as alcohol taxes, minimum unit prices and limits on sales and marketing, used to reduce alcohol harm.","category":"Health Policy","category_path":"Health Systems › Health Policy › Public Health Policy","level_1":"Health Systems","level_2":"Health Policy","level_3":"Public Health Policy","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.335Z"},{"slug":"alcohol-use-economics","canonical_uri":"https://healtheconomics.wiki/concept/alcohol-use-economics","name":"Alcohol Use Economics","short_definition":"Alcohol use economics estimates what drinking costs health services and society and tests the value for money of alcohol screening and control policies.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Mental Health","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Mental Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.917Z"},{"slug":"alert-fatigue","canonical_uri":"https://healtheconomics.wiki/concept/alert-fatigue","name":"Alert Fatigue","short_definition":"Alert fatigue is clinicians' falling response when too many low-value computerised alerts consume time and attention, so important ones are overridden too.","category":"Health Economics","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-14T23:51:56.639Z"},{"slug":"all-cause-mortality","canonical_uri":"https://healtheconomics.wiki/concept/all-cause-mortality","name":"All-Cause Mortality","short_definition":"All-cause mortality is the rate of death from any cause in a population; models take background rates from life tables, and trials use it as an endpoint.","category":"Outcome Measures","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.104Z"},{"slug":"all-payer-system","canonical_uri":"https://healtheconomics.wiki/concept/all-payer-system","name":"All-Payer System","short_definition":"An all-payer system is a provider payment arrangement in which a regulator sets the rates that every payer, public or private, pays for the same service.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health System Models","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Models","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.936Z"},{"slug":"alliance-model","canonical_uri":"https://healtheconomics.wiki/concept/alliance-model","name":"Alliance Model","short_definition":"An alliance model is a health care arrangement in which independent providers and commissioners share goals, decisions, risk and reward without merging.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Models","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Models","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.392Z"},{"slug":"allocation-concealment","canonical_uri":"https://healtheconomics.wiki/concept/allocation-concealment","name":"Allocation Concealment","short_definition":"Allocation concealment hides the next assignment in a randomised trial from recruiters until allocation, protecting the treatment effects that inform HTA.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.165Z"},{"slug":"allocative-efficiency","canonical_uri":"https://healtheconomics.wiki/concept/allocative-efficiency","name":"Allocative Efficiency","short_definition":"Allocative efficiency is spending a health budget on the mix of services that yields the most health or welfare, so that no reallocation could do better.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.228Z"},{"slug":"alma-ata-declaration","canonical_uri":"https://healtheconomics.wiki/concept/alma-ata-declaration","name":"Alma-Ata Declaration","short_definition":"The Alma-Ata Declaration is the 1978 WHO and UNICEF conference statement that defined primary health care and made it the key to Health for All by 2000.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Delivery","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.064Z"},{"slug":"alpha-spending","canonical_uri":"https://healtheconomics.wiki/concept/alpha-spending","name":"Alpha Spending","short_definition":"Alpha spending is a group sequential trial method that spreads the type I error rate (alpha) across interim and final analyses as information accrues.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-13T23:32:16.507Z"},{"slug":"ambulatory-care","canonical_uri":"https://healtheconomics.wiki/concept/ambulatory-care","name":"Ambulatory Care","short_definition":"Ambulatory care is health care without an overnight hospital stay, such as GP, outpatient and day-case care, counted apart from inpatient care spending.","category":"Health Economics","category_path":"Health Systems › Health Policy › Healthcare Delivery","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.291Z"},{"slug":"ambulatory-payment-classification","canonical_uri":"https://healtheconomics.wiki/concept/ambulatory-payment-classification","name":"Ambulatory Payment Classification","short_definition":"Ambulatory Payment Classification (APC) is Medicare's grouping of clinically similar, similarly costly hospital outpatient services sharing one base rate.","category":"Regulatory Concepts","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.776Z"},{"slug":"amcp-dossier","canonical_uri":"https://healtheconomics.wiki/concept/amcp-dossier","name":"AMCP Dossier","short_definition":"The AMCP dossier is a manufacturer's evidence package, built to AMCP's Format for Formulary Submissions, that US health plans use in formulary decisions.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Pharmaceutical Economics","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Pharmaceutical Economics","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.353Z"},{"slug":"amr-economic-burden","canonical_uri":"https://healtheconomics.wiki/concept/amr-economic-burden","name":"AMR Economic Burden","short_definition":"AMR economic burden is the extra cost antimicrobial resistance imposes on health systems and economies, measured against susceptible or no infection.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Infectious Disease","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Infectious Disease","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.849Z"},{"slug":"analysis-error","canonical_uri":"https://healtheconomics.wiki/concept/analysis-error","name":"Analysis Error","short_definition":"Analysis error is a mistake in specifying, coding or reporting a statistical or economic analysis, such as a model slip that alters an ICER.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.416Z"},{"slug":"analytic-epidemiology","canonical_uri":"https://healtheconomics.wiki/concept/analytic-epidemiology","name":"Analytic Epidemiology","short_definition":"Analytic epidemiology tests causes of disease by comparing groups, estimating the relative risks and attributable fractions used in economic models.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T16:03:51.896Z"},{"slug":"anchor-based-mid","canonical_uri":"https://healtheconomics.wiki/concept/anchor-based-mid","name":"Anchor-Based MID","short_definition":"Anchor-based MID is a minimal important difference estimated by linking score changes to an external anchor, such as a patient's global rating of change.","category":"Outcome Measures","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.539Z"},{"slug":"anchoring","canonical_uri":"https://healtheconomics.wiki/concept/anchoring","name":"Anchoring Bias","short_definition":"Anchoring bias is the pull of a starting value, such as an opening bid or the first offer in a time trade-off, on answers in health valuation surveys.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.467Z"},{"slug":"anchoring-bias-in-elicitation","canonical_uri":"https://healtheconomics.wiki/concept/anchoring-bias-in-elicitation","name":"Anchoring Bias in Elicitation","short_definition":"Anchoring bias in elicitation is an expert's insufficient adjustment from a starting value, giving shifted, too-narrow distributions for model inputs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.601Z"},{"slug":"annualisation","canonical_uri":"https://healtheconomics.wiki/concept/annualisation","name":"Annualisation","short_definition":"Annualisation is the conversion of a capital outlay into an equal yearly cost over the asset's useful life, using an annuity factor and the discount rate.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:51:56.842Z"},{"slug":"annuity-payment","canonical_uri":"https://healtheconomics.wiki/concept/annuity-payment","name":"Annuity Payment","short_definition":"Annuity payment is an agreement to pay for a one-off therapy in yearly instalments, not upfront, with later ones sometimes stopping if the therapy fails.","category":"Health Economics","category_path":"Health Economics › Pharmacoeconomics › Advanced Therapies","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Advanced Therapies","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.664Z"},{"slug":"anonymization","canonical_uri":"https://healtheconomics.wiki/concept/anonymization","name":"Anonymization","short_definition":"Anonymization is processing personal health data so no one is identifiable by means reasonably likely to be used, taking it outside data protection law.","category":"Regulatory Concepts","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:56.863Z"},{"slug":"antenatal-care-coverage","canonical_uri":"https://healtheconomics.wiki/concept/antenatal-care-coverage","name":"Antenatal Care Coverage","short_definition":"Antenatal care coverage is the share of women with a recent live birth who had at least one, four or eight antenatal contacts; ANC4+ is a UHC tracer.","category":"Outcome Measures","category_path":"Health Systems › Systems Strengthening › Health System Performance","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Health System Performance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.560Z"},{"slug":"anti-kickback-statute","canonical_uri":"https://healtheconomics.wiki/concept/anti-kickback-statute","name":"Anti-Kickback Statute","short_definition":"The Anti-Kickback Statute (AKS) is a US criminal law banning paying or receiving anything of value for referrals of care paid by federal health programmes.","category":"Regulatory Concepts","category_path":"Health Systems › Health Policy › Health System Regulation","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Regulation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.992Z"},{"slug":"antibiotic-stewardship","canonical_uri":"https://healtheconomics.wiki/concept/antibiotic-stewardship","name":"Antibiotic Stewardship","short_definition":"Antibiotic stewardship is a coordinated programme that improves antibiotic prescribing to protect patients, slow resistance and cut avoidable costs.","category":"Health Economics","category_path":"Health Economics › Pharmacoeconomics › Infectious Disease","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Infectious Disease","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:56.904Z"},{"slug":"antimicrobial-economics","canonical_uri":"https://healtheconomics.wiki/concept/antimicrobial-economics","name":"Antimicrobial Economics","short_definition":"Antimicrobial economics applies health economics to anti-infectives: resistance as an externality, population value and incentives for new antibiotics.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Infectious Disease","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Infectious Disease","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.071Z"},{"slug":"antimicrobial-resistance","canonical_uri":"https://healtheconomics.wiki/concept/antimicrobial-resistance","name":"Antimicrobial Resistance","short_definition":"Antimicrobial resistance (AMR) is the ability of microbes to withstand antimicrobial medicines, making infections harder to treat and costlier to manage.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Infectious Disease","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Infectious Disease","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.144Z"},{"slug":"antithetic-variates","canonical_uri":"https://healtheconomics.wiki/concept/antithetic-variates","name":"Antithetic Variates","short_definition":"Antithetic variates are a variance reduction method that pairs each random draw with its mirror image so errors tend to cancel in Monte Carlo simulation.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.688Z"},{"slug":"appeal-process","canonical_uri":"https://healtheconomics.wiki/concept/appeal-process","name":"Appeal Process","short_definition":"The appeal process in health technology assessment (HTA) lets consultees challenge a recommendation on set grounds, such as unfairness or unreasonableness.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.726Z"},{"slug":"appeals-design","canonical_uri":"https://healtheconomics.wiki/concept/appeals-design","name":"Appeals Design","short_definition":"Appeals design is the set of rules for contesting a health insurer's coverage denial: filing windows, deadlines, review levels and independent review.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.324Z"},{"slug":"applicability-assessment","canonical_uri":"https://healtheconomics.wiki/concept/applicability-assessment","name":"Applicability Assessment","short_definition":"Applicability assessment judges whether an economic evaluation or model fits a decision problem's population, comparators, care setting and methods.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.789Z"},{"slug":"appraisal","canonical_uri":"https://healtheconomics.wiki/concept/appraisal","name":"Appraisal","short_definition":"Appraisal in HTA is the step after assessment in which a committee weighs the evidence and recommends whether a health technology should be funded.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.851Z"},{"slug":"appraisal-committee","canonical_uri":"https://healtheconomics.wiki/concept/appraisal-committee","name":"Appraisal Committee","short_definition":"An appraisal committee is an independent expert and lay panel in an HTA body that weighs clinical and cost-effectiveness evidence to recommend on funding.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.915Z"},{"slug":"appropriate-care","canonical_uri":"https://healtheconomics.wiki/concept/appropriate-care","name":"Appropriate Care","short_definition":"Appropriate care is care whose expected benefit exceeds its harms by a clear margin, avoiding overuse and underuse that reduce health system efficiency.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.402Z"},{"slug":"appropriateness-criteria","canonical_uri":"https://healtheconomics.wiki/concept/appropriateness-criteria","name":"Appropriateness Criteria","short_definition":"Appropriateness criteria are expert panel ratings of when a procedure's benefit exceeds its harms enough to be worth doing, exclusive of cost.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.217Z"},{"slug":"aqol","canonical_uri":"https://healtheconomics.wiki/concept/aqol","name":"AQoL","short_definition":"AQoL (Assessment of Quality of Life) is a family of Australian multi-attribute utility instruments, AQoL-4D to AQoL-8D, that score health states for QALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T16:03:52.962Z"},{"slug":"area-under-curve","canonical_uri":"https://healtheconomics.wiki/concept/area-under-curve","name":"Area Under Curve","short_definition":"Area under the curve (AUC), or C-statistic, is the probability a test or risk model scores a random case above a random non-case (0.5 chance, 1 perfect).","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:09.977Z"},{"slug":"arrival-process","canonical_uri":"https://healtheconomics.wiki/concept/arrival-process","name":"Arrival Process","short_definition":"Arrival process is the pattern in time, random or scheduled, by which patients or other entities enter a queueing model or simulation of a health service.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Discrete Event Simulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Discrete Event Simulation","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.635Z"},{"slug":"artificial-intelligence-in-health","canonical_uri":"https://healtheconomics.wiki/concept/artificial-intelligence-in-health","name":"Artificial Intelligence in Health","short_definition":"Artificial intelligence in health is software that infers predictions or decisions from data, valued in HTA by its effect on costs and outcomes.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:17.362Z"},{"slug":"ascot","canonical_uri":"https://healtheconomics.wiki/concept/ascot","name":"ASCOT","short_definition":"ASCOT is the Adult Social Care Outcomes Toolkit, a preference-weighted measure of social care-related quality of life for economic evaluation of care.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-17T20:50:57.892Z"},{"slug":"asmr-rating","canonical_uri":"https://healtheconomics.wiki/concept/asmr-rating","name":"ASMR Rating","short_definition":"The ASMR rating is the French HAS grade, from major (I) to none (V), of how much a medicine improves on existing treatments, used to frame its price.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.485Z"},{"slug":"assent","canonical_uri":"https://healtheconomics.wiki/concept/assent","name":"Assent","short_definition":"Assent is a child's affirmative agreement to join research, such as a paediatric trial supplying HTA evidence, given alongside parental permission.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Delivery","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.291Z"},{"slug":"assessment","canonical_uri":"https://healtheconomics.wiki/concept/assessment","name":"Assessment","short_definition":"Assessment in HTA is the evidence-review step before appraisal: analysts critically evaluate a technology's clinical and cost-effectiveness evidence.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.102Z"},{"slug":"assistive-technology-coverage","canonical_uri":"https://healtheconomics.wiki/concept/assistive-technology-coverage","name":"Assistive Technology Coverage","short_definition":"Assistive technology coverage is how far people needing assistive products, such as wheelchairs or hearing aids, have them, and how payers fund them.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Health System Performance","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Health System Performance","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.163Z"},{"slug":"assumption-structure","canonical_uri":"https://healtheconomics.wiki/concept/assumption-structure","name":"Assumption Structure","short_definition":"Assumption structure is the full set of simplifying assumptions in a health economic model's design, such as its health states, events and extrapolation.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.226Z"},{"slug":"asymptotic-normality","canonical_uri":"https://healtheconomics.wiki/concept/asymptotic-normality","name":"Asymptotic Normality","short_definition":"Asymptotic normality means an estimator's sampling distribution is approximately normal in large samples, the basis of Wald confidence intervals.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.288Z"},{"slug":"atkinson-index","canonical_uri":"https://healtheconomics.wiki/concept/atkinson-index","name":"Atkinson Index","short_definition":"The Atkinson index measures inequality in health or income using a social welfare function with an explicit inequality aversion parameter, epsilon.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Equity","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Equity","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.762Z"},{"slug":"attachment-point","canonical_uri":"https://healtheconomics.wiki/concept/attachment-point","name":"Attachment Point","short_definition":"An attachment point is the claims level at which stop-loss insurance or health reinsurance starts to pay, per person (specific) or per group (aggregate).","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-13T23:57:41.639Z"},{"slug":"attack-rate","canonical_uri":"https://healtheconomics.wiki/concept/attack-rate","name":"Attack Rate","short_definition":"Attack rate is the proportion of an at-risk population that develops the disease during an outbreak or other defined period: a risk, not a true rate.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:57.169Z"},{"slug":"attributable-cost-estimation","canonical_uri":"https://healtheconomics.wiki/concept/attributable-cost-estimation","name":"Attributable Cost Estimation","short_definition":"Attributable cost estimation measures the extra healthcare cost a disease or risk factor causes, against what the same patients would cost without it.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.627Z"},{"slug":"attributable-fraction","canonical_uri":"https://healtheconomics.wiki/concept/attributable-fraction","name":"Attributable Fraction","short_definition":"The attributable fraction is the share of cases, in the exposed or a whole population, that would not occur without an exposure, used to apportion burden.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:57.230Z"},{"slug":"attributable-risk","canonical_uri":"https://healtheconomics.wiki/concept/attributable-risk","name":"Attributable Risk","short_definition":"Attributable risk is the risk in exposed minus unexposed people: the excess attributed to exposure, which health economic models turn into costs and QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:57.250Z"},{"slug":"attribution","canonical_uri":"https://healtheconomics.wiki/concept/attribution","name":"Attribution","short_definition":"Attribution is the assignment of patients to a provider so that their spending and quality of care count towards its performance in value-based payment.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.364Z"},{"slug":"attrition","canonical_uri":"https://healtheconomics.wiki/concept/attrition","name":"Attrition","short_definition":"Attrition is the loss of participants from a trial or cohort study before follow-up ends, leaving outcome, cost and QALY data incomplete and open to bias.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.806Z"},{"slug":"auction-theory-health","canonical_uri":"https://healtheconomics.wiki/concept/auction-theory-health","name":"Auction Theory","short_definition":"Auction theory in health economics studies how bidding rules in tenders set the price and supply of medicines, vaccines and medical equipment.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.839Z"},{"slug":"audit-and-feedback","canonical_uri":"https://healtheconomics.wiki/concept/audit-and-feedback","name":"Audit and Feedback","short_definition":"Audit and feedback (A&F) is a quality improvement strategy that measures clinicians' practice against a target and returns the results to prompt change.","category":"Health Policy","category_path":"Health Systems › Health Policy › Systems Strengthening","level_1":"Health Systems","level_2":"Health Policy","level_3":"Systems Strengthening","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.844Z"},{"slug":"automatic-substitution","canonical_uri":"https://healtheconomics.wiki/concept/automatic-substitution","name":"Automatic Substitution","short_definition":"Automatic substitution is pharmacy dispensing of a lower-cost equivalent generic or biosimilar for a prescribed brand without consulting the prescriber.","category":"Pharmaceutical Care","category_path":"Pharmacy Practice › Pharmaceutical Care › Medication Safety","level_1":"Pharmacy Practice","level_2":"Pharmaceutical Care","level_3":"Medication Safety","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.761Z"},{"slug":"autonomy","canonical_uri":"https://healtheconomics.wiki/concept/autonomy","name":"Autonomy","short_definition":"Autonomy is the ethical principle that people able to decide may make informed, voluntary choices about their own care, weighed in HTA ethical analysis.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:51:57.372Z"},{"slug":"autoregressive-correlation","canonical_uri":"https://healtheconomics.wiki/concept/autoregressive-correlation","name":"Autoregressive Correlation","short_definition":"Autoregressive correlation is a structure for repeated measures in which correlation falls by a constant factor with each time step between measurements.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.913Z"},{"slug":"available-case-analysis","canonical_uri":"https://healtheconomics.wiki/concept/available-case-analysis","name":"Available Case Analysis","short_definition":"Available case analysis is a missing data method estimating each quantity from everyone with data for it, so costs and QALYs may use different patients.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.800Z"},{"slug":"average-cost","canonical_uri":"https://healtheconomics.wiki/concept/average-cost","name":"Average Cost","short_definition":"Average cost is total cost divided by the number of units produced, such as patients treated or bed days, giving the cost per unit of a health service.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.352Z"},{"slug":"average-cost-effectiveness-ratio","canonical_uri":"https://healtheconomics.wiki/concept/average-cost-effectiveness-ratio","name":"Average Cost-Effectiveness Ratio","short_definition":"The average cost-effectiveness ratio (ACER) is an option's cost per unit of health effect, in total or against doing nothing, without comparing options.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.416Z"},{"slug":"average-length-of-stay","canonical_uri":"https://healtheconomics.wiki/concept/average-length-of-stay","name":"Average Length of Stay","short_definition":"Average length of stay (ALOS) is the mean number of days inpatients spend in hospital: total bed-days divided by discharges over the same period.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Performance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Performance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T22:25:42.914Z"},{"slug":"average-manufacturer-price","canonical_uri":"https://healtheconomics.wiki/concept/average-manufacturer-price","name":"Average Manufacturer Price","short_definition":"Average Manufacturer Price (AMP) is the average price paid to a manufacturer for a drug supplied to US retail pharmacies, the basis of Medicaid rebates.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Drug Pricing","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.838Z"},{"slug":"average-sales-price","canonical_uri":"https://healtheconomics.wiki/concept/average-sales-price","name":"Average Sales Price","short_definition":"Average sales price (ASP) is a manufacturer's average US price for a drug in a quarter, net of most discounts and rebates; it sets Medicare Part B payment.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Drug Pricing","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.435Z"},{"slug":"average-treatment-effect","canonical_uri":"https://healtheconomics.wiki/concept/average-treatment-effect","name":"Average Treatment Effect","short_definition":"The average treatment effect (ATE) is the mean change in costs or health outcomes if a whole population received a treatment rather than its comparator.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.477Z"},{"slug":"avoidable-cost","canonical_uri":"https://healtheconomics.wiki/concept/avoidable-cost","name":"Avoidable Cost","short_definition":"Avoidable cost is the cost a budget holder would no longer pay if a health service stopped or a disease was prevented, within a stated time period.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T22:25:44.232Z"},{"slug":"background-mortality","canonical_uri":"https://healtheconomics.wiki/concept/background-mortality","name":"Background Mortality","short_definition":"Background mortality is the death rate a model's patients would face without the disease, usually taken from general population life tables by age and sex.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.538Z"},{"slug":"balance-billing","canonical_uri":"https://healtheconomics.wiki/concept/balance-billing","name":"Balance Billing","short_definition":"Balance billing is a provider billing a patient for the gap between its full charge and the insurer's allowed amount, on top of normal cost sharing.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.877Z"},{"slug":"balance-billing-protection","canonical_uri":"https://healtheconomics.wiki/concept/balance-billing-protection","name":"Balance Billing Protection","short_definition":"Balance billing protection is a legal rule that stops providers billing insured patients above in-network cost sharing, as under the US No Surprises Act.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.897Z"},{"slug":"balanced-scorecard","canonical_uri":"https://healtheconomics.wiki/concept/balanced-scorecard","name":"Balanced Scorecard","short_definition":"The balanced scorecard (BSC) is a management tool linking a health care organisation's financial, patient, process and staff measures to its strategy.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Performance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Performance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:14.917Z"},{"slug":"balancing-measure","canonical_uri":"https://healtheconomics.wiki/concept/balancing-measure","name":"Balancing Measure","short_definition":"A balancing measure is a quality improvement metric that checks whether a change that improves one part of a health system causes new problems elsewhere.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T16:03:54.314Z"},{"slug":"bargaining-theory","canonical_uri":"https://healtheconomics.wiki/concept/bargaining-theory","name":"Bargaining Theory","short_definition":"Bargaining theory explains how negotiating parties divide the gains from reaching agreement, as when a payer and a manufacturer agree a drug price.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:18.290Z"},{"slug":"barrier-to-implementation","canonical_uri":"https://healtheconomics.wiki/concept/barrier-to-implementation","name":"Barrier to Implementation","short_definition":"A barrier to implementation is a factor, such as cost or staffing, that limits uptake of an effective health intervention, so health gains go unrealised.","category":"Health Policy","category_path":"Health Systems › Health Policy › Systems Strengthening","level_1":"Health Systems","level_2":"Health Policy","level_3":"Systems Strengthening","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:57.512Z"},{"slug":"barthel-index","canonical_uri":"https://healtheconomics.wiki/concept/barthel-index","name":"Barthel Index","short_definition":"Barthel Index (BI) is a ten-item rating of independence in self-care and mobility, scored 0 to 100, used as an outcome in stroke and rehabilitation trials.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.985Z"},{"slug":"base-case","canonical_uri":"https://healtheconomics.wiki/concept/base-case","name":"Base Case","short_definition":"The base case is a model's preferred set of inputs and assumptions and the primary results they produce, against which sensitivity analyses are compared.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.600Z"},{"slug":"base-rate","canonical_uri":"https://healtheconomics.wiki/concept/base-rate","name":"Base Rate","short_definition":"Base rate is the standard payment per unit of case weight in prospective hospital payment, adjusted for local costs and multiplied by a stay's DRG weight.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.506Z"},{"slug":"baseline-risk","canonical_uri":"https://healtheconomics.wiki/concept/baseline-risk","name":"Baseline Risk","short_definition":"Baseline risk is the probability of an event without the intervention under study; models apply relative treatment effects to it to give absolute benefit.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.577Z"},{"slug":"basic-reproduction-number","canonical_uri":"https://healtheconomics.wiki/concept/basic-reproduction-number","name":"Basic Reproduction Number","short_definition":"The basic reproduction number (R0) is the average number of infections one typical case causes in a fully susceptible population, used in vaccine models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:18.414Z"},{"slug":"basket-of-countries","canonical_uri":"https://healtheconomics.wiki/concept/basket-of-countries","name":"Basket of Countries","short_definition":"The basket of countries is the set of foreign markets whose drug prices a regulator compares in external reference pricing to set a domestic price.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Market Access","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Market Access","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.648Z"},{"slug":"basket-trial","canonical_uri":"https://healtheconomics.wiki/concept/basket-trial","name":"Basket Trial","short_definition":"A basket trial tests one targeted treatment in several diseases, usually tumour types, that share the same biomarker, with each disease forming a basket.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.722Z"},{"slug":"bathtub-hazard","canonical_uri":"https://healtheconomics.wiki/concept/bathtub-hazard","name":"Bathtub Hazard","short_definition":"A bathtub hazard is a U-shaped hazard that is high soon after an event such as surgery, falls to a lower stable level, then rises again as patients age.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.720Z"},{"slug":"baumol-effect","canonical_uri":"https://healtheconomics.wiki/concept/baumol-effect","name":"Baumol Effect","short_definition":"The Baumol effect is the rising relative cost of labour-intensive services such as health care as their pay tracks faster productivity growth elsewhere.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.846Z"},{"slug":"bayes-theorem","canonical_uri":"https://healtheconomics.wiki/concept/bayes-theorem","name":"Bayes Theorem","short_definition":"Bayes theorem is the rule that updates a prior probability with new evidence to give a posterior probability, used for diagnostic tests and model inputs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.791Z"},{"slug":"bayesian-adaptive-design","canonical_uri":"https://healtheconomics.wiki/concept/bayesian-adaptive-design","name":"Bayesian Adaptive Design","short_definition":"Bayesian adaptive design is a clinical trial design in which pre-set rules on posterior or predictive probabilities trigger changes such as early stopping.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:10.969Z"},{"slug":"bayesian-analysis","canonical_uri":"https://healtheconomics.wiki/concept/bayesian-analysis","name":"Bayesian Analysis","short_definition":"Bayesian analysis updates a prior distribution with data via Bayes' theorem to give a posterior, used in HTA for evidence synthesis and decision models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.864Z"},{"slug":"bayesian-analysis-cea","canonical_uri":"https://healtheconomics.wiki/concept/bayesian-analysis-cea","name":"Bayesian Analysis CEA","short_definition":"Bayesian cost-effectiveness analysis updates prior evidence on costs and health effects with new data to estimate net benefit and decision uncertainty.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.096Z"},{"slug":"bayesian-information-criterion","canonical_uri":"https://healtheconomics.wiki/concept/bayesian-information-criterion","name":"Bayesian Information Criterion","short_definition":"Bayesian information criterion (BIC) ranks models fitted to the same data, such as HTA survival curves, by fit with a penalty that grows with sample size.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.157Z"},{"slug":"bayesian-meta-analysis","canonical_uri":"https://healtheconomics.wiki/concept/bayesian-meta-analysis","name":"Bayesian Meta-Analysis","short_definition":"Bayesian meta-analysis combines prior distributions with results from several studies to give posterior and predictive distributions for an effect.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.217Z"},{"slug":"bayesian-optimisation","canonical_uri":"https://healtheconomics.wiki/concept/bayesian-optimisation","name":"Bayesian Optimisation","short_definition":"Bayesian optimisation seeks the inputs that optimise a costly function, such as a model's fit to calibration targets, using a surrogate to pick each run.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:18.600Z"},{"slug":"bed-capacity","canonical_uri":"https://healtheconomics.wiki/concept/bed-capacity","name":"Bed Capacity","short_definition":"Bed capacity is the number of staffed hospital beds immediately available for admitted patients, often reported per 1,000 population as a supply measure.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Capacity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Capacity","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:52.935Z"},{"slug":"bed-turnover","canonical_uri":"https://healtheconomics.wiki/concept/bed-turnover","name":"Bed Turnover","short_definition":"Bed turnover is the number of discharges, including deaths, per available hospital bed over a period, using the average number of beds available.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Capacity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Capacity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T22:25:40.041Z"},{"slug":"beers-criteria","canonical_uri":"https://healtheconomics.wiki/concept/beers-criteria","name":"Beers Criteria","short_definition":"The Beers Criteria are the American Geriatrics Society's list of medicines best avoided in older adults, also used to evaluate quality of care and cost.","category":"Pharmacoeconomics","category_path":"Pharmacy Practice › Pharmacoeconomics › Medication Safety","level_1":"Pharmacy Practice","level_2":"Pharmacoeconomics","level_3":"Medication Safety","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.038Z"},{"slug":"before-and-after-study","canonical_uri":"https://healtheconomics.wiki/concept/before-and-after-study","name":"Before-and-After Study","short_definition":"A before-and-after study compares outcomes or costs measured before and after a health intervention or policy change, in one group or with a control group.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.727Z"},{"slug":"begg-test","canonical_uri":"https://healtheconomics.wiki/concept/begg-test","name":"Begg Test","short_definition":"The Begg test is a rank correlation test (Kendall's tau) for small-study effects in a meta-analysis, a possible sign of publication bias.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.278Z"},{"slug":"behaviour-change","canonical_uri":"https://healtheconomics.wiki/concept/behaviour-change","name":"Behaviour Change","short_definition":"Behaviour change is a lasting shift in health-related actions such as smoking, diet or physical activity, pursued by policy to cut disease and its costs.","category":"Health Policy","category_path":"Health Systems › Health Policy › Systems Strengthening","level_1":"Health Systems","level_2":"Health Policy","level_3":"Systems Strengthening","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.058Z"},{"slug":"behaviour-change-intervention","canonical_uri":"https://healtheconomics.wiki/concept/behaviour-change-intervention","name":"Behaviour Change Intervention","short_definition":"A behaviour change intervention is a coordinated set of behaviour change techniques aiming to change a health behaviour, judged by cost per health gain.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Chronic Disease","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Chronic Disease","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-14T00:10:16.165Z"},{"slug":"behaviour-change-technique","canonical_uri":"https://healtheconomics.wiki/concept/behaviour-change-technique","name":"Behaviour Change Technique","short_definition":"A behaviour change technique (BCT) is the smallest replicable part of a health behaviour programme, such as goal setting, coded to cost what is delivered.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:18.769Z"},{"slug":"behavioural-analytics","canonical_uri":"https://healtheconomics.wiki/concept/behavioural-analytics","name":"Behavioural Analytics","short_definition":"Behavioural analytics is the analysis of health behaviour records, such as prescription refills or app use, to predict behaviour and target interventions.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Digital Health","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Digital Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T16:05:03.878Z"},{"slug":"behavioural-health-carve-out","canonical_uri":"https://healtheconomics.wiki/concept/behavioural-health-carve-out","name":"Behavioural Health Carve-Out","short_definition":"A behavioural health carve-out is an insurance arrangement that finances and manages mental health and substance use services under a separate contract.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:18.812Z"},{"slug":"behavioural-theory","canonical_uri":"https://healtheconomics.wiki/concept/behavioural-theory","name":"Behavioural Theory","short_definition":"Behavioural theory explains how limited attention, present bias and other biases push health and insurance choices away from full rationality.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:57.611Z"},{"slug":"benchmark-comparison","canonical_uri":"https://healtheconomics.wiki/concept/benchmark-comparison","name":"Benchmark Comparison","short_definition":"Benchmark comparison assesses a health care provider's measured performance against a reference level, such as a peer average, best practice or a target.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Performance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Performance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.976Z"},{"slug":"benchmark-development","canonical_uri":"https://healtheconomics.wiki/concept/benchmark-development","name":"Benchmark Development","short_definition":"Benchmark development is the process of deriving from provider data the level of health care quality or outcomes used to judge performance and set targets.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.097Z"},{"slug":"benchmark-price","canonical_uri":"https://healtheconomics.wiki/concept/benchmark-price","name":"Benchmark Price","short_definition":"Benchmark price is a payer-set reference amount, such as a Medicare Advantage or ACA benchmark, compared with bids, premiums or spending to set payment.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.007Z"},{"slug":"benchmarking","canonical_uri":"https://healtheconomics.wiki/concept/benchmarking","name":"Benchmarking","short_definition":"Benchmarking is the structured comparison of a health care provider's performance, costs or processes with peers or standards to adopt better practice.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Productivity Measurement","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Productivity Measurement","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.135Z"},{"slug":"benefit-design","canonical_uri":"https://healtheconomics.wiki/concept/benefit-design","name":"Benefit Design","short_definition":"Benefit design is the set of health plan rules on covered services, cost sharing, networks and utilisation review that sets what members pay and can use.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.154Z"},{"slug":"benefit-incidence","canonical_uri":"https://healtheconomics.wiki/concept/benefit-incidence","name":"Benefit Incidence","short_definition":"Benefit incidence analysis shows how public health care subsidies reach each income group by multiplying the group's service use by the unit subsidy.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.018Z"},{"slug":"benefit-package","canonical_uri":"https://healtheconomics.wiki/concept/benefit-package","name":"Benefit Package","short_definition":"A benefit package is the set of health services, medicines and technologies that a public system or insurer guarantees to fund for its covered population.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.339Z"},{"slug":"benefit-transfer","canonical_uri":"https://healtheconomics.wiki/concept/benefit-transfer","name":"Benefit Transfer","short_definition":"Benefit transfer reuses willingness-to-pay values from earlier studies, such as the value of a statistical life, to value health benefits in a new setting.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.232Z"},{"slug":"benefit-cost-ratio","canonical_uri":"https://healtheconomics.wiki/concept/benefit-cost-ratio","name":"Benefit-Cost Ratio","short_definition":"Benefit-cost ratio (BCR) is a health programme's monetised benefits divided by its costs, in present values, used to summarise a cost-benefit analysis.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:57.651Z"},{"slug":"benefit-risk-assessment","canonical_uri":"https://healtheconomics.wiki/concept/benefit-risk-assessment","name":"Benefit-Risk Assessment","short_definition":"Benefit-risk assessment is how regulators such as the FDA and EMA judge whether a medicine's benefits outweigh its harms, given the uncertainties.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.400Z"},{"slug":"best-interest-standard","canonical_uri":"https://healtheconomics.wiki/concept/best-interest-standard","name":"Best Interest Standard","short_definition":"The best interest standard requires healthcare decisions for a patient lacking capacity, such as a young child, to be those that best serve their welfare.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Delivery","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.464Z"},{"slug":"best-practice","canonical_uri":"https://healtheconomics.wiki/concept/best-practice","name":"Best Practice","short_definition":"Best practice in health care is an intervention shown to be effective and efficient in one setting that other providers could adopt with similar results.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Productivity Measurement","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Productivity Measurement","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.080Z"},{"slug":"best-price","canonical_uri":"https://healtheconomics.wiki/concept/best-price","name":"Best Price","short_definition":"Best price is the lowest US price a manufacturer offers almost any buyer for a brand-name drug in a quarter, used to set its Medicaid rebate.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Drug Pricing","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.152Z"},{"slug":"best-supportive-care","canonical_uri":"https://healtheconomics.wiki/concept/best-supportive-care","name":"Best Supportive Care","short_definition":"Best supportive care (BSC) is symptom-directed care without anticancer treatment, used as a control arm in oncology trials and as a comparator in HTA.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Oncology Outcomes","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology Outcomes","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.525Z"},{"slug":"best-worst-scaling","canonical_uri":"https://healtheconomics.wiki/concept/best-worst-scaling","name":"Best-Worst Scaling","short_definition":"Best-worst scaling (BWS) is a stated preference method in which people pick the best and worst item in each set, to rank priorities or value health states.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:19.316Z"},{"slug":"beta-distribution","canonical_uri":"https://healtheconomics.wiki/concept/beta-distribution","name":"Beta Distribution","short_definition":"The beta distribution is a probability distribution on values between zero and one, used in decision models to represent uncertainty in probabilities.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.587Z"},{"slug":"beta-level","canonical_uri":"https://healtheconomics.wiki/concept/beta-level","name":"Beta Level","short_definition":"The predetermined acceptable probability of failing to detect a true effect, with one minus beta defining a study's statistical power.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:32:19.357Z"},{"slug":"between-patient-analysis","canonical_uri":"https://healtheconomics.wiki/concept/between-patient-analysis","name":"Between-Patient Analysis","short_definition":"Between-patient analysis compares costs or outcomes across separate groups of patients, as in a parallel-group trial, rather than within the same patients.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.224Z"},{"slug":"between-study-heterogeneity","canonical_uri":"https://healtheconomics.wiki/concept/between-study-heterogeneity","name":"Between-Study Heterogeneity","short_definition":"Between-study heterogeneity is variation in effects across trials in a meta-analysis beyond chance, so one pooled effect may not fit every HTA setting.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.295Z"},{"slug":"between-subject-variation","canonical_uri":"https://healtheconomics.wiki/concept/between-subject-variation","name":"Between-Subject Variation","short_definition":"Between-subject variation is how much costs or outcomes differ from one patient to another, as opposed to variation in one person's repeated measurements.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.768Z"},{"slug":"beveridge-model","canonical_uri":"https://healtheconomics.wiki/concept/beveridge-model","name":"Beveridge Model","short_definition":"The Beveridge model is a health system funded mainly by general taxation, with universal entitlement and largely public provision, as in the UK NHS.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Models","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Models","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.828Z"},{"slug":"bias","canonical_uri":"https://healtheconomics.wiki/concept/bias","name":"Bias","short_definition":"Bias is systematic error that pushes a treatment effect or cost estimate in economic evaluation away from the true value; larger samples do not remove it.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.890Z"},{"slug":"bias-variance-tradeoff","canonical_uri":"https://healtheconomics.wiki/concept/bias-variance-tradeoff","name":"Bias-Variance Tradeoff","short_definition":"The bias-variance tradeoff is how cutting systematic error (bias) tends to raise sampling variance, as in choosing HTA survival curves or subgroup inputs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.366Z"},{"slug":"bibliographic-database","canonical_uri":"https://healtheconomics.wiki/concept/bibliographic-database","name":"Bibliographic Database","short_definition":"A bibliographic database is an indexed set of records describing published research, such as MEDLINE or Embase, searched to find studies for reviews.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.384Z"},{"slug":"big-data","canonical_uri":"https://healtheconomics.wiki/concept/big-data","name":"Big Data","short_definition":"Big data is a term for very large, varied and fast-growing health datasets, such as linked records, claims and genomic data, that need specialised methods.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Real-World Evidence","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Real-World Evidence","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.261Z"},{"slug":"binomial-distribution","canonical_uri":"https://healtheconomics.wiki/concept/binomial-distribution","name":"Binomial Distribution","short_definition":"The binomial distribution models how many of a fixed number of patients have an event when each has the same probability and outcomes are independent.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.423Z"},{"slug":"bioavailability","canonical_uri":"https://healtheconomics.wiki/concept/bioavailability","name":"Bioavailability","short_definition":"Bioavailability is the rate and extent to which an active drug reaches the systemic circulation, which sets the dose and drug cost of a target exposure.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Clinical Pharmacology","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Clinical Pharmacology","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.445Z"},{"slug":"biobank-data","canonical_uri":"https://healtheconomics.wiki/concept/biobank-data","name":"Biobank Data","short_definition":"Biobank data are stored biological samples and participant measurements linked to health records, used in health economics to estimate costs and outcomes.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.465Z"},{"slug":"bioequivalence","canonical_uri":"https://healtheconomics.wiki/concept/bioequivalence","name":"Bioequivalence","short_definition":"Bioequivalence means two products with the same active ingredient have rates and extents of absorption within preset limits, the basis of generic approval.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Generic Competition","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Generic Competition","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:11.950Z"},{"slug":"biological-therapy","canonical_uri":"https://healtheconomics.wiki/concept/biological-therapy","name":"Biological Therapy","short_definition":"Treatment using a medicinal product made from or derived from a biological source, assessed for a specific indication, delivery pathway and patient outcome.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Biological Medicines","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Biological Medicines","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.504Z"},{"slug":"biomarker","canonical_uri":"https://healtheconomics.wiki/concept/biomarker","name":"Biomarker","short_definition":"A biomarker is a measured biological characteristic, such as a gene or protein, signalling disease or treatment response; HTA may tie treatment to it.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Therapeutic Innovation","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Therapeutic Innovation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.367Z"},{"slug":"biomarker-endpoint","canonical_uri":"https://healtheconomics.wiki/concept/biomarker-endpoint","name":"Biomarker Endpoint","short_definition":"A biomarker endpoint is a trial outcome built on a measured biological marker, such as LDL cholesterol, which cost-utility models must convert into QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.075Z"},{"slug":"biosimilar","canonical_uri":"https://healtheconomics.wiki/concept/biosimilar","name":"Biosimilar","short_definition":"A biosimilar is a biological medicine licensed as highly similar to an approved reference biologic, bringing price competition once its exclusivity ends.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Generic Competition","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Generic Competition","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T22:38:33.438Z"},{"slug":"biosimilar-approval","canonical_uri":"https://healtheconomics.wiki/concept/biosimilar-approval","name":"Biosimilar Approval","short_definition":"Biosimilar approval is the regulatory licensing of a biosimilar shown to be highly similar to an approved reference biologic, so the two can compete.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Biological Medicines","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Biological Medicines","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T22:38:33.458Z"},{"slug":"biosimilar-pricing","canonical_uri":"https://healtheconomics.wiki/concept/biosimilar-pricing","name":"Biosimilar Pricing","short_definition":"Biosimilar pricing is how a biosimilar's price to health systems is set against its reference biologic, through discounts, tenders and funding rules.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Drug Pricing","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.137Z"},{"slug":"biosimilar-substitution","canonical_uri":"https://healtheconomics.wiki/concept/biosimilar-substitution","name":"Biosimilar Substitution","short_definition":"Biosimilar substitution is dispensing a biosimilar instead of a prescribed reference biologic without consulting the prescriber, where rules allow.","category":"Pharmacoeconomics","category_path":"Pharmacy Practice › Pharmacoeconomics › Formulary Management","level_1":"Pharmacy Practice","level_2":"Pharmacoeconomics","level_3":"Formulary Management","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.603Z"},{"slug":"bismarck-model","canonical_uri":"https://healtheconomics.wiki/concept/bismarck-model","name":"Bismarck Model","short_definition":"The Bismarck model is a health system of compulsory social health insurance: employers and employees pay income-related contributions to sickness funds.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Health System Models","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Health System Models","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:19.792Z"},{"slug":"black-box-model","canonical_uri":"https://healtheconomics.wiki/concept/black-box-model","name":"Black Box Model","short_definition":"A black box model is a model whose workings cannot be inspected or understood, such as a locked cost-effectiveness model or a deep learning algorithm.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.642Z"},{"slug":"blame-free-reporting","canonical_uri":"https://healtheconomics.wiki/concept/blame-free-reporting","name":"Blame-Free Reporting","short_definition":"Blame-free reporting lets health staff report patient safety incidents and near misses without fear of punishment, so learning targets system causes.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.679Z"},{"slug":"blended-payment","canonical_uri":"https://healtheconomics.wiki/concept/blended-payment","name":"Blended Payment","short_definition":"Blended payment pays health care providers by mixing methods, such as capitation plus fee-for-service or case rates, so each offsets the others' flaws.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.442Z"},{"slug":"blinding","canonical_uri":"https://healtheconomics.wiki/concept/blinding","name":"Blinding","short_definition":"Blinding (masking) keeps trial participants, clinicians, assessors or analysts unaware of assignment, limiting bias in effect, utility and cost estimates.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.197Z"},{"slug":"block-randomization","canonical_uri":"https://healtheconomics.wiki/concept/block-randomization","name":"Block Randomization","short_definition":"Block randomisation assigns participants in small blocks with set numbers per arm in random order, keeping arms balanced throughout trials that inform HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T21:24:07.696Z"},{"slug":"body-of-evidence","canonical_uri":"https://healtheconomics.wiki/concept/body-of-evidence","name":"Body of Evidence","short_definition":"A body of evidence is all studies on one outcome of a guideline or HTA question, judged together; GRADE rates certainty as high, moderate, low or very low.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.514Z"},{"slug":"bond-financing","canonical_uri":"https://healtheconomics.wiki/concept/bond-financing","name":"Bond Financing","short_definition":"Bond financing is borrowing for health by issuing bonds, debt repaid with interest over many years, so hospitals and other large costs can be paid for now.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:19.961Z"},{"slug":"bootstrap-standard-error","canonical_uri":"https://healtheconomics.wiki/concept/bootstrap-standard-error","name":"Bootstrap Standard Error","short_definition":"Bootstrap standard error is the standard deviation of an estimate, such as mean trial cost, recalculated across many resamples of the observed data.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.737Z"},{"slug":"bootstrapping","canonical_uri":"https://healtheconomics.wiki/concept/bootstrapping","name":"Bootstrapping","short_definition":"Bootstrapping is a resampling method that estimates sampling uncertainty in trial costs, QALYs and net benefit from patient samples drawn with replacement.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.756Z"},{"slug":"borrowing-for-health","canonical_uri":"https://healtheconomics.wiki/concept/borrowing-for-health","name":"Borrowing For Health","short_definition":"Borrowing for health is when a household takes on debt to pay for health care, a coping strategy that signals weak financial risk protection.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:20.045Z"},{"slug":"bottom-up-cost-of-illness","canonical_uri":"https://healtheconomics.wiki/concept/bottom-up-cost-of-illness","name":"Bottom-Up Cost-of-Illness","short_definition":"Bottom-Up Cost-of-Illness estimates a disease's economic burden by valuing patient-level resource use at unit costs and scaling it to the population.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-of-Illness","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-of-Illness","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.258Z"},{"slug":"bottom-up-costing","canonical_uri":"https://healtheconomics.wiki/concept/bottom-up-costing","name":"Bottom-Up Costing","short_definition":"Bottom-up costing estimates the cost of care by recording each patient's use of resources and multiplying every item by its unit cost.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.319Z"},{"slug":"bounded-rationality-concept","canonical_uri":"https://healtheconomics.wiki/concept/bounded-rationality-concept","name":"Bounded Rationality Concept","short_definition":"The bounded rationality concept holds that patients, clinicians and payers with limited information, time and computation settle for good enough options.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.208Z"},{"slug":"brain-drain","canonical_uri":"https://healtheconomics.wiki/concept/brain-drain","name":"Brain Drain","short_definition":"Brain drain is the emigration of trained health workers from poorer to richer countries, costing source countries their care and publicly funded training.","category":"Health Policy","category_path":"Health Systems › Health Policy › Workforce Planning","level_1":"Health Systems","level_2":"Health Policy","level_3":"Workforce Planning","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.813Z"},{"slug":"branching-logic","canonical_uri":"https://healtheconomics.wiki/concept/branching-logic","name":"Branching Logic","short_definition":"Branching logic is the set of if-then rules that route a health survey respondent, or a patient in a decision model, by earlier answers or chance events.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.832Z"},{"slug":"break-even-analysis","canonical_uri":"https://healtheconomics.wiki/concept/break-even-analysis","name":"Break-Even Analysis","short_definition":"Break-even analysis finds the price, effect or volume at which a health technology or service becomes cost-effective, cost-neutral or self-financing.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.380Z"},{"slug":"breast-cancer-screening","canonical_uri":"https://healtheconomics.wiki/concept/breast-cancer-screening","name":"Breast Cancer Screening","short_definition":"Breast Cancer Screening is regular mammography of women without symptoms to cut deaths, judged economically against overdiagnosis and cost per QALY.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Oncology Prevention","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology Prevention","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:20.192Z"},{"slug":"brier-score","canonical_uri":"https://healtheconomics.wiki/concept/brier-score","name":"Brier Score","short_definition":"The Brier score is the mean squared difference between predicted risks and observed binary outcomes, used to judge prediction models; lower is better.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.586Z"},{"slug":"budget-allocation","canonical_uri":"https://healtheconomics.wiki/concept/budget-allocation","name":"Budget Allocation","short_definition":"Budget allocation is the division of a fixed health budget between areas or programmes, using needs-based formulae, priority setting or optimisation.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.264Z"},{"slug":"budget-approval","canonical_uri":"https://healtheconomics.wiki/concept/budget-approval","name":"Budget Approval","short_definition":"The authorised decision to allocate or permit specified spending for a defined health purpose, budget holder and period, often with explicit conditions.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.929Z"},{"slug":"budget-cap","canonical_uri":"https://healtheconomics.wiki/concept/budget-cap","name":"Budget Cap","short_definition":"Budget cap is a preset ceiling on what a payer will spend on a sector, provider or medicines bill, enforced by fixed budgets, tariff cuts or rebates.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Drug Pricing","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.283Z"},{"slug":"budget-constraint","canonical_uri":"https://healtheconomics.wiki/concept/budget-constraint","name":"Budget Constraint","short_definition":"Budget constraint is the limit that a fixed budget and given costs place on what can be bought, so funding one health programme means forgoing another.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:15.966Z"},{"slug":"budget-control","canonical_uri":"https://healtheconomics.wiki/concept/budget-control","name":"Budget Control","short_definition":"Budget control is the in-year monitoring of health spending against an approved budget, tracing variances to price or volume and acting to stay within it.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:58.304Z"},{"slug":"budget-cycle","canonical_uri":"https://healtheconomics.wiki/concept/budget-cycle","name":"Budget Cycle","short_definition":"Budget Cycle is the yearly sequence of formulation, approval, execution and review by which government health budgets are set, spent and audited.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:20.359Z"},{"slug":"budget-envelope","canonical_uri":"https://healtheconomics.wiki/concept/budget-envelope","name":"Budget Envelope","short_definition":"Budget Envelope is the fixed total set in advance for a health sector, programme or fund, within which detailed spending and coverage choices must fit.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.302Z"},{"slug":"budget-execution","canonical_uri":"https://healtheconomics.wiki/concept/budget-execution","name":"Budget Execution","short_definition":"Budget execution is the stage of the budget cycle in which an approved health budget is released, committed and spent, tracked by its execution rate.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:20.380Z"},{"slug":"budget-impact","canonical_uri":"https://healtheconomics.wiki/concept/budget-impact","name":"Budget Impact","short_definition":"Budget impact is the change in spending a budget holder can expect from adopting a health technology or policy, estimated by budget impact analysis.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-26T23:14:42.733Z"},{"slug":"budget-impact-analysis","canonical_uri":"https://healtheconomics.wiki/concept/budget-impact-analysis","name":"Budget Impact Analysis","short_definition":"Budget impact analysis (BIA) estimates how adopting a new health technology would change spending for a particular budget holder over the next few years.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.5.26","status":"PUBLISHED","published_at":"2026-10-26T23:14:42.582Z"},{"slug":"budget-impact-model","canonical_uri":"https://healtheconomics.wiki/concept/budget-impact-model","name":"Budget Impact Model","short_definition":"Budget Impact Model is the calculation tool that forecasts a payer's yearly spending with and without a new health technology, usually over 1 to 5 years.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:58.365Z"},{"slug":"budget-impact-modelling","canonical_uri":"https://healtheconomics.wiki/concept/budget-impact-modelling","name":"Budget Impact Modelling","short_definition":"Budget impact modelling is the practice of building, testing and documenting a model of how a new health technology changes a payer's yearly spending.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T23:14:42.658Z"},{"slug":"budget-planning","canonical_uri":"https://healtheconomics.wiki/concept/budget-planning","name":"Budget Planning","short_definition":"Budget planning is forecasting a health organisation's activity, costs and income for the next period and setting a spending plan before approval.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.120Z"},{"slug":"bundled-payment","canonical_uri":"https://healtheconomics.wiki/concept/bundled-payment","name":"Bundled Payment","short_definition":"Bundled payment pays a single price for all services in a defined episode of care, such as surgery and recovery, often spanning several providers.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.414Z"},{"slug":"burden-of-illness","canonical_uri":"https://healtheconomics.wiki/concept/burden-of-illness","name":"Burden of Illness","short_definition":"Burden of Illness is the total health loss and economic cost a disease imposes on a population, measured in cases, deaths, DALYs and money.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.441Z"},{"slug":"cadth","canonical_uri":"https://healtheconomics.wiki/concept/cadth","name":"CADTH","short_definition":"CADTH is the former name of Canada's Drug Agency (CDA-AMC), which assesses drugs and health technologies and advises Canada's public drug plans on funding.","category":"Health Policy","category_path":"Health Systems › Health Policy › HTA Organizations","level_1":"Health Systems","level_2":"Health Policy","level_3":"HTA Organizations","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.196Z"},{"slug":"cahps","canonical_uri":"https://healtheconomics.wiki/concept/cahps","name":"CAHPS","short_definition":"CAHPS (Consumer Assessment of Healthcare Providers and Systems) is AHRQ's family of patient experience surveys, used in US quality reporting and payment.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.216Z"},{"slug":"calibration","canonical_uri":"https://healtheconomics.wiki/concept/calibration","name":"Calibration","short_definition":"Calibration is the estimation of unobservable or uncertain parameters in a health economic model by adjusting them until model outputs match observed data.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.470Z"},{"slug":"calibration-of-experts","canonical_uri":"https://healtheconomics.wiki/concept/calibration-of-experts","name":"Calibration of Experts","short_definition":"Calibration of Experts scores experts' probability judgements on seed questions with known answers, to weight their views on decision model inputs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.502Z"},{"slug":"cancer-burden","canonical_uri":"https://healtheconomics.wiki/concept/cancer-burden","name":"Cancer Burden","short_definition":"Cancer Burden is the toll of cancer on a population, counted as new cases, deaths and disability-adjusted life years, and often valued as economic cost.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Oncology","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:58.588Z"},{"slug":"cancer-epidemiology","canonical_uri":"https://healtheconomics.wiki/concept/cancer-epidemiology","name":"Cancer Epidemiology","short_definition":"Cancer Epidemiology studies how often cancer occurs, what causes it and who survives or dies, supplying incidence and survival inputs to economic models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.562Z"},{"slug":"cancer-registry","canonical_uri":"https://healtheconomics.wiki/concept/cancer-registry","name":"Cancer Registry","short_definition":"Cancer Registry is an information system holding data on people with cancer, from tumour stage to treatment and survival, used to model survival in HTA.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Oncology Prevention","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology Prevention","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.622Z"},{"slug":"cancer-screening","canonical_uri":"https://healtheconomics.wiki/concept/cancer-screening","name":"Cancer Screening","short_definition":"Cancer Screening is testing symptom-free people to find cancer or precancer early, judged economically on deaths prevented against cost and overdiagnosis.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Oncology Prevention","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology Prevention","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:20.962Z"},{"slug":"capability-index-values","canonical_uri":"https://healtheconomics.wiki/concept/capability-index-values","name":"Capability Index Values","short_definition":"Capability index values are preference weights, often from best-worst scaling, that turn ICECAP answers into one score anchored at full and no capability.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.049Z"},{"slug":"capacity","canonical_uri":"https://healtheconomics.wiki/concept/capacity","name":"Capacity","short_definition":"Capacity is the maximum output, such as patients treated or scans per week, that a health service can sustain with its fixed staff, beds and equipment.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Capacity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Capacity","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.682Z"},{"slug":"capacity-management","canonical_uri":"https://healtheconomics.wiki/concept/capacity-management","name":"Capacity Management","short_definition":"Capacity management matches existing hospital beds and staff to patient demand by scheduling admissions and discharges, reducing waits and idle beds.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Healthcare Delivery","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.311Z"},{"slug":"capacity-planning","canonical_uri":"https://healtheconomics.wiki/concept/capacity-planning","name":"Capacity Planning","short_definition":"Capacity planning estimates the beds, staff, theatre time and equipment a health service needs to meet expected demand to a stated standard of access.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Capacity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Capacity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.986Z"},{"slug":"capacity-utilisation","canonical_uri":"https://healtheconomics.wiki/concept/capacity-utilisation","name":"Capacity Utilisation","short_definition":"Capacity utilisation is the share of available health care capacity, such as staffed beds, theatre sessions or scanner time, that is used over a period.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Capacity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Capacity","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.742Z"},{"slug":"capital-budget","canonical_uri":"https://healtheconomics.wiki/concept/capital-budget","name":"Capital Budget","short_definition":"Capital Budget is a health system's spending limit for long-lived assets such as hospitals, equipment and IT, kept apart from day-to-day running costs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.350Z"},{"slug":"capital-cost","canonical_uri":"https://healtheconomics.wiki/concept/capital-cost","name":"Capital Cost","short_definition":"Capital Cost is the cost of assets used for over a year, such as buildings and medical equipment, spread over their useful life in economic evaluation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.803Z"},{"slug":"capitation","canonical_uri":"https://healtheconomics.wiki/concept/capitation","name":"Capitation","short_definition":"Capitation is a provider payment method paying a fixed amount per enrolled person per period for a defined package of care, whatever care each person uses.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.660Z"},{"slug":"capitation-payment","canonical_uri":"https://healtheconomics.wiki/concept/capitation-payment","name":"Capitation Payment","short_definition":"A capitation payment is a predetermined amount paid to a healthcare provider or organisation per covered person over a defined period for a specified set of services, largely independent of that person's actual service use.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.369Z"},{"slug":"car-t-therapy","canonical_uri":"https://healtheconomics.wiki/concept/car-t-therapy","name":"CAR-T Therapy","short_definition":"CAR-T Therapy is a one-off cancer treatment made from a patient's own T cells, engineered to attack the cancer; its high price rests on lasting remission.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Therapeutic Innovation","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Therapeutic Innovation","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.924Z"},{"slug":"cardiac-rehabilitation","canonical_uri":"https://healtheconomics.wiki/concept/cardiac-rehabilitation","name":"Cardiac Rehabilitation","short_definition":"Cardiac Rehabilitation is supervised exercise, education and psychological care after a cardiac event; most economic evaluations find it cost-effective.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Cardiovascular","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Cardiovascular","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:21.253Z"},{"slug":"cardinal-scaling","canonical_uri":"https://healtheconomics.wiki/concept/cardinal-scaling","name":"Cardinal Scaling","short_definition":"Cardinal scaling values health states so that differences between values show strength of preference, as QALYs require; ordinal scales give rank only.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.733Z"},{"slug":"care-bundle","canonical_uri":"https://healtheconomics.wiki/concept/care-bundle","name":"Care Bundle","short_definition":"Care Bundle is a quality improvement intervention of three to five evidence-based practices given together to each eligible patient, audited all-or-none.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:21.377Z"},{"slug":"care-coordination","canonical_uri":"https://healtheconomics.wiki/concept/care-coordination","name":"Care Coordination","short_definition":"Care coordination is the deliberate organisation of care among a patient's providers and the patient, sharing information for appropriate, efficient care.","category":"Health Policy","category_path":"Health Systems › Health Policy › Integrated Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Integrated Care","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.432Z"},{"slug":"care-management","canonical_uri":"https://healtheconomics.wiki/concept/care-management","name":"Care Management","short_definition":"Care Management is planned support for high-need, high-cost patients, in which a care manager agrees a care plan and follows up to avoid costly admissions.","category":"Health Policy","category_path":"Health Systems › Health Policy › Integrated Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Integrated Care","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.452Z"},{"slug":"care-pathway","canonical_uri":"https://healtheconomics.wiki/concept/care-pathway","name":"Care Pathway","short_definition":"Care pathway is the organised sequence of care for a defined patient group and period; in economic evaluation it shows where a new technology is used.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:12.985Z"},{"slug":"care-transition","canonical_uri":"https://healtheconomics.wiki/concept/care-transition","name":"Care Transition","short_definition":"Care Transition is a patient's move between care settings or providers, such as hospital discharge home, a period of raised risk of harm and readmission.","category":"Health Policy","category_path":"Health Systems › Health Policy › Integrated Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Integrated Care","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.804Z"},{"slug":"caregiver-burden","canonical_uri":"https://healtheconomics.wiki/concept/caregiver-burden","name":"Caregiver Burden","short_definition":"Caregiver Burden is the strain unpaid caring puts on a carer's health, time, finances and social life, a family spillover economic evaluations can count.","category":"Health Policy","category_path":"Health Systems › Health Policy › Patient-Centered Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Patient-Centered Care","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.047Z"},{"slug":"caregiver-quality-of-life","canonical_uri":"https://healtheconomics.wiki/concept/caregiver-quality-of-life","name":"Caregiver Quality of Life","short_definition":"Caregiver Quality of Life is an unpaid carer's own health and wellbeing as affected by caring, measured in economic evaluation with EQ-5D or CarerQol.","category":"Health Policy","category_path":"Health Systems › Health Policy › Patient-Centered Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Patient-Centered Care","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.106Z"},{"slug":"carer","canonical_uri":"https://healtheconomics.wiki/concept/carer","name":"Carer","short_definition":"A carer is a person, usually a family member or friend, who gives unpaid care to someone with illness, disability or frailty, unlike a paid care worker.","category":"Health Policy","category_path":"Health Systems › Health Policy › Patient-Centered Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Patient-Centered Care","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.594Z"},{"slug":"carryover-effect","canonical_uri":"https://healtheconomics.wiki/concept/carryover-effect","name":"Carryover Effect","short_definition":"Carryover Effect is a treatment's effect persisting into a later crossover trial period, which can bias effect estimates used in HTA and economic models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.169Z"},{"slug":"carve-out","canonical_uri":"https://healtheconomics.wiki/concept/carve-out","name":"Carve-Out","short_definition":"Carve-Out is the removal of a service, such as pharmacy or behavioural health, from a health plan or payment unit so it is managed and paid for separately.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:58.872Z"},{"slug":"case-complexity","canonical_uri":"https://healtheconomics.wiki/concept/case-complexity","name":"Case Complexity","short_definition":"Case Complexity is how demanding a patient's case is to treat, given comorbidity, illness severity and social circumstances, which drive its resource use.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Performance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Performance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.653Z"},{"slug":"case-fatality-rate","canonical_uri":"https://healtheconomics.wiki/concept/case-fatality-rate","name":"Case Fatality Rate","short_definition":"Case fatality rate (CFR) is the proportion of people diagnosed with a disease who die of it within a defined period, a measure of severity.","category":"Health Policy","category_path":"Health Systems › Health Policy › Population Health Outcomes","level_1":"Health Systems","level_2":"Health Policy","level_3":"Population Health Outcomes","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:21.627Z"},{"slug":"case-management","canonical_uri":"https://healtheconomics.wiki/concept/case-management","name":"Case Management","short_definition":"Case Management is a service in which a case manager or team assesses, plans and coordinates care for people with complex needs and high expected costs.","category":"Health Policy","category_path":"Health Systems › Health Policy › Integrated Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Integrated Care","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.672Z"},{"slug":"case-mix","canonical_uri":"https://healtheconomics.wiki/concept/case-mix","name":"Case Mix","short_definition":"Case mix is the composition of a provider's patients by diagnosis, procedure, severity and expected resource use, usually measured with DRGs or HRGs.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.291Z"},{"slug":"case-mix-index","canonical_uri":"https://healtheconomics.wiki/concept/case-mix-index","name":"Case Mix Index","short_definition":"Case Mix Index (CMI) is the average diagnosis-related group relative weight of a hospital's discharges, showing how resource-intensive its cases are.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.710Z"},{"slug":"case-report","canonical_uri":"https://healtheconomics.wiki/concept/case-report","name":"Case Report","short_definition":"A case report details one patient's presentation, management and outcome; in HTA it can flag rare harms but not estimate their rate or a treatment effect.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.781Z"},{"slug":"case-series-design","canonical_uri":"https://healtheconomics.wiki/concept/case-series-design","name":"Case Series Design","short_definition":"Case Series Design is an uncontrolled observational study of patients sharing a condition or treatment; in HTA it gives event rates, not treatment effects.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.353Z"},{"slug":"case-weight","canonical_uri":"https://healtheconomics.wiki/concept/case-weight","name":"Case Weight","short_definition":"Case weight is a relative value for a diagnosis-related group showing its expected cost against the average case, used to scale payment from a base rate.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.413Z"},{"slug":"case-based-payment","canonical_uri":"https://healtheconomics.wiki/concept/case-based-payment","name":"Case-Based Payment","short_definition":"Case-Based Payment pays a hospital a fixed amount per treated case, set in advance for the case's group, often by diagnosis, not by the services used.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.230Z"},{"slug":"case-control-design","canonical_uri":"https://healtheconomics.wiki/concept/case-control-design","name":"Case-Control Design","short_definition":"Case-Control Design is an observational study comparing past exposures of cases (with an outcome) and controls (without it), used in HTA for rare outcomes.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.673Z"},{"slug":"case-mix-adjustment","canonical_uri":"https://healtheconomics.wiki/concept/case-mix-adjustment","name":"Case-Mix Adjustment","short_definition":"Case-mix adjustment corrects comparisons of providers' costs or outcomes for differences in the patients they treat, so that like is compared with like.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.875Z"},{"slug":"cash-budget","canonical_uri":"https://healtheconomics.wiki/concept/cash-budget","name":"Cash Budget","short_definition":"A cash budget is a period-by-period forecast of cash receipts and payments that shows when a health organisation will need financing or have spare cash.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.748Z"},{"slug":"cash-flow","canonical_uri":"https://healtheconomics.wiki/concept/cash-flow","name":"Cash Flow","short_definition":"Cash flow is the money an organisation such as a hospital or health payer receives and pays out over a period, which can differ from its surplus or costs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.474Z"},{"slug":"catastrophic-health-expenditure","canonical_uri":"https://healtheconomics.wiki/concept/catastrophic-health-expenditure","name":"Catastrophic Health Expenditure","short_definition":"Catastrophic health expenditure (CHE) is out-of-pocket health spending that exceeds a set share of a household's total budget or its capacity to pay.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.692Z"},{"slug":"categorical-data","canonical_uri":"https://healtheconomics.wiki/concept/categorical-data","name":"Categorical Data","short_definition":"Categorical data record which of a set of categories each observation falls in, such as alive or dead or an EQ-5D level, instead of a measured amount.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:43.053Z"},{"slug":"categorical-targeting","canonical_uri":"https://healtheconomics.wiki/concept/categorical-targeting","name":"Categorical Targeting","short_definition":"Categorical targeting makes everyone in an easily observed group, such as children or older people, eligible for a benefit without testing individual need.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Equity","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Equity","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.536Z"},{"slug":"category-rating","canonical_uri":"https://healtheconomics.wiki/concept/category-rating","name":"Category Rating","short_definition":"Category rating is a health state valuation method where people place health states on a scale of ordered, equal-interval categories between two anchors.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.598Z"},{"slug":"causal-inference","canonical_uri":"https://healtheconomics.wiki/concept/causal-inference","name":"Causal Inference","short_definition":"Causal inference estimates what would happen to health outcomes or costs if a treatment or policy changed, using data, study design and stated assumptions.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.710Z"},{"slug":"causal-loop-diagram","canonical_uri":"https://healtheconomics.wiki/concept/causal-loop-diagram","name":"Causal Loop Diagram","short_definition":"A causal loop diagram (CLD) maps signed cause-and-effect links between variables to show the feedback loops driving a health system or decision problem.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.861Z"},{"slug":"causal-pathway","canonical_uri":"https://healtheconomics.wiki/concept/causal-pathway","name":"Causal Pathway","short_definition":"A causal pathway is the sequence of steps through which an intervention or exposure produces a health outcome, acting through intermediate variables.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:51:59.091Z"},{"slug":"ceiling-effect","canonical_uri":"https://healtheconomics.wiki/concept/ceiling-effect","name":"Ceiling Effect","short_definition":"A ceiling effect is a measurement limitation in which many respondents score at the top of a health scale, so further improvement cannot be detected.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.918Z"},{"slug":"censoring","canonical_uri":"https://healtheconomics.wiki/concept/censoring","name":"Censoring","short_definition":"Censoring in survival analysis occurs when a patient's time to an event is only partly known, for example still event-free when trial follow-up ends.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.784Z"},{"slug":"census-data","canonical_uri":"https://healtheconomics.wiki/concept/census-data","name":"Census Data","short_definition":"Census data are counts and characteristics of a whole population from periodic official enumeration, used in health economics for denominators and models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T01:32:51.698Z"},{"slug":"central-limit-theorem","canonical_uri":"https://healtheconomics.wiki/concept/central-limit-theorem","name":"Central Limit Theorem","short_definition":"The central limit theorem states that the mean of many independent observations with finite variance is approximately normal, whatever their distribution.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:59.171Z"},{"slug":"certainty-of-evidence","canonical_uri":"https://healtheconomics.wiki/concept/certainty-of-evidence","name":"Certainty of Evidence","short_definition":"Certainty of evidence is GRADE's rating, from high to very low, of confidence that a true effect falls on one side of a threshold or within a chosen range.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:16.975Z"},{"slug":"certificate-of-need","canonical_uri":"https://healtheconomics.wiki/concept/certificate-of-need","name":"Certificate of Need","short_definition":"A certificate of need (CON) is a US state approval that health care providers must obtain before major capital spending, new facilities or new services.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Regulation","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Regulation","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:59.230Z"},{"slug":"chance-node","canonical_uri":"https://healtheconomics.wiki/concept/chance-node","name":"Chance Node","short_definition":"A chance node is a point in a decision tree where an uncertain event, not a choice, decides the pathway, and its branch probabilities sum to one.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.059Z"},{"slug":"charge-master","canonical_uri":"https://healtheconomics.wiki/concept/charge-master","name":"Charge Master","short_definition":"A charge master (chargemaster) is a US hospital's list of gross charges for every item and service it bills, before any discount or negotiated rate.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.052Z"},{"slug":"charity-care","canonical_uri":"https://healtheconomics.wiki/concept/charity-care","name":"Charity Care","short_definition":"Charity care is free or discounted care a provider gives to patients who meet its financial assistance criteria and cannot pay all or part of the bill.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:59.312Z"},{"slug":"chi-square-distribution","canonical_uri":"https://healtheconomics.wiki/concept/chi-square-distribution","name":"Chi-Square Distribution","short_definition":"The chi-square distribution describes a sum of squared independent standard normals and is the reference for likelihood ratio, heterogeneity and fit tests.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:22.477Z"},{"slug":"choice-architecture-intervention","canonical_uri":"https://healtheconomics.wiki/concept/choice-architecture-intervention","name":"Choice Architecture Intervention","short_definition":"A choice architecture intervention changes how health options are set out, such as defaults, order or placement, to shift choices without removing options.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.109Z"},{"slug":"choice-experiment-design","canonical_uri":"https://healtheconomics.wiki/concept/choice-experiment-design","name":"Choice Experiment Design","short_definition":"Choice experiment design is the plan of attributes, levels and choice tasks in a DCE, which fixes the health preference effects that can be estimated.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.995Z"},{"slug":"choice-model-estimate","canonical_uri":"https://healtheconomics.wiki/concept/choice-model-estimate","name":"Choice Model Estimate","short_definition":"Choice model estimate is a preference weight, or a derived value such as willingness to pay, from a choice model fitted to stated or revealed choices.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:29.027Z"},{"slug":"choice-overload","canonical_uri":"https://healtheconomics.wiki/concept/choice-overload","name":"Choice Overload","short_definition":"Choice overload is the effect in which a large or complex set of options can lead people to defer a choice or regret it, as in health insurance markets.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:59.372Z"},{"slug":"choice-set","canonical_uri":"https://healtheconomics.wiki/concept/choice-set","name":"Choice Set","short_definition":"The group of alternatives, typically hypothetical options and sometimes a status quo, presented to a respondent in a single choice task.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T01:26:21.990Z"},{"slug":"choice-theory","canonical_uri":"https://healtheconomics.wiki/concept/choice-theory","name":"Choice Theory","short_definition":"Choice theory is the economic theory of how people choose among options given preferences and limited resources, underpinning demand and health valuation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:59.392Z"},{"slug":"choice-based-conjoint","canonical_uri":"https://healtheconomics.wiki/concept/choice-based-conjoint","name":"Choice-Based Conjoint","short_definition":"Choice-based conjoint (CBC) is conjoint analysis in which patients or others choose between sets of described treatments or services rather than rate them.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.128Z"},{"slug":"cholesky-decomposition","canonical_uri":"https://healtheconomics.wiki/concept/cholesky-decomposition","name":"Cholesky Decomposition","short_definition":"Cholesky decomposition factorises a positive-definite covariance matrix into a triangular matrix and its transpose, used to sample correlated PSA inputs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.167Z"},{"slug":"choosing-wisely","canonical_uri":"https://healtheconomics.wiki/concept/choosing-wisely","name":"Choosing Wisely","short_definition":"Choosing Wisely is a clinician-led campaign in which specialty societies list overused tests and treatments that doctors and patients should question.","category":"Health Policy","category_path":"Health Systems › Health Policy › Horizon Scanning","level_1":"Health Systems","level_2":"Health Policy","level_3":"Horizon Scanning","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.186Z"},{"slug":"chu9d","canonical_uri":"https://healtheconomics.wiki/concept/chu9d","name":"CHU9D","short_definition":"CHU9D (Child Health Utility 9D) is a generic preference-based measure of children's health-related quality of life, used to calculate paediatric QALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:25.946Z"},{"slug":"citizen-jury","canonical_uri":"https://healtheconomics.wiki/concept/citizen-jury","name":"Citizen Jury","short_definition":"A citizen jury is a small, randomly selected group of the public who hear expert evidence on a health policy question, deliberate and make recommendations.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.205Z"},{"slug":"claims-adjudication","canonical_uri":"https://healtheconomics.wiki/concept/claims-adjudication","name":"Claims Adjudication","short_definition":"Claims adjudication is a payer's review of a healthcare claim to decide whether to pay it in full, in part or not at all, and what the patient owes.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.225Z"},{"slug":"claims-data","canonical_uri":"https://healtheconomics.wiki/concept/claims-data","name":"Claims Data","short_definition":"Claims data are records providers submit to insurers or public payers to be paid, reused in health economics to measure resource use, costs and outcomes.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.847Z"},{"slug":"accuracy","canonical_uri":"https://healtheconomics.wiki/concept/accuracy","name":"Classification Accuracy","short_definition":"Classification accuracy is the proportion of cases a test, coder or prediction rule assigns to the correct category, judged against a reference standard.","category":"Statistical Methods","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:08.233Z"},{"slug":"classification-methods","canonical_uri":"https://healtheconomics.wiki/concept/classification-methods","name":"Classification Methods","short_definition":"Classification methods are statistical and machine learning techniques that assign patients or other cases to predefined classes, such as risk groups.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.245Z"},{"slug":"clawback","canonical_uri":"https://healtheconomics.wiki/concept/clawback","name":"Clawback","short_definition":"Clawback is a payment that medicine manufacturers return to a payer when total public spending on medicines exceeds an agreed cap.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Drug Pricing","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.910Z"},{"slug":"clinical-alert","canonical_uri":"https://healtheconomics.wiki/concept/clinical-alert","name":"Clinical Alert","short_definition":"A clinical alert is an automated message in a health record or ordering system warning a clinician of a patient-specific risk, such as a drug interaction.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T01:34:02.218Z"},{"slug":"clinical-algorithm","canonical_uri":"https://healtheconomics.wiki/concept/clinical-algorithm","name":"Clinical Algorithm","short_definition":"A clinical algorithm is a set of explicit step-by-step rules, drawn as a flowchart or run in software, that sets the next test or treatment for a patient.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Digital Health","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Digital Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.303Z"},{"slug":"algorithm-development","canonical_uri":"https://healtheconomics.wiki/concept/algorithm-development","name":"Clinical Algorithm Development","short_definition":"Clinical algorithm development is building a step-by-step diagnosis or treatment pathway from evidence review, consensus and often economic evaluation.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-14T23:51:56.659Z"},{"slug":"clinical-analytics","canonical_uri":"https://healtheconomics.wiki/concept/clinical-analytics","name":"Clinical Analytics","short_definition":"Clinical analytics is the analysis of patient-level clinical data, such as electronic health records, to describe care, predict risk and inform decisions.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T01:34:02.334Z"},{"slug":"clinical-audit","canonical_uri":"https://healtheconomics.wiki/concept/clinical-audit","name":"Clinical Audit","short_definition":"Clinical audit is a quality improvement cycle that checks care against explicit evidence-based standards, acts on gaps and re-measures to confirm change.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.896Z"},{"slug":"clinical-benefit-rate","canonical_uri":"https://healtheconomics.wiki/concept/clinical-benefit-rate","name":"Clinical Benefit Rate","short_definition":"Clinical benefit rate (CBR) is the share of cancer trial patients with a complete or partial response, or stable disease lasting a set minimum time.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Oncology Outcomes","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology Outcomes","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.971Z"},{"slug":"clinical-decision-analysis","canonical_uri":"https://healtheconomics.wiki/concept/clinical-decision-analysis","name":"Clinical Decision Analysis","short_definition":"Clinical decision analysis is a method for choosing a patient's test or treatment by combining outcome probabilities and utilities in a decision tree.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Decision Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Decision Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:23.004Z"},{"slug":"clinical-decision-support","canonical_uri":"https://healtheconomics.wiki/concept/clinical-decision-support","name":"Clinical Decision Support","short_definition":"Clinical decision support (CDS) is software that matches a patient's data to clinical knowledge and gives clinicians tailored advice at the point of care.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.360Z"},{"slug":"clinical-development-plan","canonical_uri":"https://healtheconomics.wiki/concept/clinical-development-plan","name":"Clinical Development Plan","short_definition":"A clinical development plan is a sponsor's ordered programme of clinical trials, with decision points, to support marketing approval and often HTA.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Drug Development","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Drug Development","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.033Z"},{"slug":"clinical-effectiveness-review","canonical_uri":"https://healtheconomics.wiki/concept/clinical-effectiveness-review","name":"Clinical Effectiveness Review","short_definition":"Clinical effectiveness review is the part of an HTA that systematically reviews evidence on a technology's benefits and harms compared with alternatives.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.096Z"},{"slug":"clinical-efficiency","canonical_uri":"https://healtheconomics.wiki/concept/clinical-efficiency","name":"Clinical Efficiency","short_definition":"Clinical efficiency is the extent to which clinicians and teams achieve good patient outcomes with the least staff time, tests, drugs and bed-days.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Health System Performance","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Health System Performance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.380Z"},{"slug":"clinical-endpoint","canonical_uri":"https://healtheconomics.wiki/concept/clinical-endpoint","name":"Clinical Endpoint","short_definition":"A clinical endpoint is a predefined trial outcome for judging a treatment; strictly, one directly measuring how a patient feels, functions or survives.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.158Z"},{"slug":"clinical-epidemiology","canonical_uri":"https://healtheconomics.wiki/concept/clinical-epidemiology","name":"Clinical Epidemiology","short_definition":"Clinical epidemiology applies epidemiology to patients, measuring test accuracy, prognosis and treatment effects for clinical and economic decisions.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.220Z"},{"slug":"clinical-evidence","canonical_uri":"https://healtheconomics.wiki/concept/clinical-evidence","name":"Clinical Evidence","short_definition":"Clinical evidence is data from trials and observational studies on an intervention's benefits and harms, used in HTA and economic evaluation.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.281Z"},{"slug":"clinical-guideline","canonical_uri":"https://healtheconomics.wiki/concept/clinical-guideline","name":"Clinical Guideline","short_definition":"A clinical guideline is a set of care recommendations for a defined clinical situation, based on a systematic review of evidence on benefits and harms.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.342Z"},{"slug":"clinical-integration","canonical_uri":"https://healtheconomics.wiki/concept/clinical-integration","name":"Clinical Integration","short_definition":"Clinical integration is the coordination of a patient's care across professionals, services and settings so that it runs as one continuous process.","category":"Health Policy","category_path":"Health Systems › Health Policy › Integrated Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Integrated Care","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.494Z"},{"slug":"clinical-meaningfulness","canonical_uri":"https://healtheconomics.wiki/concept/clinical-meaningfulness","name":"Clinical Meaningfulness","short_definition":"Clinical meaningfulness is whether a treatment effect is large enough to matter to patients and change their care, not just statistically significant.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.403Z"},{"slug":"clinical-outcome","canonical_uri":"https://healtheconomics.wiki/concept/clinical-outcome","name":"Clinical Outcome","short_definition":"A clinical outcome is a result showing how a patient feels, functions or survives, such as stroke or death, used to judge benefit in economic evaluation.","category":"Health Policy","category_path":"Health Systems › Health Policy › Clinical Outcomes","level_1":"Health Systems","level_2":"Health Policy","level_3":"Clinical Outcomes","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.464Z"},{"slug":"clinical-outcome-assessment","canonical_uri":"https://healtheconomics.wiki/concept/clinical-outcome-assessment","name":"Clinical Outcome Assessment","short_definition":"A clinical outcome assessment (COA) measures how a patient feels or functions, through patient, clinician or observer reports or a standardised task.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:55.990Z"},{"slug":"clinical-pathway","canonical_uri":"https://healtheconomics.wiki/concept/clinical-pathway","name":"Clinical Pathway","short_definition":"A clinical pathway is a structured multidisciplinary plan setting out the expected steps and timing of hospital care for a specific clinical problem.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.524Z"},{"slug":"clinical-plausibility","canonical_uri":"https://healtheconomics.wiki/concept/clinical-plausibility","name":"Clinical Plausibility","short_definition":"Clinical plausibility is the extent to which a health economic model's structure, inputs and results agree with clinical knowledge of the disease.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.584Z"},{"slug":"clinical-practice-variation","canonical_uri":"https://healtheconomics.wiki/concept/clinical-practice-variation","name":"Clinical Practice Variation","short_definition":"Clinical practice variation is the difference in care that similar patients receive from different clinicians, hospitals or regions, warranted or not.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.645Z"},{"slug":"clinical-trial","canonical_uri":"https://healtheconomics.wiki/concept/clinical-trial","name":"Clinical Trial","short_definition":"A clinical trial is a study that prospectively assigns people to health interventions to measure their effects, giving evidence for regulators and HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.704Z"},{"slug":"clinical-trial-design","canonical_uri":"https://healtheconomics.wiki/concept/clinical-trial-design","name":"Clinical Trial Design","short_definition":"Clinical trial design is the protocol plan for a trial's comparator, population, endpoints, follow-up and sample size, setting how far results inform HTA.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Drug Development","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Drug Development","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-15T01:26:22.047Z"},{"slug":"clinician-reported-outcome","canonical_uri":"https://healtheconomics.wiki/concept/clinician-reported-outcome","name":"Clinician-Reported Outcome","short_definition":"A clinician-reported outcome (ClinRO) is a clinical outcome assessment in which a trained health professional rates the patient using clinical judgement.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.764Z"},{"slug":"analytical-method","canonical_uri":"https://healtheconomics.wiki/concept/analytical-method","name":"Closed-Form Analytical Method","short_definition":"A closed-form analytical method solves a health economic model with a formula, such as a matrix inverse, instead of by simulation or random sampling.","category":"Economic Methods","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:51.920Z"},{"slug":"club-goods","canonical_uri":"https://healtheconomics.wiki/concept/club-goods","name":"Club Goods","short_definition":"Club goods are excludable goods a group can share without rivalry until congestion sets in, so users can be charged and membership limited.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Common Resource Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Common Resource Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T01:26:22.065Z"},{"slug":"cluster-analysis","canonical_uri":"https://healtheconomics.wiki/concept/cluster-analysis","name":"Cluster Analysis","short_definition":"Cluster analysis is an unsupervised method that sorts patients, providers or countries into groups whose members are more alike than those in other groups.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.825Z"},{"slug":"cluster-effect","canonical_uri":"https://healtheconomics.wiki/concept/cluster-effect","name":"Cluster Effect","short_definition":"A cluster effect is the tendency of patients in the same practice or hospital to have similar outcomes and costs, so their data are not independent.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.629Z"},{"slug":"cluster-randomization","canonical_uri":"https://healtheconomics.wiki/concept/cluster-randomization","name":"Cluster Randomization","short_definition":"Cluster randomization allocates groups, such as hospitals or GP practices, to trial arms, so clinical and economic analyses must allow for clustering.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:23.503Z"},{"slug":"co-primary-outcome","canonical_uri":"https://healtheconomics.wiki/concept/co-primary-outcome","name":"Co-Primary Outcome","short_definition":"A co-primary outcome is one of two or more primary outcomes in a trial, each of which must show a significant treatment effect for the trial to succeed.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.885Z"},{"slug":"coase-theorem","canonical_uri":"https://healtheconomics.wiki/concept/coase-theorem","name":"Coase Theorem","short_definition":"The Coase theorem holds that, with clear property rights and no transaction costs, bargaining reaches an efficient outcome whoever holds the rights.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Common Resource Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Common Resource Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:59.889Z"},{"slug":"cobra-coverage","canonical_uri":"https://healtheconomics.wiki/concept/cobra-coverage","name":"COBRA Coverage","short_definition":"COBRA coverage is the US right to keep an employer group health plan for a limited time after job loss or another qualifying event, usually at full cost.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.648Z"},{"slug":"coercion","canonical_uri":"https://healtheconomics.wiki/concept/coercion","name":"Coercion","short_definition":"Coercion in health research is a threat of harm used to make someone take part against their will, so their consent is not voluntary and not valid.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Governance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Governance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:59.948Z"},{"slug":"cognitive-bias-concept","canonical_uri":"https://healtheconomics.wiki/concept/cognitive-bias-concept","name":"Cognitive Bias Concept","short_definition":"The cognitive bias concept is systematic error in judgement, often from mental shortcuts, that skews how patients, clinicians and experts weigh evidence.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:51:59.968Z"},{"slug":"cognitively-impaired-research","canonical_uri":"https://healtheconomics.wiki/concept/cognitively-impaired-research","name":"Cognitively Impaired Research","short_definition":"Cognitively impaired research is research with people whose impaired capacity may prevent valid consent, so proxy involvement and extra safeguards apply.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Governance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Governance","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:14.945Z"},{"slug":"cohens-d","canonical_uri":"https://healtheconomics.wiki/concept/cohens-d","name":"Cohen's d","short_definition":"Cohen's d is a standardised effect size: the difference between two group means divided by their pooled standard deviation, used to compare studies.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.005Z"},{"slug":"cohort-design","canonical_uri":"https://healtheconomics.wiki/concept/cohort-design","name":"Cohort Design","short_definition":"A cohort design is an observational study that follows people grouped by exposure or treatment forward from a common start to compare later outcomes.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-10T01:35:37.880Z"},{"slug":"cohort-model","canonical_uri":"https://healtheconomics.wiki/concept/cohort-model","name":"Cohort Model","short_definition":"A cohort model is a health economic decision model that estimates mean costs and outcomes for a patient group as a whole, without simulating individuals.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.071Z"},{"slug":"cohort-simulation","canonical_uri":"https://healtheconomics.wiki/concept/cohort-simulation","name":"Cohort Simulation","short_definition":"Cohort simulation runs a Markov or other state-transition model by moving the expected shares of a hypothetical cohort between health states each cycle.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.722Z"},{"slug":"cohort-trace","canonical_uri":"https://healtheconomics.wiki/concept/cohort-trace","name":"Cohort Trace","short_definition":"A cohort trace is the cycle-by-cycle record of a state-transition model’s expected cohort distribution across its health states under a specified strategy.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:56.121Z"},{"slug":"coinsurance","canonical_uri":"https://healtheconomics.wiki/concept/coinsurance","name":"Coinsurance","short_definition":"Coinsurance is the percentage of the allowed cost of a covered health service that an insured patient pays, usually after the deductible has been met.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.133Z"},{"slug":"coinsurance-rate","canonical_uri":"https://healtheconomics.wiki/concept/coinsurance-rate","name":"Coinsurance Rate","short_definition":"The specific percentage of a covered service's cost an insured person is responsible for paying under a coinsurance arrangement.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:56.139Z"},{"slug":"cointervention","canonical_uri":"https://healtheconomics.wiki/concept/cointervention","name":"Cointervention","short_definition":"A cointervention (co-intervention) is a treatment other than the one under study that trial participants receive; unequal use across arms can bias results.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.152Z"},{"slug":"collaborative-care","canonical_uri":"https://healtheconomics.wiki/concept/collaborative-care","name":"Collaborative Care","short_definition":"Collaborative care is a primary care model, mainly for depression, in which a care manager works with the patient's doctor and a mental health specialist.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Integrated Care","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Integrated Care","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:56.158Z"},{"slug":"collinearity-diagnostics","canonical_uri":"https://healtheconomics.wiki/concept/collinearity-diagnostics","name":"Collinearity Diagnostics","short_definition":"Collinearity diagnostics are regression checks, such as variance inflation factors, showing when predictors overlap too much to estimate separate effects.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:56.177Z"},{"slug":"common-cause-variation","canonical_uri":"https://healtheconomics.wiki/concept/common-cause-variation","name":"Common Cause Variation","short_definition":"Common cause variation is the routine variation a stable process produces from many small chance causes, predictable within limits from past data.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.182Z"},{"slug":"common-comparator","canonical_uri":"https://healtheconomics.wiki/concept/common-comparator","name":"Common Comparator","short_definition":"A common comparator is a treatment, such as placebo or standard care, that two other treatments were each tested against, anchoring an indirect comparison.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.193Z"},{"slug":"common-cost-allocation","canonical_uri":"https://healtheconomics.wiki/concept/common-cost-allocation","name":"Common Cost Allocation","short_definition":"Common cost allocation is the division of a cost shared by several health services, such as overheads or a joint input, among them by a chosen rule.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.254Z"},{"slug":"common-pool-resources","canonical_uri":"https://healtheconomics.wiki/concept/common-pool-resources","name":"Common Pool Resources","short_definition":"Common pool resources are goods where one user's use leaves less for others and excluding users is difficult or costly.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Common Resource Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Common Resource Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:56.270Z"},{"slug":"common-random-numbers","canonical_uri":"https://healtheconomics.wiki/concept/common-random-numbers","name":"Common Random Numbers","short_definition":"Common random numbers (CRN) is a simulation method that runs competing strategies on the same random draws, so their estimated difference is less noisy.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.820Z"},{"slug":"communality","canonical_uri":"https://healtheconomics.wiki/concept/communality","name":"Communality","short_definition":"Communality is the proportion of an observed variable's variance explained by the common factors in a factor analysis, the complement of its uniqueness.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.202Z"},{"slug":"community-health-needs-assessment","canonical_uri":"https://healtheconomics.wiki/concept/community-health-needs-assessment","name":"Community Health Needs Assessment","short_definition":"Community health needs assessment (CHNA) is the three-yearly study of local health needs that US tax-exempt hospitals must publish to keep their exemption.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Healthcare Quality","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.265Z"},{"slug":"community-rating","canonical_uri":"https://healtheconomics.wiki/concept/community-rating","name":"Community Rating","short_definition":"Community rating is a health insurance pricing rule that stops premiums varying with health or claims, allowing at most limited variation by age or area.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T00:51:23.461Z"},{"slug":"community-based-insurance","canonical_uri":"https://healtheconomics.wiki/concept/community-based-insurance","name":"Community-Based Insurance","short_definition":"Community-based insurance is voluntary, not-for-profit health insurance run by a local community, whose members prepay small premiums into a shared fund.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:56.326Z"},{"slug":"community-based-research","canonical_uri":"https://healtheconomics.wiki/concept/community-based-research","name":"Community-Based Research","short_definition":"Community-based research is health research in which community members, organisations and researchers share every stage, from research questions to action.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Governance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Governance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:24.186Z"},{"slug":"comorbidity","canonical_uri":"https://healtheconomics.wiki/concept/comorbidity","name":"Comorbidity","short_definition":"Comorbidity is any other condition a patient has alongside the index disease under study; in health economics it shifts costs, utilities and survival.","category":"Health Policy","category_path":"Health Systems › Health Policy › Population Health Outcomes","level_1":"Health Systems","level_2":"Health Policy","level_3":"Population Health Outcomes","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.317Z"},{"slug":"companion-diagnostic","canonical_uri":"https://healtheconomics.wiki/concept/companion-diagnostic","name":"Companion Diagnostic","short_definition":"A companion diagnostic (CDx) is a test that identifies patients a specific drug is likely to help or harm, so the drug and test are assessed together.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Therapeutic Innovation","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Therapeutic Innovation","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.378Z"},{"slug":"comparability-study","canonical_uri":"https://healtheconomics.wiki/concept/comparability-study","name":"Comparability Study","short_definition":"A comparability study is a stepwise comparison showing a biologic is highly similar to its pre-change version or, for a biosimilar, its reference product.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Biological Medicines","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Biological Medicines","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:17.955Z"},{"slug":"comparative-effectiveness-research","canonical_uri":"https://healtheconomics.wiki/concept/comparative-effectiveness-research","name":"Comparative Effectiveness Research","short_definition":"Comparative effectiveness research (CER) compares the benefits and harms of different health care options in routine care to show what works best for whom.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:53.947Z"},{"slug":"comparator","canonical_uri":"https://healtheconomics.wiki/concept/comparator","name":"Comparator","short_definition":"A comparator is the alternative, such as current practice or another treatment, against which a new health intervention is compared in economic evaluation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Evaluation Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.19","status":"PUBLISHED","published_at":"2026-10-15T23:53:56.419Z"},{"slug":"comparator-selection","canonical_uri":"https://healtheconomics.wiki/concept/comparator-selection","name":"Comparator Selection","short_definition":"Comparator selection is the HTA step that decides which existing treatments a new technology is compared with, usually current care or what it replaces.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.441Z"},{"slug":"compartmental-model","canonical_uri":"https://healtheconomics.wiki/concept/compartmental-model","name":"Compartmental Model","short_definition":"A compartmental model splits a population into compartments, such as susceptible, infectious and recovered, and uses equations for the flows between them.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:18.050Z"},{"slug":"compassionate-use","canonical_uri":"https://healtheconomics.wiki/concept/compassionate-use","name":"Compassionate Use","short_definition":"Compassionate use is the supply of an unauthorised medicine, outside a trial, to patients with a serious disease and no satisfactory authorised treatment.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Market Access","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Market Access","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:18.069Z"},{"slug":"compensating-variation","canonical_uri":"https://healtheconomics.wiki/concept/compensating-variation","name":"Compensating Variation","short_definition":"Compensating variation (CV) is the sum that restores original utility after a health or policy change: willingness to pay for a gain or to accept a loss.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.438Z"},{"slug":"competence","canonical_uri":"https://healtheconomics.wiki/concept/competence","name":"Competence","short_definition":"Competence is a person's legal authority to make their own decisions, such as consenting to treatment, as distinct from clinical assessment of capacity.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Delivery","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.502Z"},{"slug":"competing-risks","canonical_uri":"https://healtheconomics.wiki/concept/competing-risks","name":"Competing Risks","short_definition":"Competing risks are events that each end a patient's time at risk, such as cardiovascular and other-cause death, so the first to occur rules out the rest.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:18.107Z"},{"slug":"competition-theory","canonical_uri":"https://healtheconomics.wiki/concept/competition-theory","name":"Competition Theory","short_definition":"Competition theory explains how rivalry between firms and market structure shape prices and quality, including in hospital and health insurance markets.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.624Z"},{"slug":"competition-based-pricing","canonical_uri":"https://healtheconomics.wiki/concept/competition-based-pricing","name":"Competition-Based Pricing","short_definition":"Competition-based pricing sets a medicine's price from the prices of rival treatments for the same condition, not from its own cost or added health value.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Drug Pricing","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.563Z"},{"slug":"compliance","canonical_uri":"https://healtheconomics.wiki/concept/compliance","name":"Compliance","short_definition":"Compliance is conformity with a requirement: a patient following a prescribed regimen (now often termed adherence) or a provider meeting legal rules.","category":"Pharmaceutical Care","category_path":"Pharmacy Practice › Pharmaceutical Care › Adherence Support","level_1":"Pharmacy Practice","level_2":"Pharmaceutical Care","level_3":"Adherence Support","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.572Z"},{"slug":"compliance-programme","canonical_uri":"https://healtheconomics.wiki/concept/compliance-programme","name":"Compliance Programme","short_definition":"A compliance programme is the internal system a health care organisation uses to prevent, detect and correct breaches of health care law and payer rules.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Regulation","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Regulation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.174Z"},{"slug":"composite-endpoint","canonical_uri":"https://healtheconomics.wiki/concept/composite-endpoint","name":"Composite Endpoint","short_definition":"A composite endpoint is a trial outcome combining two or more events, such as death or hospitalisation, usually counting a patient once at the first event.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.685Z"},{"slug":"computer-vision-health","canonical_uri":"https://healtheconomics.wiki/concept/computer-vision-health","name":"Computer Vision Health","short_definition":"Computer vision health tools use AI, mostly deep learning, to read medical images such as X-rays, retinal scans and pathology slides to detect disease.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Digital Health","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Digital Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:50:53.503Z"},{"slug":"computerized-order-entry","canonical_uri":"https://healtheconomics.wiki/concept/computerized-order-entry","name":"Computerized Order Entry","short_definition":"Computerized order entry (CPOE) lets clinicians enter medication, test and other orders electronically instead of on paper, often with decision support.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T00:10:16.320Z"},{"slug":"concentration-curve","canonical_uri":"https://healtheconomics.wiki/concept/concentration-curve","name":"Concentration Curve","short_definition":"A concentration curve plots the cumulative share of a health variable against the cumulative share of the population ranked from poorest to richest.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.641Z"},{"slug":"concentration-index","canonical_uri":"https://healtheconomics.wiki/concept/concentration-index","name":"Concentration Index","short_definition":"The concentration index measures socioeconomic inequality in a health variable; a negative value means it is disproportionately held by the poor.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.131Z"},{"slug":"concurrent-control","canonical_uri":"https://healtheconomics.wiki/concept/concurrent-control","name":"Concurrent Control","short_definition":"A concurrent control is a control group drawn from the same population as the treated group and followed over the same period, so time trends affect both.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.836Z"},{"slug":"concurrent-risk-adjustment","canonical_uri":"https://healtheconomics.wiki/concept/concurrent-risk-adjustment","name":"Concurrent Risk Adjustment","short_definition":"Concurrent risk adjustment predicts health care spending for a period from diagnoses recorded in that same period, often to adjust health plan payments.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.021Z"},{"slug":"condition-index","canonical_uri":"https://healtheconomics.wiki/concept/condition-index","name":"Condition Index","short_definition":"A condition index is the ratio of the largest singular value of a scaled regression design matrix to another singular value, used to assess near-linear dependence among predictors.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-01T03:14:55.024Z"},{"slug":"conditional-logic","canonical_uri":"https://healtheconomics.wiki/concept/conditional-logic","name":"Conditional Logic","short_definition":"Conditional logic is the set of if-then rules in a health economic model that make risks, costs or treatment depend on age, time, history or response.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.747Z"},{"slug":"conditional-probability","canonical_uri":"https://healtheconomics.wiki/concept/conditional-probability","name":"Conditional Probability","short_definition":"Conditional probability is the chance of an event given that another has occurred; health economic models use it for branch and transition probabilities.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:25.312Z"},{"slug":"confidence-interval","canonical_uri":"https://healtheconomics.wiki/concept/confidence-interval","name":"Confidence Interval","short_definition":"A confidence interval (CI) is a range around an estimate, such as a cost difference, built so a set share, often 95%, of such ranges hold the true value.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T00:10:16.379Z"},{"slug":"confidence-interval-estimation","canonical_uri":"https://healtheconomics.wiki/concept/confidence-interval-estimation","name":"Confidence Interval Estimation","short_definition":"The statistical process of calculating a range of plausible values for an unknown parameter based on sample data and a specified confidence level.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:32:25.414Z"},{"slug":"confidence-profile-method","canonical_uri":"https://healtheconomics.wiki/concept/confidence-profile-method","name":"Confidence Profile Method","short_definition":"The confidence profile method is a Bayesian method that adjusts studies of varied design for bias and pools them into parameter distributions for HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.695Z"},{"slug":"confidential-pricing","canonical_uri":"https://healtheconomics.wiki/concept/confidential-pricing","name":"Confidential Pricing","short_definition":"Confidential pricing keeps a medicine's negotiated net price secret between manufacturer and payer, while a higher list price stays public.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Drug Pricing","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.762Z"},{"slug":"confidentiality","canonical_uri":"https://healtheconomics.wiki/concept/confidentiality","name":"Confidentiality","short_definition":"Confidentiality is the ethical and legal duty to protect identifiable patient information from disclosure unless there is consent or another lawful basis.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.784Z"},{"slug":"confirmatory-factor-analysis","canonical_uri":"https://healtheconomics.wiki/concept/confirmatory-factor-analysis","name":"Confirmatory Factor Analysis","short_definition":"Confirmatory factor analysis (CFA) tests whether data fit a prespecified model linking health questionnaire items to the latent factors they measure.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.808Z"},{"slug":"confirmatory-trial","canonical_uri":"https://healtheconomics.wiki/concept/confirmatory-trial","name":"Confirmatory Trial","short_definition":"A confirmatory trial is a controlled trial testing pre-set hypotheses to give firm evidence of efficacy or safety, for licensing or after early approval.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Drug Development","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Drug Development","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.868Z"},{"slug":"conflict-of-interest","canonical_uri":"https://healtheconomics.wiki/concept/conflict-of-interest","name":"Conflict of Interest","short_definition":"Conflict of interest is a situation where a secondary interest, such as a manufacturer's payment, risks unduly swaying judgement in research, care or HTA.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Governance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Governance","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.806Z"},{"slug":"confounder","canonical_uri":"https://healtheconomics.wiki/concept/confounder","name":"Confounder","short_definition":"A confounder is a variable, such as disease severity, that affects both the treatment a patient receives and the outcome, biasing unadjusted comparisons.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.092Z"},{"slug":"confounding","canonical_uri":"https://healtheconomics.wiki/concept/confounding","name":"Confounding","short_definition":"Confounding is bias in an estimated treatment effect when a common cause of treatment and outcome mixes the treatment's effect with group differences.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.932Z"},{"slug":"confounding-by-aggregation","canonical_uri":"https://healtheconomics.wiki/concept/confounding-by-aggregation","name":"Confounding by Aggregation","short_definition":"Confounding by aggregation is bias when group-level data, such as regional or trial averages, mix differences between groups into an exposure's effect.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:25.582Z"},{"slug":"confounding-by-indication","canonical_uri":"https://healtheconomics.wiki/concept/confounding-by-indication","name":"Confounding by Indication","short_definition":"Confounding by indication is bias in observational treatment studies arising when the reason a patient is treated also affects their risk of the outcome.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T22:25:38.286Z"},{"slug":"conjoint-analysis","canonical_uri":"https://healtheconomics.wiki/concept/conjoint-analysis","name":"Conjoint Analysis","short_definition":"Conjoint analysis is a family of stated preference methods estimating how people value treatment or service attributes from ratings, rankings or choices.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:18:40.034Z"},{"slug":"consensus-building","canonical_uri":"https://healtheconomics.wiki/concept/consensus-building","name":"Consensus Building","short_definition":"Consensus building is the use of structured group methods, such as Delphi panels, to agree judgements for guidelines and policy when evidence is thin.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T22:25:38.777Z"},{"slug":"constant-hazard","canonical_uri":"https://healtheconomics.wiki/concept/constant-hazard","name":"Constant Hazard","short_definition":"Constant hazard is the survival modelling assumption that the event rate among people still at risk stays the same over time, giving exponential survival.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:25.815Z"},{"slug":"constrained-optimisation","canonical_uri":"https://healtheconomics.wiki/concept/constrained-optimisation","name":"Constrained Optimisation","short_definition":"Constrained optimisation finds the choice that does best on an objective, such as QALYs gained, without breaking limits such as a fixed health budget.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:25.836Z"},{"slug":"construct-validity","canonical_uri":"https://healtheconomics.wiki/concept/construct-validity","name":"Construct Validity","short_definition":"Construct validity is how well a PROM's scores fit hypotheses about it, covering structural validity, hypotheses testing and cross-cultural validity.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:15.992Z"},{"slug":"consumer-choice","canonical_uri":"https://healtheconomics.wiki/concept/consumer-choice","name":"Consumer Choice","short_definition":"Consumer choice is the economic theory of how people choose goods and services, including health care, to best satisfy their preferences within a budget.","category":"Health Policy","category_path":"Health Systems › Health Policy › Policy Analysis","level_1":"Health Systems","level_2":"Health Policy","level_3":"Policy Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.279Z"},{"slug":"consumer-price-index","canonical_uri":"https://healtheconomics.wiki/concept/consumer-price-index","name":"Consumer Price Index","short_definition":"The consumer price index (CPI) measures change in the prices households pay for a fixed basket of goods and services, used to adjust costs for inflation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.116Z"},{"slug":"consumer-surplus","canonical_uri":"https://healtheconomics.wiki/concept/consumer-surplus","name":"Consumer Surplus","short_definition":"Consumer surplus is the most that buyers would pay for a good or service minus what they pay, measured as the area under the demand curve above the price.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:00.989Z"},{"slug":"consumer-directed-health-plan","canonical_uri":"https://healtheconomics.wiki/concept/consumer-directed-health-plan","name":"Consumer-Directed Health Plan","short_definition":"A consumer-directed health plan (CDHP) is a US health plan pairing a high deductible with a tax-favoured account, such as an HSA or HRA, to pay for care.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.055Z"},{"slug":"contact-rate","canonical_uri":"https://healtheconomics.wiki/concept/contact-rate","name":"Contact Rate","short_definition":"Contact rate is the expected number of defined, potentially transmission-relevant encounters an individual has per unit time in an infectious-disease model.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:56.715Z"},{"slug":"contact-tracing","canonical_uri":"https://healtheconomics.wiki/concept/contact-tracing","name":"Contact Tracing","short_definition":"Contact tracing finds and follows up people exposed to an infectious case so they can be tested, treated or quarantined before infecting others.","category":"Health Policy","category_path":"Health Systems › Health Policy › Global Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Global Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.030Z"},{"slug":"contamination","canonical_uri":"https://healtheconomics.wiki/concept/contamination","name":"Contamination","short_definition":"Contamination occurs when trial participants receive the other arm's intervention, usually controls getting the new one, diluting the measured effect.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:38.904Z"},{"slug":"content-validity","canonical_uri":"https://healtheconomics.wiki/concept/content-validity","name":"Content Validity","short_definition":"Content validity is how far a health measure's items are relevant, comprehensive and understood for its construct, target population and context of use.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.176Z"},{"slug":"contingency-table","canonical_uri":"https://healtheconomics.wiki/concept/contingency-table","name":"Contingency Table","short_definition":"A contingency table counts observations cross-classified by two or more categorical variables, such as trial arm by outcome or test result by disease.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.642Z"},{"slug":"contingent-valuation","canonical_uri":"https://healtheconomics.wiki/concept/contingent-valuation","name":"Contingent Valuation","short_definition":"Contingent valuation (CV) is a stated preference survey method asking people what they would pay for, or accept to give up, a described change in health.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.238Z"},{"slug":"contingent-valuation-method","canonical_uri":"https://healtheconomics.wiki/concept/contingent-valuation-method","name":"Contingent Valuation Method","short_definition":"The contingent valuation method elicits a monetary value for a specified nonmarket health-related change by asking people what they would pay or accept in a carefully described hypothetical scenario.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:41.923Z"},{"slug":"continuity-of-care","canonical_uri":"https://healtheconomics.wiki/concept/continuity-of-care","name":"Continuity of Care","short_definition":"Continuity of care is the extent to which a patient's care over time is joined up, through a known clinician, shared information or a consistent plan.","category":"Health Policy","category_path":"Health Systems › Health Policy › Integrated Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Integrated Care","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:18.474Z"},{"slug":"continuous-coverage","canonical_uri":"https://healtheconomics.wiki/concept/continuous-coverage","name":"Continuous Coverage","short_definition":"Continuous coverage is health insurance held with no gap longer than a set limit, often 63 days in US law, which can shorten pre-existing exclusions.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:18.493Z"},{"slug":"continuous-data","canonical_uri":"https://healtheconomics.wiki/concept/continuous-data","name":"Continuous Data","short_definition":"Continuous data are outcomes measured on a numerical scale that can take any value within a range, such as blood pressure, cost or utility.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:40.219Z"},{"slug":"continuous-model","canonical_uri":"https://healtheconomics.wiki/concept/continuous-model","name":"Continuous Model","short_definition":"A continuous model is a decision model run in continuous time rather than fixed cycles, so health events can occur at any moment, governed by rates.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.352Z"},{"slug":"continuous-quality-improvement","canonical_uri":"https://healtheconomics.wiki/concept/continuous-quality-improvement","name":"Continuous Quality Improvement","short_definition":"Continuous quality improvement (CQI) is an approach in which health services use systematic data and repeated tests of change to improve care.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:53:17.931Z"},{"slug":"contract-theory","canonical_uri":"https://healtheconomics.wiki/concept/contract-theory","name":"Contract Theory","short_definition":"Contract theory studies how contracts, such as provider payment rules, can align incentives when actions or information are hidden or cannot be verified.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.111Z"},{"slug":"control-arm","canonical_uri":"https://healtheconomics.wiki/concept/control-arm","name":"Control Arm","short_definition":"A control arm is the trial group given placebo, no treatment, another dose or another treatment, against which outcomes on the new treatment are compared.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.298Z"},{"slug":"control-chart","canonical_uri":"https://healtheconomics.wiki/concept/control-chart","name":"Control Chart","short_definition":"A control chart is a time-series plot of a health service measure with a centre line and control limits that separate routine variation from real change.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T22:25:40.261Z"},{"slug":"control-variates","canonical_uri":"https://healtheconomics.wiki/concept/control-variates","name":"Control Variates","short_definition":"Control variates is a variance reduction method that corrects a Monte Carlo estimate, such as mean cost or QALYs, using a correlated output of known mean.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.171Z"},{"slug":"controllable-cost","canonical_uri":"https://healtheconomics.wiki/concept/controllable-cost","name":"Controllable Cost","short_definition":"Controllable cost is a health service cost that a named budget holder can influence within the budget period, such as ward overtime or agency staffing.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.360Z"},{"slug":"convergence","canonical_uri":"https://healtheconomics.wiki/concept/convergence","name":"Convergence","short_definition":"Convergence is the point at which an MCMC run or other iterative simulation settles on a stable result as the number of iterations increases.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.421Z"},{"slug":"convergent-validity","canonical_uri":"https://healtheconomics.wiki/concept/convergent-validity","name":"Convergent Validity","short_definition":"Convergent validity is evidence that a health measure correlates, as predicted in advance, with other measures of the same or a closely related construct.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.482Z"},{"slug":"conversion-factor","canonical_uri":"https://healtheconomics.wiki/concept/conversion-factor","name":"Conversion Factor","short_definition":"Conversion factor (CF) is the money amount per relative value unit that turns fee schedule relative values, such as Medicare RVUs, into payment amounts.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.526Z"},{"slug":"cooks-distance","canonical_uri":"https://healtheconomics.wiki/concept/cooks-distance","name":"Cook's Distance","short_definition":"Cook's distance is a regression diagnostic measuring how much all fitted values change when one observation, such as one patient's cost record, is removed.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.231Z"},{"slug":"copas-model","canonical_uri":"https://healtheconomics.wiki/concept/copas-model","name":"Copas Model","short_definition":"The Copas model is a selection model for publication bias in meta-analysis that re-estimates the pooled effect under assumed rates of non-publication.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:26.618Z"},{"slug":"copayment","canonical_uri":"https://healtheconomics.wiki/concept/copayment","name":"Copayment","short_definition":"A copayment (copay) is a fixed amount an insured person pays for a covered health service, such as USD 20 per visit, unlike percentage-based coinsurance.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.543Z"},{"slug":"copd-assessment-test","canonical_uri":"https://healtheconomics.wiki/concept/copd-assessment-test","name":"COPD Assessment Test","short_definition":"COPD Assessment Test (CAT) is an eight-item patient questionnaire, scored 0 to 40, on how COPD affects health status, used in trials and GOLD assessment.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.543Z"},{"slug":"core-outcome-set","canonical_uri":"https://healtheconomics.wiki/concept/core-outcome-set","name":"Core Outcome Set","short_definition":"Core outcome set (COS) is the agreed minimum set of outcomes all trials in a condition should measure and report, so results can be compared and combined.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.536Z"},{"slug":"core-outcome-set-development","canonical_uri":"https://healtheconomics.wiki/concept/core-outcome-set-development","name":"Core Outcome Set Development","short_definition":"Core outcome set development is the consensus study, usually a review, Delphi and meeting, agreeing what trials in a condition should measure and report.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-17T15:03:09.338Z"},{"slug":"correlation","canonical_uri":"https://healtheconomics.wiki/concept/correlation","name":"Correlation","short_definition":"Correlation is how strongly two variables move together or in opposite directions, such as costs and QALYs, without showing that one causes the other.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.604Z"},{"slug":"correlation-coefficient","canonical_uri":"https://healtheconomics.wiki/concept/correlation-coefficient","name":"Correlation Coefficient","short_definition":"A correlation coefficient is a statistic from -1 to +1 giving the direction and strength of association between paired variables, such as costs and QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.665Z"},{"slug":"correlation-matrix","canonical_uri":"https://healtheconomics.wiki/concept/correlation-matrix","name":"Correlation Matrix","short_definition":"A correlation matrix is a square table containing the pairwise correlation coefficients among a set of variables.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:18.687Z"},{"slug":"cost","canonical_uri":"https://healtheconomics.wiki/concept/cost","name":"Cost","short_definition":"In health economics, cost is the value of resources used by a healthcare intervention, measured as the benefit forgone from their best alternative use.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.2.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.727Z"},{"slug":"cost-accounting","canonical_uri":"https://healtheconomics.wiki/concept/cost-accounting","name":"Cost Accounting","short_definition":"Cost accounting is the recording of a health care provider's costs and their assignment to departments, activities and services to produce unit costs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.788Z"},{"slug":"cost-allocation","canonical_uri":"https://healtheconomics.wiki/concept/cost-allocation","name":"Cost Allocation","short_definition":"Cost allocation is the sharing of overhead and other indirect costs among health services or patients by a stated rule, such as bed-days or staff time.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.848Z"},{"slug":"cost-analysis","canonical_uri":"https://healtheconomics.wiki/concept/cost-analysis","name":"Cost Analysis","short_definition":"Cost analysis is a partial economic evaluation that compares the costs of two or more healthcare alternatives without measuring their health outcomes.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.910Z"},{"slug":"cost-containment","canonical_uri":"https://healtheconomics.wiki/concept/cost-containment","name":"Cost Containment","short_definition":"Cost containment is the use of policies such as budget caps, payment controls and patient charges to hold down the level or growth of health spending.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Expenditure","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Expenditure","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:16.970Z"},{"slug":"cost-driver","canonical_uri":"https://healtheconomics.wiki/concept/cost-driver","name":"Cost Driver","short_definition":"A cost driver is a factor that causes a health service's costs to change over a period, such as patient visits, bed-days, staff time or case mix.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:27.140Z"},{"slug":"cost-function","canonical_uri":"https://healtheconomics.wiki/concept/cost-function","name":"Cost Function","short_definition":"A cost function is the relationship between output, input prices and the lowest cost of production, used to study hospital scale, scope and efficiency.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:18.860Z"},{"slug":"cost-measurement","canonical_uri":"https://healtheconomics.wiki/concept/cost-measurement","name":"Cost Measurement","short_definition":"Cost measurement is the step in economic evaluation that counts the resources each alternative uses, such as GP visits or bed-days, before they are valued.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Resource Measurement","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Resource Measurement","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.212Z"},{"slug":"cost-minimisation","canonical_uri":"https://healtheconomics.wiki/concept/cost-minimisation","name":"Cost Minimisation","short_definition":"An approach to selecting among interventions already shown to produce equivalent outcomes, in which the choice reduces to the lowest-cost option.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:32:27.392Z"},{"slug":"cost-per-qaly","canonical_uri":"https://healtheconomics.wiki/concept/cost-per-qaly","name":"Cost per QALY","short_definition":"Cost per QALY gained is the extra cost of a treatment compared with an alternative, divided by the quality-adjusted life years (QALYs) it adds.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Utility Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Utility Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:18.937Z"},{"slug":"cost-sharing","canonical_uri":"https://healtheconomics.wiki/concept/cost-sharing","name":"Cost Sharing","short_definition":"Cost sharing is the part of the cost of covered care that an insured patient pays directly, through deductibles, co-payments or coinsurance, not premiums.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.598Z"},{"slug":"cost-shifting","canonical_uri":"https://healtheconomics.wiki/concept/cost-shifting","name":"Cost Shifting","short_definition":"Cost shifting is the transfer of health care costs from one payer or sector to another, as when hospitals raise private prices after public payment cuts.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Expenditure","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Expenditure","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.273Z"},{"slug":"cost-valuation","canonical_uri":"https://healtheconomics.wiki/concept/cost-valuation","name":"Cost Valuation","short_definition":"Cost valuation is the assignment of monetary values to measured resource use in accordance with a specified perspective, setting, price year, and decision purpose.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.334Z"},{"slug":"cost-based-pricing","canonical_uri":"https://healtheconomics.wiki/concept/cost-based-pricing","name":"Cost-Based Pricing","short_definition":"Cost-based pricing sets the price of a medicine from its research and development, manufacturing, regulatory and overhead costs plus a profit margin.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Drug Pricing","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:26.995Z"},{"slug":"cost-based-reimbursement","canonical_uri":"https://healtheconomics.wiki/concept/cost-based-reimbursement","name":"Cost-Based Reimbursement","short_definition":"Cost-based reimbursement is a provider payment method in which a payer pays a hospital or other provider the costs it incurred, settled after care.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.309Z"},{"slug":"cost-benefit-analysis","canonical_uri":"https://healtheconomics.wiki/concept/cost-benefit-analysis","name":"Cost-Benefit Analysis","short_definition":"Cost-benefit analysis values the costs and benefits of healthcare options in money, so they can be compared by their net benefit, usually to society.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.5.22","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.372Z"},{"slug":"cost-consequence-analysis","canonical_uri":"https://healtheconomics.wiki/concept/cost-consequence-analysis","name":"Cost-Consequence Analysis","short_definition":"Cost-consequence analysis sets out the costs and each separate outcome of healthcare options side by side, without combining them into one result.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Evaluation Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Evaluation Methods","evidence_level":"high","version":"1.5.27","status":"PUBLISHED","published_at":"2026-10-15T23:53:56.976Z"},{"slug":"cost-effectiveness","canonical_uri":"https://healtheconomics.wiki/concept/cost-effectiveness","name":"Cost-Effectiveness","short_definition":"Cost-effectiveness means an intervention's health gain justifies any extra cost versus an alternative, usually judged by the ICER against a threshold.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.031Z"},{"slug":"ceac","canonical_uri":"https://healtheconomics.wiki/concept/ceac","name":"Cost-Effectiveness Acceptability Curve (CEAC)","short_definition":"A cost-effectiveness acceptability curve (CEAC) plots, across cost-effectiveness thresholds, the probability that each option is the most cost-effective.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.14","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.660Z"},{"slug":"ceaf","canonical_uri":"https://healtheconomics.wiki/concept/ceaf","name":"Cost-Effectiveness Acceptability Frontier","short_definition":"The cost-effectiveness acceptability frontier (CEAF) plots the chance the option with the highest expected net benefit is cost-effective, by threshold.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:13.723Z"},{"slug":"cost-effectiveness-analysis","canonical_uri":"https://healtheconomics.wiki/concept/cost-effectiveness-analysis","name":"Cost-Effectiveness Analysis","short_definition":"Cost-effectiveness analysis compares healthcare options by the extra cost of each extra unit of health gained, such as cost per life-year gained.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.5.76","status":"PUBLISHED","published_at":"2026-10-15T00:58:18.822Z"},{"slug":"cost-effectiveness-frontier","canonical_uri":"https://healtheconomics.wiki/concept/cost-effectiveness-frontier","name":"Cost-Effectiveness Frontier","short_definition":"The cost-effectiveness frontier joins the strategies not ruled out by strict or extended dominance on a plot of expected cost against health effect.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.092Z"},{"slug":"cost-effectiveness-league-table","canonical_uri":"https://healtheconomics.wiki/concept/cost-effectiveness-league-table","name":"Cost-Effectiveness League Table","short_definition":"A cost-effectiveness league table ranks health care interventions by cost per QALY or a similar ratio so decision makers can compare value for money.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.513Z"},{"slug":"cost-effectiveness-plane","canonical_uri":"https://healtheconomics.wiki/concept/cost-effectiveness-plane","name":"Cost-Effectiveness Plane","short_definition":"The cost-effectiveness plane graphs incremental cost (y-axis) against incremental effect (x-axis); its four quadrants show dominance or a trade-off.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.18","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.533Z"},{"slug":"cost-effectiveness-threshold","canonical_uri":"https://healtheconomics.wiki/concept/cost-effectiveness-threshold","name":"Cost-Effectiveness Threshold","short_definition":"A cost-effectiveness threshold is the maximum cost per QALY gained that a health system treats as value for money when deciding which treatments to fund.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Decision Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Decision Analysis","evidence_level":"high","version":"1.2.17","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.152Z"},{"slug":"cost-minimisation-analysis","canonical_uri":"https://healtheconomics.wiki/concept/cost-minimisation-analysis","name":"Cost-Minimisation Analysis","short_definition":"Cost-minimisation analysis compares only the costs of healthcare options, and is valid only when evidence shows their health outcomes are equivalent.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Evaluation Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Evaluation Methods","evidence_level":"high","version":"1.5.24","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.592Z"},{"slug":"cost-of-illness-study","canonical_uri":"https://healtheconomics.wiki/concept/cost-of-illness-study","name":"Cost-of-Illness Study","short_definition":"A cost-of-illness study estimates the economic burden of a disease, including healthcare costs, patient and carer costs, and lost productivity.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-of-Illness","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-of-Illness","evidence_level":"high","version":"1.5.16","status":"PUBLISHED","published_at":"2026-10-17T20:34:52.574Z"},{"slug":"cost-plus-pricing","canonical_uri":"https://healtheconomics.wiki/concept/cost-plus-pricing","name":"Cost-Plus Pricing","short_definition":"Cost-plus pricing sets the price of a medicine or health product as its estimated unit cost plus a profit mark-up, either a percentage or a fixed amount.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Drug Pricing","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.381Z"},{"slug":"cost-to-charge-ratio","canonical_uri":"https://healtheconomics.wiki/concept/cost-to-charge-ratio","name":"Cost-to-Charge Ratio","short_definition":"The cost-to-charge ratio (CCR) is a hospital's reported costs divided by its billed charges, used to estimate costs from the charges on patient records.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Healthcare Payment","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Healthcare Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.454Z"},{"slug":"cost-utility-analysis","canonical_uri":"https://healtheconomics.wiki/concept/cost-utility-analysis","name":"Cost-Utility Analysis","short_definition":"Cost-utility analysis is an economic evaluation that measures health gains in quality-adjusted life years (QALYs) and reports cost per QALY gained.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Utility Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Utility Analysis","evidence_level":"high","version":"1.5.33","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.147Z"},{"slug":"country-specific-value-set","canonical_uri":"https://healtheconomics.wiki/concept/country-specific-value-set","name":"Country-Specific Value Set","short_definition":"A country-specific value set is a set of utility weights, elicited from one country's general public, that turns EQ-5D or similar responses into utilities.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-13T23:32:27.694Z"},{"slug":"coverage-decision","canonical_uri":"https://healtheconomics.wiki/concept/coverage-decision","name":"Coverage Decision","short_definition":"A coverage decision is a payer's or HTA body's formal ruling on whether a health technology will be funded, for which patients and on what conditions.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.395Z"},{"slug":"coverage-error","canonical_uri":"https://healtheconomics.wiki/concept/coverage-error","name":"Coverage Error","short_definition":"Coverage error arises when the sampling frame of a health survey or register misses part of the target population or includes people outside it.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.456Z"},{"slug":"coverage-expansion","canonical_uri":"https://healtheconomics.wiki/concept/coverage-expansion","name":"Coverage Expansion","short_definition":"Coverage expansion is a policy change that extends health cover to more people, adds services or cuts cost sharing, moving towards universal coverage.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.814Z"},{"slug":"coverage-gap","canonical_uri":"https://healtheconomics.wiki/concept/coverage-gap","name":"Coverage Gap","short_definition":"A coverage gap is a band of drug spending that a plan covers little or not at all, best known as the Medicare Part D doughnut hole, which ended in 2025.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T23:53:57.201Z"},{"slug":"coverage-policy","canonical_uri":"https://healtheconomics.wiki/concept/coverage-policy","name":"Coverage Policy","short_definition":"Coverage policy is the set of rules a health payer uses to decide which services and technologies it funds, for whom and what share of the cost it meets.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.516Z"},{"slug":"cox-proportional-hazards","canonical_uri":"https://healtheconomics.wiki/concept/cox-proportional-hazards","name":"Cox Proportional Hazards","short_definition":"The Cox proportional hazards model is a semi-parametric survival regression that estimates hazard ratios without specifying the baseline hazard.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.578Z"},{"slug":"cox-snell-residual","canonical_uri":"https://healtheconomics.wiki/concept/cox-snell-residual","name":"Cox-Snell Residual","short_definition":"A Cox-Snell residual is a survival model's fitted cumulative hazard at a patient's observed time, used to check overall fit against a unit exponential.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:01.895Z"},{"slug":"cream-skimming","canonical_uri":"https://healtheconomics.wiki/concept/cream-skimming","name":"Cream Skimming","short_definition":"Cream skimming is when an insurer or provider attracts people expected to cost less than it is paid for them and deters those expected to cost more.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:32:27.986Z"},{"slug":"credence-good","canonical_uri":"https://healtheconomics.wiki/concept/credence-good","name":"Credence Good","short_definition":"A credence good is a good or service whose quality or need a buyer cannot judge even after use, such as medical care, where the expert seller knows more.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-13T23:32:28.009Z"},{"slug":"credentialing","canonical_uri":"https://healtheconomics.wiki/concept/credentialing","name":"Credentialing","short_definition":"Credentialing is how a hospital or health insurer verifies a clinician's licence, certification and disciplinary record before they treat its patients.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Regulation","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Regulation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T23:53:57.239Z"},{"slug":"credibility-assessment","canonical_uri":"https://healtheconomics.wiki/concept/credibility-assessment","name":"Credibility Assessment","short_definition":"An overall evaluation of whether a model's structure, evidence base, and validation results provide enough confidence to inform a real decision.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.261Z"},{"slug":"credible-interval","canonical_uri":"https://healtheconomics.wiki/concept/credible-interval","name":"Credible Interval","short_definition":"A credible interval is a Bayesian range that contains an unknown parameter, such as a treatment effect, with a stated posterior probability, often 95%.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.640Z"},{"slug":"credible-interval-estimation","canonical_uri":"https://healtheconomics.wiki/concept/credible-interval-estimation","name":"Credible Interval Estimation","short_definition":"The Bayesian process of calculating a range of plausible values for a parameter based on its estimated posterior probability distribution.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.279Z"},{"slug":"criterion-validity","canonical_uri":"https://healtheconomics.wiki/concept/criterion-validity","name":"Criterion Validity","short_definition":"Criterion validity is the degree to which a measure's scores agree with a gold standard for the same concept, assessed at the same time or later.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.701Z"},{"slug":"critical-appraisal","canonical_uri":"https://healtheconomics.wiki/concept/critical-appraisal","name":"Critical Appraisal","short_definition":"Critical appraisal is the structured judgement of whether a study, model or economic evaluation is sound and relevant enough to inform a health decision.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.763Z"},{"slug":"critical-value","canonical_uri":"https://healtheconomics.wiki/concept/critical-value","name":"Critical Value","short_definition":"A critical value is a cutoff on a test statistic's reference distribution that defines a rejection boundary for a specified hypothesis test and error level.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:57.295Z"},{"slug":"cross-cultural-validity","canonical_uri":"https://healtheconomics.wiki/concept/cross-cultural-validity","name":"Cross-Cultural Validity","short_definition":"Cross-cultural validity is how far items in a translated or culturally adapted health questionnaire, such as the EQ-5D, perform like the original version.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.700Z"},{"slug":"cross-price-elasticity","canonical_uri":"https://healtheconomics.wiki/concept/cross-price-elasticity","name":"Cross-Price Elasticity","short_definition":"Cross-price elasticity measures how demand for one good responds to a change in another good's price: positive for substitutes, negative for complements.","category":"Health Policy","category_path":"Health Systems › Health Policy › Policy Analysis","level_1":"Health Systems","level_2":"Health Policy","level_3":"Policy Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.355Z"},{"slug":"cross-sectional-design","canonical_uri":"https://healtheconomics.wiki/concept/cross-sectional-design","name":"Cross-Sectional Design","short_definition":"A cross-sectional design is an observational design that measures exposure and outcome in a population at one point in time, often to estimate prevalence.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.825Z"},{"slug":"cross-validation","canonical_uri":"https://healtheconomics.wiki/concept/cross-validation","name":"Cross-Validation","short_definition":"Cross-validation estimates how well a prediction model, such as a cost or risk model, will perform on new data by testing it on data held out from fitting.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T22:25:43.174Z"},{"slug":"crossover-design","canonical_uri":"https://healtheconomics.wiki/concept/crossover-design","name":"Crossover Design","short_definition":"Crossover design is a clinical trial design in which each participant receives two or more treatments in a randomised order and acts as their own control.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.887Z"},{"slug":"crossover-trial","canonical_uri":"https://healtheconomics.wiki/concept/crossover-trial","name":"Crossover Trial","short_definition":"A trial in which participants sequentially receive two or more treatments under comparison, with each participant's response compared against their own.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.412Z"},{"slug":"crosswalk","canonical_uri":"https://healtheconomics.wiki/concept/crosswalk","name":"Crosswalk","short_definition":"A statistical mapping converting health state scores from one version of an instrument to an equivalent score on another version.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T20:50:57.770Z"},{"slug":"crowding-out","canonical_uri":"https://healtheconomics.wiki/concept/crowding-out","name":"Crowding Out","short_definition":"Crowding out occurs when public spending or intervention displaces private activity that would have happened anyway, reducing the programme's net effect.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Policy","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Policy","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.431Z"},{"slug":"cubic-spline","canonical_uri":"https://healtheconomics.wiki/concept/cubic-spline","name":"Cubic Spline","short_definition":"A cubic spline is a smooth curve made of cubic polynomial pieces joined at knots, used in health economics to fit flexible survival and hazard curves.","category":"Numerical Analysis","category_path":"Computer Science › Numerical Analysis › Interpolation","level_1":"Computer Science","level_2":"Numerical Analysis","level_3":"Interpolation","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:17.949Z"},{"slug":"cumulative-hazard","canonical_uri":"https://healtheconomics.wiki/concept/cumulative-hazard","name":"Cumulative Hazard","short_definition":"Cumulative hazard, H(t), is the hazard rate summed over time in survival models. Survival equals exp(-H(t)), and unlike a probability H(t) can exceed 1.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.682Z"},{"slug":"cumulative-incidence","canonical_uri":"https://healtheconomics.wiki/concept/cumulative-incidence","name":"Cumulative Incidence","short_definition":"Cumulative incidence, or risk, is the proportion of people free of an event at the start of a period who have it by the end, such as a 5-year stroke risk.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.469Z"},{"slug":"cumulative-meta-analysis","canonical_uri":"https://healtheconomics.wiki/concept/cumulative-meta-analysis","name":"Cumulative Meta-Analysis","short_definition":"Cumulative meta-analysis is a meta-analysis repeated as each new study is added, usually by date, showing how the pooled effect and its uncertainty evolve.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.488Z"},{"slug":"cure-fraction","canonical_uri":"https://healtheconomics.wiki/concept/cure-fraction","name":"Cure Fraction","short_definition":"The cure fraction is the proportion of patients a survival model expects never to die from their disease, the level at which relative survival plateaus.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.010Z"},{"slug":"cure-fraction-model","canonical_uri":"https://healtheconomics.wiki/concept/cure-fraction-model","name":"Cure Fraction Model","short_definition":"A survival model separating a population into a cured subgroup facing only background mortality and an uncured subgroup remaining at risk of the disease event.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:32:28.579Z"},{"slug":"cure-model","canonical_uri":"https://healtheconomics.wiki/concept/cure-model","name":"Cure Model","short_definition":"A cure model is a survival model in which disease-related excess mortality falls to zero for a share of patients, so the survival curve levels off.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.071Z"},{"slug":"cure-rate-model","canonical_uri":"https://healtheconomics.wiki/concept/cure-rate-model","name":"Cure Rate Model","short_definition":"A cure rate model is a survival model that estimates the cure fraction and survival of uncured patients, used in HTA to extrapolate long-term survival.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.132Z"},{"slug":"curve-fitting","canonical_uri":"https://healtheconomics.wiki/concept/curve-fitting","name":"Curve Fitting","short_definition":"Curve fitting is estimating a mathematical function's parameters to match observed data, as when survival curves are fitted to trial data and extrapolated.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.192Z"},{"slug":"cycle","canonical_uri":"https://healtheconomics.wiki/concept/cycle","name":"Cycle","short_definition":"A cycle is a defined time interval during which a discrete-time state-transition model updates health-state occupancy and accumulates relevant outcomes and costs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:32:28.852Z"},{"slug":"cycle-length","canonical_uri":"https://healtheconomics.wiki/concept/cycle-length","name":"Cycle Length","short_definition":"Cycle length is the duration of one cycle in a Markov or other discrete-time state-transition model, such as a month or a year, set before the model runs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.252Z"},{"slug":"d-efficient-design","canonical_uri":"https://healtheconomics.wiki/concept/d-efficient-design","name":"D-Efficient Design","short_definition":"A D-efficient design is a discrete choice experiment design chosen for low D-error, giving precise preference estimates under an assumed model.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-13T23:32:28.956Z"},{"slug":"daly-calculation-method","canonical_uri":"https://healtheconomics.wiki/concept/daly-calculation-method","name":"DALY Calculation Method","short_definition":"The methodology used to compute disability-adjusted life years, combining years of life lost to premature death with years lived with disability, weighted by severity.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Disability-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Disability-Adjusted Life Years","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.641Z"},{"slug":"data-analytics","canonical_uri":"https://healtheconomics.wiki/concept/data-analytics","name":"Data Analytics","short_definition":"Data analytics is the use of statistical and computational methods on health data to describe what happened, predict outcomes and guide decisions.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T22:25:39.820Z"},{"slug":"data-envelopment-analysis","canonical_uri":"https://healtheconomics.wiki/concept/data-envelopment-analysis","name":"Data Envelopment Analysis","short_definition":"Data envelopment analysis (DEA) is a linear programming method that scores hospitals and other health care units on technical efficiency against peers.","category":"Health Policy","category_path":"Health Systems › Health Policy › Productivity Measurement","level_1":"Health Systems","level_2":"Health Policy","level_3":"Productivity Measurement","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.697Z"},{"slug":"data-exclusivity","canonical_uri":"https://healtheconomics.wiki/concept/data-exclusivity","name":"Data Exclusivity","short_definition":"Data exclusivity is the period after a medicine's first approval in which generic or biosimilar applicants may not rely on the originator's trial data.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Intellectual Property","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Intellectual Property","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.373Z"},{"slug":"data-extraction","canonical_uri":"https://healtheconomics.wiki/concept/data-extraction","name":"Data Extraction","short_definition":"Data extraction is the recording of study details and results on a structured form for use in a systematic review, meta-analysis or economic model.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.434Z"},{"slug":"data-governance","canonical_uri":"https://healtheconomics.wiki/concept/data-governance","name":"Data Governance","short_definition":"Data governance is the set of rules, roles and controls that decides who may access and use health data, for what purpose and under which safeguards.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Digital Health","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:02.182Z"},{"slug":"data-mining","canonical_uri":"https://healtheconomics.wiki/concept/data-mining","name":"Data Mining","short_definition":"Data mining is the computational search of large health datasets, such as claims or patient records, for patterns that were not specified in advance.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.754Z"},{"slug":"data-pooling","canonical_uri":"https://healtheconomics.wiki/concept/data-pooling","name":"Data Pooling","short_definition":"Data pooling is the statistical combining of results from several studies into one summary estimate, usually weighting each study by its precision.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.495Z"},{"slug":"data-quality","canonical_uri":"https://healtheconomics.wiki/concept/data-quality","name":"Data Quality","short_definition":"Data quality is the fitness of data for a specific use in health research or HTA, judged by completeness, accuracy, consistency, timeliness and relevance.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.555Z"},{"slug":"data-safety-monitoring-board","canonical_uri":"https://healtheconomics.wiki/concept/data-safety-monitoring-board","name":"Data Safety Monitoring Board","short_definition":"Data Safety Monitoring Board (DSMB) is an independent committee that reviews unblinded interim trial data and advises whether to continue, change or stop.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.616Z"},{"slug":"data-security","canonical_uri":"https://healtheconomics.wiki/concept/data-security","name":"Data Security","short_definition":"Data security is the set of technical, physical and administrative safeguards that keep health data confidential, unaltered and available when needed.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T23:53:57.464Z"},{"slug":"days-in-accounts-receivable","canonical_uri":"https://healtheconomics.wiki/concept/days-in-accounts-receivable","name":"Days in Accounts Receivable","short_definition":"Days in accounts receivable (AR days) is a provider's net receivables divided by average daily net patient revenue, giving days of revenue still unpaid.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.758Z"},{"slug":"de-identification","canonical_uri":"https://healtheconomics.wiki/concept/de-identification","name":"De-Identification","short_definition":"De-identification is the removal or alteration of identifiers in health data, such as names, exact dates and postcodes, to lower re-identification risk.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:02.321Z"},{"slug":"deadweight-loss","canonical_uri":"https://healtheconomics.wiki/concept/deadweight-loss","name":"Deadweight Loss","short_definition":"Deadweight loss is the net loss of total surplus when a tax, subsidy, market power or insurance drives a wedge between price and marginal cost.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.832Z"},{"slug":"death-spiral","canonical_uri":"https://healtheconomics.wiki/concept/death-spiral","name":"Death Spiral","short_definition":"A death spiral is a cycle in which rising health insurance premiums drive lower-risk members out, raising the pool's average cost and the next premium.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:02.361Z"},{"slug":"decentralization","canonical_uri":"https://healtheconomics.wiki/concept/decentralization","name":"Decentralization","short_definition":"Decentralization is the transfer of authority over health financing, purchasing or delivery from central government to regional, local or other bodies.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Models","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Models","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-13T23:32:29.646Z"},{"slug":"decision","canonical_uri":"https://healtheconomics.wiki/concept/decision","name":"Decision","short_definition":"A decision in health economics is a choice between alternative uses of health care resources, such as funding a technology, informed by evidence.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":null,"version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.676Z"},{"slug":"decision-aid","canonical_uri":"https://healtheconomics.wiki/concept/decision-aid","name":"Decision Aid","short_definition":"A decision aid is a tool that helps patients choose between treatment or screening options by setting out benefits and harms and clarifying their values.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Delivery","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.829Z"},{"slug":"decision-algorithm","canonical_uri":"https://healtheconomics.wiki/concept/decision-algorithm","name":"Decision Algorithm","short_definition":"A decision algorithm is a fixed sequence of explicit rules that turns evidence into a decision, such as an outcome-level HTA benefit grade or a test order.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.737Z"},{"slug":"decision-criteria","canonical_uri":"https://healtheconomics.wiki/concept/decision-criteria","name":"Decision Criteria","short_definition":"Decision criteria are the factors an HTA body weighs in a funding recommendation, such as clinical benefit, cost-effectiveness and severity.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.798Z"},{"slug":"decision-curve-analysis","canonical_uri":"https://healtheconomics.wiki/concept/decision-curve-analysis","name":"Decision Curve Analysis","short_definition":"Decision curve analysis (DCA) plots the net benefit of a prediction model or test across risk thresholds against treating all or no patients.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.904Z"},{"slug":"decision-fatigue-concept","canonical_uri":"https://healtheconomics.wiki/concept/decision-fatigue-concept","name":"Decision Fatigue Concept","short_definition":"The decision fatigue concept holds that decision quality falls after a long run of choices, as when clinicians treat patients differently late in a shift.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:02.460Z"},{"slug":"decision-making","canonical_uri":"https://healtheconomics.wiki/concept/decision-making","name":"Decision Making","short_definition":"Decision making in health care is the process by which payers, HTA bodies and clinicians choose between options using evidence, costs, criteria and values.","category":"Health Policy","category_path":"Health Systems › Health Policy › Policy Analysis","level_1":"Health Systems","level_2":"Health Policy","level_3":"Policy Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.858Z"},{"slug":"decision-node","canonical_uri":"https://healtheconomics.wiki/concept/decision-node","name":"Decision Node","short_definition":"A decision node is a point in a decision tree, drawn as a square, where the decision maker chooses between options and no probabilities are attached.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.918Z"},{"slug":"decision-problem","canonical_uri":"https://healtheconomics.wiki/concept/decision-problem","name":"Decision Problem","short_definition":"A decision problem is the choice an economic evaluation or model must inform, stated as population, options compared, outcomes, costs and decision maker.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Decision Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Decision Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.867Z"},{"slug":"decision-rule","canonical_uri":"https://healtheconomics.wiki/concept/decision-rule","name":"Decision Rule","short_definition":"A decision rule is an explicit criterion, such as an ICER threshold or net benefit, for choosing between healthcare interventions in economic evaluation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.5.12","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.979Z"},{"slug":"decision-support","canonical_uri":"https://healtheconomics.wiki/concept/decision-support","name":"Decision Support","short_definition":"Decision support is software or a structured tool that gives clinicians or patients relevant evidence when a health care choice is being made.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Digital Health","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:19.924Z"},{"slug":"decision-tree","canonical_uri":"https://healtheconomics.wiki/concept/decision-tree","name":"Decision Tree","short_definition":"A decision tree is a branching model used in economic evaluation: strategies, chance events and end points give each option's expected costs and QALYs.","category":"Model Structures","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.15","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.040Z"},{"slug":"decision-tree-model","canonical_uri":"https://healtheconomics.wiki/concept/decision-tree-model","name":"Decision Tree Model","short_definition":"A decision-analytic model built on the decision tree structure, with all possible patient pathways explicitly represented as branches to calculate expected cost.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:32:29.997Z"},{"slug":"decision-uncertainty","canonical_uri":"https://healtheconomics.wiki/concept/decision-uncertainty","name":"Decision Uncertainty","short_definition":"Decision uncertainty is the probability that the option preferred on current evidence is not the best, given uncertainty in costs and health effects.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.101Z"},{"slug":"decommissioning","canonical_uri":"https://healtheconomics.wiki/concept/decommissioning","name":"Decommissioning","short_definition":"Decommissioning is the formal step that ends funding or provision of a health service or technology, in full or for some patients, once judged low value.","category":"Health Policy","category_path":"Health Systems › Health Policy › Horizon Scanning","level_1":"Health Systems","level_2":"Health Policy","level_3":"Horizon Scanning","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.161Z"},{"slug":"deductible","canonical_uri":"https://healtheconomics.wiki/concept/deductible","name":"Deductible","short_definition":"A deductible is the amount an insured person must pay for covered health care in a period before the insurance plan starts to pay its share.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.222Z"},{"slug":"deep-learning-health","canonical_uri":"https://healtheconomics.wiki/concept/deep-learning-health","name":"Deep Learning Health","short_definition":"Deep learning health, or deep learning in health care, uses many-layered neural networks on images, records and text for diagnosis and risk prediction.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Digital Health","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.527Z"},{"slug":"default-effect-concept","canonical_uri":"https://healtheconomics.wiki/concept/default-effect-concept","name":"Default Effect","short_definition":"The default effect is the tendency to stay with a pre-selected option, so opt-out schemes for organ donation or HIV testing raise uptake over opt-in.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:20.065Z"},{"slug":"degrees-of-freedom","canonical_uri":"https://healtheconomics.wiki/concept/degrees-of-freedom","name":"Degrees of Freedom","short_definition":"Degrees of freedom (df) count values left free to vary after estimation and set the t, chi-squared or F curve for tests in trials and meta-analyses.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:57.631Z"},{"slug":"deliberative-process","canonical_uri":"https://healtheconomics.wiki/concept/deliberative-process","name":"Deliberative Process","short_definition":"A deliberative process is structured group discussion where experts and stakeholders weigh evidence and values to guide HTA or priority-setting decisions.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:20.104Z"},{"slug":"delphi-method","canonical_uri":"https://healtheconomics.wiki/concept/delphi-method","name":"Delphi Method","short_definition":"The Delphi method is an expert survey run in anonymous rounds with group feedback, used in health economics to agree judgements or estimate model inputs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.282Z"},{"slug":"delta-method","canonical_uri":"https://healtheconomics.wiki/concept/delta-method","name":"Delta Method","short_definition":"The delta method approximates the variance of a function of estimated parameters, such as an ICER or mean survival, using a first-order Taylor expansion.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.598Z"},{"slug":"demand","canonical_uri":"https://healtheconomics.wiki/concept/demand","name":"Demand","short_definition":"Demand is the schedule of quantities of a good or service, such as health care, that people are willing and able to buy at each price over a given period.","category":"Health Policy","category_path":"Health Systems › Health Policy › Policy Analysis","level_1":"Health Systems","level_2":"Health Policy","level_3":"Policy Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:09.982Z"},{"slug":"demand-curve","canonical_uri":"https://healtheconomics.wiki/concept/demand-curve","name":"Demand Curve","short_definition":"A demand curve shows how much of a good or service, such as health care, is demanded at each price, other factors held fixed. It usually slopes downward.","category":"Health Policy","category_path":"Health Systems › Health Policy › Policy Analysis","level_1":"Health Systems","level_2":"Health Policy","level_3":"Policy Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.055Z"},{"slug":"demand-for-health","canonical_uri":"https://healtheconomics.wiki/concept/demand-for-health","name":"Demand for Health","short_definition":"Demand for health is the idea, from the Grossman model, that people value health as a capital stock, so their demand for healthcare is derived from it.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.22","status":"PUBLISHED","published_at":"2026-10-15T00:58:20.142Z"},{"slug":"demand-forecasting","canonical_uri":"https://healtheconomics.wiki/concept/demand-forecasting","name":"Demand Forecasting","short_definition":"Demand forecasting projects future use of health services and medicines, and the staff needed, from past utilisation, population change and other drivers.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Capacity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Capacity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.128Z"},{"slug":"demand-inducement","canonical_uri":"https://healtheconomics.wiki/concept/demand-inducement","name":"Demand Inducement","short_definition":"Demand inducement is a provider's use of an information advantage to shift a patient's demand for care away from the patient's best interests.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:02.680Z"},{"slug":"departure-process","canonical_uri":"https://healtheconomics.wiki/concept/departure-process","name":"Departure Process","short_definition":"Departure process is the pattern of times at which patients leave a clinic, ward or other stage of care in a queueing model or discrete event simulation.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Discrete Event Simulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Discrete Event Simulation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.324Z"},{"slug":"dependent-censoring","canonical_uri":"https://healtheconomics.wiki/concept/dependent-censoring","name":"Dependent Censoring","short_definition":"Dependent censoring occurs when the chance of being censored is linked to a patient's risk of the event, so standard survival estimates can be biased.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.343Z"},{"slug":"derived-demand-for-healthcare","canonical_uri":"https://healtheconomics.wiki/concept/derived-demand-for-healthcare","name":"Derived Demand for Healthcare","short_definition":"Derived demand for healthcare is the idea that people want medical care mainly as an input for producing health, the thing they actually value.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.202Z"},{"slug":"descriptive-epidemiology","canonical_uri":"https://healtheconomics.wiki/concept/descriptive-epidemiology","name":"Descriptive Epidemiology","short_definition":"Descriptive epidemiology describes how disease is distributed by person, place and time, supplying the counts, rates and trends used in health economics.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-11T19:31:56.452Z"},{"slug":"descriptive-statistics","canonical_uri":"https://healtheconomics.wiki/concept/descriptive-statistics","name":"Descriptive Statistics","short_definition":"Descriptive statistics summarise the centre, spread and shape of data, such as skewed patient costs, whose arithmetic mean sets the total budget.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:02.761Z"},{"slug":"design-effect","canonical_uri":"https://healtheconomics.wiki/concept/design-effect","name":"Design Effect","short_definition":"The design effect (DEFF) is the ratio of an estimate's variance under a clustered or complex sample to that under a simple random sample of equal size.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:02.781Z"},{"slug":"detection-bias","canonical_uri":"https://healtheconomics.wiki/concept/detection-bias","name":"Detection Bias","short_definition":"Detection bias is systematic error from unequal finding, measuring or judging of outcomes between study groups, often because assessors know allocation.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:20.293Z"},{"slug":"deterministic-model","canonical_uri":"https://healtheconomics.wiki/concept/deterministic-model","name":"Deterministic Model","short_definition":"A deterministic model is a health economic model with no random elements, so the same inputs always give the same costs, QALYs and ICER.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.404Z"},{"slug":"deterministic-sensitivity-analysis","canonical_uri":"https://healtheconomics.wiki/concept/deterministic-sensitivity-analysis","name":"Deterministic Sensitivity Analysis","short_definition":"Deterministic sensitivity analysis (DSA) reruns a health economic model with chosen inputs set to fixed values to see how results and decisions change.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.464Z"},{"slug":"development-assistance-for-health","canonical_uri":"https://healtheconomics.wiki/concept/development-assistance-for-health","name":"Development Assistance for Health","short_definition":"Development assistance for health (DAH) is the grants, loans and in-kind aid for health that development agencies give to low- and middle-income countries.","category":"Health Policy","category_path":"Health Systems › Health Policy › Global Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Global Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T23:53:57.743Z"},{"slug":"deviance-residual","canonical_uri":"https://healtheconomics.wiki/concept/deviance-residual","name":"Deviance Residual","short_definition":"A deviance residual is a signed measure of how poorly a generalised linear or survival model fits each patient; in a GLM its squares sum to the deviance.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.274Z"},{"slug":"devolution","canonical_uri":"https://healtheconomics.wiki/concept/devolution","name":"Devolution","short_definition":"Devolution is the transfer of formal responsibility and power over health services from central government to elected regional or local governments.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Models","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Models","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.669Z"},{"slug":"dfle-calculation","canonical_uri":"https://healtheconomics.wiki/concept/dfle-calculation","name":"DFLE Calculation","short_definition":"The process of computing disability-free life expectancy using a life table combining age-specific mortality rates with age-specific disability prevalence.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:20.388Z"},{"slug":"diabetes-complications","canonical_uri":"https://healtheconomics.wiki/concept/diabetes-complications","name":"Diabetes Complications","short_definition":"Long-term health consequences of poorly controlled diabetes, including cardiovascular disease, kidney disease, nerve damage, and eye disease.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Diabetes","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Diabetes","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:02.901Z"},{"slug":"diagnosis-related-group","canonical_uri":"https://healtheconomics.wiki/concept/diagnosis-related-group","name":"Diagnosis Related Group","short_definition":"A diagnosis related group (DRG) is a category of inpatient stays with similar diagnoses, procedures and expected costs, used to pay or fund hospitals.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.583Z"},{"slug":"diagnosis-based-risk-score","canonical_uri":"https://healtheconomics.wiki/concept/diagnosis-based-risk-score","name":"Diagnosis-Based Risk Score","short_definition":"A diagnosis-based risk score uses a person's recorded diagnoses and demographics to predict their healthcare costs relative to a population average.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.730Z"},{"slug":"diagnostic-accuracy","canonical_uri":"https://healtheconomics.wiki/concept/diagnostic-accuracy","name":"Diagnostic Accuracy","short_definition":"Diagnostic accuracy is how well a test agrees with a reference standard in detecting a target condition, usually reported as sensitivity and specificity.","category":"Health Economics","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.643Z"},{"slug":"diagnostic-model","canonical_uri":"https://healtheconomics.wiki/concept/diagnostic-model","name":"Diagnostic Model","short_definition":"A diagnostic model is a multivariable prediction model estimating the probability a condition is present now, to guide testing, referral and treatment.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.704Z"},{"slug":"diagnostic-safety","canonical_uri":"https://healtheconomics.wiki/concept/diagnostic-safety","name":"Diagnostic Safety","short_definition":"Diagnostic safety is avoiding harm and wasted care from missed, delayed or wrong diagnoses, through correct, timely diagnoses explained to patients.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.764Z"},{"slug":"difference-in-differences","canonical_uri":"https://healtheconomics.wiki/concept/difference-in-differences","name":"Difference-in-Differences","short_definition":"Difference-in-differences (DiD) estimates a policy's causal effect by comparing outcome changes over time in an exposed group and a comparison group.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.346Z"},{"slug":"differential-discounting","canonical_uri":"https://healtheconomics.wiki/concept/differential-discounting","name":"Differential Discounting","short_definition":"Differential discounting applies a lower annual discount rate to future health effects, such as QALYs, than to future costs in an economic evaluation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Discounting","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Discounting","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.417Z"},{"slug":"differential-pricing","canonical_uri":"https://healtheconomics.wiki/concept/differential-pricing","name":"Differential Pricing","short_definition":"Differential pricing is charging different prices for the same patented medicine in different markets, typically lower where ability to pay is lower.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Drug Pricing","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.741Z"},{"slug":"diffusion","canonical_uri":"https://healtheconomics.wiki/concept/diffusion","name":"Diffusion","short_definition":"Diffusion in health economics is the spread of a new technology's use among eligible patients and providers over time, shaping costs and health gains.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Budget Impact Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Budget Impact Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.812Z"},{"slug":"diffusion-of-innovation","canonical_uri":"https://healtheconomics.wiki/concept/diffusion-of-innovation","name":"Diffusion of Innovation","short_definition":"Diffusion of innovation is Rogers' theory of how new treatments and practices spread through a health system over time, via communication and imitation.","category":"Health Policy","category_path":"Health Systems › Health Policy › Systems Strengthening","level_1":"Health Systems","level_2":"Health Policy","level_3":"Systems Strengthening","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.886Z"},{"slug":"digital-adoption","canonical_uri":"https://healtheconomics.wiki/concept/digital-adoption","name":"Digital Adoption","short_definition":"Digital adoption is the uptake and continued use of a digital health technology by patients, carers, clinicians or the organisations that provide care.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T01:02:54.748Z"},{"slug":"digital-divide","canonical_uri":"https://healtheconomics.wiki/concept/digital-divide","name":"Digital Divide","short_definition":"The digital divide is the gap between people who can access, use and benefit from digital technology and those who cannot, often along social lines.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T01:02:54.814Z"},{"slug":"digital-equity","canonical_uri":"https://healtheconomics.wiki/concept/digital-equity","name":"Digital Equity","short_definition":"Digital equity in health is fair access to digital health care, with the devices, connection and skills to use it, and fair outcomes across social groups.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T01:02:54.877Z"},{"slug":"digital-evidence-framework","canonical_uri":"https://healtheconomics.wiki/concept/digital-evidence-framework","name":"Digital Evidence Framework","short_definition":"A digital evidence framework sets the evidence a digital health technology should show before it is bought, scaled to its clinical and financial risk.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:03.042Z"},{"slug":"digital-health","canonical_uri":"https://healtheconomics.wiki/concept/digital-health","name":"Digital Health","short_definition":"Digital health is the use of digital technologies, such as apps, wearables, telemedicine and AI, to improve health and the delivery of health care.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:24:07.348Z"},{"slug":"digital-implementation","canonical_uri":"https://healtheconomics.wiki/concept/digital-implementation","name":"Digital Implementation","short_definition":"Digital implementation is the work of putting a digital health technology into routine care with workflow redesign, integration, training and governance.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T23:53:57.892Z"},{"slug":"digital-interoperability","canonical_uri":"https://healtheconomics.wiki/concept/digital-interoperability","name":"Digital Interoperability","short_definition":"Digital interoperability is the ability of different digital health systems to exchange data and use it with a shared meaning, without manual re-entry.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T01:02:55.133Z"},{"slug":"digital-therapeutic","canonical_uri":"https://healtheconomics.wiki/concept/digital-therapeutic","name":"Digital Therapeutic","short_definition":"A digital therapeutic (DTx) is health software that treats or alleviates a disease by delivering a medical intervention of proven therapeutic benefit.","category":"Health Policy","category_path":"Health Systems › Health Policy › Digital Health","level_1":"Health Systems","level_2":"Health Policy","level_3":"Digital Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T01:02:55.197Z"},{"slug":"diminishing-returns","canonical_uri":"https://healtheconomics.wiki/concept/diminishing-returns","name":"Diminishing Returns","short_definition":"Diminishing returns is the eventual fall in extra health from each added unit of care, such as another screening round, when other inputs stay fixed.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T01:02:55.261Z"},{"slug":"direct-cost","canonical_uri":"https://healtheconomics.wiki/concept/direct-cost","name":"Direct Cost","short_definition":"Direct cost is a cost traced to a service or patient or, in economic evaluation, resources used for care or due to illness, such as medicines and travel.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T01:02:55.324Z"},{"slug":"direct-elicitation","canonical_uri":"https://healtheconomics.wiki/concept/direct-elicitation","name":"Direct Elicitation","short_definition":"Direct elicitation is the valuation of a health state by asking people to trade it against life years or risk of death, rather than through a value set.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.397Z"},{"slug":"dirichlet-distribution","canonical_uri":"https://healtheconomics.wiki/concept/dirichlet-distribution","name":"Dirichlet Distribution","short_definition":"The Dirichlet distribution is a multivariate distribution for proportions that sum to one, used for uncertain transition probabilities from a model state.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:19.948Z"},{"slug":"disability-weight","canonical_uri":"https://healtheconomics.wiki/concept/disability-weight","name":"Disability Weight","short_definition":"A disability weight is a value from 0 (full health) to 1 (equivalent to death) rating health loss in a non-fatal state, used to calculate YLDs and DALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Disability-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Disability-Adjusted Life Years","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.489Z"},{"slug":"daly","canonical_uri":"https://healtheconomics.wiki/concept/daly","name":"Disability-Adjusted Life Year","short_definition":"The disability-adjusted life year (DALY) measures health loss by adding years of life lost to premature death and years lived with disability.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Disability-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Disability-Adjusted Life Years","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:18.312Z"},{"slug":"discount-rate","canonical_uri":"https://healtheconomics.wiki/concept/discount-rate","name":"Discount Rate","short_definition":"The discount rate is the annual rate, such as NICE's 3.5%, used in economic evaluation to convert future costs and health outcomes into present values.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Discounting","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Discounting","evidence_level":"high","version":"1.5.25","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.009Z"},{"slug":"discounting","canonical_uri":"https://healtheconomics.wiki/concept/discounting","name":"Discounting","short_definition":"Discounting converts future costs and health effects, such as QALYs, into present values so that options with different timings can be compared.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Discounting","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Discounting","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:03.204Z"},{"slug":"discrete-choice-experiment","canonical_uri":"https://healtheconomics.wiki/concept/discrete-choice-experiment","name":"Discrete Choice Experiment","short_definition":"A discrete choice experiment, or DCE, presents respondents with repeated sets of hypothetical alternatives described by attributes and asks them to select a preferred option.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T15:03:09.458Z"},{"slug":"discrete-data","canonical_uri":"https://healtheconomics.wiki/concept/discrete-data","name":"Discrete Data","short_definition":"Discrete data are values that can only be counted in whole steps, such as the number of hospital admissions, GP visits or exacerbations per patient.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.966Z"},{"slug":"discrete-event-simulation","canonical_uri":"https://healtheconomics.wiki/concept/discrete-event-simulation","name":"Discrete Event Simulation","short_definition":"Discrete event simulation (DES) is a modelling method that follows each patient from event to event over time, tracking their history and use of resources.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Discrete Event Simulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Discrete Event Simulation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-13T23:57:42.704Z"},{"slug":"discrete-model","canonical_uri":"https://healtheconomics.wiki/concept/discrete-model","name":"Discrete Model","short_definition":"A discrete model represents at least one aspect of a system through distinct states, events, or time steps, allowing changes to be analysed as transitions among those elements rather than solely as continuously varying quantities.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:20.882Z"},{"slug":"discriminant-validity","canonical_uri":"https://healtheconomics.wiki/concept/discriminant-validity","name":"Discriminant Validity","short_definition":"Discriminant validity is evidence that a health measure correlates less with measures of other constructs than with its own, as predicted in advance.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.070Z"},{"slug":"disease-free-survival","canonical_uri":"https://healtheconomics.wiki/concept/disease-free-survival","name":"Disease-Free Survival","short_definition":"Disease-free survival (DFS) is the time from randomisation until cancer recurrence or death from any cause, an endpoint of adjuvant trials and models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.104Z"},{"slug":"distribution-fitting","canonical_uri":"https://healtheconomics.wiki/concept/distribution-fitting","name":"Distribution Fitting","short_definition":"Distribution fitting selects a probability distribution and estimates its parameters from data to represent the frequency of possible values under stated assumptions.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:21.221Z"},{"slug":"distribution-based-mid","canonical_uri":"https://healtheconomics.wiki/concept/distribution-based-mid","name":"Distribution-Based MID","short_definition":"A distribution-based MID is a minimal important difference estimated from score spread or instrument reliability, such as half a standard deviation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.131Z"},{"slug":"distributional-cost-effectiveness","canonical_uri":"https://healtheconomics.wiki/concept/distributional-cost-effectiveness","name":"Distributional Cost-Effectiveness","short_definition":"Distributional cost-effectiveness analysis (DCEA) is an economic evaluation showing who gains and loses health from a policy and its effect on inequality.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.192Z"},{"slug":"disutility","canonical_uri":"https://healtheconomics.wiki/concept/disutility","name":"Disutility","short_definition":"Disutility is the loss of utility caused by a health state, adverse event or treatment, measured from a stated baseline and used to reduce QALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.560Z"},{"slug":"dlqi","canonical_uri":"https://healtheconomics.wiki/concept/dlqi","name":"DLQI","short_definition":"DLQI is a ten-question skin-specific quality of life questionnaire scored 0 to 30, used in dermatology trials and NICE appraisals to define response.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.161Z"},{"slug":"dominance","canonical_uri":"https://healtheconomics.wiki/concept/dominance","name":"Dominance","short_definition":"Dominance in cost-effectiveness analysis excludes an option when another option, or a blend of two others, is no worse on cost or effect and better on one.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.15","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.254Z"},{"slug":"dominance-analysis","canonical_uri":"https://healtheconomics.wiki/concept/dominance-analysis","name":"Dominance Analysis","short_definition":"Dominance analysis identifies interventions that are inferior to another feasible option or to the efficient combination of options on cost and health outcome, leaving a frontier for fully incremental comparison.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:50:55.881Z"},{"slug":"dose-response","canonical_uri":"https://healtheconomics.wiki/concept/dose-response","name":"Dose Response","short_definition":"Dose response is the relationship between the amount of a drug or exposure and the size or probability of its effect, used in dose selection and HTA.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Drug Therapy","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Drug Therapy","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.318Z"},{"slug":"drg-creep","canonical_uri":"https://healtheconomics.wiki/concept/drg-creep","name":"DRG Creep","short_definition":"DRG creep is a rise in recorded hospital case mix, and so in DRG payments, that comes from coding changes rather than from sicker or more complex patients.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.380Z"},{"slug":"drug-pricing","canonical_uri":"https://healtheconomics.wiki/concept/drug-pricing","name":"Drug Pricing","short_definition":"The setting and negotiation of medicine prices and payments across a specified product, purchaser, market and point in the supply chain.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Drug Pricing","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:21.507Z"},{"slug":"dynamic-model","canonical_uri":"https://healtheconomics.wiki/concept/dynamic-model","name":"Dynamic Model","short_definition":"A model representing how a system's variables change over time in response to feedback and interaction among components, unlike a static model.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:21.624Z"},{"slug":"dynamic-programming-health","canonical_uri":"https://healtheconomics.wiki/concept/dynamic-programming-health","name":"Dynamic Programming Health","short_definition":"An optimisation technique solving complex sequential decision problems by breaking them into smaller, nested subproblems solved in relation to one another.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:58.603Z"},{"slug":"dynamic-transmission-model","canonical_uri":"https://healtheconomics.wiki/concept/dynamic-transmission-model","name":"Dynamic Transmission Model","short_definition":"A dynamic transmission model represents how an infectious disease spreads through a population while the risk of infection changes with the number and characteristics of infectious people.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:58.621Z"},{"slug":"early-health-technology-assessment","canonical_uri":"https://healtheconomics.wiki/concept/early-health-technology-assessment","name":"Early Health Technology Assessment","short_definition":"The assessment of a health technology during development to inform design, evidence generation, pricing and market-access strategy.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:39.580Z"},{"slug":"ecog-performance-status","canonical_uri":"https://healtheconomics.wiki/concept/ecog-performance-status","name":"ECOG Performance Status","short_definition":"ECOG Performance Status is a clinician-rated six-grade scale of a cancer patient's functioning, grade 5 being death, used for trial eligibility and models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.263Z"},{"slug":"economic-evaluation","canonical_uri":"https://healtheconomics.wiki/concept/economic-evaluation","name":"Economic Evaluation","short_definition":"Economic evaluation, often called health economic evaluation, compares the costs and outcomes of healthcare options to judge which offers the best value.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Evaluation Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Evaluation Methods","evidence_level":"high","version":"1.4.60","status":"PUBLISHED","published_at":"2026-10-15T00:58:21.763Z"},{"slug":"economically-justifiable-price","canonical_uri":"https://healtheconomics.wiki/concept/economically-justifiable-price","name":"Economically Justifiable Price","short_definition":"The economically justifiable price (EJP) is the top price a manufacturer can defend on cost-effectiveness grounds at a given payer's threshold.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Pharmaceutical Economics","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Pharmaceutical Economics","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-13T23:57:42.969Z"},{"slug":"effect-size","canonical_uri":"https://healtheconomics.wiki/concept/effect-size","name":"Effect Size","short_definition":"An effect size is a measure of the magnitude of an association or intervention effect for a specified outcome, comparator, population, and scale.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:21.936Z"},{"slug":"effect-size-estimation","canonical_uri":"https://healtheconomics.wiki/concept/effect-size-estimation","name":"Effect Size Estimation","short_definition":"The statistical process of calculating a quantitative measure of a treatment effect's magnitude, often standardised to allow comparison across differing measurement scales.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:42.023Z"},{"slug":"effective-reproduction-number","canonical_uri":"https://healtheconomics.wiki/concept/effective-reproduction-number","name":"Effective Reproduction Number","short_definition":"The average number of secondary infections from one infected person in a population not entirely susceptible, accounting for existing immunity or control measures.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:50:57.203Z"},{"slug":"effective-sample-size","canonical_uri":"https://healtheconomics.wiki/concept/effective-sample-size","name":"Effective Sample Size","short_definition":"The sample size a simple random sample would need to match the precision of an actual sample from a more complex design, such as clustered.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:04.006Z"},{"slug":"effectiveness","canonical_uri":"https://healtheconomics.wiki/concept/effectiveness","name":"Effectiveness","short_definition":"The benefits and harms an intervention produces under care conditions relevant to a specified population, comparator, outcome and time horizon.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:40.680Z"},{"slug":"efficiency","canonical_uri":"https://healtheconomics.wiki/concept/efficiency","name":"Efficiency","short_definition":"Efficiency is getting the most health or other valued outcomes from scarce healthcare resources, avoiding waste and allocating them to their best uses.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.18","status":"PUBLISHED","published_at":"2026-10-14T23:52:04.067Z"},{"slug":"efficiency-frontier","canonical_uri":"https://healtheconomics.wiki/concept/efficiency-frontier","name":"Efficiency Frontier","short_definition":"In cost-effectiveness analysis, an efficiency frontier connects the available strategies that remain after excluding options subject to simple or extended dominance.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:50:57.395Z"},{"slug":"efficiency-index","canonical_uri":"https://healtheconomics.wiki/concept/efficiency-index","name":"Efficiency Index","short_definition":"An efficiency index is one number comparing the resources a hospital or health system uses with its outputs, against peers, national costs or a frontier.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Productivity Measurement","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Productivity Measurement","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.737Z"},{"slug":"efficient-design","canonical_uri":"https://healtheconomics.wiki/concept/efficient-design","name":"Efficient Design","short_definition":"An experimental design built to maximise the statistical information obtained from a given number of choice tasks.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T20:50:57.707Z"},{"slug":"egger-test","canonical_uri":"https://healtheconomics.wiki/concept/egger-test","name":"Egger Test","short_definition":"The Egger test is a regression test of funnel plot asymmetry, used in meta-analysis to detect small-study effects that may signal publication bias.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.470Z"},{"slug":"eigenvalue","canonical_uri":"https://healtheconomics.wiki/concept/eigenvalue","name":"Eigenvalue","short_definition":"An eigenvalue describes how a matrix scales a particular direction without changing that direction.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:58.827Z"},{"slug":"elastic-demand","canonical_uri":"https://healtheconomics.wiki/concept/elastic-demand","name":"Elastic Demand","short_definition":"Elastic demand is demand whose price elasticity exceeds one in absolute value, so a price rise, such as a health tax, cuts total spending on the product.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.543Z"},{"slug":"electronic-health-record","canonical_uri":"https://healtheconomics.wiki/concept/electronic-health-record","name":"Electronic Health Record","short_definition":"A digital, longitudinal record of a person’s health information maintained for care and, where permitted, shared or reused across authorised settings and purposes.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:22.092Z"},{"slug":"enbs-calculation","canonical_uri":"https://healtheconomics.wiki/concept/enbs-calculation","name":"ENBS Calculation","short_definition":"ENBS calculation scales a study's per-person EVSI to the population who could benefit, then subtracts its fixed, per-participant and opportunity costs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.616Z"},{"slug":"eortc-qlq-c30","canonical_uri":"https://healtheconomics.wiki/concept/eortc-qlq-c30","name":"EORTC QLQ-C30","short_definition":"EORTC QLQ-C30 is the 30-item core cancer quality of life questionnaire, whose answers can be mapped to EQ-5D or scored with the QLU-C10D for QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.227Z"},{"slug":"eortc-qlu-c10d","canonical_uri":"https://healtheconomics.wiki/concept/eortc-qlu-c10d","name":"EORTC QLU-C10D","short_definition":"EORTC QLU-C10D is a cancer-specific preference-based measure that scores 13 QLQ-C30 items with national value sets to give utilities for QALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-17T15:03:09.158Z"},{"slug":"epds","canonical_uri":"https://healtheconomics.wiki/concept/epds","name":"EPDS","short_definition":"EPDS is a ten-item self-report scale scored 0 to 30 that screens for depression in pregnancy and after birth, used in trials and screening models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.885Z"},{"slug":"eq-5d-3l-value-set","canonical_uri":"https://healtheconomics.wiki/concept/eq-5d-3l-value-set","name":"EQ-5D-3L Value Set","short_definition":"EQ-5D-3L value sets are utility weights, elicited from a population's health state valuations, that score all 243 EQ-5D-3L states for QALY calculation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:25.504Z"},{"slug":"eq-5d-5l-value-set","canonical_uri":"https://healtheconomics.wiki/concept/eq-5d-5l-value-set","name":"EQ-5D-5L Value Set","short_definition":"EQ-5D-5L value set is a scoring algorithm, estimated from a general public valuation study, that gives each of the 3,125 EQ-5D-5L states a QALY utility.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:25.561Z"},{"slug":"eq-hwb","canonical_uri":"https://healtheconomics.wiki/concept/eq-hwb","name":"EQ-HWB","short_definition":"EQ-HWB is the EQ Health and Wellbeing measure, a 25-item questionnaire for patients, social care users and carers used in economic evaluation.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.117Z"},{"slug":"eq-hwb-s","canonical_uri":"https://healtheconomics.wiki/concept/eq-hwb-s","name":"EQ-HWB-S","short_definition":"EQ-HWB-S, renamed EQ-HWB-9, is the nine-item short form of the EQ Health and Wellbeing measure, with a UK pilot value set giving utilities for QALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-17T15:03:09.093Z"},{"slug":"equilibrium","canonical_uri":"https://healtheconomics.wiki/concept/equilibrium","name":"Equilibrium","short_definition":"Equilibrium is a state in which economic forces balance, as when demand for health care equals supply, so no one has reason to change prices or plans.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.690Z"},{"slug":"equilibrium-price","canonical_uri":"https://healtheconomics.wiki/concept/equilibrium-price","name":"Equilibrium Price","short_definition":"An equilibrium price is the price at which quantity demanded equals quantity supplied in a specified market under the model's stated conditions.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:04.485Z"},{"slug":"equipoise","canonical_uri":"https://healtheconomics.wiki/concept/equipoise","name":"Equipoise","short_definition":"Equipoise is genuine uncertainty among informed experts about which treatment in a trial is better, the usual ethical test for randomising patients.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:22.492Z"},{"slug":"equity","canonical_uri":"https://healtheconomics.wiki/concept/equity","name":"Equity","short_definition":"Equity is fairness in how health, healthcare and its financing are distributed: equal treatment for equal need, and appropriately more for greater need.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.22","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.503Z"},{"slug":"equity-analysis","canonical_uri":"https://healtheconomics.wiki/concept/equity-analysis","name":"Equity Analysis","short_definition":"An assessment of whether the distribution of health, access, or financing burden across a population is fair, distinct from merely equal.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:04.525Z"},{"slug":"equity-efficiency-trade-off","canonical_uri":"https://healtheconomics.wiki/concept/equity-efficiency-trade-off","name":"Equity-Efficiency Trade-off","short_definition":"The equity-efficiency trade-off is the total health given up for a fairer distribution when the option that maximises health is not the fairest one.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.634Z"},{"slug":"equity-weighted-analysis","canonical_uri":"https://healtheconomics.wiki/concept/equity-weighted-analysis","name":"Equity-Weighted Analysis","short_definition":"Equity-weighted analysis is a cost-effectiveness analysis in which health gains for priority groups, such as the severely ill, are weighted more heavily.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.708Z"},{"slug":"equivalence-trial","canonical_uri":"https://healtheconomics.wiki/concept/equivalence-trial","name":"Equivalence Trial","short_definition":"An equivalence trial tests whether two treatments differ by less than a preset margin either way, evidence used to justify cost-minimisation analysis.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.764Z"},{"slug":"equivalent-variation","canonical_uri":"https://healtheconomics.wiki/concept/equivalent-variation","name":"Equivalent Variation","short_definition":"Equivalent variation (EV) is the income change, made instead of a price, health or policy change, that leaves a person as well off as that change would.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:04.566Z"},{"slug":"euler-method","canonical_uri":"https://healtheconomics.wiki/concept/euler-method","name":"Euler Method","short_definition":"The Euler method is a first-order numerical procedure that approximates the solution of an initial-value ordinary differential equation by advancing from the current value along the derivative over discrete steps.","category":"Differential Equations","category_path":"Computer Science › Differential Equations › Numerical ODE Methods","level_1":"Computer Science","level_2":"Differential Equations","level_3":"Numerical ODE Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:50:59.021Z"},{"slug":"event-probability","canonical_uri":"https://healtheconomics.wiki/concept/event-probability","name":"Event Probability","short_definition":"An event probability is the chance that a specified event occurs in a defined population or risk set over a stated time interval.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:22.643Z"},{"slug":"event-queue","canonical_uri":"https://healtheconomics.wiki/concept/event-queue","name":"Event Queue","short_definition":"An event queue is the time-ordered collection of pending events that a discrete-event simulation processes to advance its clock and update system states.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Discrete Event Simulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Discrete Event Simulation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:59.357Z"},{"slug":"event-free-survival","canonical_uri":"https://healtheconomics.wiki/concept/event-free-survival","name":"Event-Free Survival","short_definition":"Event-free survival is the time from a specified starting point to the first event in a prespecified endpoint, with incomplete event-free follow-up handled according to the study's censoring rules.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:50:59.117Z"},{"slug":"evidence","canonical_uri":"https://healtheconomics.wiki/concept/evidence","name":"Evidence","short_definition":"Evidence is the information from studies, routine data and expert judgement used in health economics to estimate costs and outcomes of decision options.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.563Z"},{"slug":"adaptation","canonical_uri":"https://healtheconomics.wiki/concept/adaptation","name":"Evidence Adaptation","short_definition":"Evidence adaptation is modifying an economic evaluation from one country or setting so that it reflects another setting's costs, practice and population.","category":"Economic Methods","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.127Z"},{"slug":"evidence-synthesis","canonical_uri":"https://healtheconomics.wiki/concept/evidence-synthesis","name":"Evidence Synthesis","short_definition":"The structured integration and appraisal of findings from multiple studies to answer a defined question while accounting for comparability, bias and uncertainty.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:22.834Z"},{"slug":"evidence-table","canonical_uri":"https://healtheconomics.wiki/concept/evidence-table","name":"Evidence Table","short_definition":"An evidence table is a structured table setting out the design, participants, interventions, outcomes, results and quality of each study in a review.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:22.854Z"},{"slug":"evidence-based-decision-making","canonical_uri":"https://healtheconomics.wiki/concept/evidence-based-decision-making","name":"Evidence-Based Decision Making","short_definition":"Evidence-based decision making is the systematic use of the best research evidence, with values and context, to make health policy and coverage decisions.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:24.020Z"},{"slug":"exchangeable-correlation","canonical_uri":"https://healtheconomics.wiki/concept/exchangeable-correlation","name":"Exchangeable Correlation","short_definition":"Exchangeable correlation is a GEE working correlation in which all observations in a cluster, such as patients in a practice, share a common correlation.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.835Z"},{"slug":"expanded-disability-status-scale","canonical_uri":"https://healtheconomics.wiki/concept/expanded-disability-status-scale","name":"Expanded Disability Status Scale","short_definition":"Expanded Disability Status Scale (EDSS) is a clinician-rated 0 to 10 scale of multiple sclerosis disability, often used to set health states in MS models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.152Z"},{"slug":"expected-net-benefit","canonical_uri":"https://healtheconomics.wiki/concept/expected-net-benefit","name":"Expected Net Benefit","short_definition":"Expected net benefit is the mean net benefit of a healthcare option across parameter uncertainty at a set threshold; the option with the highest is chosen.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Decision Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Decision Analysis","evidence_level":"high","version":"1.2.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.742Z"},{"slug":"expected-net-benefit-of-sampling","canonical_uri":"https://healtheconomics.wiki/concept/expected-net-benefit-of-sampling","name":"Expected Net Benefit of Sampling","short_definition":"Expected net benefit of sampling (ENBS) is a proposed study's population expected value of sample information minus its expected total cost.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:54.884Z"},{"slug":"expected-utility","canonical_uri":"https://healtheconomics.wiki/concept/expected-utility","name":"Expected Utility","short_definition":"Expected utility is the probability-weighted average of the utilities assigned to an uncertain option's possible outcomes, used to rank choices under risk when preferences satisfy the required axioms.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:23.046Z"},{"slug":"expected-value","canonical_uri":"https://healtheconomics.wiki/concept/expected-value","name":"Expected Value","short_definition":"Expected value is the probability-weighted mean of an uncertain outcome, such as a cost or QALY total, across all its possible values.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:18:40.104Z"},{"slug":"expected-value-analysis","canonical_uri":"https://healtheconomics.wiki/concept/expected-value-analysis","name":"Expected Value Analysis","short_definition":"Expected value analysis compares health care options under uncertainty by their probability-weighted average outcomes, such as expected costs and QALYs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.802Z"},{"slug":"evppi","canonical_uri":"https://healtheconomics.wiki/concept/evppi","name":"Expected Value of Partial Perfect Information","short_definition":"Expected value of partial perfect information (EVPPI) is the expected gain in net benefit from knowing selected model parameters exactly before deciding.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.683Z"},{"slug":"evpi","canonical_uri":"https://healtheconomics.wiki/concept/evpi","name":"Expected Value of Perfect Information","short_definition":"Expected value of perfect information (EVPI) is the expected gain from removing all uncertainty in a funding decision, the upper limit on research value.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.623Z"},{"slug":"evsi","canonical_uri":"https://healtheconomics.wiki/concept/evsi","name":"Expected Value of Sample Information","short_definition":"Expected value of sample information (EVSI) is the expected net benefit gained by deciding after a specific proposed study reports instead of deciding now.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:22.874Z"},{"slug":"experience-rating","canonical_uri":"https://healtheconomics.wiki/concept/experience-rating","name":"Experience Rating","short_definition":"Experience rating sets health insurance premiums from the insured group's or person's own past claims, so buyers with costlier claims histories pay more.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.909Z"},{"slug":"experimental-design","canonical_uri":"https://healtheconomics.wiki/concept/experimental-design","name":"Experimental Design","short_definition":"Experimental design is the planning of how a trial or choice experiment assigns interventions or attributes so their effects can be estimated without bias.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:39.982Z"},{"slug":"explanatory-trial","canonical_uri":"https://healtheconomics.wiki/concept/explanatory-trial","name":"Explanatory Trial","short_definition":"An explanatory trial is a randomised trial run under ideal, tightly controlled conditions to test whether a treatment can work, so it measures efficacy.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T02:26:45.450Z"},{"slug":"exploratory-factor-analysis","canonical_uri":"https://healtheconomics.wiki/concept/exploratory-factor-analysis","name":"Exploratory Factor Analysis","short_definition":"Exploratory factor analysis is a latent-variable method that examines whether correlations among observed variables can be represented by a smaller, initially unspecified set of common factors.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:43.213Z"},{"slug":"exponential-distribution","canonical_uri":"https://healtheconomics.wiki/concept/exponential-distribution","name":"Exponential Distribution","short_definition":"A probability distribution characterised by a constant hazard rate over time, used to model event timing when risk is assumed not to change.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:00.165Z"},{"slug":"exponential-model","canonical_uri":"https://healtheconomics.wiki/concept/exponential-model","name":"Exponential Model","short_definition":"A survival model assuming time-to-event data follow an exponential distribution, implying a constant hazard rate throughout the modelled time horizon.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:00.184Z"},{"slug":"extended-cost-effectiveness","canonical_uri":"https://healtheconomics.wiki/concept/extended-cost-effectiveness","name":"Extended Cost-Effectiveness","short_definition":"Extended cost-effectiveness analysis (ECEA) is an economic evaluation that reports a policy's health gains, financial protection and costs by income group.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:40.055Z"},{"slug":"extended-dominance","canonical_uri":"https://healtheconomics.wiki/concept/extended-dominance","name":"Extended Dominance","short_definition":"Extended dominance excludes an option in cost-effectiveness analysis when a blend of a less and a more effective option gives its health gain for less.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.13","status":"PUBLISHED","published_at":"2026-10-13T23:51:00.242Z"},{"slug":"external-reference-pricing","canonical_uri":"https://healtheconomics.wiki/concept/external-reference-pricing","name":"External Reference Pricing","short_definition":"A medicine-pricing policy that uses prices for the same or comparable product in other jurisdictions as benchmarks for a domestic price or reimbursement decision.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Drug Pricing","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:23.160Z"},{"slug":"externality","canonical_uri":"https://healtheconomics.wiki/concept/externality","name":"Externality","short_definition":"An externality is a cost or benefit, such as antimicrobial resistance or herd immunity, that falls on third parties and is ignored by the person deciding.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.12","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.863Z"},{"slug":"extrapolation","canonical_uri":"https://healtheconomics.wiki/concept/extrapolation","name":"Extrapolation","short_definition":"Extrapolation projects outcomes beyond the range or follow-up directly observed in the available evidence.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:53:59.577Z"},{"slug":"f-distribution","canonical_uri":"https://healtheconomics.wiki/concept/f-distribution","name":"F-Distribution","short_definition":"The F distribution describes the ratio of two independent variance estimates and underlies F tests on cost and outcome regressions in health economics.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:40.127Z"},{"slug":"fact-g","canonical_uri":"https://healtheconomics.wiki/concept/fact-g","name":"FACT-G","short_definition":"FACT-G is a 27-item cancer quality of life questionnaire used as a trial outcome, whose scores need mapping or the FACT-8D before they can inform QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.216Z"},{"slug":"factor-analysis","canonical_uri":"https://healtheconomics.wiki/concept/factor-analysis","name":"Factor Analysis","short_definition":"Factor analysis explains correlations among observed variables using a smaller number of unobserved latent factors.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:23.313Z"},{"slug":"factor-loading","canonical_uri":"https://healtheconomics.wiki/concept/factor-loading","name":"Factor Loading","short_definition":"A factor loading is a model-estimated coefficient that relates an observed variable to a latent factor under a specified factor-analytic measurement model.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:05.318Z"},{"slug":"factor-rotation","canonical_uri":"https://healtheconomics.wiki/concept/factor-rotation","name":"Factor Rotation","short_definition":"Factor rotation transforms an extracted factor solution to make its loading pattern easier to interpret while preserving the model-implied common covariance under an equivalent transformation.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:05.337Z"},{"slug":"factorial-design","canonical_uri":"https://healtheconomics.wiki/concept/factorial-design","name":"Factorial Design","short_definition":"Factorial design is a trial design randomising people to combinations of two or more treatments, so one trial estimates each effect and any interaction.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:40.200Z"},{"slug":"failure-to-rescue","canonical_uri":"https://healtheconomics.wiki/concept/failure-to-rescue","name":"Failure to Rescue","short_definition":"Failure to rescue (FTR) is a hospital quality measure giving the share of patients who die after developing a complication, most often following surgery.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.110Z"},{"slug":"falls-rate","canonical_uri":"https://healtheconomics.wiki/concept/falls-rate","name":"Falls Rate","short_definition":"Falls rate is inpatient falls per 1,000 occupied bed days (patient days), a hospital patient safety indicator also reported for injurious falls.","category":"Health Economics","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.856Z"},{"slug":"feasibility-assessment","canonical_uri":"https://healtheconomics.wiki/concept/feasibility-assessment","name":"Feasibility Assessment","short_definition":"An evaluation of whether a proposed study or intervention can practically be conducted given available resources, infrastructure, and population characteristics.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:05.397Z"},{"slug":"fee-for-service","canonical_uri":"https://healtheconomics.wiki/concept/fee-for-service","name":"Fee-for-Service","short_definition":"Fee-for-service (FFS) is a provider payment method in which a purchaser pays separately for each item of care, such as a consultation, test or procedure.","category":"Health Economics","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.581Z"},{"slug":"fieller-method","canonical_uri":"https://healtheconomics.wiki/concept/fieller-method","name":"Fieller Method","short_definition":"The Fieller method calculates a confidence interval for a ratio such as the ICER, allowing for joint uncertainty in the cost and effect differences.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:40.272Z"},{"slug":"financial-barrier","canonical_uri":"https://healtheconomics.wiki/concept/financial-barrier","name":"Financial Barrier","short_definition":"A financial barrier is a cost that stops or delays people using health or social care, such as charges, travel or lost pay, when they cannot afford it.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T20:34:52.519Z"},{"slug":"finite-difference-method","canonical_uri":"https://healtheconomics.wiki/concept/finite-difference-method","name":"Finite Difference Method","short_definition":"The finite difference method replaces derivatives with algebraic differences between function values at neighbouring grid points.","category":"Differential Equations","category_path":"Computer Science › Differential Equations › Partial Differential Equations","level_1":"Computer Science","level_2":"Differential Equations","level_3":"Partial Differential Equations","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:00.000Z"},{"slug":"finite-mixture-model","canonical_uri":"https://healtheconomics.wiki/concept/finite-mixture-model","name":"Finite Mixture Model","short_definition":"A finite mixture model treats data such as patient costs or utilities as coming from a fixed number of hidden subgroups, each with its own distribution.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:40.345Z"},{"slug":"first-order-index","canonical_uri":"https://healtheconomics.wiki/concept/first-order-index","name":"First-Order Index","short_definition":"A first-order index in variance-based sensitivity analysis is the fraction of model-output variance explained by changes in the conditional mean when one uncertain input varies on its own under the specified input distribution.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:40.561Z"},{"slug":"fixed-effect-model","canonical_uri":"https://healtheconomics.wiki/concept/fixed-effect-model","name":"Fixed Effect Model","short_definition":"A meta-analysis model assuming all included studies estimate the same true effect, with observed variation attributed entirely to sampling error.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:00.065Z"},{"slug":"fixed-effects","canonical_uri":"https://healtheconomics.wiki/concept/fixed-effects","name":"Fixed Effects","short_definition":"Fixed effects are unit-specific terms in panel data regression that remove bias from stable unmeasured traits of patients, hospitals or areas.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:40.417Z"},{"slug":"flacc","canonical_uri":"https://healtheconomics.wiki/concept/flacc","name":"FLACC Scale","short_definition":"FLACC Scale is an observer-rated pain score for young or non-verbal children, totalling 0 to 10, used as a trial outcome but unable to give QALYs directly.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.655Z"},{"slug":"fleming-harrington-estimator","canonical_uri":"https://healtheconomics.wiki/concept/fleming-harrington-estimator","name":"Fleming-Harrington Estimator","short_definition":"A statistical technique for estimating the survival function from censored data, more flexible than the Kaplan-Meier estimator in weighting events over time.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:05.637Z"},{"slug":"fleming-harrington-test","canonical_uri":"https://healtheconomics.wiki/concept/fleming-harrington-test","name":"Fleming-Harrington Test","short_definition":"A hypothesis test comparing survival distributions between groups, generalising the log-rank test by allowing different weights for events at different follow-up times.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:00.084Z"},{"slug":"flexible-parametric-model","canonical_uri":"https://healtheconomics.wiki/concept/flexible-parametric-model","name":"Flexible Parametric Model","short_definition":"A flexible parametric model is a fully specified regression model that represents a transformed survival function with smooth functions of time, commonly restricted cubic splines, so complex hazards and time-varying effects can be estimated and extrapolated.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:56:03.922Z"},{"slug":"focus-group","canonical_uri":"https://healtheconomics.wiki/concept/focus-group","name":"Focus Group","short_definition":"A focus group is a moderated small-group discussion used in health research and economic evaluation to explore people's views through their interaction.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.396Z"},{"slug":"folding-back","canonical_uri":"https://healtheconomics.wiki/concept/folding-back","name":"Folding Back","short_definition":"Folding back is the backward evaluation of a decision tree that takes probability-weighted values at chance nodes and selects the preferred feasible action at decision nodes under a stated objective.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:01.806Z"},{"slug":"force-of-infection","canonical_uri":"https://healtheconomics.wiki/concept/force-of-infection","name":"Force of Infection","short_definition":"The force of infection is the rate at which a susceptible person acquires infection, the hazard driving dynamic models of vaccines and infection control.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.028Z"},{"slug":"formulary","canonical_uri":"https://healtheconomics.wiki/concept/formulary","name":"Formulary","short_definition":"A list of medications approved for coverage by a health plan or system, often organised into tiers reflecting patient cost-sharing levels.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Market Access","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Market Access","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:23.901Z"},{"slug":"fractional-polynomial","canonical_uri":"https://healtheconomics.wiki/concept/fractional-polynomial","name":"Fractional Polynomial","short_definition":"A flexible modelling technique representing a non-linear relationship using a small number of power transformations of a continuous variable.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:02.054Z"},{"slug":"frailty-model","canonical_uri":"https://healtheconomics.wiki/concept/frailty-model","name":"Frailty Model","short_definition":"A survival model incorporating an unobserved random effect, called frailty, to represent risk heterogeneity not captured by observed covariates.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:23.939Z"},{"slug":"frequentist-analysis","canonical_uri":"https://healtheconomics.wiki/concept/frequentist-analysis","name":"Frequentist Analysis","short_definition":"Frequentist analysis judges estimates, tests and confidence intervals by their behaviour over repeated samples, as in trial-based economic evaluation.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:40.562Z"},{"slug":"frequentist-meta-analysis","canonical_uri":"https://healtheconomics.wiki/concept/frequentist-meta-analysis","name":"Frequentist Meta-Analysis","short_definition":"An approach combining evidence using classical frequentist methods, producing a point estimate and confidence interval without formally incorporating prior beliefs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:02.245Z"},{"slug":"friction-cost-method","canonical_uri":"https://healtheconomics.wiki/concept/friction-cost-method","name":"Friction Cost Method","short_definition":"A productivity loss valuation approach estimating only the cost of the finite period needed to restore normal production, generally lower than human capital estimates.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Indirect Cost Methods","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Indirect Cost Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:05.857Z"},{"slug":"full-economic-evaluation","canonical_uri":"https://healtheconomics.wiki/concept/full-economic-evaluation","name":"Full Economic Evaluation","short_definition":"Full economic evaluation is a study design that compares the costs and health outcomes of two or more healthcare options to judge value for money.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Evaluation Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Evaluation Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T02:28:40.636Z"},{"slug":"fully-incremental-analysis","canonical_uri":"https://healtheconomics.wiki/concept/fully-incremental-analysis","name":"Fully Incremental Analysis","short_definition":"Fully incremental analysis compares all mutually exclusive strategies in an ordered sequence to identify the cost-effectiveness frontier.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:05.878Z"},{"slug":"futility-analysis","canonical_uri":"https://healtheconomics.wiki/concept/futility-analysis","name":"Futility Analysis","short_definition":"A futility analysis assesses interim trial evidence against a prespecified rule to judge whether continuing is sufficiently likely to meet the study's final objective.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:02.569Z"},{"slug":"gad-7","canonical_uri":"https://healtheconomics.wiki/concept/gad-7","name":"GAD-7","short_definition":"GAD-7 is a seven-item self-report scale scoring generalised anxiety symptoms 0 to 21, used as an outcome in mental health trials and economic evaluations.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:25.726Z"},{"slug":"game-theory-health","canonical_uri":"https://healtheconomics.wiki/concept/game-theory-health","name":"Game Theory","short_definition":"Game theory in health economics analyses strategic choices by payers, providers, manufacturers and patients whose outcomes depend on what the others do.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:05.959Z"},{"slug":"gamma-distribution","canonical_uri":"https://healtheconomics.wiki/concept/gamma-distribution","name":"Gamma Distribution","short_definition":"The gamma distribution is a continuous probability distribution on positive values, defined here by shape and scale parameters that control its mean, variance, and skew.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:24.091Z"},{"slug":"gaussian-process","canonical_uri":"https://healtheconomics.wiki/concept/gaussian-process","name":"Gaussian Process","short_definition":"A flexible statistical framework modelling an unknown function by treating any finite set of its values as jointly normally distributed.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:00.500Z"},{"slug":"gaussian-process-regression","canonical_uri":"https://healtheconomics.wiki/concept/gaussian-process-regression","name":"Gaussian Process Regression","short_definition":"Gaussian process regression is a probabilistic method that predicts an unknown function from observed input-output pairs by conditioning a joint Gaussian model specified through a mean and covariance function.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:02.816Z"},{"slug":"gaussian-quadrature","canonical_uri":"https://healtheconomics.wiki/concept/gaussian-quadrature","name":"Gaussian Quadrature","short_definition":"Gaussian quadrature is a family of numerical integration methods that approximates a definite integral using carefully chosen evaluation points and weights.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:02.835Z"},{"slug":"generalized-cost-effectiveness","canonical_uri":"https://healtheconomics.wiki/concept/generalized-cost-effectiveness","name":"Generalized Cost-Effectiveness","short_definition":"Generalized cost-effectiveness analysis (GCEA) is a WHO method that compares health interventions, alone and combined, with a null where none is provided.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:40.755Z"},{"slug":"generalized-estimating-equations","canonical_uri":"https://healtheconomics.wiki/concept/generalized-estimating-equations","name":"Generalized Estimating Equations","short_definition":"Generalized estimating equations are a regression approach for estimating population-averaged associations from correlated observations by specifying a marginal mean model and accounting for within-cluster dependence.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:00.576Z"},{"slug":"generalized-gamma-model","canonical_uri":"https://healtheconomics.wiki/concept/generalized-gamma-model","name":"Generalized Gamma Model","short_definition":"A survival model based on the generalised gamma distribution, nesting simpler distributions, such as the Weibull and log-normal, within one framework.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:03.089Z"},{"slug":"generalized-linear-model","canonical_uri":"https://healtheconomics.wiki/concept/generalized-linear-model","name":"Generalized Linear Model","short_definition":"A generalised linear model (GLM) relates an outcome's mean to covariates via a link function, used in health economics for skewed costs and counts.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:40.834Z"},{"slug":"genetic-algorithm","canonical_uri":"https://healtheconomics.wiki/concept/genetic-algorithm","name":"Genetic Algorithm","short_definition":"A genetic algorithm is a search method based on natural selection that evolves candidate solutions, used to calibrate and optimise health economic models.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:40.908Z"},{"slug":"accessibility","canonical_uri":"https://healtheconomics.wiki/concept/accessibility","name":"Geographic Accessibility of Healthcare","short_definition":"Accessibility is the dimension of health care access concerned with how easily people can reach services, given location, travel time, distance and cost.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:07.655Z"},{"slug":"gibbs-sampling","canonical_uri":"https://healtheconomics.wiki/concept/gibbs-sampling","name":"Gibbs Sampling","short_definition":"Gibbs sampling is a Markov chain Monte Carlo method that fits Bayesian models, such as meta-analyses, by drawing each parameter in turn given the others.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:40.984Z"},{"slug":"gini-coefficient-health","canonical_uri":"https://healtheconomics.wiki/concept/gini-coefficient-health","name":"Gini Coefficient Health","short_definition":"A health Gini coefficient is a scale-normalised measure of relative inequality in a specified nonnegative health variable across a population, obtained from pairwise differences or its Lorenz curve.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Equity","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Equity","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T00:10:16.923Z"},{"slug":"global-sensitivity-analysis","canonical_uri":"https://healtheconomics.wiki/concept/global-sensitivity-analysis","name":"Global Sensitivity Analysis","short_definition":"Global sensitivity analysis, or GSA, evaluates how uncertainty in model inputs contributes to variation in model outputs when inputs vary across their full specified ranges or distributions.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:00.844Z"},{"slug":"gompertz-distribution","canonical_uri":"https://healtheconomics.wiki/concept/gompertz-distribution","name":"Gompertz Distribution","short_definition":"A probability distribution characterised by a hazard rate rising exponentially with time, originally developed to describe human mortality increasing with age.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:03.843Z"},{"slug":"gompertz-model","canonical_uri":"https://healtheconomics.wiki/concept/gompertz-model","name":"Gompertz Model","short_definition":"A survival model based on the Gompertz distribution, assuming the hazard rate rises exponentially over time, a pattern common in age-related mortality.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:24.738Z"},{"slug":"goodness-of-fit","canonical_uri":"https://healtheconomics.wiki/concept/goodness-of-fit","name":"Goodness of Fit","short_definition":"Goodness of fit describes how adequately a statistical model or probability distribution represents the observed data for its intended purpose.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T01:26:22.272Z"},{"slug":"goodness-of-fit-test","canonical_uri":"https://healtheconomics.wiki/concept/goodness-of-fit-test","name":"Goodness of Fit Test","short_definition":"A goodness of fit test assesses whether a specified discrepancy between observed data and a proposed probability model is unusually large under that model’s sampling assumptions.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:24.795Z"},{"slug":"gradient-descent","canonical_uri":"https://healtheconomics.wiki/concept/gradient-descent","name":"Gradient Descent","short_definition":"Gradient descent is an iterative first-order optimization method that reduces a differentiable objective function by repeatedly moving the parameter vector in the direction opposite its gradient.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:18.954Z"},{"slug":"grid-search","canonical_uri":"https://healtheconomics.wiki/concept/grid-search","name":"Grid Search","short_definition":"Grid search is an optimisation method that tests every combination of preset parameter values, used to calibrate and tune health economic models.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.057Z"},{"slug":"grossman-model","canonical_uri":"https://healtheconomics.wiki/concept/grossman-model","name":"Grossman Model","short_definition":"A theoretical model treating health as durable capital that individuals inherit, invest in, and that depreciates over time, produced using healthcare and other inputs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:24.965Z"},{"slug":"grounded-theory","canonical_uri":"https://healtheconomics.wiki/concept/grounded-theory","name":"Grounded Theory","short_definition":"Grounded theory is a qualitative research method that builds theory from data through constant comparison, theoretical sampling and coding.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.100Z"},{"slug":"group-sequential-design","canonical_uri":"https://healtheconomics.wiki/concept/group-sequential-design","name":"Group Sequential Design","short_definition":"A group sequential design is a trial design with prespecified interim analyses and stopping boundaries that permit early decisions while controlling the relevant overall error rates.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:25.023Z"},{"slug":"group-based-trajectory-model","canonical_uri":"https://healtheconomics.wiki/concept/group-based-trajectory-model","name":"Group-Based Trajectory Model","short_definition":"A group-based trajectory model (GBTM) is a finite mixture method that sorts patients into latent groups with similar paths of cost or symptoms over time.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.130Z"},{"slug":"growth-curve-model","canonical_uri":"https://healtheconomics.wiki/concept/growth-curve-model","name":"Growth Curve Model","short_definition":"A growth curve model estimates how a repeatedly measured outcome changes over time, allowing the average trajectory and individual trajectories to differ under specified assumptions.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:04.308Z"},{"slug":"growth-mixture-model","canonical_uri":"https://healtheconomics.wiki/concept/growth-mixture-model","name":"Growth Mixture Model","short_definition":"A growth mixture model sorts patients into latent classes whose health or cost follows a different average path over time, with variation in each class.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.206Z"},{"slug":"habit-formation","canonical_uri":"https://healtheconomics.wiki/concept/habit-formation","name":"Habit Formation","short_definition":"The development of a cue-linked tendency to perform a behaviour more automatically through repetition in a recurring context.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:06.506Z"},{"slug":"hads","canonical_uri":"https://healtheconomics.wiki/concept/hads","name":"HADS","short_definition":"HADS is a self-assessment scale giving separate anxiety and depression scores in physical illness, used as a non-preference-based trial outcome.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.337Z"},{"slug":"hale-calculation","canonical_uri":"https://healtheconomics.wiki/concept/hale-calculation","name":"Hale Calculation","short_definition":"The process of computing health-adjusted life expectancy, combining mortality data with health state prevalence and severity weights into one summary measure.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:01.147Z"},{"slug":"half-cycle-correction","canonical_uri":"https://healtheconomics.wiki/concept/half-cycle-correction","name":"Half-Cycle Correction","short_definition":"Half-cycle correction is a within-cycle adjustment in discrete-time state-transition models that approximates time-accruing costs or health effects between recorded state-occupancy endpoints.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Discounting","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Discounting","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:04.574Z"},{"slug":"half-life","canonical_uri":"https://healtheconomics.wiki/concept/half-life","name":"Half-Life","short_definition":"A half-life is the time required for a defined quantity to decline to half its initial value under a specified decay process.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Clinical Pharmacology","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Clinical Pharmacology","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:01.165Z"},{"slug":"haq-di","canonical_uri":"https://healtheconomics.wiki/concept/haq-di","name":"HAQ-DI","short_definition":"HAQ-DI is a 20-question patient-reported physical function index scored 0 to 3, used in rheumatology trials and mapped to EQ-5D in arthritis models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.930Z"},{"slug":"harm-rate","canonical_uri":"https://healtheconomics.wiki/concept/harm-rate","name":"Harm Rate","short_definition":"A harm rate is the number of injuries caused by healthcare per 1,000 patient days or per 100 admissions, used by hospitals to track patient safety.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.853Z"},{"slug":"harrell-c-index","canonical_uri":"https://healtheconomics.wiki/concept/harrell-c-index","name":"Harrell C-Index","short_definition":"Harrell's C-index measures how well a survival model ranks patients, the share of usable pairs where the patient with the earlier event had higher risk.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.279Z"},{"slug":"hazard-rate","canonical_uri":"https://healtheconomics.wiki/concept/hazard-rate","name":"Hazard Rate","short_definition":"In survival analysis, the instantaneous rate of an event at a given time among people still free of it; a rate, not a probability, so it can exceed 1.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:06.526Z"},{"slug":"hazard-ratio","canonical_uri":"https://healtheconomics.wiki/concept/hazard-ratio","name":"Hazard Ratio","short_definition":"A hazard ratio (HR) is the ratio of the event rates (hazards) in two groups, the usual measure of a treatment effect on survival in trials and HTA models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.923Z"},{"slug":"health-capital","canonical_uri":"https://healtheconomics.wiki/concept/health-capital","name":"Health Capital","short_definition":"Health capital is a conceptual stock of health that yields healthy time and changes through deterioration and health-producing investment over a person’s life.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:06.648Z"},{"slug":"health-economic-model","canonical_uri":"https://healtheconomics.wiki/concept/health-economic-model","name":"Health Economic Model","short_definition":"A health economic model, or decision model, is a mathematical framework combining evidence to estimate the costs and health outcomes of healthcare options.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:20.983Z"},{"slug":"health-economics","canonical_uri":"https://healtheconomics.wiki/concept/health-economics","name":"Health Economics","short_definition":"Health economics studies how scarce resources are best used to provide healthcare and improve health, and how the costs and benefits are shared in society.","category":"Foundations","category_path":"Health Economics › Foundations › Health Economics","level_1":"Health Economics","level_2":"Foundations","level_3":"Health Economics","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.044Z"},{"slug":"health-equity","canonical_uri":"https://healtheconomics.wiki/concept/health-equity","name":"Health Equity","short_definition":"Health equity (equity in health) means everyone has a fair chance to reach their full health potential, free of avoidable and unfair differences in health.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.104Z"},{"slug":"health-inequality","canonical_uri":"https://healtheconomics.wiki/concept/health-inequality","name":"Health Inequality","short_definition":"Health inequality is a measurable difference in health between individuals or groups, described without judging whether the difference is unfair.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:25.323Z"},{"slug":"health-inequity","canonical_uri":"https://healtheconomics.wiki/concept/health-inequity","name":"Health Inequity","short_definition":"Health inequity is a difference in health judged avoidable, unfair and unjust, often arising from social or economic disadvantage rather than biology.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.164Z"},{"slug":"health-insurance","canonical_uri":"https://healtheconomics.wiki/concept/health-insurance","name":"Health Insurance","short_definition":"Health insurance is a prepaid arrangement that pools contributions to pay for members' covered care, protecting them from large, uncertain medical costs.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.218Z"},{"slug":"health-needs-assessment","canonical_uri":"https://healtheconomics.wiki/concept/health-needs-assessment","name":"Health Needs Assessment","short_definition":"Health needs assessment is a systematic method for finding unmet capacity to benefit from care in a population, to set priorities and allocate resources.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.562Z"},{"slug":"health-policy","canonical_uri":"https://healtheconomics.wiki/concept/health-policy","name":"Health Policy","short_definition":"Health policy is the decisions, rules and spending choices by which governments and health bodies set priorities and use scarce resources for health.","category":"Health Policy","category_path":"Health Systems › Health Policy › Policy Analysis","level_1":"Health Systems","level_2":"Health Policy","level_3":"Policy Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.248Z"},{"slug":"health-production-function","canonical_uri":"https://healtheconomics.wiki/concept/health-production-function","name":"Health Production Function","short_definition":"A health production function shows how medical care, other market goods and own time produce health, with education raising efficiency (Grossman model).","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:10.928Z"},{"slug":"health-spending-as-gdp-share","canonical_uri":"https://healtheconomics.wiki/concept/health-spending-as-gdp-share","name":"Health Spending as GDP Share","short_definition":"Health spending as GDP share is current health expenditure divided by gross domestic product, used to compare health spending across countries and years.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Expenditure","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Expenditure","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-15T00:58:25.490Z"},{"slug":"health-state-utility-value","canonical_uri":"https://healtheconomics.wiki/concept/health-state-utility-value","name":"Health State Utility Value","short_definition":"A health state utility value, or HSU value, is a preference-based numerical weight assigned to a health state for use in economic evaluation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Utility Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Utility Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T01:26:22.309Z"},{"slug":"health-state-valuation","canonical_uri":"https://healtheconomics.wiki/concept/health-state-valuation","name":"Health State Valuation","short_definition":"Health state valuation is the elicitation and modelling of preferences for defined states of health to assign scores on a scale anchored by dead and full health for use in economic evaluation and related decisions.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:06.991Z"},{"slug":"health-system-building-blocks","canonical_uri":"https://healtheconomics.wiki/concept/health-system-building-blocks","name":"Health System Building Blocks","short_definition":"Health system building blocks are the six components of a health system named by WHO, such as financing, workforce and medicines, used to plan investment.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Health System Governance","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Health System Governance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.515Z"},{"slug":"health-system-financing","canonical_uri":"https://healtheconomics.wiki/concept/health-system-financing","name":"Health System Financing","short_definition":"Health system financing is how a country raises money for health, pools it to share risk and buys services, shaping access and financial protection.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":"high","version":"1.0.24","status":"PUBLISHED","published_at":"2026-10-13T23:51:05.661Z"},{"slug":"health-system-organization","canonical_uri":"https://healtheconomics.wiki/concept/health-system-organization","name":"Health System Organization","short_definition":"Health system organisation is the way a health system's regulators, funders, purchasers and providers are arranged, linked and held to account for care.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Models","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Models","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.589Z"},{"slug":"adoption-curve","canonical_uri":"https://healtheconomics.wiki/concept/adoption-curve","name":"Health Technology Adoption Curve","short_definition":"A health technology adoption curve shows how use of a new medicine or device grows over time, usually S-shaped: slow, then rapid, then levelling off.","category":"Model Structures","category_path":"Health Systems › Health Policy › Systems Strengthening","level_1":"Health Systems","level_2":"Health Policy","level_3":"Systems Strengthening","evidence_level":"high","version":"1.0.6","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.722Z"},{"slug":"health-technology-assessment","canonical_uri":"https://healtheconomics.wiki/concept/health-technology-assessment","name":"Health Technology Assessment","short_definition":"Health technology assessment (HTA) evaluates the clinical, economic, social and ethical effects of a drug, test, device or procedure to guide its use.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.5.6","status":"PUBLISHED","published_at":"2026-10-15T23:54:01.560Z"},{"slug":"health-adjusted-life-year","canonical_uri":"https://healtheconomics.wiki/concept/health-adjusted-life-year","name":"Health-Adjusted Life Year","short_definition":"Health-adjusted life years (HALYs) are a family of measures, such as the QALY and DALY, that combine length of life and health status in one number.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Quality-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Quality-Adjusted Life Years","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.354Z"},{"slug":"health-related-quality-of-life","canonical_uri":"https://healtheconomics.wiki/concept/health-related-quality-of-life","name":"Health-Related Quality of Life","short_definition":"A multidimensional concept covering the physical, psychological, and social aspects of wellbeing affected by a person's health status or its treatment.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health-Related Quality of Life","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health-Related Quality of Life","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:25.471Z"},{"slug":"accreditation","canonical_uri":"https://healtheconomics.wiki/concept/accreditation","name":"Healthcare Accreditation","short_definition":"Healthcare accreditation is external review of health services against published standards by an accrediting body, with public recognition if they comply.","category":"Regulatory Concepts","category_path":"Health Systems › Health Policy › Health System Regulation","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Regulation","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-15T00:58:13.413Z"},{"slug":"healthcare-production-function","canonical_uri":"https://healtheconomics.wiki/concept/healthcare-production-function","name":"Healthcare Production Function","short_definition":"A healthcare production function gives the maximum care output, such as visits or hospital episodes, obtainable from given staff, capital and technology.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-15T23:54:01.616Z"},{"slug":"healthy-life-expectancy","canonical_uri":"https://healtheconomics.wiki/concept/healthy-life-expectancy","name":"Healthy Life Expectancy","short_definition":"Healthy life expectancy (HLE) is the average number of years a person is expected to live in good health, given current rates of death and ill health.","category":"Health Policy","category_path":"Health Systems › Health Policy › Population Health Outcomes","level_1":"Health Systems","level_2":"Health Policy","level_3":"Population Health Outcomes","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.429Z"},{"slug":"healthy-year-equivalent","canonical_uri":"https://healtheconomics.wiki/concept/healthy-year-equivalent","name":"Healthy Year Equivalent","short_definition":"A healthy year equivalent (HYE) is the number of years in full health a person values as highly as a lifetime health profile, an alternative to the QALY.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Quality-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Quality-Adjusted Life Years","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.502Z"},{"slug":"hedges-g","canonical_uri":"https://healtheconomics.wiki/concept/hedges-g","name":"Hedges' g","short_definition":"Hedges' g is a standardised mean difference, the gap between two group means divided by their pooled standard deviation, corrected for small-sample bias.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T20:34:52.352Z"},{"slug":"heterogeneity-assessment","canonical_uri":"https://healtheconomics.wiki/concept/heterogeneity-assessment","name":"Heterogeneity Assessment","short_definition":"Heterogeneity assessment evaluates the nature, extent, and possible causes of differences in effects or outcomes across studies, populations, or settings.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:01.746Z"},{"slug":"heterogeneous-treatment-effect","canonical_uri":"https://healtheconomics.wiki/concept/heterogeneous-treatment-effect","name":"Heterogeneous Treatment Effect","short_definition":"A heterogeneous treatment effect is variation in a treatment's benefit or harm across patients, so the average can mislead treatment and funding decisions.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.576Z"},{"slug":"hidden-markov-model","canonical_uri":"https://healtheconomics.wiki/concept/hidden-markov-model","name":"Hidden Markov Model","short_definition":"A hidden Markov model (HMM) is a Markov model of disease progression whose true states are unobserved and inferred from error-prone tests or markers.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.650Z"},{"slug":"hierarchical-condition-category","canonical_uri":"https://healtheconomics.wiki/concept/hierarchical-condition-category","name":"Hierarchical Condition Category","short_definition":"A hierarchical condition category (HCC) groups related diagnosis codes by severity so that CMS risk models can predict an enrolee's relative future cost.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.722Z"},{"slug":"hierarchical-model","canonical_uri":"https://healtheconomics.wiki/concept/hierarchical-model","name":"Hierarchical Model","short_definition":"A hierarchical model represents observations or parameters at multiple related levels and estimates variation within and between those levels.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:06.584Z"},{"slug":"hierarchical-testing","canonical_uri":"https://healtheconomics.wiki/concept/hierarchical-testing","name":"Hierarchical Testing","short_definition":"Hierarchical testing controls false positives across trial endpoints by testing them in a prespecified order at full alpha, stopping at the first failure.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.796Z"},{"slug":"diagnostic-efficacy-hierarchy","canonical_uri":"https://healtheconomics.wiki/concept/diagnostic-efficacy-hierarchy","name":"Hierarchy of Diagnostic Efficacy","short_definition":"The hierarchy of diagnostic efficacy is Fryback and Thornbury's six-level model for judging a test, from image quality and accuracy to societal value.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:20.503Z"},{"slug":"historical-control","canonical_uri":"https://healtheconomics.wiki/concept/historical-control","name":"Historical Control","short_definition":"Historical control is a comparison group of past patients, from earlier trials or registries, used instead of or alongside a concurrently randomised group.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:26.001Z"},{"slug":"horizontal-equity","canonical_uri":"https://healtheconomics.wiki/concept/horizontal-equity","name":"Horizontal Equity","short_definition":"Horizontal equity is equal treatment of equals in health care: equal care for people in equal need and equal payments from those with equal ability to pay.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:54:01.918Z"},{"slug":"hosmer-lemeshow-test","canonical_uri":"https://healtheconomics.wiki/concept/hosmer-lemeshow-test","name":"Hosmer-Lemeshow Test","short_definition":"A goodness of fit test assessing how well a logistic regression model's predicted probabilities match observed outcome frequencies across risk groups.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:40.621Z"},{"slug":"human-capital-approach","canonical_uri":"https://healtheconomics.wiki/concept/human-capital-approach","name":"Human Capital Approach","short_definition":"A way to value productivity lost to illness or premature death by applying an economic value, often based on earnings, to forgone productive time.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:07.595Z"},{"slug":"hyperbolic-discounting","canonical_uri":"https://healtheconomics.wiki/concept/hyperbolic-discounting","name":"Hyperbolic Discounting","short_definition":"Hyperbolic discounting is time preference in which the discount rate falls as delay grows, so plans made for later are often reversed when the time comes.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Discounting","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Discounting","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.225Z"},{"slug":"hypothesis-testing","canonical_uri":"https://healtheconomics.wiki/concept/hypothesis-testing","name":"Hypothesis Testing","short_definition":"Hypothesis testing is a statistical decision framework that evaluates how compatible observed data are with a prespecified null hypothesis by comparing a test statistic with its sampling distribution under stated assumptions.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:26.379Z"},{"slug":"i-squared","canonical_uri":"https://healtheconomics.wiki/concept/i-squared","name":"I-Squared","short_definition":"I-squared (I2) is the percentage of variation in effect estimates across studies in a meta-analysis that is due to heterogeneity rather than chance.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.869Z"},{"slug":"icecap-a","canonical_uri":"https://healtheconomics.wiki/concept/icecap-a","name":"ICECAP-A","short_definition":"ICECAP-A is a self-report capability wellbeing measure for adults, with five attributes scored on UK index values, for economic evaluation beyond health.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:25.781Z"},{"slug":"icecap-o","canonical_uri":"https://healtheconomics.wiki/concept/icecap-o","name":"ICECAP-O","short_definition":"ICECAP-O is a five-attribute capability wellbeing measure for people aged 65 and over, with UK index values for evaluating health and social care.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:25.834Z"},{"slug":"ichom-standard-set","canonical_uri":"https://healtheconomics.wiki/concept/ichom-standard-set","name":"ICHOM Standard Set","short_definition":"An ICHOM Standard Set is an agreed set of outcomes and case-mix variables for one medical condition, used to compare providers on the value of care.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.645Z"},{"slug":"immortal-time","canonical_uri":"https://healtheconomics.wiki/concept/immortal-time","name":"Immortal Time","short_definition":"A period of follow-up during which, due to how exposure groups were defined, a participant could not possibly have experienced the outcome.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:07.797Z"},{"slug":"importance-sampling","canonical_uri":"https://healtheconomics.wiki/concept/importance-sampling","name":"Importance Sampling","short_definition":"Importance sampling is a Monte Carlo method that samples rare or influential model inputs more often, then reweights draws so estimates match the model.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:41.943Z"},{"slug":"impoverishing-health-expenditure","canonical_uri":"https://healtheconomics.wiki/concept/impoverishing-health-expenditure","name":"Impoverishing Health Expenditure","short_definition":"Impoverishing health expenditure is out-of-pocket health spending that pushes a household below a poverty line, or deeper into poverty if already poor.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Financing","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Financing","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.023Z"},{"slug":"imputation","canonical_uri":"https://healtheconomics.wiki/concept/imputation","name":"Imputation","short_definition":"Imputation replaces missing values in a dataset, such as unrecorded trial costs or EQ-5D scores, with estimated values so every record can be analysed.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.097Z"},{"slug":"incidence","canonical_uri":"https://healtheconomics.wiki/concept/incidence","name":"Incidence","short_definition":"Incidence is the number of new cases of a disease arising in a population at risk over a set period, used to size patient groups and set model event rates.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.172Z"},{"slug":"incidence-rate-ratio","canonical_uri":"https://healtheconomics.wiki/concept/incidence-rate-ratio","name":"Incidence Rate Ratio","short_definition":"A measure comparing the incidence rate of an outcome between two groups, accounting for differences in total person-time at risk.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T01:26:22.364Z"},{"slug":"income-elasticity-of-demand","canonical_uri":"https://healtheconomics.wiki/concept/income-elasticity-of-demand","name":"Income Elasticity of Demand","short_definition":"Income elasticity of demand is the percentage change in demand for a good, such as health care, divided by the percentage change in income.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.250Z"},{"slug":"incremental-cost","canonical_uri":"https://healtheconomics.wiki/concept/incremental-cost","name":"Incremental Cost","short_definition":"Incremental cost is the difference in expected total cost between one healthcare option and its stated comparator, calculated using the same population, perspective, time horizon, currency, price year and costing methods.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.2.14","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.286Z"},{"slug":"icer","canonical_uri":"https://healtheconomics.wiki/concept/icer","name":"Incremental Cost-Effectiveness Ratio (ICER)","short_definition":"The incremental cost-effectiveness ratio (ICER) is a treatment's extra cost divided by its extra health gain versus a comparator, such as cost per QALY.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.2.22","status":"PUBLISHED","published_at":"2026-10-14T23:52:07.777Z"},{"slug":"incremental-cost-utility-ratio","canonical_uri":"https://healtheconomics.wiki/concept/incremental-cost-utility-ratio","name":"Incremental Cost-Utility Ratio","short_definition":"The incremental cost-utility ratio (ICUR) is the ICER of a cost-utility analysis: extra cost over a comparator divided by extra QALYs gained.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Utility Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Utility Analysis","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.346Z"},{"slug":"incremental-effectiveness","canonical_uri":"https://healtheconomics.wiki/concept/incremental-effectiveness","name":"Incremental Effectiveness","short_definition":"Incremental effectiveness is the difference in health outcomes between an intervention and its comparator, calculated in a consistent outcome unit and comparison direction.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Results","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Results","evidence_level":"high","version":"1.2.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.406Z"},{"slug":"incremental-net-benefit","canonical_uri":"https://healtheconomics.wiki/concept/incremental-net-benefit","name":"Incremental Net Benefit","short_definition":"The difference in expected net benefit between two competing interventions, found by converting the incremental health effect into money and subtracting incremental cost.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:08.590Z"},{"slug":"incremental-net-monetary-benefit","canonical_uri":"https://healtheconomics.wiki/concept/incremental-net-monetary-benefit","name":"Incremental Net Monetary Benefit","short_definition":"Incremental net monetary benefit (INMB) is the extra health of an option over its comparator, valued at a threshold, minus the extra cost, per patient.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.2.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.466Z"},{"slug":"independent-censoring","canonical_uri":"https://healtheconomics.wiki/concept/independent-censoring","name":"Independent Censoring","short_definition":"An assumption that, within the information used for a survival analysis, censoring does not convey additional information about a person’s unobserved event time.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:26.893Z"},{"slug":"indirect-comparison","canonical_uri":"https://healtheconomics.wiki/concept/indirect-comparison","name":"Indirect Comparison","short_definition":"An indirect comparison estimates, for HTA, how two treatments never trialled head to head compare, using each one's trials against a common comparator.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.328Z"},{"slug":"indirect-treatment-comparison","canonical_uri":"https://healtheconomics.wiki/concept/indirect-treatment-comparison","name":"Indirect Treatment Comparison","short_definition":"Indirect treatment comparison (ITC) is the umbrella term for methods, such as NMA or MAIC, that compare treatments no trial has tested head to head.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.526Z"},{"slug":"indirect-utility-assessment","canonical_uri":"https://healtheconomics.wiki/concept/indirect-utility-assessment","name":"Indirect Utility Assessment","short_definition":"Indirect utility assessment derives health state utilities by scoring patients' answers to a questionnaire such as the EQ-5D with a published value set.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.402Z"},{"slug":"individual-patient-data-meta-analysis","canonical_uri":"https://healtheconomics.wiki/concept/individual-patient-data-meta-analysis","name":"Individual Patient Data Meta-Analysis","short_definition":"Individual patient data meta-analysis systematically obtains, checks, and jointly synthesises participant-level records from eligible studies to estimate effects and investigate variation across studies or patients.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:08.990Z"},{"slug":"individual-patient-simulation","canonical_uri":"https://healtheconomics.wiki/concept/individual-patient-simulation","name":"Individual Patient Simulation","short_definition":"Individual patient simulation is a modelling approach that generates separate patient histories under specified rules and aggregates their costs and health outcomes for a target population.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Microsimulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Microsimulation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:27.083Z"},{"slug":"inelastic-demand","canonical_uri":"https://healtheconomics.wiki/concept/inelastic-demand","name":"Inelastic Demand","short_definition":"Inelastic demand is demand with a price elasticity between zero and minus one, so use falls proportionally less than price rises, as for most medical care.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.476Z"},{"slug":"information-asymmetry","canonical_uri":"https://healtheconomics.wiki/concept/information-asymmetry","name":"Information Asymmetry","short_definition":"Information asymmetry occurs when one party to an economic decision has more or better information than another, affecting choices, bargaining power and the efficiency of resulting outcomes.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.12","status":"PUBLISHED","published_at":"2026-10-15T00:58:27.240Z"},{"slug":"information-bias","canonical_uri":"https://healtheconomics.wiki/concept/information-bias","name":"Information Bias","short_definition":"A category of bias from errors in how exposure, outcome, or covariate data are measured or recorded, including recall bias and measurement error.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T21:24:07.879Z"},{"slug":"informed-choice","canonical_uri":"https://healtheconomics.wiki/concept/informed-choice","name":"Informed Choice","short_definition":"Informed choice is a decision about a screening test or treatment based on relevant knowledge, consistent with the decision maker's values and acted upon.","category":"Health Policy","category_path":"Health Systems › Health Policy › Patient-Centered Care","level_1":"Health Systems","level_2":"Health Policy","level_3":"Patient-Centered Care","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:22.650Z"},{"slug":"informed-consent-for-research","canonical_uri":"https://healtheconomics.wiki/concept/informed-consent-for-research","name":"Informed Consent for Research","short_definition":"Informed consent for research is a capable person's voluntary, understood agreement to join a study, the ethical gate for trial and registry evidence.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Governance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Governance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.367Z"},{"slug":"instrumental-variable","canonical_uri":"https://healtheconomics.wiki/concept/instrumental-variable","name":"Instrumental Variable","short_definition":"An instrumental variable is a variable that changes treatment or exposure uptake while, under specified causal assumptions, being independent of potential outcomes and affecting the outcome only through that treatment or exposure.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Real-World Evidence","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Real-World Evidence","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:27.473Z"},{"slug":"instrumental-variable-analysis","canonical_uri":"https://healtheconomics.wiki/concept/instrumental-variable-analysis","name":"Instrumental Variable Analysis","short_definition":"Instrumental variable analysis is a causal estimation approach that uses variation in treatment or exposure induced by a qualifying instrument to estimate an effect under explicit identification and modelling assumptions.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:02.696Z"},{"slug":"intangible-cost","canonical_uri":"https://healtheconomics.wiki/concept/intangible-cost","name":"Intangible Cost","short_definition":"Intangible cost is the pain, distress and lost quality of life caused by illness or treatment, which has no market price and is often measured in QALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.550Z"},{"slug":"integer-programming-health","canonical_uri":"https://healtheconomics.wiki/concept/integer-programming-health","name":"Integer Programming","short_definition":"Integer programming chooses which indivisible health programmes or medicines to fund to maximise health gain, such as QALYs, within a fixed budget.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.000Z"},{"slug":"intention-to-treat-analysis","canonical_uri":"https://healtheconomics.wiki/concept/intention-to-treat-analysis","name":"Intention-to-Treat Analysis","short_definition":"Intention-to-treat analysis compares outcomes according to participants’ original randomised assignments, irrespective of subsequent treatment receipt or adherence, while explicitly addressing missing outcome data.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:27.628Z"},{"slug":"interaction-effect","canonical_uri":"https://healtheconomics.wiki/concept/interaction-effect","name":"Interaction Effect","short_definition":"A difference in one variable’s effect across levels of another variable, defined on a specified outcome and measurement scale.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:27.687Z"},{"slug":"interim-analysis","canonical_uri":"https://healtheconomics.wiki/concept/interim-analysis","name":"Interim Analysis","short_definition":"A planned analysis of trial data conducted before final completion, typically to assess safety, efficacy, or futility and inform continuation decisions.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:10.254Z"},{"slug":"internal-consistency-reliability","canonical_uri":"https://healtheconomics.wiki/concept/internal-consistency-reliability","name":"Internal Consistency Reliability","short_definition":"Internal consistency reliability is how strongly the items in one health questionnaire scale agree with each other, usually measured by Cronbach's alpha.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.623Z"},{"slug":"international-comparison","canonical_uri":"https://healtheconomics.wiki/concept/international-comparison","name":"International Comparison","short_definition":"International comparison analyses health spending, prices and outcomes across countries to judge health system performance and learn policy lessons.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Global Health","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Global Health","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.442Z"},{"slug":"interpolation","canonical_uri":"https://healtheconomics.wiki/concept/interpolation","name":"Interpolation","short_definition":"Interpolation estimates a value between observed or modelled data points using an assumed relationship across the interval.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:10.593Z"},{"slug":"interquartile-range","canonical_uri":"https://healtheconomics.wiki/concept/interquartile-range","name":"Interquartile Range","short_definition":"The interquartile range (IQR) is the gap between the 25th and 75th percentiles, the spread of the middle half of data such as skewed patient costs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.696Z"},{"slug":"interrupted-time-series","canonical_uri":"https://healtheconomics.wiki/concept/interrupted-time-series","name":"Interrupted Time Series","short_definition":"Interrupted time series (ITS) is a quasi-experimental design tracking an outcome before and after a health policy to estimate changes in level and trend.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.769Z"},{"slug":"interval-censoring","canonical_uri":"https://healtheconomics.wiki/concept/interval-censoring","name":"Interval Censoring","short_definition":"Interval censoring occurs when a patient's event time, such as disease progression, is known only to lie between two assessments, such as two trial scans.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.844Z"},{"slug":"interval-scaling","canonical_uri":"https://healtheconomics.wiki/concept/interval-scaling","name":"Interval Scaling","short_definition":"Interval scaling means equal score differences reflect equal differences in health or preference, with an arbitrary zero, so ratios of scores mean nothing.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.916Z"},{"slug":"intervention","canonical_uri":"https://healtheconomics.wiki/concept/intervention","name":"Intervention","short_definition":"An intervention is any test, treatment, programme, strategy or policy aimed at health or care; HTA compares its costs and effects with alternatives.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Evaluation Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Evaluation Methods","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.646Z"},{"slug":"interviewer-bias","canonical_uri":"https://healtheconomics.wiki/concept/interviewer-bias","name":"Interviewer Bias","short_definition":"Interviewer bias is systematic error caused by how an interviewer asks questions or behaves, as in time trade-off or willingness-to-pay surveys.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.206Z"},{"slug":"intraclass-correlation","canonical_uri":"https://healtheconomics.wiki/concept/intraclass-correlation","name":"Intraclass Correlation","short_definition":"The intraclass correlation (ICC) is the share of variance in a health outcome lying between patients or clusters, used to judge reliability and clustering.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:42.991Z"},{"slug":"investigational-device-exemption","canonical_uri":"https://healtheconomics.wiki/concept/investigational-device-exemption","name":"Investigational Device Exemption","short_definition":"An investigational device exemption (IDE) is a US FDA permit to test an unapproved medical device in a clinical study, often to support premarket approval.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Regulation","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Regulation","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:28.074Z"},{"slug":"jackknife","canonical_uri":"https://healtheconomics.wiki/concept/jackknife","name":"Jackknife","short_definition":"The jackknife is a resampling method that recomputes an estimate, such as mean cost, leaving out each observation in turn to gauge bias and standard error.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:43.066Z"},{"slug":"joint-model","canonical_uri":"https://healtheconomics.wiki/concept/joint-model","name":"Joint Model","short_definition":"A statistical approach analysing a longitudinal outcome, such as a repeated biomarker, alongside a time-to-event outcome, accounting for the link between them.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:51:11.205Z"},{"slug":"k-fold-cross-validation","canonical_uri":"https://healtheconomics.wiki/concept/k-fold-cross-validation","name":"K-Fold Cross-Validation","short_definition":"An internal validation procedure that repeatedly fits a model on all but one of K data folds and evaluates it on the held-out fold.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:43.353Z"},{"slug":"k10","canonical_uri":"https://healtheconomics.wiki/concept/k10","name":"K10","short_definition":"K10 is the ten-item Kessler scale, a non-preference-based measure of psychological distress used in population surveys and mental health trials.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.316Z"},{"slug":"kakwani-index","canonical_uri":"https://healtheconomics.wiki/concept/kakwani-index","name":"Kakwani Index","short_definition":"A measure of the progressivity of a tax or financing system, calculated as the concentration index of payments minus the Gini coefficient of pre-tax income.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Equity","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Equity","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:28.227Z"},{"slug":"kalman-filter","canonical_uri":"https://healtheconomics.wiki/concept/kalman-filter","name":"Kalman Filter","short_definition":"A recursive estimator that predicts an evolving latent state and updates that estimate and its uncertainty when a new noisy measurement arrives.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:03.068Z"},{"slug":"kaplan-meier-curve","canonical_uri":"https://healtheconomics.wiki/concept/kaplan-meier-curve","name":"Kaplan-Meier Curve","short_definition":"A graphical display of the Kaplan-Meier survival estimate, shown as a step function that decreases at each observed event over time.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:28.246Z"},{"slug":"kaplan-meier-estimator","canonical_uri":"https://healtheconomics.wiki/concept/kaplan-meier-estimator","name":"Kaplan-Meier Estimator","short_definition":"The Kaplan–Meier estimator calculates a non-parametric estimate of the survival function when follow-up can be right-censored.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:28.266Z"},{"slug":"kaplan-meier-method","canonical_uri":"https://healtheconomics.wiki/concept/kaplan-meier-method","name":"Kaplan-Meier Method","short_definition":"The overall approach of estimating and comparing survival functions using the Kaplan-Meier estimator, accounting for censored observations in time-to-event data.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:09.456Z"},{"slug":"kappa-statistic","canonical_uri":"https://healtheconomics.wiki/concept/kappa-statistic","name":"Kappa Statistic","short_definition":"The kappa statistic (Cohen's kappa) measures chance-corrected agreement between two raters on a categorical judgement, such as reviewers screening studies.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:28.285Z"},{"slug":"karnofsky-performance-status","canonical_uri":"https://healtheconomics.wiki/concept/karnofsky-performance-status","name":"Karnofsky Performance Status","short_definition":"Karnofsky Performance Status is a clinician-rated 11-level score of a cancer patient's function, 100 normal and 0 dead, used to set treatment eligibility.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.319Z"},{"slug":"katz-index","canonical_uri":"https://healtheconomics.wiki/concept/katz-index","name":"Katz ADL Index","short_definition":"Katz ADL Index is a rating of independence in six basic activities of daily living, used to define dependency in trials and care models for older people.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.041Z"},{"slug":"kccq","canonical_uri":"https://healtheconomics.wiki/concept/kccq","name":"KCCQ","short_definition":"KCCQ is a 23-item heart failure questionnaire scoring symptoms, function, social limitation and quality of life 0 to 100, used as a trial and HTA outcome.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.709Z"},{"slug":"kendall-tau","canonical_uri":"https://healtheconomics.wiki/concept/kendall-tau","name":"Kendall Tau","short_definition":"Kendall tau is a rank correlation from minus one to one, comparing how often two rankings of health states or treatments order pairs alike or reversed.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:43.139Z"},{"slug":"kidscreen-10","canonical_uri":"https://healtheconomics.wiki/concept/kidscreen-10","name":"KIDSCREEN-10","short_definition":"KIDSCREEN-10 is a ten-item measure of health-related quality of life and wellbeing for ages 8 to 18, scored as a Rasch T-value against European norms.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.380Z"},{"slug":"knowledge-brokering","canonical_uri":"https://healtheconomics.wiki/concept/knowledge-brokering","name":"Knowledge Brokering","short_definition":"Knowledge brokering is work by people or organisations that link researchers with health decision makers so that research evidence is used in decisions.","category":"Health Policy","category_path":"Health Systems › Health Policy › Systems Strengthening","level_1":"Health Systems","level_2":"Health Policy","level_3":"Systems Strengthening","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:28.342Z"},{"slug":"kurtosis","canonical_uri":"https://healtheconomics.wiki/concept/kurtosis","name":"Kurtosis","short_definition":"Kurtosis is the standardised fourth moment of a distribution, a measure of tail heaviness that flags rare extreme values such as very high patient costs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:43.211Z"},{"slug":"landmark-analysis","canonical_uri":"https://healtheconomics.wiki/concept/landmark-analysis","name":"Landmark Analysis","short_definition":"Landmark analysis is a survival method that starts follow-up at a set time, keeps only patients still event-free then and groups them by their status then.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T20:34:52.407Z"},{"slug":"language-bias","canonical_uri":"https://healtheconomics.wiki/concept/language-bias","name":"Language Bias","short_definition":"Language bias is a reporting bias in which a study's language of publication depends on its results, so reviews limited to English can misstate effects.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:38.679Z"},{"slug":"large-simple-trial","canonical_uri":"https://healtheconomics.wiki/concept/large-simple-trial","name":"Large Simple Trial","short_definition":"A large simple trial randomises thousands of patients with simple entry rules and minimal data to detect moderate effects on death or serious disability.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.231Z"},{"slug":"last-observation-carried-forward","canonical_uri":"https://healtheconomics.wiki/concept/last-observation-carried-forward","name":"Last Observation Carried Forward","short_definition":"Last observation carried forward (LOCF) fills missing trial follow-up values with each participant's last observed value, assuming no change after dropout.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.074Z"},{"slug":"latent-class-analysis","canonical_uri":"https://healtheconomics.wiki/concept/latent-class-analysis","name":"Latent Class Analysis","short_definition":"Latent class analysis (LCA) finds unobserved patient subgroups from patterns in categorical data, such as recorded conditions or diagnostic test results.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:43.284Z"},{"slug":"latent-class-model","canonical_uri":"https://healtheconomics.wiki/concept/latent-class-model","name":"Latent Class Model","short_definition":"A statistical model that assumes a population consists of unobserved subgroups with distinct preferences, estimating both each subgroup's traits and individual membership probability.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:28.535Z"},{"slug":"latent-growth-model","canonical_uri":"https://healtheconomics.wiki/concept/latent-growth-model","name":"Latent Growth Model","short_definition":"A latent growth model is a structural equation model treating each patient's starting level and rate of change in repeated health scores as latent factors.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:43.356Z"},{"slug":"latent-transition-analysis","canonical_uri":"https://healtheconomics.wiki/concept/latent-transition-analysis","name":"Latent Transition Analysis","short_definition":"Latent transition analysis (LTA) is a longitudinal latent class method that estimates how patients move between unobserved health or behaviour states.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:43.430Z"},{"slug":"latent-variable","canonical_uri":"https://healtheconomics.wiki/concept/latent-variable","name":"Latent Variable","short_definition":"A latent variable is an unobserved quantity, such as health-related quality of life or preference class membership, estimated from observed indicators.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.146Z"},{"slug":"latin-hypercube-sampling","canonical_uri":"https://healtheconomics.wiki/concept/latin-hypercube-sampling","name":"Latin Hypercube Sampling","short_definition":"Latin hypercube sampling is a stratified Monte Carlo design that draws each input to a health economic model once from each of n equally likely intervals.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:43.502Z"},{"slug":"law-of-large-numbers","canonical_uri":"https://healtheconomics.wiki/concept/law-of-large-numbers","name":"Law of Large Numbers","short_definition":"The law of large numbers says the average of independent patient costs or simulation draws settles on the true mean as more are added.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:43.575Z"},{"slug":"least-squares-approximation","canonical_uri":"https://healtheconomics.wiki/concept/least-squares-approximation","name":"Least Squares Approximation","short_definition":"Least squares approximation estimates the coefficients of a chosen model by minimizing the sum of squared residuals between observed or target values and the corresponding model values.","category":"Numerical Analysis","category_path":"Computer Science › Numerical Analysis › Approximation","level_1":"Computer Science","level_2":"Numerical Analysis","level_3":"Approximation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:20.156Z"},{"slug":"leave-one-out","canonical_uri":"https://healtheconomics.wiki/concept/leave-one-out","name":"Leave-One-Out","short_definition":"Leave-one-out cross-validation tests a cost or risk prediction model by refitting it without each observation in turn and predicting the one left out.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-26T21:36:43.648Z"},{"slug":"left-censoring","canonical_uri":"https://healtheconomics.wiki/concept/left-censoring","name":"Left Censoring","short_definition":"Left censoring occurs when a patient's event, such as disease onset, is known only to have happened before the first observation, at an unknown time.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.032Z"},{"slug":"left-truncation","canonical_uri":"https://healtheconomics.wiki/concept/left-truncation","name":"Left Truncation","short_definition":"Left truncation (delayed entry) occurs when people join a survival analysis risk set after time zero and are observed only if still event free at entry.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.220Z"},{"slug":"leverage-point","canonical_uri":"https://healtheconomics.wiki/concept/leverage-point","name":"Leverage Point","short_definition":"An observation with an unusual combination of predictor values, distinct from the bulk of the data, capable of disproportionately influencing a regression model.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:03.362Z"},{"slug":"life-expectancy","canonical_uri":"https://healtheconomics.wiki/concept/life-expectancy","name":"Life Expectancy","short_definition":"The expected number of additional years lived from a specified age under a stated set of mortality rates.","category":"Health Policy","category_path":"Health Systems › Health Policy › Population Health Outcomes","level_1":"Health Systems","level_2":"Health Policy","level_3":"Population Health Outcomes","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:28.864Z"},{"slug":"life-table","canonical_uri":"https://healtheconomics.wiki/concept/life-table","name":"Life Table","short_definition":"A structured table that follows a hypothetical population through age or time intervals to summarize deaths, survivors, person-years, and expected remaining life.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:09.958Z"},{"slug":"life-table-method","canonical_uri":"https://healtheconomics.wiki/concept/life-table-method","name":"Life Table Method","short_definition":"The life table (actuarial) method estimates survival from deaths and withdrawals in fixed intervals, treating withdrawals as at risk for half an interval.","category":"Statistical Methods","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-13T23:53:20.581Z"},{"slug":"life-years-gained","canonical_uri":"https://healtheconomics.wiki/concept/life-years-gained","name":"Life Years Gained","short_definition":"Life years gained (LYG) are the extra years of mean survival an intervention gives over its comparator, without quality adjustment, in economic evaluation.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.501Z"},{"slug":"likelihood-ratio","canonical_uri":"https://healtheconomics.wiki/concept/likelihood-ratio","name":"Likelihood Ratio","short_definition":"A ratio comparing the likelihood of the same observed evidence under two specified conditions or statistical models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:28.921Z"},{"slug":"likelihood-ratio-test","canonical_uri":"https://healtheconomics.wiki/concept/likelihood-ratio-test","name":"Likelihood Ratio Test","short_definition":"The likelihood ratio test (LRT) compares nested models, such as Weibull and exponential survival curves, to judge whether extra parameters improve fit.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.108Z"},{"slug":"linear-pool","canonical_uri":"https://healtheconomics.wiki/concept/linear-pool","name":"Linear Pool","short_definition":"A method combining multiple experts' probability distributions by taking a weighted arithmetic average, producing a single pooled distribution.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.038Z"},{"slug":"linear-programming","canonical_uri":"https://healtheconomics.wiki/concept/linear-programming","name":"Linear Programming","short_definition":"Linear programming identifies the best feasible allocation of limited resources when the objective and constraints can be expressed as linear relationships.","category":"Optimisation","category_path":"Computer Science › Optimisation › Constrained Optimisation","level_1":"Computer Science","level_2":"Optimisation","level_3":"Constrained Optimisation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.058Z"},{"slug":"linear-programming-health","canonical_uri":"https://healtheconomics.wiki/concept/linear-programming-health","name":"Linear Programming Health","short_definition":"An optimisation technique identifying the resource allocation that maximises or minimises a linear objective subject to linear constraints, such as a fixed budget.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:20.921Z"},{"slug":"linear-regression","canonical_uri":"https://healtheconomics.wiki/concept/linear-regression","name":"Linear Regression","short_definition":"Linear regression models a continuous outcome, such as cost or QALYs, as a weighted sum of predictors plus error, usually fitted by least squares.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.185Z"},{"slug":"liquidity-ratio","canonical_uri":"https://healtheconomics.wiki/concept/liquidity-ratio","name":"Liquidity Ratio","short_definition":"A liquidity ratio compares a health provider's cash and current assets with its short-term liabilities to show whether it can pay bills as they fall due.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.929Z"},{"slug":"listwise-deletion","canonical_uri":"https://healtheconomics.wiki/concept/listwise-deletion","name":"Listwise Deletion","short_definition":"Listwise deletion, or complete-case analysis, drops any patient missing an analysis variable, so trial costs and QALYs come only from complete records.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.260Z"},{"slug":"living-hta","canonical_uri":"https://healtheconomics.wiki/concept/living-hta","name":"Living HTA","short_definition":"Living HTA is a health technology assessment planned from the start to be updated at set intervals or triggers as evidence, comparators or prices change.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.387Z"},{"slug":"log-logistic-distribution","canonical_uri":"https://healtheconomics.wiki/concept/log-logistic-distribution","name":"Log-Logistic Distribution","short_definition":"A two-parameter continuous distribution for positive event times whose logarithm is logistic; its survival function has a heavy tail, and its hazard may rise and then fall.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.192Z"},{"slug":"log-logistic-model","canonical_uri":"https://healtheconomics.wiki/concept/log-logistic-model","name":"Log-Logistic Model","short_definition":"A survival model based on the log-logistic distribution, representing a hazard function that rises to a peak and then declines.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:21.319Z"},{"slug":"log-normal-distribution","canonical_uri":"https://healtheconomics.wiki/concept/log-normal-distribution","name":"Log-Normal Distribution","short_definition":"A probability distribution in which the logarithm of the variable follows a normal distribution, often used for hazards that rise then fall.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.211Z"},{"slug":"log-normal-model","canonical_uri":"https://healtheconomics.wiki/concept/log-normal-model","name":"Log-Normal Model","short_definition":"A survival model based on the log-normal distribution, capable of representing a hazard that rises then falls, similar in shape to log-logistic.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:21.356Z"},{"slug":"log-rank-test","canonical_uri":"https://healtheconomics.wiki/concept/log-rank-test","name":"Log-Rank Test","short_definition":"The log-rank test is a nonparametric hypothesis test that compares the event-time distributions of two or more groups by accumulating observed-minus-expected events across distinct event times while accounting for right censoring.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T01:49:17.444Z"},{"slug":"logarithmic-pool","canonical_uri":"https://healtheconomics.wiki/concept/logarithmic-pool","name":"Logarithmic Pool","short_definition":"A method combining multiple experts' probability distributions by taking a weighted geometric average rather than a simple arithmetic average.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.230Z"},{"slug":"logistic-regression","canonical_uri":"https://healtheconomics.wiki/concept/logistic-regression","name":"Logistic Regression","short_definition":"Logistic regression models the log odds of a yes or no outcome, such as an admission, from patient covariates, giving odds ratios and event probabilities.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.335Z"},{"slug":"long-term-care-economics","canonical_uri":"https://healtheconomics.wiki/concept/long-term-care-economics","name":"Long-Term Care Economics","short_definition":"The study of resources, financing, incentives and outcomes involved in sustained formal and unpaid support for people with ongoing care needs.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Chronic Disease","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Chronic Disease","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-17T01:49:22.529Z"},{"slug":"longitudinal-design","canonical_uri":"https://healtheconomics.wiki/concept/longitudinal-design","name":"Longitudinal Design","short_definition":"A longitudinal design observes the same individuals or other study units at multiple time points to characterize within-unit change, temporal sequence, and differences in trajectories over time.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:21.565Z"},{"slug":"lorenz-curve","canonical_uri":"https://healtheconomics.wiki/concept/lorenz-curve","name":"Lorenz Curve","short_definition":"The Lorenz curve is a graph of the share of a total, such as health or health spending, held by each cumulative share of people ranked lowest to highest.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.411Z"},{"slug":"loss-to-follow-up","canonical_uri":"https://healtheconomics.wiki/concept/loss-to-follow-up","name":"Loss to Follow-Up","short_definition":"Loss to follow-up occurs when trial participants stop providing data before follow-up ends, so later outcomes, costs and QALYs can be missing.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.400Z"},{"slug":"malmquist-index","canonical_uri":"https://healtheconomics.wiki/concept/malmquist-index","name":"Malmquist Index","short_definition":"The Malmquist index measures change in hospital or health system productivity between two periods, split into catch-up to best practice and frontier shift.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Productivity Measurement","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Productivity Measurement","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.961Z"},{"slug":"managed-access-agreement","canonical_uri":"https://healtheconomics.wiki/concept/managed-access-agreement","name":"Managed Access Agreement","short_definition":"A managed access agreement is a time-limited NHS England deal funding a promising but uncertain medicine while data are collected for a NICE reappraisal.","category":"Health Policy","category_path":"Health Systems › Health Policy › Market Access","level_1":"Health Systems","level_2":"Health Policy","level_3":"Market Access","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-13T23:53:22.048Z"},{"slug":"managed-entry-agreement","canonical_uri":"https://healtheconomics.wiki/concept/managed-entry-agreement","name":"Managed Entry Agreement","short_definition":"An arrangement governing the conditions under which a technology enters the market, often incorporating outcomes-based payment or coverage with evidence development.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Market Access","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Market Access","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:10.319Z"},{"slug":"mantel-haenszel-method","canonical_uri":"https://healtheconomics.wiki/concept/mantel-haenszel-method","name":"Mantel-Haenszel Method","short_definition":"The Mantel-Haenszel method pools 2x2 tables from trials or strata into one fixed-effect odds ratio, risk ratio or risk difference for HTA meta-analysis.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T22:25:39.041Z"},{"slug":"mapping-function","canonical_uri":"https://healtheconomics.wiki/concept/mapping-function","name":"Mapping Function","short_definition":"A mapping function is a fitted equation predicting a preference-based utility such as EQ-5D from clinical or other outcome scores, to estimate QALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.487Z"},{"slug":"mapping-study","canonical_uri":"https://healtheconomics.wiki/concept/mapping-study","name":"Mapping Study","short_definition":"Mapping study is research that estimates and validates a model predicting health state utilities from a non-preference-based measure, for use in QALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.447Z"},{"slug":"marginal-analysis","canonical_uri":"https://healtheconomics.wiki/concept/marginal-analysis","name":"Marginal Analysis","short_definition":"Marginal analysis compares the extra cost and extra benefit of a small change in a health service, to judge whether expanding or cutting it is worthwhile.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.18","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.710Z"},{"slug":"marginal-cost","canonical_uri":"https://healtheconomics.wiki/concept/marginal-cost","name":"Marginal Cost","short_definition":"Marginal cost is the change in total economic cost caused by producing one additional unit of output at a specified level of activity and over a specified time horizon.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:10.419Z"},{"slug":"marginal-cost-of-healthcare","canonical_uri":"https://healtheconomics.wiki/concept/marginal-cost-of-healthcare","name":"Marginal Cost of Healthcare","short_definition":"The additional cost of providing one more unit of healthcare service, such as treating one further patient.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:03.716Z"},{"slug":"marginal-rate-of-substitution","canonical_uri":"https://healtheconomics.wiki/concept/marginal-rate-of-substitution","name":"Marginal Rate of Substitution","short_definition":"The rate at which a consumer is willing to trade one good for another while keeping the same overall level of satisfaction.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:10.459Z"},{"slug":"market-equilibrium","canonical_uri":"https://healtheconomics.wiki/concept/market-equilibrium","name":"Market Equilibrium","short_definition":"Market equilibrium is a price-and-quantity outcome at which planned demand equals planned supply for a specified good or service under the conditions of a stated market model.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:10.499Z"},{"slug":"market-failure","canonical_uri":"https://healtheconomics.wiki/concept/market-failure","name":"Market Failure","short_definition":"Market failure occurs when markets do not allocate resources efficiently, as in health care through externalities, unequal information or insurance gaps.","category":"Economic Evaluation","category_path":"Health Economics › Microeconomics› Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.12","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.551Z"},{"slug":"markov-assumption","canonical_uri":"https://healtheconomics.wiki/concept/markov-assumption","name":"Markov Assumption","short_definition":"The Markov assumption is that the next transition in a state-transition model depends only on the current state and model time, not on earlier history.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.296Z"},{"slug":"markov-chain","canonical_uri":"https://healtheconomics.wiki/concept/markov-chain","name":"Markov Chain","short_definition":"A Markov chain is a random process moving between states in which the next state depends only on the current state. It underlies Markov cohort models.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.371Z"},{"slug":"markov-chain-monte-carlo","canonical_uri":"https://healtheconomics.wiki/concept/markov-chain-monte-carlo","name":"Markov Chain Monte Carlo","short_definition":"Markov chain Monte Carlo is a class of simulation methods that constructs a Markov chain with a chosen target distribution as its stationary distribution and uses dependent draws from the chain to approximate expectations and uncertainty under that distribution.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.626Z"},{"slug":"markov-cohort-model","canonical_uri":"https://healtheconomics.wiki/concept/markov-cohort-model","name":"Markov Cohort Model","short_definition":"A Markov cohort model is a health economic model that moves a hypothetical cohort between health states each cycle to estimate expected costs and QALYs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.563Z"},{"slug":"markov-microsimulation","canonical_uri":"https://healtheconomics.wiki/concept/markov-microsimulation","name":"Markov Microsimulation","short_definition":"Markov microsimulation is an individual-level state-transition modeling method that simulates each person's sequence of health states over time using transition probabilities that may depend on current state, personal characteristics, time, and explicitly retained history.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:22.595Z"},{"slug":"markov-model","canonical_uri":"https://healtheconomics.wiki/concept/markov-model","name":"Markov Model","short_definition":"A Markov model is a memoryless state-transition model used in economic evaluation: people move between health states each cycle, accruing costs and QALYs.","category":"Model Structures","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.48","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.770Z"},{"slug":"martingale-residual","canonical_uri":"https://healtheconomics.wiki/concept/martingale-residual","name":"Martingale Residual","short_definition":"A residual used to diagnose the fit of a Cox model, checking the functional form of continuous covariates and identifying influential observations.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:22.633Z"},{"slug":"matching-adjusted-indirect-comparison","canonical_uri":"https://healtheconomics.wiki/concept/matching-adjusted-indirect-comparison","name":"Matching-Adjusted Indirect Comparison","short_definition":"Matching-adjusted indirect comparison (MAIC) compares treatments across trials in HTA by weighting one trial's patients to match another's published data.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.638Z"},{"slug":"matrix-algebra","canonical_uri":"https://healtheconomics.wiki/concept/matrix-algebra","name":"Matrix Algebra","short_definition":"Matrix algebra provides a compact way to represent and manipulate related quantities arranged in rows and columns.","category":"Linear Algebra","category_path":"Computer Science › Linear Algebra › Matrix Operations","level_1":"Computer Science","level_2":"Linear Algebra","level_3":"Matrix Operations","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:10.638Z"},{"slug":"matrix-inversion","canonical_uri":"https://healtheconomics.wiki/concept/matrix-inversion","name":"Matrix Inversion","short_definition":"Matrix inversion finds a matrix that reverses the effect of a square matrix.","category":"Linear Algebra","category_path":"Computer Science › Linear Algebra › Matrix Operations","level_1":"Computer Science","level_2":"Linear Algebra","level_3":"Matrix Operations","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.702Z"},{"slug":"matrix-multiplication","canonical_uri":"https://healtheconomics.wiki/concept/matrix-multiplication","name":"Matrix Multiplication","short_definition":"Matrix multiplication combines two organised sets of quantities so that the rows of the first matrix are matched with the columns of the second.","category":"Linear Algebra","category_path":"Computer Science › Linear Algebra › Matrix Operations","level_1":"Computer Science","level_2":"Linear Algebra","level_3":"Matrix Operations","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:22.803Z"},{"slug":"maximum-likelihood-estimation","canonical_uri":"https://healtheconomics.wiki/concept/maximum-likelihood-estimation","name":"Maximum Likelihood Estimation","short_definition":"Maximum likelihood estimation (MLE) fits models such as survival curves by choosing the parameter values that make the observed data most probable.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.713Z"},{"slug":"mcda-in-hta","canonical_uri":"https://healtheconomics.wiki/concept/mcda-in-hta","name":"MCDA in HTA","short_definition":"MCDA in HTA uses multi-criteria decision analysis to appraise health technologies on explicit, often weighted, criteria such as health gain and severity.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.443Z"},{"slug":"mean","canonical_uri":"https://healtheconomics.wiki/concept/mean","name":"Mean","short_definition":"A measure of central tendency obtained, in its arithmetic form, by dividing the sum of values by their count; a population mean is the corresponding expected value.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:22.899Z"},{"slug":"mean-absolute-error","canonical_uri":"https://healtheconomics.wiki/concept/mean-absolute-error","name":"Mean Absolute Error","short_definition":"The arithmetic average of the absolute differences between numerical predictions and their corresponding observed values, expressed in the outcome’s units.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.760Z"},{"slug":"mean-difference","canonical_uri":"https://healtheconomics.wiki/concept/mean-difference","name":"Mean Difference","short_definition":"The mean difference (MD) is the difference between two groups' average values on one continuous scale, the usual effect measure for continuous outcomes.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.616Z"},{"slug":"mean-squared-error","canonical_uri":"https://healtheconomics.wiki/concept/mean-squared-error","name":"Mean Squared Error","short_definition":"Mean squared error is the average of squared differences between predictions or estimates and their corresponding observed or reference values, evaluated over a specified set or sampling process.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.779Z"},{"slug":"measurement-error","canonical_uri":"https://healtheconomics.wiki/concept/measurement-error","name":"Measurement Error","short_definition":"Measurement error is the discrepancy between an observed or recorded value and the intended value of the quantity being measured, arising from the measurement process rather than sampling alone.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.798Z"},{"slug":"measurement-scale-type","canonical_uri":"https://healtheconomics.wiki/concept/measurement-scale-type","name":"Measurement Scale Type","short_definition":"Measurement scale type is a variable's level, nominal, ordinal, interval or ratio, which sets valid arithmetic, as with EQ-5D level medians or cost ratios.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:29.139Z"},{"slug":"mechanism-design","canonical_uri":"https://healtheconomics.wiki/concept/mechanism-design","name":"Mechanism Design","short_definition":"Mechanism design uses game theory to set rules, such as auctions, tenders or matching schemes, under which self-interested choices serve a chosen goal.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.515Z"},{"slug":"mediation-analysis","canonical_uri":"https://healtheconomics.wiki/concept/mediation-analysis","name":"Mediation Analysis","short_definition":"Mediation analysis is a statistical method that splits a treatment's effect on health or costs into a direct effect and an indirect effect via a mediator.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.787Z"},{"slug":"medical-loss-ratio","canonical_uri":"https://healtheconomics.wiki/concept/medical-loss-ratio","name":"Medical Loss Ratio","short_definition":"The medical loss ratio (MLR) is the share of a health insurer's premium income spent on medical claims and quality improvement, with a US legal minimum.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.861Z"},{"slug":"medical-malpractice","canonical_uri":"https://healtheconomics.wiki/concept/medical-malpractice","name":"Medical Malpractice","short_definition":"Medical malpractice is injury to a patient caused by a health professional's negligent care, for which the law allows a claim for compensation.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Regulation","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Regulation","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.426Z"},{"slug":"medication-adherence","canonical_uri":"https://healtheconomics.wiki/concept/medication-adherence","name":"Medication Adherence","short_definition":"The extent to which a patient takes a prescribed medication as recommended, covering consistent daily use and appropriate long-term continuation.","category":"Pharmaceutical Care","category_path":"Pharmacy Practice › Pharmaceutical Care › Medication Adherence","level_1":"Pharmacy Practice","level_2":"Pharmaceutical Care","level_3":"Medication Adherence","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:29.892Z"},{"slug":"medication-possession-ratio","canonical_uri":"https://healtheconomics.wiki/concept/medication-possession-ratio","name":"Medication Possession Ratio","short_definition":"The medication possession ratio (MPR) is the total days' supply dispensed divided by the days in the period. Unlike PDC, it can exceed 1 unless capped.","category":"Outcome Measures","category_path":"Pharmacy Practice › Pharmaceutical Care › Medication Adherence","level_1":"Pharmacy Practice","level_2":"Pharmaceutical Care","level_3":"Medication Adherence","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-13T23:53:23.309Z"},{"slug":"memorylessness","canonical_uri":"https://healtheconomics.wiki/concept/memorylessness","name":"Memorylessness","short_definition":"Memorylessness is the property that the chance of the next event does not depend on time already waited, as in Markov models and exponential survival.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:15.934Z"},{"slug":"mental-health-economics","canonical_uri":"https://healtheconomics.wiki/concept/mental-health-economics","name":"Mental Health Economics","short_definition":"The broad application of health economic evaluation to mental health conditions and treatment, spanning prevention, psychotherapy, medication, and specialist psychiatric services.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Mental Health","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Mental Health","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-17T01:49:22.569Z"},{"slug":"meta-analysis","canonical_uri":"https://healtheconomics.wiki/concept/meta-analysis","name":"Meta-Analysis","short_definition":"Meta-analysis statistically combines effect estimates from multiple studies addressing a sufficiently similar question.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:03.957Z"},{"slug":"meta-regression","canonical_uri":"https://healtheconomics.wiki/concept/meta-regression","name":"Meta-Regression","short_definition":"Meta-regression is a precision-weighted regression of study effect estimates on study characteristics, explaining heterogeneity in meta-analyses for HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T02:26:45.753Z"},{"slug":"method-of-moments","canonical_uri":"https://healtheconomics.wiki/concept/method-of-moments","name":"Method of Moments","short_definition":"A technique estimating a distribution's parameters by equating sample moments, such as mean and variance, to their theoretical population equivalents.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:23.707Z"},{"slug":"metropolis-hastings","canonical_uri":"https://healtheconomics.wiki/concept/metropolis-hastings","name":"Metropolis-Hastings","short_definition":"Metropolis-Hastings is a Markov chain Monte Carlo algorithm that samples the posterior of health economic model inputs by accepting or rejecting proposals.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.007Z"},{"slug":"micro-costing","canonical_uri":"https://healtheconomics.wiki/concept/micro-costing","name":"Micro-Costing","short_definition":"Micro-costing is a detailed method of estimating the cost of healthcare activities by identifying and measuring their individual resource components and valuing each component with an appropriate unit cost.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.890Z"},{"slug":"microsimulation","canonical_uri":"https://healtheconomics.wiki/concept/microsimulation","name":"Microsimulation","short_definition":"Microsimulation models individuals one at a time, allowing their characteristics and event histories to influence future outcomes.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Microsimulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Microsimulation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:03.994Z"},{"slug":"minimal-clinically-important-difference","canonical_uri":"https://healtheconomics.wiki/concept/minimal-clinically-important-difference","name":"Minimal Clinically Important Difference","short_definition":"The minimal clinically important difference (MCID) is the smallest change in an outcome score that patients perceive as important, beneficial or harmful.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:21.950Z"},{"slug":"minimisation","canonical_uri":"https://healtheconomics.wiki/concept/minimisation","name":"Minimisation (Trial Allocation)","short_definition":"Minimisation is a trial allocation method steering each new participant to the arm best balancing chosen prognostic factors, often with a random element.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:11.224Z"},{"slug":"misclassification","canonical_uri":"https://healtheconomics.wiki/concept/misclassification","name":"Misclassification","short_definition":"Misclassification is recording people in the wrong category of exposure, outcome or covariate, which can bias effect, cost and outcome estimates.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:38.847Z"},{"slug":"missing-at-random","canonical_uri":"https://healtheconomics.wiki/concept/missing-at-random","name":"Missing at Random","short_definition":"Missing at random is a missing-data mechanism in which, conditional on observed data, the probability of a missingness pattern does not depend on the values that remain unobserved.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.123Z"},{"slug":"missing-completely-at-random","canonical_uri":"https://healtheconomics.wiki/concept/missing-completely-at-random","name":"Missing Completely at Random","short_definition":"Missing completely at random (MCAR) is a missing data mechanism in which the chance a cost or outcome is missing is unrelated to any data, seen or unseen.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.081Z"},{"slug":"missing-data","canonical_uri":"https://healtheconomics.wiki/concept/missing-data","name":"Missing Data","short_definition":"Unobserved or unavailable values required for a specified analysis, whose consequences depend on the pattern, mechanism and target estimand.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.163Z"},{"slug":"missing-not-at-random","canonical_uri":"https://healtheconomics.wiki/concept/missing-not-at-random","name":"Missing Not at Random","short_definition":"Missing not at random describes a missing-data mechanism in which the probability that a value is unobserved depends on that unobserved value even after conditioning on the available observed information.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.201Z"},{"slug":"mixed-effects-model","canonical_uri":"https://healtheconomics.wiki/concept/mixed-effects-model","name":"Mixed Effects Model","short_definition":"A mixed effects model combines population-level fixed coefficients with probability-modelled variation across groups or individuals to analyse outcomes with clustered or repeated observations.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:24.217Z"},{"slug":"mixture-cure-model","canonical_uri":"https://healtheconomics.wiki/concept/mixture-cure-model","name":"Mixture Cure Model","short_definition":"A cure model treating the population as a mixture of a cured fraction facing only background mortality and an uncured fraction remaining at risk.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:24.294Z"},{"slug":"mixture-model","canonical_uri":"https://healtheconomics.wiki/concept/mixture-model","name":"Mixture Model","short_definition":"A statistical model representing a population as a combination of two or more distinct subgroups, each following its own underlying distribution.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.220Z"},{"slug":"model-averaging","canonical_uri":"https://healtheconomics.wiki/concept/model-averaging","name":"Model Averaging","short_definition":"Model averaging combines results from several plausible models, weighted by their support, so health economic estimates reflect doubt about model choice.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.156Z"},{"slug":"model-diagnostics","canonical_uri":"https://healtheconomics.wiki/concept/model-diagnostics","name":"Model Diagnostics","short_definition":"Model diagnostics are checks that show whether a health economic model, or a statistical model feeding it, fits its data and behaves as intended.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.229Z"},{"slug":"model-selection","canonical_uri":"https://healtheconomics.wiki/concept/model-selection","name":"Model Selection","short_definition":"The process of choosing a model from plausible alternatives using criteria suited to the intended question, data, predictive or explanatory performance, and decision context.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:04.278Z"},{"slug":"model-validation","canonical_uri":"https://healtheconomics.wiki/concept/model-validation","name":"Model Validation","short_definition":"Model validation is the structured assessment of whether a model is sufficiently accurate, credible, and fit for its stated decision purpose.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.454Z"},{"slug":"modified-rankin-scale","canonical_uri":"https://healtheconomics.wiki/concept/modified-rankin-scale","name":"Modified Rankin Scale","short_definition":"Modified Rankin Scale (mRS) is a clinician-rated 0 to 6 grade of disability after stroke, used as a trial outcome and to define stroke model health states.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.459Z"},{"slug":"monetary-valuation","canonical_uri":"https://healtheconomics.wiki/concept/monetary-valuation","name":"Monetary Valuation","short_definition":"Monetary valuation expresses a health outcome or other non-market good in money terms, using stated preference, revealed preference or wellbeing methods.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.012Z"},{"slug":"monte-carlo-error","canonical_uri":"https://healtheconomics.wiki/concept/monte-carlo-error","name":"Monte Carlo Error","short_definition":"Monte Carlo error is the random numerical difference between a finite-simulation estimate and the target quantity it would approach with sufficiently many valid draws under the specified model.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.073Z"},{"slug":"monte-carlo-integration","canonical_uri":"https://healtheconomics.wiki/concept/monte-carlo-integration","name":"Monte Carlo Integration","short_definition":"Monte Carlo integration estimates an integral, such as a model's expected cost or QALYs, by averaging the integrand over randomly sampled inputs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.303Z"},{"slug":"monte-carlo-simulation","canonical_uri":"https://healtheconomics.wiki/concept/monte-carlo-simulation","name":"Monte Carlo Simulation","short_definition":"Monte Carlo simulation uses repeated random sampling to show how uncertainty in model inputs produces uncertainty in model outputs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Microsimulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Microsimulation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:04.390Z"},{"slug":"moral-hazard","canonical_uri":"https://healtheconomics.wiki/concept/moral-hazard","name":"Moral Hazard","short_definition":"Moral hazard is the change in behaviour, such as greater use of healthcare, that occurs when insurance shields people from the full cost of their choices.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.13","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.592Z"},{"slug":"moral-hazard-in-health-insurance","canonical_uri":"https://healtheconomics.wiki/concept/moral-hazard-in-health-insurance","name":"Moral Hazard in Health Insurance","short_definition":"Moral hazard in health insurance is extra healthcare use when cover lowers the price patients pay, and any reduced effort to stay healthy once insured.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Insurance","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Insurance","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.588Z"},{"slug":"morris-method","canonical_uri":"https://healtheconomics.wiki/concept/morris-method","name":"Morris Method","short_definition":"A global sensitivity-screening method that samples one-input-at-a-time elementary effects across multiple model-input settings to identify influential or varying inputs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:04.409Z"},{"slug":"mortality-rate","canonical_uri":"https://healtheconomics.wiki/concept/mortality-rate","name":"Mortality Rate","short_definition":"A mortality rate measures deaths in a defined population over a specified period relative to the corresponding population or person-time at risk, with its scale and denominator stated explicitly.","category":"Health Policy","category_path":"Health Systems › Health Policy › Population Health Outcomes","level_1":"Health Systems","level_2":"Health Policy","level_3":"Population Health Outcomes","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.630Z"},{"slug":"moving-target-problem","canonical_uri":"https://healtheconomics.wiki/concept/moving-target-problem","name":"Moving Target Problem","short_definition":"The moving target problem arises when a device, software or procedure changes during HTA, so evidence on it may be out of date by the time of the decision.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.372Z"},{"slug":"multi-attribute-utility","canonical_uri":"https://healtheconomics.wiki/concept/multi-attribute-utility","name":"Multi-Attribute Utility","short_definition":"Multi-attribute utility is a health state utility built by combining utilities for several health dimensions with an additive or multiplicative function.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.376Z"},{"slug":"multi-criteria-decision-analysis","canonical_uri":"https://healtheconomics.wiki/concept/multi-criteria-decision-analysis","name":"Multi-Criteria Decision Analysis","short_definition":"Multi-criteria decision analysis is a family of structured methods that compares alternatives across multiple explicit criteria and incorporates judgments about the trade-offs among them.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.688Z"},{"slug":"multi-objective-optimisation","canonical_uri":"https://healtheconomics.wiki/concept/multi-objective-optimisation","name":"Multi-Objective Optimisation","short_definition":"Multi-objective optimisation finds the efficient trade-offs when a health budget decision has conflicting goals, such as total QALYs and health equity.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.450Z"},{"slug":"multi-state-life-table","canonical_uri":"https://healtheconomics.wiki/concept/multi-state-life-table","name":"Multi-State Life Table","short_definition":"A life-table framework that uses transitions among multiple living states and death to estimate how long a specified population or starting group is expected to spend in each state.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:04.446Z"},{"slug":"multicollinearity","canonical_uri":"https://healtheconomics.wiki/concept/multicollinearity","name":"Multicollinearity","short_definition":"A condition in which predictors in a model are linearly dependent or nearly so, making their separate coefficients difficult or impossible to estimate precisely.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:11.811Z"},{"slug":"multinomial-logit-model","canonical_uri":"https://healtheconomics.wiki/concept/multinomial-logit-model","name":"Multinomial Logit Model","short_definition":"Multinomial logit model (MNL) is a random utility choice model used to estimate preference weights from DCE data, assuming IID extreme value errors.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.940Z"},{"slug":"multiple-imputation","canonical_uri":"https://healtheconomics.wiki/concept/multiple-imputation","name":"Multiple Imputation","short_definition":"Multiple imputation is a missing-data method that creates several plausible completed datasets, analyses each for the same target, and pools the estimates and their uncertainty to reflect uncertainty about unobserved values.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.811Z"},{"slug":"multiple-regression","canonical_uri":"https://healtheconomics.wiki/concept/multiple-regression","name":"Multiple Regression","short_definition":"Multiple regression models one outcome, such as patient cost or QALYs, on two or more explanatory variables, adjusting each coefficient for the others.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.534Z"},{"slug":"multivariate-meta-analysis","canonical_uri":"https://healtheconomics.wiki/concept/multivariate-meta-analysis","name":"Multivariate Meta-Analysis","short_definition":"Multivariate meta-analysis pools study results on two or more correlated outcomes, such as progression-free and overall survival, in a single joint model.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.523Z"},{"slug":"n-of-1-trial","canonical_uri":"https://healtheconomics.wiki/concept/n-of-1-trial","name":"N-of-1 Trial","short_definition":"An N-of-1 trial is a randomised multiple crossover trial in one patient, comparing treatments over repeated periods to guide that patient's treatment.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.597Z"},{"slug":"narrative-review","canonical_uri":"https://healtheconomics.wiki/concept/narrative-review","name":"Narrative Review","short_definition":"A narrative review is a literature review that summarises research on a topic without a prespecified, reproducible search, selection and appraisal method.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:30.888Z"},{"slug":"nash-equilibrium-health","canonical_uri":"https://healtheconomics.wiki/concept/nash-equilibrium-health","name":"Nash Equilibrium","short_definition":"A Nash equilibrium is a set of strategies, one per player, from which no player, such as a payer, provider or patient, gains by changing strategy alone.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.666Z"},{"slug":"near-miss-rate","canonical_uri":"https://healtheconomics.wiki/concept/near-miss-rate","name":"Near Miss Rate","short_definition":"A near miss rate is a patient safety indicator counting incidents stopped before they reach a patient per unit of care, such as per 1,000 medication doses.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.621Z"},{"slug":"negative-binomial","canonical_uri":"https://healtheconomics.wiki/concept/negative-binomial","name":"Negative Binomial","short_definition":"A discrete probability distribution modelling count data with more variability than a Poisson distribution would predict, known as overdispersion.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:39.082Z"},{"slug":"negative-binomial-regression","canonical_uri":"https://healtheconomics.wiki/concept/negative-binomial-regression","name":"Negative Binomial Regression","short_definition":"Negative binomial regression models counts of health care use, such as admissions or exacerbations, whose variance is larger than a Poisson model allows.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.670Z"},{"slug":"negative-externality","canonical_uri":"https://healtheconomics.wiki/concept/negative-externality","name":"Negative Externality","short_definition":"A negative externality is an uncompensated cost, such as second-hand smoke or antibiotic resistance, that an activity imposes on third parties.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.744Z"},{"slug":"negative-likelihood-ratio","canonical_uri":"https://healtheconomics.wiki/concept/negative-likelihood-ratio","name":"Negative Likelihood Ratio","short_definition":"Negative Likelihood Ratio (LR-): (1 minus sensitivity) over specificity, the factor by which a negative test multiplies disease odds in decision models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.133Z"},{"slug":"negative-predictive-value","canonical_uri":"https://healtheconomics.wiki/concept/negative-predictive-value","name":"Negative Predictive Value","short_definition":"Negative predictive value (NPV) is the share of people with a negative test result who truly lack the condition, which models use to count missed cases.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.817Z"},{"slug":"negative-study","canonical_uri":"https://healtheconomics.wiki/concept/negative-study","name":"Negative Study","short_definition":"A negative study is one whose main result shows no statistically significant or clinically important effect, which is not proof that no effect exists.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-15T00:58:31.081Z"},{"slug":"nelder-mead-method","canonical_uri":"https://healtheconomics.wiki/concept/nelder-mead-method","name":"Nelder-Mead Method","short_definition":"The Nelder-Mead method is a derivative-free algorithm that moves a simplex of trial points to minimise a score, used to calibrate health economic models.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.892Z"},{"slug":"nelson-aalen-estimator","canonical_uri":"https://healtheconomics.wiki/concept/nelson-aalen-estimator","name":"Nelson-Aalen Estimator","short_definition":"A non-parametric method for estimating the cumulative hazard function from censored data, closely related to the Kaplan-Meier estimator.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:31.138Z"},{"slug":"net-benefit","canonical_uri":"https://healtheconomics.wiki/concept/net-benefit","name":"Net Benefit","short_definition":"Net benefit places health gains and costs on one scale by valuing health at a cost-effectiveness threshold, or directly in money, and subtracting costs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.193Z"},{"slug":"net-benefit-approach","canonical_uri":"https://healtheconomics.wiki/concept/net-benefit-approach","name":"Net Benefit Approach","short_definition":"The net benefit approach is a cost-effectiveness decision framework that ranks options by net benefit at a stated threshold instead of by ratios.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.254Z"},{"slug":"net-health-benefit","canonical_uri":"https://healtheconomics.wiki/concept/net-health-benefit","name":"Net Health Benefit","short_definition":"Net health benefit (NHB) is the health an option gains, in QALYs, minus the QALYs its extra cost would buy elsewhere at the cost-effectiveness threshold.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.18","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.314Z"},{"slug":"net-monetary-benefit","canonical_uri":"https://healtheconomics.wiki/concept/net-monetary-benefit","name":"Net Monetary Benefit","short_definition":"Net monetary benefit (NMB) is an option's health outcome valued in money at a cost-effectiveness threshold minus its cost, used to rank healthcare options.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.35","status":"PUBLISHED","published_at":"2026-10-17T20:34:52.464Z"},{"slug":"net-present-value","canonical_uri":"https://healtheconomics.wiki/concept/net-present-value","name":"Net Present Value","short_definition":"Net present value is the sum of monetary net flows at different times after each has been discounted to a common valuation date, including the initial flow.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.374Z"},{"slug":"net-survival-model","canonical_uri":"https://healtheconomics.wiki/concept/net-survival-model","name":"Net Survival Model","short_definition":"A survival model estimating the survival a population would experience if the disease studied were the only possible cause of death.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T00:51:24.239Z"},{"slug":"network-meta-analysis","canonical_uri":"https://healtheconomics.wiki/concept/network-meta-analysis","name":"Network Meta-Analysis","short_definition":"Network meta-analysis (NMA) compares three or more treatments in one analysis, pooling direct and indirect trial evidence to inform HTA decisions.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.433Z"},{"slug":"network-meta-analysis-hta","canonical_uri":"https://healtheconomics.wiki/concept/network-meta-analysis-hta","name":"Network Meta-Analysis HTA","short_definition":"The application of network meta-analysis specifically within health technology assessment, generating comparative effectiveness estimates when treatments were never studied together.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:26.881Z"},{"slug":"newton-raphson-method","canonical_uri":"https://healtheconomics.wiki/concept/newton-raphson-method","name":"Newton-Raphson Method","short_definition":"The Newton–Raphson method is an iterative numerical algorithm that uses local derivative information to find a root of an equation.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:27.052Z"},{"slug":"node-splitting","canonical_uri":"https://healtheconomics.wiki/concept/node-splitting","name":"Node-Splitting","short_definition":"Node-splitting is a network meta-analysis inconsistency check that estimates one comparison separately from direct and indirect evidence and compares them.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:16.967Z"},{"slug":"nominal-scale","canonical_uri":"https://healtheconomics.wiki/concept/nominal-scale","name":"Nominal Scale","short_definition":"Nominal scale is a level of measurement whose numbers only name categories, such as trial arm or EQ-5D dimension, so counts are valid but averages are not.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-17T15:03:09.638Z"},{"slug":"non-inferiority-trial","canonical_uri":"https://healtheconomics.wiki/concept/non-inferiority-trial","name":"Non-Inferiority Trial","short_definition":"A non-inferiority trial tests whether a new treatment is worse than an active comparator by less than a preset margin, often because it costs less.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.043Z"},{"slug":"non-mixture-cure-model","canonical_uri":"https://healtheconomics.wiki/concept/non-mixture-cure-model","name":"Non-Mixture Cure Model","short_definition":"An alternative cure model structure formulating survival directly in terms of the cured fraction without explicitly splitting the population into two subgroups.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:27.241Z"},{"slug":"non-parametric-estimation","canonical_uri":"https://healtheconomics.wiki/concept/non-parametric-estimation","name":"Non-Parametric Estimation","short_definition":"Non-parametric estimation derives a survival curve or other distribution from observed data, as Kaplan-Meier does, with no assumed mathematical form.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.117Z"},{"slug":"non-parametric-survival","canonical_uri":"https://healtheconomics.wiki/concept/non-parametric-survival","name":"Non-Parametric Survival","short_definition":"Non-parametric survival is a survival estimate taken directly from observed time-to-event data, such as a Kaplan-Meier curve, with no assumed distribution.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.191Z"},{"slug":"non-randomised-controlled-trial","canonical_uri":"https://healtheconomics.wiki/concept/non-randomised-controlled-trial","name":"Non-Randomised Controlled Trial","short_definition":"A non-randomised controlled trial is a trial where investigators assign people to treatment or control without chance, so its estimates risk confounding.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.286Z"},{"slug":"nonlinear-programming","canonical_uri":"https://healtheconomics.wiki/concept/nonlinear-programming","name":"Nonlinear Programming","short_definition":"Nonlinear programming is the optimization of an objective function subject to equality, inequality, or bound constraints when the objective or at least one constraint is nonlinear in the decision variables.","category":"Optimisation","category_path":"Computer Science › Optimisation › Constrained Optimisation","level_1":"Computer Science","level_2":"Optimisation","level_3":"Constrained Optimisation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:27.453Z"},{"slug":"normal-distribution","canonical_uri":"https://healtheconomics.wiki/concept/normal-distribution","name":"Normal Distribution","short_definition":"A normal distribution is a continuous, symmetric probability distribution characterised by a mean that sets its centre and a positive standard deviation that sets its spread.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:31.489Z"},{"slug":"nottingham-health-profile","canonical_uri":"https://healtheconomics.wiki/concept/nottingham-health-profile","name":"Nottingham Health Profile","short_definition":"Nottingham Health Profile (NHP) is a generic measure of perceived physical, social and emotional health problems, scored by section, not as a QALY utility.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.488Z"},{"slug":"null-hypothesis","canonical_uri":"https://healtheconomics.wiki/concept/null-hypothesis","name":"Null Hypothesis","short_definition":"In hypothesis testing, the default assumption of no true effect or difference between the groups or conditions being compared.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:04.841Z"},{"slug":"number-needed-to-treat","canonical_uri":"https://healtheconomics.wiki/concept/number-needed-to-treat","name":"Number Needed to Treat","short_definition":"The reciprocal of a nonzero absolute difference in event risk between an intervention and comparator, interpreted as the expected number treated for one additional beneficial or harmful outcome over a stated period.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:31.636Z"},{"slug":"numerical-integration","canonical_uri":"https://healtheconomics.wiki/concept/numerical-integration","name":"Numerical Integration","short_definition":"Numerical integration approximates the area represented by a definite integral when an exact antiderivative is unavailable, inconvenient or evaluated from discrete data.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:27.659Z"},{"slug":"numerical-method","canonical_uri":"https://healtheconomics.wiki/concept/numerical-method","name":"Numerical Method","short_definition":"A numerical method is a systematic computational procedure that approximates the solution of a mathematical problem through finite arithmetic operations, with accuracy assessed through error, convergence, stability, and conditioning.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:31.656Z"},{"slug":"numerical-optimisation","canonical_uri":"https://healtheconomics.wiki/concept/numerical-optimisation","name":"Numerical Optimisation","short_definition":"Numerical optimisation uses iterative computational methods to find decision or parameter values that minimise or maximise an objective function.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:53:27.697Z"},{"slug":"nyha-functional-classification","canonical_uri":"https://healtheconomics.wiki/concept/nyha-functional-classification","name":"NYHA Functional Classification","short_definition":"NYHA Functional Classification is a clinician-rated four-class grading of heart failure, used to set eligibility, health states and utilities in models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-17T15:03:09.220Z"},{"slug":"objective-response-rate","canonical_uri":"https://healtheconomics.wiki/concept/objective-response-rate","name":"Objective Response Rate","short_definition":"Objective response rate is the proportion of participants in a prespecified analysis population who achieve a complete or partial tumor response according to defined response criteria during the assessment period, with any confirmation requirement stated.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Oncology Outcomes","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology Outcomes","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:31.719Z"},{"slug":"oblique-rotation","canonical_uri":"https://healtheconomics.wiki/concept/oblique-rotation","name":"Oblique Rotation","short_definition":"Oblique rotation is a factor analysis step that lets rotated factors correlate, used when health domains such as physical and mental health are related.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.265Z"},{"slug":"observational-study","canonical_uri":"https://healtheconomics.wiki/concept/observational-study","name":"Observational Study","short_definition":"A study that observes exposures and outcomes without investigator assignment of the exposure under investigation, using a specified design to describe patterns or assess associations and, under additional assumptions, causal effects.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:04.933Z"},{"slug":"observed-to-expected-ratio","canonical_uri":"https://healtheconomics.wiki/concept/observed-to-expected-ratio","name":"Observed-to-Expected Ratio","short_definition":"The observed-to-expected (O/E) ratio divides a provider's observed events, such as deaths, by the number expected for its case mix, so 1 means as expected.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.663Z"},{"slug":"occupancy-rate","canonical_uri":"https://healtheconomics.wiki/concept/occupancy-rate","name":"Occupancy Rate","short_definition":"Occupancy rate (bed occupancy) is the percentage of a hospital's available staffed beds that hold inpatients, averaged from daily bed counts over a period.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Capacity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Capacity","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.740Z"},{"slug":"odds-ratio","canonical_uri":"https://healtheconomics.wiki/concept/odds-ratio","name":"Odds Ratio","short_definition":"The odds ratio (OR) is the odds of an outcome in one group divided by the odds in another, a common effect measure for binary outcomes in trials and HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.340Z"},{"slug":"one-way-sensitivity-analysis","canonical_uri":"https://healtheconomics.wiki/concept/one-way-sensitivity-analysis","name":"One-Way Sensitivity Analysis","short_definition":"One-way sensitivity analysis (OWSA) varies one model input at a time, holding the rest at base case, to show which inputs drive cost-effectiveness results.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.496Z"},{"slug":"opportunity-cost","canonical_uri":"https://healtheconomics.wiki/concept/opportunity-cost","name":"Opportunity Cost","short_definition":"Opportunity cost is the value of the best alternative given up when a resource is put to one use; in health care, usually health lost elsewhere.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.32","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.557Z"},{"slug":"optimal-sample-size","canonical_uri":"https://healtheconomics.wiki/concept/optimal-sample-size","name":"Optimal Sample Size","short_definition":"A study sample size selected to meet a stated design objective, such as adequate power or precision, or to maximise the expected value of information after accounting for research costs and decision delays.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:32.106Z"},{"slug":"ordinal-scaling","canonical_uri":"https://healtheconomics.wiki/concept/ordinal-scaling","name":"Ordinal Scaling","short_definition":"Ordinal scaling ranks health states or responses, such as EQ-5D levels, with unknown gaps, so medians are meaningful but sums and means of codes are not.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.415Z"},{"slug":"orthogonal-design","canonical_uri":"https://healtheconomics.wiki/concept/orthogonal-design","name":"Orthogonal Design","short_definition":"An experimental design for a choice experiment in which attribute levels are varied independently, so each attribute's effect on preference can be separated statistically.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T20:50:57.644Z"},{"slug":"orthogonal-rotation","canonical_uri":"https://healtheconomics.wiki/concept/orthogonal-rotation","name":"Orthogonal Rotation","short_definition":"Orthogonal rotation is a factor analysis step that turns factor axes to simplify loadings while keeping factors uncorrelated, as in health questionnaires.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.491Z"},{"slug":"out-of-pocket-cost","canonical_uri":"https://healtheconomics.wiki/concept/out-of-pocket-cost","name":"Out-of-Pocket Cost","short_definition":"Out-of-pocket cost is what a household pays directly for health care that no insurer or public scheme meets or repays, such as charges or private care.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Healthcare Costs","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Healthcare Costs","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:05.994Z"},{"slug":"outcome-measure","canonical_uri":"https://healtheconomics.wiki/concept/outcome-measure","name":"Outcome Measure","short_definition":"An outcome measure is an instrument or data rule quantifying a result of care, such as survival or restored function, to judge care quality and value.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.281Z"},{"slug":"outcomes-research","canonical_uri":"https://healtheconomics.wiki/concept/outcomes-research","name":"Outcomes Research","short_definition":"Outcomes research, often joined with health economics as HEOR, studies the end results of health care, such as survival, function and quality of life.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Health Services Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Health Services Research","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T02:26:45.813Z"},{"slug":"overall-survival","canonical_uri":"https://healtheconomics.wiki/concept/overall-survival","name":"Overall Survival","short_definition":"Overall survival is the time from a prespecified origin, such as randomization, diagnosis, or treatment initiation, until death from any cause, with participants not known to have died censored at their last date known alive.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Oncology Outcomes","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology Outcomes","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:56:05.142Z"},{"slug":"overfitting","canonical_uri":"https://healtheconomics.wiki/concept/overfitting","name":"Overfitting","short_definition":"Overfitting is when a cost, risk or utility model fits chance noise in its development data, so it predicts worse for new patients than its fit suggests.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.566Z"},{"slug":"oxford-hip-score","canonical_uri":"https://healtheconomics.wiki/concept/oxford-hip-score","name":"Oxford Hip Score","short_definition":"Oxford Hip Score (OHS) is a 12-item patient-reported measure of hip pain and function, scored 0 to 48, used as the hip replacement outcome in NHS PROMs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.764Z"},{"slug":"oxford-knee-score","canonical_uri":"https://healtheconomics.wiki/concept/oxford-knee-score","name":"Oxford Knee Score","short_definition":"Oxford Knee Score (OKS) is a 12-item patient-reported measure of knee pain and function, scored 0 to 48, used to judge knee replacement in NHS PROMs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.819Z"},{"slug":"p-value","canonical_uri":"https://healtheconomics.wiki/concept/p-value","name":"P-Value","short_definition":"A tail probability, calculated under a specified null hypothesis and statistical model, of obtaining a test statistic at least as extreme as the observed statistic according to the chosen test.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:56:05.184Z"},{"slug":"pairwise-deletion","canonical_uri":"https://healtheconomics.wiki/concept/pairwise-deletion","name":"Pairwise Deletion","short_definition":"Pairwise deletion is a missing data method that computes each correlation or covariance from all patients observed on both variables, so sample sizes vary.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.643Z"},{"slug":"pairwise-meta-analysis","canonical_uri":"https://healtheconomics.wiki/concept/pairwise-meta-analysis","name":"Pairwise Meta-Analysis","short_definition":"Pairwise meta-analysis is the statistical pooling of trials of the same two treatments, such as head-to-head RCTs, into one estimate of relative effect.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.617Z"},{"slug":"parameter-distribution","canonical_uri":"https://healtheconomics.wiki/concept/parameter-distribution","name":"Parameter Distribution","short_definition":"A parameter distribution is a probability model for the plausible values of an uncertain model input, specified from evidence and assumptions so its uncertainty can be propagated through an analysis.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.677Z"},{"slug":"parameter-estimation","canonical_uri":"https://healtheconomics.wiki/concept/parameter-estimation","name":"Parameter Estimation","short_definition":"Parameter estimation is the process of using evidence and a specified model or estimating rule to infer the values of quantities needed to describe a population, relationship, or decision model.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.736Z"},{"slug":"parameter-input","canonical_uri":"https://healtheconomics.wiki/concept/parameter-input","name":"Parameter Input","short_definition":"A parameter input (model parameter) is a value or distribution entered into a health economic model for a quantity such as a probability, cost or utility.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.608Z"},{"slug":"parameter-uncertainty","canonical_uri":"https://healtheconomics.wiki/concept/parameter-uncertainty","name":"Parameter Uncertainty","short_definition":"Parameter uncertainty is uncertainty in the estimated values of a health economic model's inputs, such as treatment effects, costs and utilities.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.856Z"},{"slug":"parametric-estimation","canonical_uri":"https://healtheconomics.wiki/concept/parametric-estimation","name":"Parametric Estimation","short_definition":"A statistical approach estimating a survival function by assuming the data follow a specific distribution, such as Weibull or log-normal, with estimated parameters.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:33.017Z"},{"slug":"parametric-survival","canonical_uri":"https://healtheconomics.wiki/concept/parametric-survival","name":"Parametric Survival","short_definition":"Survival estimates derived from a fitted mathematical distribution rather than directly from observed data alone, allowing extrapolation beyond the data.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:33.037Z"},{"slug":"parametric-survival-model","canonical_uri":"https://healtheconomics.wiki/concept/parametric-survival-model","name":"Parametric Survival Model","short_definition":"A parametric survival model specifies a probability distribution for time to a defined event, enabling estimation of survival and hazard functions and projection beyond observed follow-up under stated assumptions.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.915Z"},{"slug":"pareto-efficiency","canonical_uri":"https://healtheconomics.wiki/concept/pareto-efficiency","name":"Pareto Efficiency","short_definition":"Pareto efficiency, or Pareto optimality, is a state where resources such as a health budget cannot be reallocated to help anyone without harming someone.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:13.109Z"},{"slug":"pareto-frontier","canonical_uri":"https://healtheconomics.wiki/concept/pareto-frontier","name":"Pareto Frontier","short_definition":"The set of feasible options that are not dominated by another option that is at least as good on every specified objective and strictly better on at least one.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:33.113Z"},{"slug":"pareto-improvement","canonical_uri":"https://healtheconomics.wiki/concept/pareto-improvement","name":"Pareto Improvement","short_definition":"A Pareto improvement is a change, such as a reallocation of a health budget, that makes at least one person better off and nobody worse off.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:22.974Z"},{"slug":"partial-correlation","canonical_uri":"https://healtheconomics.wiki/concept/partial-correlation","name":"Partial Correlation","short_definition":"Partial correlation is the correlation between two variables, such as costs and QALYs, after the linear effects of other variables are removed from both.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.717Z"},{"slug":"partial-economic-evaluation","canonical_uri":"https://healtheconomics.wiki/concept/partial-economic-evaluation","name":"Partial Economic Evaluation","short_definition":"A partial economic evaluation studies costs alone, outcomes alone, or one option's costs and outcomes without a comparator, so cannot show value for money.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Evaluation Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Evaluation Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.793Z"},{"slug":"particle-filter","canonical_uri":"https://healtheconomics.wiki/concept/particle-filter","name":"Particle Filter","short_definition":"A sequential Monte Carlo algorithm that approximates the evolving probability distribution of a hidden state with weighted simulated particles, updating their weights as observations arrive.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:05.676Z"},{"slug":"particle-swarm-optimisation","canonical_uri":"https://healtheconomics.wiki/concept/particle-swarm-optimisation","name":"Particle Swarm Optimisation","short_definition":"Particle swarm optimisation (PSO) is a search method that moves candidate solutions towards the best ones found, used to calibrate health economic models.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.869Z"},{"slug":"partitioned-survival-model","canonical_uri":"https://healtheconomics.wiki/concept/partitioned-survival-model","name":"Partitioned Survival Model","short_definition":"A partitioned survival model is a cancer economic model that uses PFS and OS curves to split a cohort into progression-free, progressed and dead states.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.813Z"},{"slug":"patient-information-leaflet","canonical_uri":"https://healtheconomics.wiki/concept/patient-information-leaflet","name":"Patient Information Leaflet","short_definition":"A patient information leaflet (PIL) is the approved leaflet in a medicine's pack telling users how to use it safely, based on the official product summary.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Regulation","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Regulation","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:22.985Z"},{"slug":"patient-time-cost","canonical_uri":"https://healtheconomics.wiki/concept/patient-time-cost","name":"Patient Time Cost","short_definition":"Patient time cost is the value of the hours patients spend travelling to, waiting for and receiving health care, often valued at a wage rate.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:22.704Z"},{"slug":"patient-reported-outcome","canonical_uri":"https://healtheconomics.wiki/concept/patient-reported-outcome","name":"Patient-Reported Outcome","short_definition":"Any report of a patient's health status that comes directly from the patient without clinical interpretation, from symptom ratings to full quality of life instruments.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:33.720Z"},{"slug":"pattern-mixture-model","canonical_uri":"https://healtheconomics.wiki/concept/pattern-mixture-model","name":"Pattern Mixture Model","short_definition":"A pattern mixture model fits a separate model for each missing data pattern, so trial dropouts can differ from completers in health economic evaluation.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:17.943Z"},{"slug":"pearson-correlation","canonical_uri":"https://healtheconomics.wiki/concept/pearson-correlation","name":"Pearson Correlation","short_definition":"Pearson correlation is a -1 to +1 measure of linear association, the covariance over the product of standard deviations, as between costs and QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.018Z"},{"slug":"pedsql","canonical_uri":"https://healtheconomics.wiki/concept/pedsql","name":"PedsQL 4.0 Generic Core Scales","short_definition":"PedsQL 4.0 Generic Core Scales are a 23-item paediatric health-related quality of life measure, scored 0 to 100 and often mapped to utilities for QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.326Z"},{"slug":"performance-bias","canonical_uri":"https://healtheconomics.wiki/concept/performance-bias","name":"Performance Bias","short_definition":"Performance bias is systematic error from differences in care, co-interventions or behaviour between trial arms, often because people know the allocation.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:38.616Z"},{"slug":"period-prevalence","canonical_uri":"https://healtheconomics.wiki/concept/period-prevalence","name":"Period Prevalence","short_definition":"Period prevalence is the share of a population with a condition at any time in a set interval, such as a year, used to count cases in annual costings.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.093Z"},{"slug":"permutation-test","canonical_uri":"https://healtheconomics.wiki/concept/permutation-test","name":"Permutation Test","short_definition":"A non-parametric hypothesis test determining significance by repeatedly rearranging observed data labels to build an empirical distribution under the null hypothesis.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:06.267Z"},{"slug":"person-trade-off","canonical_uri":"https://healtheconomics.wiki/concept/person-trade-off","name":"Person Trade-Off","short_definition":"Person trade-off (PTO) is a valuation method asking how many people helped one way equal a set number helped another, giving social values for health care.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:25.890Z"},{"slug":"perspective","canonical_uri":"https://healtheconomics.wiki/concept/perspective","name":"Perspective","short_definition":"Perspective in health economic evaluation is the viewpoint, such as the health system, payer or society, that decides which costs and outcomes are counted.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Perspective","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.25","status":"PUBLISHED","published_at":"2026-10-21T00:55:23.036Z"},{"slug":"peto-test","canonical_uri":"https://healtheconomics.wiki/concept/peto-test","name":"Peto Test","short_definition":"The Peto test is a weighted log-rank test comparing survival between groups, weighting each event time by pooled survival so earlier events count more.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:06.285Z"},{"slug":"pharmacokinetics","canonical_uri":"https://healtheconomics.wiki/concept/pharmacokinetics","name":"Pharmacokinetics","short_definition":"Pharmacokinetics is the quantitative study of how a drug enters, distributes within, is transformed by, and is eliminated from the body over time.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Clinical Pharmacology","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Clinical Pharmacology","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:13.921Z"},{"slug":"phq-9","canonical_uri":"https://healtheconomics.wiki/concept/phq-9","name":"PHQ-9","short_definition":"PHQ-9 is a nine-item patient-reported depression severity measure scored 0 to 27, used as a trial outcome and mapped to EQ-5D utilities for QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:25.670Z"},{"slug":"piecewise-model","canonical_uri":"https://healtheconomics.wiki/concept/piecewise-model","name":"Piecewise Model","short_definition":"A piecewise model is a survival model used in economic evaluation that splits follow-up at cut points and fits a separate hazard within each interval.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.168Z"},{"slug":"pigouvian-subsidy","canonical_uri":"https://healtheconomics.wiki/concept/pigouvian-subsidy","name":"Pigouvian Subsidy","short_definition":"A Pigouvian subsidy is a payment for an activity that benefits others, set equal to its marginal external benefit at the socially efficient level.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Policy","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Policy","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.888Z"},{"slug":"pigouvian-tax","canonical_uri":"https://healtheconomics.wiki/concept/pigouvian-tax","name":"Pigouvian Tax","short_definition":"A Pigouvian tax is a tax on an activity that harms others, set equal to its marginal external cost at the efficient level of that activity.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Policy","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Policy","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:34.521Z"},{"slug":"allocation-method","canonical_uri":"https://healtheconomics.wiki/concept/allocation-method","name":"Point Allocation Method","short_definition":"The point allocation method asks respondents to divide a fixed total of points, often 100, among health outcomes or criteria to show their relative value.","category":"Economic Methods","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T23:53:54.410Z"},{"slug":"point-estimate","canonical_uri":"https://healtheconomics.wiki/concept/point-estimate","name":"Point Estimate","short_definition":"A point estimate is a single numerical value calculated from observed data or a fitted model to represent a specified unknown quantity on a stated scale.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:14.084Z"},{"slug":"point-prevalence","canonical_uri":"https://healtheconomics.wiki/concept/point-prevalence","name":"Point Prevalence","short_definition":"Point prevalence is the share of a population with a condition on one date, counting new and existing cases, used to size caseloads and model cohorts.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.243Z"},{"slug":"poisson-distribution","canonical_uri":"https://healtheconomics.wiki/concept/poisson-distribution","name":"Poisson Distribution","short_definition":"The Poisson distribution is a probability model for counts of events, such as hospital admissions, that occur independently at a constant rate over time.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.318Z"},{"slug":"poisson-regression","canonical_uri":"https://healtheconomics.wiki/concept/poisson-regression","name":"Poisson Regression","short_definition":"Poisson regression models counts of health care events, such as admissions, as rates that change multiplicatively with patient and treatment factors.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.393Z"},{"slug":"population","canonical_uri":"https://healtheconomics.wiki/concept/population","name":"Population","short_definition":"Population, in health economic evaluation, is the group of people a decision or analysis concerns, defined by condition, characteristics and care pathway.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.683Z"},{"slug":"population-attributable-fraction","canonical_uri":"https://healtheconomics.wiki/concept/population-attributable-fraction","name":"Population Attributable Fraction","short_definition":"The population attributable fraction (PAF) is the share of a population's disease cases or burden that would not occur if a causal exposure were removed.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.467Z"},{"slug":"population-evpi","canonical_uri":"https://healtheconomics.wiki/concept/population-evpi","name":"Population EVPI","short_definition":"Population EVPI is the expected value of perfect information scaled up to all patients a health care decision will affect, discounted over its lifetime.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.541Z"},{"slug":"positive-externality","canonical_uri":"https://healtheconomics.wiki/concept/positive-externality","name":"Positive Externality","short_definition":"A positive externality is an uncompensated benefit, such as lower infection risk for others after vaccination, that an activity gives to third parties.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.616Z"},{"slug":"positive-likelihood-ratio","canonical_uri":"https://healtheconomics.wiki/concept/positive-likelihood-ratio","name":"Positive Likelihood Ratio","short_definition":"The positive likelihood ratio (LR+) is sensitivity over (1 minus specificity), the factor by which a positive result multiplies disease odds in HTA models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T20:33:18.690Z"},{"slug":"positive-predictive-value","canonical_uri":"https://healtheconomics.wiki/concept/positive-predictive-value","name":"Positive Predictive Value","short_definition":"Positive predictive value (PPV) is the share of people with a positive test result who truly have the condition, which models use to count false positives.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.080Z"},{"slug":"post-test-probability","canonical_uri":"https://healtheconomics.wiki/concept/post-test-probability","name":"Post-Test Probability","short_definition":"Post-test probability is the chance of a condition after a test result, updated from pre-test probability by its likelihood ratio, in diagnostic models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.156Z"},{"slug":"posterior-distribution","canonical_uri":"https://healtheconomics.wiki/concept/posterior-distribution","name":"Posterior Distribution","short_definition":"The posterior distribution is the probability distribution of an uncertain model input, such as a treatment effect, after a prior is updated with new data.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.230Z"},{"slug":"pre-test-probability","canonical_uri":"https://healtheconomics.wiki/concept/pre-test-probability","name":"Pre-Test Probability","short_definition":"Pre-test probability is the chance a patient has the condition before testing, judged from presenting features, and it shapes test cost-effectiveness.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.305Z"},{"slug":"precision-medicine","canonical_uri":"https://healtheconomics.wiki/concept/precision-medicine","name":"Precision Medicine","short_definition":"An approach to prevention, diagnosis or treatment that uses relevant individual or disease characteristics to select a more appropriate care strategy.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Therapeutic Innovation","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Therapeutic Innovation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:14.471Z"},{"slug":"preference-elicitation","canonical_uri":"https://healtheconomics.wiki/concept/preference-elicitation","name":"Preference Elicitation","short_definition":"Preference elicitation measures what people value in health care from stated or revealed choices, yielding QALY weights, money values or risk trade-offs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.973Z"},{"slug":"premarket-approval","canonical_uri":"https://healtheconomics.wiki/concept/premarket-approval","name":"Premarket Approval","short_definition":"Premarket approval (PMA) is the FDA review a high-risk Class III medical device must pass before US sale, on evidence of its safety and effectiveness.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Regulation","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Regulation","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.757Z"},{"slug":"present-value","canonical_uri":"https://healtheconomics.wiki/concept/present-value","name":"Present Value","short_definition":"Present value is what a future cost or health gain, or a stream of them, is worth today, found in economic evaluation by discounting each year's amount.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Discounting","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Discounting","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.380Z"},{"slug":"prevalence","canonical_uri":"https://healtheconomics.wiki/concept/prevalence","name":"Prevalence","short_definition":"Prevalence is the proportion of a population living with a condition at a given time or over a period, used to size patient groups and annual costs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Epidemiology","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Epidemiology","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.454Z"},{"slug":"prevalence-ratio","canonical_uri":"https://healtheconomics.wiki/concept/prevalence-ratio","name":"Prevalence Ratio","short_definition":"The prevalence ratio (PR) is the prevalence of a condition in an exposed group divided by that in an unexposed group, used to compare disease burden.","category":"Outcome Measures","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-15T00:58:35.166Z"},{"slug":"price-elasticity-of-demand","canonical_uri":"https://healtheconomics.wiki/concept/price-elasticity-of-demand","name":"Price Elasticity of Demand","short_definition":"Price elasticity of demand measures the proportional change in quantity demanded associated with a proportional change in price, holding other determinants of demand constant.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:40.761Z"},{"slug":"primary-research","canonical_uri":"https://healtheconomics.wiki/concept/primary-research","name":"Primary Research","short_definition":"Primary research is research that collects new data, as in trials, cohort studies and preference or costing surveys, rather than reusing existing data.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.830Z"},{"slug":"principal-agent-model","canonical_uri":"https://healtheconomics.wiki/concept/principal-agent-model","name":"Principal Agent Model","short_definition":"A formal framework analysing situations where a principal delegates decisions to an agent whose interests may not fully align with their own.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:15.024Z"},{"slug":"principal-component","canonical_uri":"https://healtheconomics.wiki/concept/principal-component","name":"Principal Component","short_definition":"A principal component is an uncorrelated linear combination of centered variables whose loading vector identifies a successive direction of maximum variance in the data.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:35.398Z"},{"slug":"principal-agent-problem","canonical_uri":"https://healtheconomics.wiki/concept/principal-agent-problem","name":"Principal-Agent Problem","short_definition":"The principal-agent problem arises when patients or payers rely on providers who know more than they do, act unobserved and may pursue other interests.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:11.966Z"},{"slug":"principal-agent-problem-in-healthcare","canonical_uri":"https://healtheconomics.wiki/concept/principal-agent-problem-in-healthcare","name":"Principal-Agent Problem in Healthcare","short_definition":"The specific version of the principal-agent problem in the physician-patient relationship, where clinical expertise gaps create both helpful guidance and risk of distorted recommendations.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:35.379Z"},{"slug":"prior-authorization","canonical_uri":"https://healtheconomics.wiki/concept/prior-authorization","name":"Prior Authorization","short_definition":"A health plan’s advance review of a patient-specific service, medicine or item against coverage criteria before it is provided.","category":"Drug Costs","category_path":"Health Systems › Drug Costs › Market Access","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Market Access","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:35.417Z"},{"slug":"prior-distribution","canonical_uri":"https://healtheconomics.wiki/concept/prior-distribution","name":"Prior Distribution","short_definition":"A prior distribution is the probability distribution for an uncertain model input, such as a treatment effect, before new data enter a Bayesian analysis.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.528Z"},{"slug":"psa","canonical_uri":"https://healtheconomics.wiki/concept/psa","name":"Probabilistic Sensitivity Analysis","short_definition":"Probabilistic sensitivity analysis (PSA) runs a decision model many times on jointly drawn inputs to estimate expected outcomes and decision uncertainty.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:23.278Z"},{"slug":"probability","canonical_uri":"https://healtheconomics.wiki/concept/probability","name":"Probability","short_definition":"Probability is a number between zero and one assigned to the likelihood of a precisely defined event under stated conditions.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:15.187Z"},{"slug":"probability-of-cost-effectiveness","canonical_uri":"https://healtheconomics.wiki/concept/probability-of-cost-effectiveness","name":"Probability of Cost-Effectiveness","short_definition":"The probability of cost-effectiveness is the model-based probability that an intervention meets a stated net-benefit criterion against specified alternatives at a given willingness-to-pay threshold under the assumed uncertainty distribution.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:23.217Z"},{"slug":"producer-surplus","canonical_uri":"https://healtheconomics.wiki/concept/producer-surplus","name":"Producer Surplus","short_definition":"Producer surplus is the gain suppliers of health care, such as drug makers, make by selling each unit at a price above the least they would have accepted.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.603Z"},{"slug":"production-possibility-frontier","canonical_uri":"https://healtheconomics.wiki/concept/production-possibility-frontier","name":"Production Possibility Frontier","short_definition":"A graph showing the maximum combinations of two goods or outcomes producible given a fixed set of resources and existing technology.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:15.326Z"},{"slug":"productive-efficiency","canonical_uri":"https://healtheconomics.wiki/concept/productive-efficiency","name":"Productive Efficiency","short_definition":"Productive efficiency is producing a health service or outcome at the lowest feasible cost, wasting no inputs and combining them in the least-cost mix.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.678Z"},{"slug":"progression-free-survival","canonical_uri":"https://healtheconomics.wiki/concept/progression-free-survival","name":"Progression-Free Survival","short_definition":"Progression-free survival is the time from a prespecified origin, usually randomisation or treatment initiation, until objectively defined disease progression or death from any cause, whichever occurs first.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Oncology Outcomes","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Oncology Outcomes","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:35.900Z"},{"slug":"promis-29","canonical_uri":"https://healtheconomics.wiki/concept/promis-29","name":"PROMIS-29","short_definition":"PROMIS-29 is a 29-item generic health profile of seven domains plus a pain rating, used as a trial outcome and convertible to PROPr utilities for QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.902Z"},{"slug":"propensity-score","canonical_uri":"https://healtheconomics.wiki/concept/propensity-score","name":"Propensity Score","short_definition":"The propensity score is a patient's probability of receiving a treatment given baseline characteristics, used to balance groups in observational studies.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.752Z"},{"slug":"propensity-score-matching","canonical_uri":"https://healtheconomics.wiki/concept/propensity-score-matching","name":"Propensity Score Matching","short_definition":"Propensity score matching is an observational study design method that pairs treated and untreated individuals with similar probabilities of treatment given measured baseline characteristics to estimate a treatment contrast in the population retained by the matches.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Real-World Evidence","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Real-World Evidence","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:35.977Z"},{"slug":"property-rights","canonical_uri":"https://healtheconomics.wiki/concept/property-rights","name":"Property Rights","short_definition":"Property rights are entitlements to use a resource, exclude others, take its income and transfer it, as with medicine patents or pharmacy contracts.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Common Resource Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Common Resource Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-14T23:52:15.564Z"},{"slug":"proportion-of-days-covered","canonical_uri":"https://healtheconomics.wiki/concept/proportion-of-days-covered","name":"Proportion of Days Covered","short_definition":"The proportion of days covered (PDC) is the share of days in a period on which pharmacy refill records show a patient had medicine, each day counted once.","category":"Outcome Measures","category_path":"Pharmacy Practice › Pharmaceutical Care › Medication Adherence","level_1":"Pharmacy Practice","level_2":"Pharmaceutical Care","level_3":"Medication Adherence","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-15T00:58:36.018Z"},{"slug":"proportional-hazards-assumption","canonical_uri":"https://healtheconomics.wiki/concept/proportional-hazards-assumption","name":"Proportional Hazards Assumption","short_definition":"The proportional hazards assumption is that the hazard ratio between groups, such as trial arms, is constant over follow-up while each hazard may change.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.241Z"},{"slug":"proportional-shortfall","canonical_uri":"https://healtheconomics.wiki/concept/proportional-shortfall","name":"Proportional Shortfall","short_definition":"Proportional shortfall is the share of remaining expected QALYs that patients lose to a condition versus healthy peers, used to grade severity in HTA.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Utility Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Utility Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.311Z"},{"slug":"prospective-risk-adjustment","canonical_uri":"https://healtheconomics.wiki/concept/prospective-risk-adjustment","name":"Prospective Risk Adjustment","short_definition":"Prospective risk adjustment adjusts health plan or provider payments for a coming period using diagnoses and demographics from an earlier base period.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.070Z"},{"slug":"provider-payment","canonical_uri":"https://healtheconomics.wiki/concept/provider-payment","name":"Provider Payment","short_definition":"Provider payment is how health purchasers pay doctors and hospitals, for example by budget, salary, fee-for-service, per diem, case (DRG) or capitation.","category":"Health Economics","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.7","status":"PUBLISHED","published_at":"2026-10-15T23:54:07.514Z"},{"slug":"pseudo-random-number","canonical_uri":"https://healtheconomics.wiki/concept/pseudo-random-number","name":"Pseudo-Random Number","short_definition":"A pseudo-random number is a value produced by a deterministic algorithm whose sequence is designed to exhibit specified statistical properties of random draws.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Microsimulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Microsimulation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:36.268Z"},{"slug":"qaly-calculation-method","canonical_uri":"https://healtheconomics.wiki/concept/qaly-calculation-method","name":"QALY Calculation Method","short_definition":"The process of computing quality-adjusted life years by multiplying time spent in a health state by its utility value, then summing across states.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Quality-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Quality-Adjusted Life Years","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:36.482Z"},{"slug":"qaly-shortfall","canonical_uri":"https://healtheconomics.wiki/concept/qaly-shortfall","name":"QALY Shortfall","short_definition":"QALY shortfall is the expected QALY gap between a matched general population and patients on current care, which NICE reads as absolute or proportional.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Utility Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Utility Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.392Z"},{"slug":"quality-of-care","canonical_uri":"https://healtheconomics.wiki/concept/quality-of-care","name":"Quality of Care","short_definition":"Quality of care is the extent to which health services raise the chance of desired health outcomes and follow current professional knowledge.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.323Z"},{"slug":"quality-of-evidence","canonical_uri":"https://healtheconomics.wiki/concept/quality-of-evidence","name":"Quality of Evidence","short_definition":"A judgement about how much confidence can be placed in an effect estimate, based on study design, risk of bias, and precision.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:36.654Z"},{"slug":"quality-score","canonical_uri":"https://healtheconomics.wiki/concept/quality-score","name":"Quality Score","short_definition":"A quality score is a single number summing checklist items to rate a study's methodological quality, now discouraged in favour of risk of bias judgements.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:16.205Z"},{"slug":"qaly","canonical_uri":"https://healtheconomics.wiki/concept/qaly","name":"Quality-Adjusted Life Year (QALY)","short_definition":"A quality-adjusted life year (QALY) combines length and quality of life in one measure: a year in full health counts as one QALY and death counts as zero.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Outcomes","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Outcomes","evidence_level":"high","version":"1.5.4","status":"PUBLISHED","published_at":"2026-10-14T22:25:39.879Z"},{"slug":"quality-adjusted-time-without-symptoms","canonical_uri":"https://healtheconomics.wiki/concept/quality-adjusted-time-without-symptoms","name":"Quality-Adjusted Time Without Symptoms","short_definition":"A quality-weighted survival measure that partitions time into toxicity, time without defined symptoms or toxicity, and time after disease progression, then sums each duration multiplied by its state-specific weight.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Quality-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Quality-Adjusted Life Years","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:36.501Z"},{"slug":"quasi-experimental-design","canonical_uri":"https://healtheconomics.wiki/concept/quasi-experimental-design","name":"Quasi-Experimental Design","short_definition":"A research design estimating an intervention's causal effect without random assignment, instead using features such as a natural experiment or matched comparison group.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:56:14.385Z"},{"slug":"queuing-model","canonical_uri":"https://healtheconomics.wiki/concept/queuing-model","name":"Queuing Model","short_definition":"A queuing model is a mathematical representation of how arrivals, service times, capacity, and service rules generate waiting, congestion, and throughput in a service system.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Discrete Event Simulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Discrete Event Simulation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:36.809Z"},{"slug":"random-effects-model","canonical_uri":"https://healtheconomics.wiki/concept/random-effects-model","name":"Random Effects Model","short_definition":"A random effects model represents variation in a parameter across defined units or settings by treating their unit-specific effects as draws from a shared distribution.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:07.926Z"},{"slug":"random-number-generation","canonical_uri":"https://healtheconomics.wiki/concept/random-number-generation","name":"Random Number Generation","short_definition":"Random number generation supplies the uncertain draws used in probabilistic sensitivity analysis, microsimulation, discrete-event simulation, bootstrap procedures, and other stochastic analyses.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Microsimulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Microsimulation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:36.962Z"},{"slug":"random-parameter-model","canonical_uri":"https://healtheconomics.wiki/concept/random-parameter-model","name":"Random Parameter Model","short_definition":"A discrete choice model that lets preference parameters vary randomly across individuals according to a specified distribution, rather than assuming identical preferences.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:36.985Z"},{"slug":"random-sampling","canonical_uri":"https://healtheconomics.wiki/concept/random-sampling","name":"Random Sampling","short_definition":"Random sampling selects members of a population by chance, giving each a known, non-zero probability of selection, so sample estimates can be generalised.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:16.324Z"},{"slug":"randomised-controlled-trial","canonical_uri":"https://healtheconomics.wiki/concept/randomised-controlled-trial","name":"Randomised Controlled Trial","short_definition":"A trial design in which participants are randomly assigned to an experimental intervention or a comparator, the gold standard for causal evidence.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T01:26:22.829Z"},{"slug":"randomization","canonical_uri":"https://healtheconomics.wiki/concept/randomization","name":"Randomization","short_definition":"The process of assigning trial participants to treatment groups by chance, producing groups comparable on both known and unknown influencing factors.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:07.945Z"},{"slug":"rate-to-probability-conversion","canonical_uri":"https://healtheconomics.wiki/concept/rate-to-probability-conversion","name":"Rate-to-Probability Conversion","short_definition":"The mathematical transformation converting a continuous-time hazard rate into the probability of an event occurring within a discrete time interval.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:08.095Z"},{"slug":"ratio-scale","canonical_uri":"https://healtheconomics.wiki/concept/ratio-scale","name":"Ratio Scale","short_definition":"Ratio scale is a level of measurement with equal intervals and a true zero, such as cost or survival time, so a claim of twice the cost is meaningful.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-17T15:03:09.699Z"},{"slug":"readmission","canonical_uri":"https://healtheconomics.wiki/concept/readmission","name":"Readmission","short_definition":"A readmission is a further hospital admission soon after discharge, often within 30 days, used to judge inpatient care quality and counted as a cost.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Performance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Performance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.472Z"},{"slug":"real-option-value","canonical_uri":"https://healtheconomics.wiki/concept/real-option-value","name":"Real Option Value","short_definition":"Real option value is the extra health gain a treatment creates by keeping patients alive and eligible long enough to benefit from future innovations.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.383Z"},{"slug":"real-world-data","canonical_uri":"https://healtheconomics.wiki/concept/real-world-data","name":"Real-World Data","short_definition":"Routinely collected information about patient health or healthcare delivery that may support research and decision making when fit for a defined purpose.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Real-World Evidence","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Real-World Evidence","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:45.548Z"},{"slug":"real-world-evidence","canonical_uri":"https://healtheconomics.wiki/concept/real-world-evidence","name":"Real-World Evidence","short_definition":"Clinical evidence about a medical product's use, benefits, or risks derived from analysing real-world data, unlike evidence from a controlled trial.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Real-World Evidence","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Real-World Evidence","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:08.171Z"},{"slug":"reference-case","canonical_uri":"https://healtheconomics.wiki/concept/reference-case","name":"Reference Case","short_definition":"A reference case is the set of methods, such as perspective, outcome measure and discounting, that HTA bodies like NICE expect economic evaluations to use.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Reference Case","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Reference Case","evidence_level":"high","version":"1.5.22","status":"PUBLISHED","published_at":"2026-10-15T23:54:08.209Z"},{"slug":"reference-case-requirement","canonical_uri":"https://healtheconomics.wiki/concept/reference-case-requirement","name":"Reference Case Requirement","short_definition":"Reference case requirement is one rule in an HTA reference case, such as NICE's 3.5% discount rate, fixing a method like perspective or outcome measure.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Reference Case","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Reference Case","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.919Z"},{"slug":"reference-standard","canonical_uri":"https://healtheconomics.wiki/concept/reference-standard","name":"Reference Standard","short_definition":"The reference standard is the best available method for deciding whether a target condition is present, against which a test's accuracy is judged.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.123Z"},{"slug":"regression-analysis","canonical_uri":"https://healtheconomics.wiki/concept/regression-analysis","name":"Regression Analysis","short_definition":"Regression analysis estimates how an outcome varies with one or more explanatory variables through a specified statistical model.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:08.285Z"},{"slug":"relapse-period","canonical_uri":"https://healtheconomics.wiki/concept/relapse-period","name":"Relapse Period (REL)","short_definition":"Relapse period (REL) is the Q-TWiST health state covering survival time after relapse or progression, weighted by its own utility.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Quality-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Quality-Adjusted Life Years","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.864Z"},{"slug":"relapse-free-survival","canonical_uri":"https://healtheconomics.wiki/concept/relapse-free-survival","name":"Relapse-Free Survival","short_definition":"Relapse-free survival (RFS) is the time from randomisation, or another stated start such as surgery, to relapse of the disease or death from any cause.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T20:50:57.831Z"},{"slug":"relative-risk","canonical_uri":"https://healtheconomics.wiki/concept/relative-risk","name":"Relative Risk","short_definition":"Relative risk compares the probability of an event in one group with the probability in another group over a defined period.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:37.849Z"},{"slug":"relative-risk-reduction","canonical_uri":"https://healtheconomics.wiki/concept/relative-risk-reduction","name":"Relative Risk Reduction","short_definition":"Relative risk reduction (RRR) is the percentage by which a treatment lowers the risk of an event compared with control, equal to one minus the risk ratio.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.453Z"},{"slug":"relative-survival","canonical_uri":"https://healtheconomics.wiki/concept/relative-survival","name":"Relative Survival","short_definition":"Relative survival is patients' observed survival divided by the expected survival of a matched general population, used in cancer registries and models.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.525Z"},{"slug":"relative-survival-model","canonical_uri":"https://healtheconomics.wiki/concept/relative-survival-model","name":"Relative Survival Model","short_definition":"A statistical model estimating disease-specific survival by comparing observed survival against expected general population survival, without individual cause-of-death data.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:23.398Z"},{"slug":"relative-value-unit","canonical_uri":"https://healtheconomics.wiki/concept/relative-value-unit","name":"Relative Value Unit","short_definition":"A relative value unit (RVU) is a weight for the resources a physician service uses relative to others, which Medicare turns into fee schedule payments.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:09.005Z"},{"slug":"relative-weight","canonical_uri":"https://healtheconomics.wiki/concept/relative-weight","name":"Relative Weight","short_definition":"A numerical value assigned to a payment classification, such as a diagnosis-related group, reflecting its expected resource intensity relative to average.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:56:17.003Z"},{"slug":"reliability-assessment","canonical_uri":"https://healtheconomics.wiki/concept/reliability-assessment","name":"Reliability Assessment","short_definition":"An evaluation of the consistency and reproducibility of an instrument's results, covering internal consistency, inter-rater, and test-retest reliability.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:08.453Z"},{"slug":"reqol-10","canonical_uri":"https://healtheconomics.wiki/concept/reqol-10","name":"ReQoL-10","short_definition":"ReQoL-10 is the 10-item Recovering Quality of Life questionnaire for mental health service users, scored as a total or as ReQoL-UI utilities for QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.611Z"},{"slug":"reqol-20","canonical_uri":"https://healtheconomics.wiki/concept/reqol-20","name":"ReQoL-20","short_definition":"ReQoL-20 is the 20-item Recovering Quality of Life questionnaire for mental health service users, used at assessment and as a trial and research outcome.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.666Z"},{"slug":"reqol-ui","canonical_uri":"https://healtheconomics.wiki/concept/reqol-ui","name":"ReQoL-UI","short_definition":"ReQoL-UI is a preference-based index scoring seven ReQoL items as utilities, so mental health studies can estimate QALYs for cost-utility analysis.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-17T15:03:09.397Z"},{"slug":"resource","canonical_uri":"https://healtheconomics.wiki/concept/resource","name":"Resource","short_definition":"Resource, in health economics, means any scarce input such as staff time, medicines, beds or equipment, whose use in one place denies it to other uses.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:23.458Z"},{"slug":"resource-based-relative-value","canonical_uri":"https://healtheconomics.wiki/concept/resource-based-relative-value","name":"Resource-Based Relative Value","short_definition":"A methodology determining physician reimbursement based on a standardised measure of resources required, incorporating work, practice expense, and malpractice risk.","category":"Health Policy","category_path":"Health Systems › Health Policy › Provider Payment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Provider Payment","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:38.308Z"},{"slug":"response-level","canonical_uri":"https://healtheconomics.wiki/concept/response-level","name":"Response Level","short_definition":"Response level is one of the ordered answer categories of an instrument dimension or item, such as the five levels of each EQ-5D-5L dimension.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:29.082Z"},{"slug":"response-surface-methodology","canonical_uri":"https://healtheconomics.wiki/concept/response-surface-methodology","name":"Response Surface Methodology","short_definition":"Response surface methodology fits a polynomial to planned runs of a health economic model so outputs such as net benefit can be predicted and optimised.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.597Z"},{"slug":"responsiveness","canonical_uri":"https://healtheconomics.wiki/concept/responsiveness","name":"Responsiveness","short_definition":"The ability of an outcome measurement instrument to detect change over time in the construct it is intended to measure, in a specified population and context of use.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:46.592Z"},{"slug":"restricted-cubic-spline","canonical_uri":"https://healtheconomics.wiki/concept/restricted-cubic-spline","name":"Restricted Cubic Spline","short_definition":"A restricted cubic spline is a smooth piecewise cubic function of a continuous predictor constrained to be linear beyond its outer knots, allowing regression models to represent nonlinear associations without prescribing one global polynomial shape.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:46.633Z"},{"slug":"restricted-mean-survival-time","canonical_uri":"https://healtheconomics.wiki/concept/restricted-mean-survival-time","name":"Restricted Mean Survival Time","short_definition":"Restricted mean survival time (RMST) is the mean event-free time up to a set horizon, the area under the survival curve, used to compare treatments in HTA.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.667Z"},{"slug":"retrospective-risk-adjustment","canonical_uri":"https://healtheconomics.wiki/concept/retrospective-risk-adjustment","name":"Retrospective Risk Adjustment","short_definition":"Retrospective risk adjustment recalculates health plan or provider payments after a coverage period ends, using diagnoses and costs from that period.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:05.917Z"},{"slug":"return-on-assets","canonical_uri":"https://healtheconomics.wiki/concept/return-on-assets","name":"Return on Assets","short_definition":"Return on assets (ROA) is net income divided by average total assets, a ratio used to judge how well hospitals and health systems use their assets.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.506Z"},{"slug":"return-on-equity","canonical_uri":"https://healtheconomics.wiki/concept/return-on-equity","name":"Return on Equity","short_definition":"Return on equity (ROE) is net income divided by owners' equity, used in health economics to judge the profitability of hospitals, insurers and drug firms.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.431Z"},{"slug":"return-on-investment","canonical_uri":"https://healtheconomics.wiki/concept/return-on-investment","name":"Return on Investment","short_definition":"Return on investment is a monetary measure of the gain attributable to an intervention relative to its investment cost, calculated under an explicitly stated benefit, cost, time, and ratio convention.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:38.684Z"},{"slug":"reynolds-smolensky","canonical_uri":"https://healtheconomics.wiki/concept/reynolds-smolensky","name":"Reynolds-Smolensky","short_definition":"An index measuring the redistributive effect of a tax or transfer system, calculated as the difference between pre-tax and post-tax income Gini coefficients.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Equity","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Equity","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:38.739Z"},{"slug":"right-censoring","canonical_uri":"https://healtheconomics.wiki/concept/right-censoring","name":"Right Censoring","short_definition":"Right censoring occurs when follow-up ends before a patient's event, such as death, so the survival time is known only to exceed the last time observed.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.739Z"},{"slug":"risk-adjustment","canonical_uri":"https://healtheconomics.wiki/concept/risk-adjustment","name":"Risk Adjustment","short_definition":"Risk adjustment uses age, diagnoses and other patient data to predict expected health care costs or outcomes, to set insurer payments or compare providers.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.144Z"},{"slug":"risk-evaluation","canonical_uri":"https://healtheconomics.wiki/concept/risk-evaluation","name":"Risk Evaluation","short_definition":"A formal assessment of a drug's potential safety risks, sometimes resulting in a required mitigation strategy such as restricted distribution or mandatory counselling.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Drug Development","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Drug Development","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:47.288Z"},{"slug":"risk-pooling","canonical_uri":"https://healtheconomics.wiki/concept/risk-pooling","name":"Risk Pooling","short_definition":"Risk pooling is the sharing of prepaid health funds across a covered population, so the cost of care is borne by all members, not by those who fall ill.","category":"Health Economics","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.293Z"},{"slug":"risk-ratio","canonical_uri":"https://healtheconomics.wiki/concept/risk-ratio","name":"Risk Ratio","short_definition":"The risk ratio (RR), or relative risk, is the risk of an event in one group divided by the risk in another over the same period, used in trials and HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.812Z"},{"slug":"risk-score","canonical_uri":"https://healtheconomics.wiki/concept/risk-score","name":"Risk Score","short_definition":"A risk score is a model-based number summarising a person's expected healthcare spending or chance of a health outcome over a set period such as a year.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.026Z"},{"slug":"robust-optimisation","canonical_uri":"https://healtheconomics.wiki/concept/robust-optimisation","name":"Robust Optimisation","short_definition":"An optimisation approach that selects a feasible decision to perform well under the worst parameter values in a specified uncertainty set, often requiring constraints to hold throughout that set.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T00:51:24.582Z"},{"slug":"robust-standard-error","canonical_uri":"https://healtheconomics.wiki/concept/robust-standard-error","name":"Robust Standard Error","short_definition":"An estimate of a regression coefficient's statistical uncertainty that remains valid even when standard modelling assumptions, such as constant error variance, are violated.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:47.668Z"},{"slug":"roc-curve","canonical_uri":"https://healtheconomics.wiki/concept/roc-curve","name":"ROC Curve","short_definition":"The ROC (receiver operating characteristic) curve plots a test's sensitivity against its false positive rate at each cut-off, guiding thresholds in HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.883Z"},{"slug":"root-mean-square-error","canonical_uri":"https://healtheconomics.wiki/concept/root-mean-square-error","name":"Root Mean Square Error","short_definition":"The square root of the mean squared difference between numerical predictions and their corresponding observed values, expressed in the outcome’s original units.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:39.065Z"},{"slug":"route-of-administration","canonical_uri":"https://healtheconomics.wiki/concept/route-of-administration","name":"Route of Administration","short_definition":"The specific pathway by which a drug enters the body, such as oral, intravenous, subcutaneous, or inhaled, affecting absorption and onset of action.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Drug Formulation","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Drug Formulation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:17.507Z"},{"slug":"royston-parmar-model","canonical_uri":"https://healtheconomics.wiki/concept/royston-parmar-model","name":"Royston-Parmar Model","short_definition":"A class of flexible parametric survival models using restricted cubic splines to represent a transformed survival or hazard function while remaining fully parametric.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:23.585Z"},{"slug":"runge-kutta-method","canonical_uri":"https://healtheconomics.wiki/concept/runge-kutta-method","name":"Runge-Kutta Method","short_definition":"A Runge-Kutta method is a one-step numerical scheme for approximating the solution of an ordinary differential equation by combining several derivative evaluations within each integration step.","category":"Differential Equations","category_path":"Computer Science › Differential Equations › Numerical ODE Methods","level_1":"Computer Science","level_2":"Differential Equations","level_3":"Numerical ODE Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:47.911Z"},{"slug":"sample-size-calculation","canonical_uri":"https://healtheconomics.wiki/concept/sample-size-calculation","name":"Sample Size Calculation","short_definition":"Sample size calculation sets how many participants a trial must analyse to detect a target clinical or economic difference at set power and significance.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:22.953Z"},{"slug":"sandwich-estimator","canonical_uri":"https://healtheconomics.wiki/concept/sandwich-estimator","name":"Sandwich Estimator","short_definition":"The sandwich estimator is a variance formula for regression estimates that stays valid when cost data are heteroskedastic or patients are clustered.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.024Z"},{"slug":"scarcity","canonical_uri":"https://healtheconomics.wiki/concept/scarcity","name":"Scarcity","short_definition":"Scarcity is the condition in which health care resources, such as funding, staff and beds, cannot meet every competing need, so choices must be made.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.8","status":"PUBLISHED","published_at":"2026-10-15T00:58:39.219Z"},{"slug":"scenario-analysis","canonical_uri":"https://healtheconomics.wiki/concept/scenario-analysis","name":"Scenario Analysis","short_definition":"Scenario analysis re-runs a health economic model under alternative assumptions, such as another survival extrapolation, to see if the decision changes.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:23.704Z"},{"slug":"schoenfeld-residual","canonical_uri":"https://healtheconomics.wiki/concept/schoenfeld-residual","name":"Schoenfeld Residual","short_definition":"A Schoenfeld residual is the observed minus expected covariate value at each event in a Cox model, used to test the proportional hazards assumption.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.094Z"},{"slug":"scope-efficiency","canonical_uri":"https://healtheconomics.wiki/concept/scope-efficiency","name":"Scope Efficiency","short_definition":"Scope efficiency is whether a hospital or health system saves cost by providing several services together instead of in separate, specialised units.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.165Z"},{"slug":"screening","canonical_uri":"https://healtheconomics.wiki/concept/screening","name":"Screening","short_definition":"Screening is the process of identifying apparently healthy people at increased risk of a condition, then offering information, further tests or treatment.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:09.067Z"},{"slug":"screening-economics","canonical_uri":"https://healtheconomics.wiki/concept/screening-economics","name":"Screening Economics","short_definition":"The economic assessment of a screening programme’s full pathway, comparing its costs, health benefits, harms, budget implications and opportunity costs with feasible alternatives.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Chronic Disease","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Chronic Disease","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:23.763Z"},{"slug":"screening-theory","canonical_uri":"https://healtheconomics.wiki/concept/screening-theory","name":"Screening Theory","short_definition":"Screening theory explains how an insurer or payer that cannot observe risk or cost offers a menu of contracts so each type reveals itself by its choice.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.236Z"},{"slug":"secondary-research","canonical_uri":"https://healtheconomics.wiki/concept/secondary-research","name":"Secondary Research","short_definition":"Secondary research is research that summarises existing studies instead of collecting new data, as in systematic reviews and meta-analyses.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Sources","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Sources","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.945Z"},{"slug":"seir-model","canonical_uri":"https://healtheconomics.wiki/concept/seir-model","name":"SEIR Model","short_definition":"An extension of the basic epidemic model adding an exposed compartment for individuals infected but not yet infectious, before they become infectious.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:49.218Z"},{"slug":"selection-model","canonical_uri":"https://healtheconomics.wiki/concept/selection-model","name":"Selection Model","short_definition":"A selection model handles missing trial data by modelling the outcome alongside the chance each value is observed, allowing for data missing not at random.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.307Z"},{"slug":"self-control-concept","canonical_uri":"https://healtheconomics.wiki/concept/self-control-concept","name":"Self-Control Concept","short_definition":"The management of conflict between immediate incentives or effort and longer-term goals, especially when the timing of a choice changes what a person prefers to do.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Behavioral Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Behavioral Economics","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:09.197Z"},{"slug":"sensitivity","canonical_uri":"https://healtheconomics.wiki/concept/sensitivity","name":"Sensitivity","short_definition":"The proportion of people with a specified target condition who test positive at a stated diagnostic threshold, calculated as true positives divided by true positives plus false negatives.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:39.715Z"},{"slug":"sensitivity-analysis","canonical_uri":"https://healtheconomics.wiki/concept/sensitivity-analysis","name":"Sensitivity Analysis","short_definition":"Sensitivity analysis tests whether a health economic model's results and decision change when uncertain inputs, assumptions or model structure are varied.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:23.883Z"},{"slug":"sentinel-event-rate","canonical_uri":"https://healtheconomics.wiki/concept/sentinel-event-rate","name":"Sentinel Event Rate","short_definition":"A sentinel event rate is the number of grave patient-safety events, such as wrong-site surgery, per unit of care activity in a set period.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Quality","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.397Z"},{"slug":"sequential-analysis","canonical_uri":"https://healtheconomics.wiki/concept/sequential-analysis","name":"Sequential Analysis","short_definition":"Sequential analysis tests trial or safety data as they accumulate and stops once preset evidence boundaries are crossed, not at a fixed sample size.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.376Z"},{"slug":"sequential-monte-carlo","canonical_uri":"https://healtheconomics.wiki/concept/sequential-monte-carlo","name":"Sequential Monte Carlo","short_definition":"Sequential Monte Carlo (SMC) tracks a sequence of probability distributions with weighted samples to calibrate health models and update them with data.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.447Z"},{"slug":"sf-12","canonical_uri":"https://healtheconomics.wiki/concept/sf-12","name":"SF-12","short_definition":"SF-12 is a 12-item generic health survey taken from the SF-36 that gives physical and mental summary scores and can be scored as SF-6D utilities for QALYs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.060Z"},{"slug":"sf-6dv2","canonical_uri":"https://healtheconomics.wiki/concept/sf-6dv2","name":"SF-6Dv2","short_definition":"SF-6Dv2 is the revised SF-6D, a six-dimension preference-based classification scored from SF-36v2 answers, whose value sets give utilities for QALYs.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:25.615Z"},{"slug":"sgrq","canonical_uri":"https://healtheconomics.wiki/concept/sgrq","name":"SGRQ","short_definition":"SGRQ is the St George's Respiratory Questionnaire, a weighted 0 to 100 measure of health impairment in COPD and asthma, used in trials and mapped to EQ-5D.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-17T15:03:09.279Z"},{"slug":"shadow-price","canonical_uri":"https://healtheconomics.wiki/concept/shadow-price","name":"Shadow Price","short_definition":"The implicit value of a resource with no observable market price, reflecting the opportunity cost of using it in a particular way.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:18.377Z"},{"slug":"shadow-price-of-health","canonical_uri":"https://healtheconomics.wiki/concept/shadow-price-of-health","name":"Shadow Price of Health","short_definition":"The shadow price of health is the health a fixed budget gains from one more pound spent at the margin; its reciprocal is the cost-effectiveness threshold.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.518Z"},{"slug":"shared-frailty","canonical_uri":"https://healtheconomics.wiki/concept/shared-frailty","name":"Shared Frailty","short_definition":"Shared frailty is an unobserved random effect, shared by all patients in a cluster such as one hospital, that scales their hazard in survival analysis.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.588Z"},{"slug":"short-physical-performance-battery","canonical_uri":"https://healtheconomics.wiki/concept/short-physical-performance-battery","name":"Short Physical Performance Battery","short_definition":"Short Physical Performance Battery (SPPB) is a timed test of balance, gait speed and chair stands in older people, scored 0 to 12, used in trials.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.482Z"},{"slug":"signaling","canonical_uri":"https://healtheconomics.wiki/concept/signaling","name":"Signaling","short_definition":"Signaling is a costly, visible action by which an informed party, such as a hospital, credibly reveals hidden quality to patients or insurers.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.658Z"},{"slug":"signaling-theory","canonical_uri":"https://healtheconomics.wiki/concept/signaling-theory","name":"Signaling Theory","short_definition":"Signaling theory explains how informed parties such as hospitals reveal hidden quality to patients and payers by actions costlier for low-quality types.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.730Z"},{"slug":"significance-level","canonical_uri":"https://healtheconomics.wiki/concept/significance-level","name":"Significance Level","short_definition":"The significance level is a prespecified upper bound on the probability that a valid statistical test rejects its null hypothesis when that hypothesis is true.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:40.115Z"},{"slug":"simpson-paradox","canonical_uri":"https://healtheconomics.wiki/concept/simpson-paradox","name":"Simpson Paradox","short_definition":"Simpson's paradox occurs when a treatment comparison that holds in every patient subgroup reverses or disappears once the subgroups are pooled together.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.801Z"},{"slug":"simpson-rule","canonical_uri":"https://healtheconomics.wiki/concept/simpson-rule","name":"Simpson Rule","short_definition":"Simpson rule is a closed Newton-Cotes numerical integration formula that approximates a definite integral over pairs of equal subintervals by integrating quadratic interpolants through successive triples of function values.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:40.173Z"},{"slug":"simulated-annealing","canonical_uri":"https://healtheconomics.wiki/concept/simulated-annealing","name":"Simulated Annealing","short_definition":"Simulated annealing is a stochastic search method, used to calibrate health economic models, that sometimes accepts a worse fit to escape local optima.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.870Z"},{"slug":"simulated-treatment-comparison","canonical_uri":"https://healtheconomics.wiki/concept/simulated-treatment-comparison","name":"Simulated Treatment Comparison","short_definition":"Simulated treatment comparison (STC) is an HTA method that uses one trial's patient data to predict outcomes in another trial's population for comparison.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Comparative Effectiveness Research","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Comparative Effectiveness Research","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:23.941Z"},{"slug":"sir-model","canonical_uri":"https://healtheconomics.wiki/concept/sir-model","name":"SIR Model","short_definition":"A basic epidemic model dividing a population into susceptible, infectious, and recovered compartments, representing flow between them using differential equations.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:50.858Z"},{"slug":"six-minute-walk-test","canonical_uri":"https://healtheconomics.wiki/concept/six-minute-walk-test","name":"Six-Minute Walk Test","short_definition":"Six-minute walk test (6MWT) is a performance outcome that records distance walked in six minutes, used as an endpoint in heart and lung trials and in HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.373Z"},{"slug":"skewness","canonical_uri":"https://healtheconomics.wiki/concept/skewness","name":"Skewness","short_definition":"Skewness measures the asymmetry of a distribution around its mean, such as the long right tail that a few very costly patients give health care cost data.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.011Z"},{"slug":"slope-index-of-inequality","canonical_uri":"https://healtheconomics.wiki/concept/slope-index-of-inequality","name":"Slope Index of Inequality","short_definition":"The slope index of inequality (SII) is an absolute measure of health inequality, the predicted gap between the top and bottom of a socioeconomic ranking.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.081Z"},{"slug":"sobol-indices","canonical_uri":"https://healtheconomics.wiki/concept/sobol-indices","name":"Sobol Indices","short_definition":"Variance-based global sensitivity measures that attribute a model output’s variance to uncertain inputs and their interactions under specified input distributions.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:09.642Z"},{"slug":"sobol-sequence","canonical_uri":"https://healtheconomics.wiki/concept/sobol-sequence","name":"Sobol Sequence","short_definition":"A Sobol sequence is a deterministic low-discrepancy sequence that spreads parameter values evenly for quasi-Monte Carlo runs of health economic models.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.153Z"},{"slug":"social-health-insurance","canonical_uri":"https://healtheconomics.wiki/concept/social-health-insurance","name":"Social Health Insurance","short_definition":"Social health insurance (SHI) is compulsory health cover paid for by income-related contributions pooled in sickness funds or a national fund.","category":"Health Economics","category_path":"Health Systems › Systems Strengthening › Health System Models","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Health System Models","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.880Z"},{"slug":"social-return-on-investment","canonical_uri":"https://healtheconomics.wiki/concept/social-return-on-investment","name":"Social Return on Investment","short_definition":"Social return on investment (SROI) values a programme's health, social and environmental outcomes in money and compares the total with what it cost.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.225Z"},{"slug":"social-welfare-function","canonical_uri":"https://healtheconomics.wiki/concept/social-welfare-function","name":"Social Welfare Function","short_definition":"A social welfare function (SWF) combines individual health or wellbeing into overall social welfare, setting how equality is weighed against the total.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:12.040Z"},{"slug":"societal-perspective","canonical_uri":"https://healtheconomics.wiki/concept/societal-perspective","name":"Societal Perspective","short_definition":"The societal perspective is an economic evaluation viewpoint that counts all costs and outcomes, whoever bears them, including productivity and carer time.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:24.189Z"},{"slug":"spearman-correlation","canonical_uri":"https://healtheconomics.wiki/concept/spearman-correlation","name":"Spearman Correlation","short_definition":"Spearman correlation is a rank-based measure from -1 to +1 of how consistently two variables, such as disease severity and costs, rise or fall together.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.295Z"},{"slug":"specificity","canonical_uri":"https://healtheconomics.wiki/concept/specificity","name":"Specificity","short_definition":"The proportion of people without a specified target condition who test negative at a stated diagnostic threshold, calculated as true negatives divided by true negatives plus false positives.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Risk Measures","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Risk Measures","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:40.497Z"},{"slug":"spline-model","canonical_uri":"https://healtheconomics.wiki/concept/spline-model","name":"Spline Model","short_definition":"A model using piecewise polynomial functions joined smoothly at knots to represent a flexible, non-linear relationship such as time and hazard.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:24.250Z"},{"slug":"standard-costing","canonical_uri":"https://healtheconomics.wiki/concept/standard-costing","name":"Standard Costing","short_definition":"Standard costing sets the expected cost of a health service in advance from standard quantities and prices, then compares actual costs with this benchmark.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.366Z"},{"slug":"standard-deviation","canonical_uri":"https://healtheconomics.wiki/concept/standard-deviation","name":"Standard Deviation","short_definition":"Standard deviation is the square root of variance, expressing how dispersed values are around their mean in the variable’s original units under a specified population or sample convention.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:40.611Z"},{"slug":"standard-error","canonical_uri":"https://healtheconomics.wiki/concept/standard-error","name":"Standard Error","short_definition":"The standard error (SE) is the standard deviation of an estimate's sampling distribution, showing how precisely a mean cost or treatment effect is known.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.435Z"},{"slug":"standard-gamble","canonical_uri":"https://healtheconomics.wiki/concept/standard-gamble","name":"Standard Gamble","short_definition":"The standard gamble is a choice-based health-state valuation method that finds the probability at which a respondent is indifferent between living in a certain health state and accepting a lottery between specified better and worse outcomes.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:43.514Z"},{"slug":"standard-normal","canonical_uri":"https://healtheconomics.wiki/concept/standard-normal","name":"Standard Normal","short_definition":"The standard normal distribution is a normal distribution with mean 0 and standard deviation 1, used in health economics to read z values as probabilities.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.505Z"},{"slug":"standardised-mean-difference","canonical_uri":"https://healtheconomics.wiki/concept/standardised-mean-difference","name":"Standardised Mean Difference","short_definition":"The standardised mean difference (SMD) is a mean difference divided by a standard deviation, used to pool continuous outcomes measured on different scales.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:39.321Z"},{"slug":"standardised-mortality-ratio","canonical_uri":"https://healtheconomics.wiki/concept/standardised-mortality-ratio","name":"Standardised Mortality Ratio","short_definition":"The standardised mortality ratio (SMR) is observed deaths divided by deaths expected at reference rates for a group's age mix, used to gauge excess deaths.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.812Z"},{"slug":"standardised-residual","canonical_uri":"https://healtheconomics.wiki/concept/standardised-residual","name":"Standardised Residual","short_definition":"A standardised residual is a regression residual divided by its estimated standard deviation, used to flag outlying patients in cost and outcome models.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.575Z"},{"slug":"standardised-response-mean","canonical_uri":"https://healtheconomics.wiki/concept/standardised-response-mean","name":"Standardised Response Mean","short_definition":"The standardised response mean (SRM) is a responsiveness index for health outcome measures, the mean change divided by the standard deviation of change.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.646Z"},{"slug":"state-occupancy","canonical_uri":"https://healtheconomics.wiki/concept/state-occupancy","name":"State Occupancy","short_definition":"State occupancy is the expected time a modelled cohort spends in a health state, found by adding the share of the cohort in that state across model cycles.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.717Z"},{"slug":"state-reward","canonical_uri":"https://healtheconomics.wiki/concept/state-reward","name":"State Reward","short_definition":"A cost, utility, health outcome, or other consequence accrued while a modelled person occupies a specified state for a defined amount of time.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:52.713Z"},{"slug":"state-space-model","canonical_uri":"https://healtheconomics.wiki/concept/state-space-model","name":"State Space Model","short_definition":"A modelling framework representing a system's evolution over time through a defined set of possible states and transition probabilities between them.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:52.733Z"},{"slug":"state-transition-model","canonical_uri":"https://healtheconomics.wiki/concept/state-transition-model","name":"State Transition Model","short_definition":"A state transition model is a decision model in which a cohort or simulated patients move between health states over time to estimate costs and QALYs.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.789Z"},{"slug":"statistical-power","canonical_uri":"https://healtheconomics.wiki/concept/statistical-power","name":"Statistical Power","short_definition":"Statistical power is the probability that a study will reject a null hypothesis when a specified alternative hypothesis is true.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:19.177Z"},{"slug":"statistical-process-control","canonical_uri":"https://healtheconomics.wiki/concept/statistical-process-control","name":"Statistical Process Control","short_definition":"Statistical process control (SPC) is a set of statistical methods for monitoring health service data over time to tell routine variation from real change.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:06.886Z"},{"slug":"statistical-significance","canonical_uri":"https://healtheconomics.wiki/concept/statistical-significance","name":"Statistical Significance","short_definition":"Statistical significance is a threshold-based conclusion that an observed result is sufficiently incompatible with a prespecified null hypothesis under a stated statistical model to meet the chosen significance level.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:44.471Z"},{"slug":"steady-state","canonical_uri":"https://healtheconomics.wiki/concept/steady-state","name":"Steady State","short_definition":"A steady state in a Markov model is the stationary distribution of a cohort across health states, unchanged from cycle to cycle under fixed transitions.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Clinical Pharmacology","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Clinical Pharmacology","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T01:26:22.998Z"},{"slug":"stochastic-frontier-analysis","canonical_uri":"https://healtheconomics.wiki/concept/stochastic-frontier-analysis","name":"Stochastic Frontier Analysis","short_definition":"Stochastic frontier analysis (SFA) is a regression method that scores hospital or health system efficiency, separating inefficiency from random noise.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Productivity Measurement","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Productivity Measurement","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.206Z"},{"slug":"stochastic-programming","canonical_uri":"https://healtheconomics.wiki/concept/stochastic-programming","name":"Stochastic Programming","short_definition":"Stochastic programming is optimisation that includes parameter uncertainty, used in health care to choose a vaccination policy before outcomes are known.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.862Z"},{"slug":"stochastic-simulation","canonical_uri":"https://healtheconomics.wiki/concept/stochastic-simulation","name":"Stochastic Simulation","short_definition":"Stochastic simulation represents a system in which at least one event, transition, time or outcome is generated probabilistically.","category":"Simulation","category_path":"Computer Science › Simulation › Stochastic Methods","level_1":"Computer Science","level_2":"Simulation","level_3":"Stochastic Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:53.222Z"},{"slug":"stock-and-flow-model","canonical_uri":"https://healtheconomics.wiki/concept/stock-and-flow-model","name":"Stock and Flow Model","short_definition":"A system dynamics structure representing accumulations, called stocks, such as infected individuals, and the rates of change into and out of them, called flows.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:53.242Z"},{"slug":"stop-loss","canonical_uri":"https://healtheconomics.wiki/concept/stop-loss","name":"Stop-Loss","short_definition":"Stop-loss is insurance that reimburses health claims above an agreed attachment point, limiting what a self-funded employer pays for one member or a group.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Insurance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Insurance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.806Z"},{"slug":"strict-dominance","canonical_uri":"https://healtheconomics.wiki/concept/strict-dominance","name":"Strict Dominance","short_definition":"Strict dominance in cost-effectiveness analysis is when one option both costs less and gives more health than another, so the other option is ruled out.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:24.311Z"},{"slug":"structural-equation-model","canonical_uri":"https://healtheconomics.wiki/concept/structural-equation-model","name":"Structural Equation Model","short_definition":"A system of linked equations representing hypothesised relationships among observed and possibly latent variables, often combining a measurement model with structural paths.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:53.748Z"},{"slug":"structural-uncertainty","canonical_uri":"https://healtheconomics.wiki/concept/structural-uncertainty","name":"Structural Uncertainty","short_definition":"Structural uncertainty is doubt about how a health economic model represents a decision problem, such as its health states, pathways or extrapolation.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:24.372Z"},{"slug":"structural-validity-instrument","canonical_uri":"https://healtheconomics.wiki/concept/structural-validity-instrument","name":"Structural Validity (Measurement Instrument)","short_definition":"Structural validity of a measurement instrument is how far a health questionnaire's scores reflect the dimensions of the construct it is meant to measure.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T15:06:39.489Z"},{"slug":"subgroup-analysis","canonical_uri":"https://healtheconomics.wiki/concept/subgroup-analysis","name":"Subgroup Analysis","short_definition":"An analysis that estimates and compares an association or intervention effect across defined categories of participants, with treatment-effect differences assessed through an interaction on a specified scale.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:24.433Z"},{"slug":"sucra","canonical_uri":"https://healtheconomics.wiki/concept/sucra","name":"SUCRA","short_definition":"SUCRA, the surface under the cumulative ranking curve, is a 0 to 1 score of how highly a treatment ranks across all ranks in a network meta-analysis.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:24.934Z"},{"slug":"suits-index","canonical_uri":"https://healtheconomics.wiki/concept/suits-index","name":"Suits Index","short_definition":"A measure of the progressivity of a tax or financing system, using a concentration curve plotting cumulative tax burden against cumulative income.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Equity","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Equity","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:10.320Z"},{"slug":"sullivan-method","canonical_uri":"https://healtheconomics.wiki/concept/sullivan-method","name":"Sullivan Method","short_definition":"The Sullivan method estimates health expectancy, such as healthy life expectancy, by weighting life-table person-years by age-specific health prevalence.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.005Z"},{"slug":"summary-roc-curve","canonical_uri":"https://healtheconomics.wiki/concept/summary-roc-curve","name":"Summary ROC Curve","short_definition":"A summary ROC (SROC) curve pools diagnostic accuracy studies to show how a test's sensitivity trades off against specificity across positivity thresholds.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:39.672Z"},{"slug":"supplier-induced-demand","canonical_uri":"https://healtheconomics.wiki/concept/supplier-induced-demand","name":"Supplier-Induced Demand","short_definition":"Supplier-induced demand (SID) is use of health care that providers create through their information advantage, beyond what informed patients would choose.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.078Z"},{"slug":"supply","canonical_uri":"https://healtheconomics.wiki/concept/supply","name":"Supply","short_definition":"Supply is the amount of a good or service, such as health care, that producers are willing and able to provide at each price over a given period.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Market Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Market Economics","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.151Z"},{"slug":"surrogate-endpoint","canonical_uri":"https://healtheconomics.wiki/concept/surrogate-endpoint","name":"Surrogate Endpoint","short_definition":"A trial outcome used as a substitute for a direct clinical benefit measure, such as survival, based on its expected predictive relationship to that outcome.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:41.377Z"},{"slug":"survival-analysis","canonical_uri":"https://healtheconomics.wiki/concept/survival-analysis","name":"Survival Analysis","short_definition":"Survival analysis examines the time from a defined origin to an event such as death, disease progression, hospitalisation, recovery or treatment discontinuation.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:41.433Z"},{"slug":"survival-function","canonical_uri":"https://healtheconomics.wiki/concept/survival-function","name":"Survival Function","short_definition":"A function giving the probability that a person survives without the event of interest beyond a specified point in time.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:24.493Z"},{"slug":"survival-regression","canonical_uri":"https://healtheconomics.wiki/concept/survival-regression","name":"Survival Regression","short_definition":"Survival regression estimates how treatment and patient characteristics change the hazard of, or time to, death or progression in censored data for HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.221Z"},{"slug":"swemwbs","canonical_uri":"https://healtheconomics.wiki/concept/swemwbs","name":"SWEMWBS","short_definition":"SWEMWBS, the Short Warwick-Edinburgh Mental Wellbeing Scale, is a seven-item, Rasch-scored measure of positive mental wellbeing for programme evaluations.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.774Z"},{"slug":"synthetic-control","canonical_uri":"https://healtheconomics.wiki/concept/synthetic-control","name":"Synthetic Control","short_definition":"Synthetic control estimates a health policy's effect on one region or provider using a weighted blend of untreated units that tracked it before the policy.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.292Z"},{"slug":"system-dynamics-model","canonical_uri":"https://healtheconomics.wiki/concept/system-dynamics-model","name":"System Dynamics Model","short_definition":"A system dynamics model simulates a health system in aggregate as stocks, flows and feedback loops, projecting how policies play out over time.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.362Z"},{"slug":"systematic-review","canonical_uri":"https://healtheconomics.wiki/concept/systematic-review","name":"Systematic Review","short_definition":"A structured, comprehensive, reproducible approach to identifying, evaluating, and synthesising all available evidence relevant to a clearly defined question.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:41.696Z"},{"slug":"t-distribution","canonical_uri":"https://healtheconomics.wiki/concept/t-distribution","name":"T-Distribution","short_definition":"The t-distribution is a heavy-tailed, symmetric curve used for intervals and tests on mean costs or effects when variance is estimated from a small sample.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.431Z"},{"slug":"tarone-ware-test","canonical_uri":"https://healtheconomics.wiki/concept/tarone-ware-test","name":"Tarone-Ware Test","short_definition":"A test comparing survival distributions using a weighting scheme between the log-rank and Peto tests, a compromise depending on when treatment differences emerge.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:20.639Z"},{"slug":"tau-squared","canonical_uri":"https://healtheconomics.wiki/concept/tau-squared","name":"Tau-Squared","short_definition":"Tau-squared is the between-study variance in a random-effects meta-analysis, measuring how much true treatment effects differ across pooled trials.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Synthesis Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Synthesis Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.500Z"},{"slug":"taylor-series-expansion","canonical_uri":"https://healtheconomics.wiki/concept/taylor-series-expansion","name":"Taylor Series Expansion","short_definition":"A Taylor series expansion approximates a function near a point by a polynomial built from its derivatives, used in health economics for the delta method.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.570Z"},{"slug":"technical-efficiency","canonical_uri":"https://healtheconomics.wiki/concept/technical-efficiency","name":"Technical Efficiency","short_definition":"Technical efficiency is the extent to which a unit produces its chosen outputs with the minimum feasible inputs, or maximizes those outputs from given inputs, under a specified production technology.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Efficiency Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Efficiency Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:57:56.120Z"},{"slug":"technological-imperative","canonical_uri":"https://healtheconomics.wiki/concept/technological-imperative","name":"Technological Imperative","short_definition":"Technological imperative is the pressure in health care to adopt and use a new medical technology because it exists, whatever its cost or added benefit.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Technology Assessment","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Technology Assessment","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:22.819Z"},{"slug":"test-retest-reliability","canonical_uri":"https://healtheconomics.wiki/concept/test-retest-reliability","name":"Test-Retest Reliability","short_definition":"Test-retest reliability is the extent to which a health questionnaire, such as the EQ-5D, gives the same scores in people whose health has not changed.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Evidence Appraisal","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Evidence Appraisal","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.639Z"},{"slug":"theil-index-health","canonical_uri":"https://healtheconomics.wiki/concept/theil-index-health","name":"Theil Index Health","short_definition":"An information theory based inequality measure applied to a health outcome's distribution, decomposable into inequality within and between population subgroups.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Equity","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Equity","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:10.921Z"},{"slug":"threshold-analysis","canonical_uri":"https://healtheconomics.wiki/concept/threshold-analysis","name":"Threshold Analysis","short_definition":"Threshold analysis finds the switching value, the level an uncertain input must reach for the preferred option in a health economic model to change.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.709Z"},{"slug":"threshold-price","canonical_uri":"https://healtheconomics.wiki/concept/threshold-price","name":"Threshold Price","short_definition":"Threshold Price is the highest price at which a health technology stays cost-effective: the price where its ICER equals the cost-effectiveness threshold.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Technology Assessment","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Technology Assessment","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:24.817Z"},{"slug":"throughput","canonical_uri":"https://healtheconomics.wiki/concept/throughput","name":"Throughput","short_definition":"Throughput is the number of patients or care episodes a health service completes per unit of time, such as discharges per day, counted at a defined exit.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Capacity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Capacity","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.777Z"},{"slug":"time-dependency","canonical_uri":"https://healtheconomics.wiki/concept/time-dependency","name":"Time Dependency","short_definition":"The property of a risk, effect, cost, utility or other model input changing according to a specified time scale, such as attained age or time since an event.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:21.020Z"},{"slug":"time-horizon","canonical_uri":"https://healtheconomics.wiki/concept/time-horizon","name":"Time Horizon","short_definition":"The span of time over which an economic evaluation captures relevant differences in costs and outcomes among the options being compared.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":null,"evidence_level":"high","version":"1.5.22","status":"PUBLISHED","published_at":"2026-10-15T23:54:11.162Z"},{"slug":"time-preference","canonical_uri":"https://healtheconomics.wiki/concept/time-preference","name":"Time Preference","short_definition":"Time preference is the preference for benefits sooner and costs later; in health economics it is one reason future costs and QALYs are discounted.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Discounting","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Discounting","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.099Z"},{"slug":"time-trade-off","canonical_uri":"https://healtheconomics.wiki/concept/time-trade-off","name":"Time Trade-Off","short_definition":"The time trade-off (TTO) values a health state for QALYs by asking how many years in full health a person rates equal to a longer life in that state.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.780Z"},{"slug":"time-value-of-money","canonical_uri":"https://healtheconomics.wiki/concept/time-value-of-money","name":"Time Value of Money","short_definition":"The principle that a given sum of money is worth more today than the same sum received in the future.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.220Z"},{"slug":"time-without-symptoms-of-progression","canonical_uri":"https://healtheconomics.wiki/concept/time-without-symptoms-of-progression","name":"Time Without Symptoms of Progression","short_definition":"Time without symptoms of progression (TWiST) is survival free of disease symptoms and counted treatment toxicity, the reference state in Q-TWiST.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Quality-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Quality-Adjusted Life Years","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.849Z"},{"slug":"time-driven-activity-based-costing","canonical_uri":"https://healtheconomics.wiki/concept/time-driven-activity-based-costing","name":"Time-Driven Activity-Based Costing","short_definition":"Time-driven activity-based costing (TDABC) costs health care by multiplying each resource's cost per minute of capacity by the minutes a patient uses.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.918Z"},{"slug":"time-homogeneous-model","canonical_uri":"https://healtheconomics.wiki/concept/time-homogeneous-model","name":"Time-Homogeneous Model","short_definition":"A time-homogeneous model is a Markov model whose transition probabilities are the same in every cycle, so health state risks never change with age or time.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:25.989Z"},{"slug":"time-inhomogeneous-model","canonical_uri":"https://healtheconomics.wiki/concept/time-inhomogeneous-model","name":"Time-Inhomogeneous Model","short_definition":"A time-inhomogeneous model is a Markov model whose transition probabilities can change between cycles, so a risk such as death can rise as the cohort ages.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:26.064Z"},{"slug":"time-lag-bias","canonical_uri":"https://healtheconomics.wiki/concept/time-lag-bias","name":"Time-Lag Bias","short_definition":"Time-lag bias is distortion of the evidence available at a given time because studies with favourable or significant results are published sooner.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:38.734Z"},{"slug":"time-to-event","canonical_uri":"https://healtheconomics.wiki/concept/time-to-event","name":"Time-to-Event","short_definition":"Time-to-event data record the time until an event such as death or progression, with some times censored, and supply survival inputs to economic models.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Discrete Event Simulation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Discrete Event Simulation","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:26.133Z"},{"slug":"time-varying-covariate","canonical_uri":"https://healtheconomics.wiki/concept/time-varying-covariate","name":"Time-Varying Covariate","short_definition":"A patient characteristic in a survival model allowed to change value over follow-up, such as a repeatedly measured biomarker.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.369Z"},{"slug":"time-varying-hazard","canonical_uri":"https://healtheconomics.wiki/concept/time-varying-hazard","name":"Time-Varying Hazard","short_definition":"A hazard rate that changes in magnitude over follow-up, unlike a constant hazard that stays the same at every point.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.453Z"},{"slug":"timed-up-and-go-test","canonical_uri":"https://healtheconomics.wiki/concept/timed-up-and-go-test","name":"Timed Up and Go Test","short_definition":"Timed Up and Go Test (TUG) is a performance outcome timing how long a person takes to rise, walk 3 metres, turn and sit, used for mobility and falls risk.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.426Z"},{"slug":"tolerance-interval","canonical_uri":"https://healtheconomics.wiki/concept/tolerance-interval","name":"Tolerance Interval","short_definition":"A tolerance interval is a range that, with stated confidence, encloses at least a set share of individual values in a population, such as patient costs.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:26.202Z"},{"slug":"top-down-costing","canonical_uri":"https://healtheconomics.wiki/concept/top-down-costing","name":"Top-Down Costing","short_definition":"A costing approach that starts with aggregate costs and allocates them to services, activities or patients using documented shares and output counts.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Costing Methods","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Costing Methods","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-27T22:03:55.973Z"},{"slug":"tornado-diagram","canonical_uri":"https://healtheconomics.wiki/concept/tornado-diagram","name":"Tornado Diagram","short_definition":"A tornado diagram is a bar chart of one-way sensitivity results in a cost-effectiveness model, ranking inputs so the widest swing in the result is on top.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:26.272Z"},{"slug":"total-effect-index","canonical_uri":"https://healtheconomics.wiki/concept/total-effect-index","name":"Total Effect Index","short_definition":"The total effect index is the share of a health economic model output's variance due to one uncertain input, counting its main effect and all interactions.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:26.342Z"},{"slug":"toxicity-period","canonical_uri":"https://healtheconomics.wiki/concept/toxicity-period","name":"Toxicity Period (TOX)","short_definition":"Toxicity period (TOX) is the Q-TWiST state for time with the treatment toxicity an analysis counts, often grade 3 or worse, weighted by its own utility.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Quality-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Quality-Adjusted Life Years","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:28.810Z"},{"slug":"tragedy-of-the-commons","canonical_uri":"https://healtheconomics.wiki/concept/tragedy-of-the-commons","name":"Tragedy of the Commons","short_definition":"The tragedy of the commons is the overuse of a shared resource, such as antibiotic effectiveness, when each user keeps the gain but the cost falls on all.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Common Resource Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Common Resource Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:12.117Z"},{"slug":"transaction-cost","canonical_uri":"https://healtheconomics.wiki/concept/transaction-cost","name":"Transaction Cost","short_definition":"A transaction cost is the cost of finding, negotiating, monitoring and enforcing an exchange, such as a health service contract, beyond the price paid.","category":"Health Policy","category_path":"Health Systems › Health Policy › Common Resource Economics","level_1":"Health Systems","level_2":"Health Policy","level_3":"Common Resource Economics","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.568Z"},{"slug":"transient-state","canonical_uri":"https://healtheconomics.wiki/concept/transient-state","name":"Transient State","short_definition":"A transient state is a health state in a Markov model that patients eventually leave for good, possibly after several stays, unlike an absorbing state.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T18:21:26.411Z"},{"slug":"transition-matrix","canonical_uri":"https://healtheconomics.wiki/concept/transition-matrix","name":"Transition Matrix","short_definition":"A transition matrix is the table of probabilities of moving between, or staying in, health states in one cycle of a Markov model, with rows summing to one.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-15T23:54:11.633Z"},{"slug":"transition-probability","canonical_uri":"https://healtheconomics.wiki/concept/transition-probability","name":"Transition Probability","short_definition":"A transition probability is the chance of moving from one health state to another, or staying, during one cycle of a Markov or state-transition model.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T23:52:21.495Z"},{"slug":"transmission-model","canonical_uri":"https://healtheconomics.wiki/concept/transmission-model","name":"Transmission Model","short_definition":"A model explicitly representing how an infectious disease spreads through a population by tracking interaction between infectious and susceptible individuals.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:11.671Z"},{"slug":"trapezoidal-rule","canonical_uri":"https://healtheconomics.wiki/concept/trapezoidal-rule","name":"Trapezoidal Rule","short_definition":"The trapezoidal rule approximates a definite integral by replacing a curve with straight-line segments and summing the resulting trapezoid areas.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:42.587Z"},{"slug":"administration-cost","canonical_uri":"https://healtheconomics.wiki/concept/administration-cost","name":"Treatment Administration Cost","short_definition":"Treatment administration cost is the cost of giving a medicine to a patient, such as nurse and chair time and consumables; it varies by route.","category":"Parameters","category_path":"Health Systems › Drug Costs › Drug Acquisition and Administration","level_1":"Health Systems","level_2":"Drug Costs","level_3":"Drug Acquisition and Administration","evidence_level":"high","version":"1.0.5","status":"PUBLISHED","published_at":"2026-10-21T00:55:08.599Z"},{"slug":"treatment-sequence-model","canonical_uri":"https://healtheconomics.wiki/concept/treatment-sequence-model","name":"Treatment Sequence Model","short_definition":"A decision-analytic model representing a patient's ordered progression through a series of treatments, moving to the next option after failure or discontinuation.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Decision Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Decision Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:42.856Z"},{"slug":"treatment-switching","canonical_uri":"https://healtheconomics.wiki/concept/treatment-switching","name":"Treatment Switching","short_definition":"Treatment switching is when trial patients start a treatment they were not randomised to, typically control patients taking the new drug after progression.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T02:26:45.572Z"},{"slug":"trend-analysis","canonical_uri":"https://healtheconomics.wiki/concept/trend-analysis","name":"Trend Analysis","short_definition":"Trend analysis estimates the long-run rise or fall in a health indicator over time, separating its underlying direction from seasonal and random variation.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health System Performance","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health System Performance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.355Z"},{"slug":"truncation","canonical_uri":"https://healtheconomics.wiki/concept/truncation","name":"Truncation","short_definition":"A situation in survival or longitudinal analysis where certain observations are systematically excluded based on a variable's value, such as required registration.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:21.887Z"},{"slug":"tunnel-state","canonical_uri":"https://healtheconomics.wiki/concept/tunnel-state","name":"Tunnel State","short_definition":"A tunnel state is one of a fixed sequence of one-cycle temporary states in a Markov model, letting risks, costs or utilities vary with time in a state.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Markov Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Markov Modelling","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:12.190Z"},{"slug":"two-way-sensitivity-analysis","canonical_uri":"https://healtheconomics.wiki/concept/two-way-sensitivity-analysis","name":"Two-Way Sensitivity Analysis","short_definition":"An analysis varying two parameters together across a grid of combinations, typically shown as a contour plot or heat map of results.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.625Z"},{"slug":"type-i-error","canonical_uri":"https://healtheconomics.wiki/concept/type-i-error","name":"Type I Error","short_definition":"In hypothesis testing, the error of incorrectly rejecting a true null hypothesis, concluding a genuine effect exists when it does not.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:39.261Z"},{"slug":"type-ii-error","canonical_uri":"https://healtheconomics.wiki/concept/type-ii-error","name":"Type II Error","short_definition":"In hypothesis testing, the error of failing to reject a false null hypothesis, concluding no effect exists when a genuine effect is present.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:21.926Z"},{"slug":"unbiasedness","canonical_uri":"https://healtheconomics.wiki/concept/unbiasedness","name":"Unbiasedness","short_definition":"A property of an estimator whose expected value, across repeated samples, equals the true underlying value of the parameter being estimated.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:21.946Z"},{"slug":"uncertainty","canonical_uri":"https://healtheconomics.wiki/concept/uncertainty","name":"Uncertainty","short_definition":"Uncertainty in health economics is imperfect knowledge of a model's true inputs, structure or methods, so the option chosen as best may prove to be wrong.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.4","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.682Z"},{"slug":"uncertainty-quantification","canonical_uri":"https://healtheconomics.wiki/concept/uncertainty-quantification","name":"Uncertainty Quantification","short_definition":"The formal process of measuring how much confidence should be placed in a model's results, given the sources of uncertainty affecting it.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.738Z"},{"slug":"uniform-distribution","canonical_uri":"https://healtheconomics.wiki/concept/uniform-distribution","name":"Uniform Distribution","short_definition":"A probability distribution in which every value within a defined range is equally likely to occur.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:12.234Z"},{"slug":"unimodal-hazard","canonical_uri":"https://healtheconomics.wiki/concept/unimodal-hazard","name":"Unimodal Hazard","short_definition":"A hazard function that rises to a single peak and then declines over follow-up, rather than a monotonic or bathtub pattern.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:58:00.723Z"},{"slug":"unit-of-allocation","canonical_uri":"https://healtheconomics.wiki/concept/unit-of-allocation","name":"Unit of Allocation","short_definition":"The unit of allocation is the patient, practice, hospital or other entity a trial randomises to each arm; the analysis must allow for that level.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Clinical Trial Methods","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Clinical Trial Methods","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.803Z"},{"slug":"universal-health-coverage","canonical_uri":"https://healtheconomics.wiki/concept/universal-health-coverage","name":"Universal Health Coverage","short_definition":"Universal health coverage (UHC) means everyone can use the quality health services they need, when and where they need them, without financial hardship.","category":"Health Economics","category_path":"Health Systems › Systems Strengthening › Global Health","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Global Health","evidence_level":"high","version":"1.0.27","status":"PUBLISHED","published_at":"2026-10-13T23:58:00.865Z"},{"slug":"universal-health-coverage-index","canonical_uri":"https://healtheconomics.wiki/concept/universal-health-coverage-index","name":"Universal Health Coverage Index","short_definition":"Universal Health Coverage Index (UHC service coverage index) is WHO's 0 to 100 score for SDG 3.8.1, built from 14 tracer measures of service coverage.","category":"Systems Strengthening","category_path":"Health Systems › Systems Strengthening › Health System Performance","level_1":"Health Systems","level_2":"Systems Strengthening","level_3":"Health System Performance","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.036Z"},{"slug":"unmet-need","canonical_uri":"https://healtheconomics.wiki/concept/unmet-need","name":"Unmet Need","short_definition":"Unmet need is health care a person needed but did not receive; in drug regulation, unmet medical need is a condition without adequate treatment.","category":"Health Policy","category_path":"Health Systems › Health Policy › Health Equity","level_1":"Health Systems","level_2":"Health Policy","level_3":"Health Equity","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.796Z"},{"slug":"unstructured-correlation","canonical_uri":"https://healtheconomics.wiki/concept/unstructured-correlation","name":"Unstructured Correlation","short_definition":"A correlation structure for repeated measures allowing the correlation between every pair of time points to be estimated freely and independently.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:22.202Z"},{"slug":"urgent-care","canonical_uri":"https://healtheconomics.wiki/concept/urgent-care","name":"Urgent Care","short_definition":"Urgent care is same-day treatment for illness or injury that needs prompt attention but is not an emergency, often given outside an emergency department.","category":"Health Policy","category_path":"Health Systems › Health Policy › Healthcare Delivery","level_1":"Health Systems","level_2":"Health Policy","level_3":"Healthcare Delivery","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-15T00:58:43.084Z"},{"slug":"utilisation-review","canonical_uri":"https://healtheconomics.wiki/concept/utilisation-review","name":"Utilisation Review","short_definition":"Utilisation review (UR) is a payer's check of whether a patient's care is necessary and appropriate, used to curb unnecessary use and contain costs.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.699Z"},{"slug":"utility","canonical_uri":"https://healtheconomics.wiki/concept/utility","name":"Utility","short_definition":"Utility is a numerical measure of preference; in health economics, a health utility values a health state on a scale where 1 is full health and 0 is dead.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-27T01:29:12.262Z"},{"slug":"utility-function","canonical_uri":"https://healtheconomics.wiki/concept/utility-function","name":"Utility Function","short_definition":"A mathematical representation of preferences that assigns a numerical value to each possible outcome, so higher-utility outcomes are preferred.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:22.402Z"},{"slug":"utility-maximisation","canonical_uri":"https://healtheconomics.wiki/concept/utility-maximisation","name":"Utility Maximisation","short_definition":"The behavioural assumption that individuals make choices intended to achieve the highest possible satisfaction given their preferences and constraints.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Economic Principles","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Economic Principles","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:12.419Z"},{"slug":"vaccination-externalities","canonical_uri":"https://healtheconomics.wiki/concept/vaccination-externalities","name":"Vaccination Externalities","short_definition":"Vaccination externalities are the benefits one person's vaccination gives others by cutting disease spread, benefits that person ignores when choosing.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-27T01:29:12.334Z"},{"slug":"vaccination-policy","canonical_uri":"https://healtheconomics.wiki/concept/vaccination-policy","name":"Vaccination Policy","short_definition":"Government policy governing which vaccines are included in a national immunisation schedule and how programmes will be funded and administered.","category":"Health Policy","category_path":"Health Systems › Health Policy › Public Health Policy","level_1":"Health Systems","level_2":"Health Policy","level_3":"Public Health Policy","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:12.437Z"},{"slug":"vaccine-effectiveness","canonical_uri":"https://healtheconomics.wiki/concept/vaccine-effectiveness","name":"Vaccine Effectiveness","short_definition":"The degree to which a vaccine reduces disease risk under real-world conditions in a general population, unlike efficacy measured under trial conditions.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Infectious Disease","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Infectious Disease","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:58:01.608Z"},{"slug":"vaccine-efficacy","canonical_uri":"https://healtheconomics.wiki/concept/vaccine-efficacy","name":"Vaccine Efficacy","short_definition":"The degree to which a vaccine reduces disease risk among vaccinated individuals under the controlled conditions of a clinical trial.","category":"Pharmacoeconomics","category_path":"Health Economics › Pharmacoeconomics › Infectious Disease","level_1":"Health Economics","level_2":"Pharmacoeconomics","level_3":"Infectious Disease","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-13T23:58:01.628Z"},{"slug":"value-of-information","canonical_uri":"https://healtheconomics.wiki/concept/value-of-information","name":"Value of Information","short_definition":"Value of information (VOI) analysis estimates the expected benefit of reducing decision uncertainty, to judge whether more research is worth its cost.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.913Z"},{"slug":"value-of-statistical-life","canonical_uri":"https://healtheconomics.wiki/concept/value-of-statistical-life","name":"Value of Statistical Life","short_definition":"A monetary estimate of the value society places on reducing the risk of death, derived from willingness to pay for a small risk reduction.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:43.391Z"},{"slug":"value-of-statistical-life-year","canonical_uri":"https://healtheconomics.wiki/concept/value-of-statistical-life-year","name":"Value of Statistical Life Year","short_definition":"An adaptation of the value of statistical life expressed per life-year rather than per life, adjusted for age and remaining life expectancy.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:43.411Z"},{"slug":"value-set","canonical_uri":"https://healtheconomics.wiki/concept/value-set","name":"Value Set","short_definition":"The complete collection of utility weights from a population valuation study, used to convert every combination of instrument responses into a utility score.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:12.586Z"},{"slug":"value-based-pricing","canonical_uri":"https://healtheconomics.wiki/concept/value-based-pricing","name":"Value-Based Pricing","short_definition":"Value-based pricing sets a medicine's price by the health it adds over current care, typically the highest price that meets a cost-effectiveness threshold.","category":"Pharmacoeconomics","category_path":"Health Systems › Pharmacoeconomics › Drug Pricing","level_1":"Health Systems","level_2":"Pharmacoeconomics","level_3":"Drug Pricing","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.855Z"},{"slug":"value-based-purchasing","canonical_uri":"https://healtheconomics.wiki/concept/value-based-purchasing","name":"Value-Based Purchasing","short_definition":"Value-based purchasing is when a health purchaser ties provider payment or contracts to measured quality and outcomes, as in Medicare's hospital programme.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Value-Based Healthcare","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Value-Based Healthcare","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:07.656Z"},{"slug":"variance","canonical_uri":"https://healtheconomics.wiki/concept/variance","name":"Variance","short_definition":"A dispersion measure representing the average squared deviation of individual data points from the mean of a dataset.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:22.876Z"},{"slug":"variance-inflation-factor","canonical_uri":"https://healtheconomics.wiki/concept/variance-inflation-factor","name":"Variance Inflation Factor","short_definition":"A regression diagnostic quantifying how much an estimated coefficient's variance is inflated by correlation with other predictors, higher values meaning worse multicollinearity.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:22.935Z"},{"slug":"variance-reduction","canonical_uri":"https://healtheconomics.wiki/concept/variance-reduction","name":"Variance Reduction","short_definition":"Variance reduction is the use of simulation sampling or estimator design to lower Monte Carlo error for a specified quantity without changing the quantity being estimated.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:22.955Z"},{"slug":"variance-based-sensitivity","canonical_uri":"https://healtheconomics.wiki/concept/variance-based-sensitivity","name":"Variance-Based Sensitivity","short_definition":"Global sensitivity analysis techniques, including Sobol indices, decomposing total output variance into components attributable to each parameter and their interactions.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Uncertainty Analysis","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Uncertainty Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:22.895Z"},{"slug":"variance-covariance-matrix","canonical_uri":"https://healtheconomics.wiki/concept/variance-covariance-matrix","name":"Variance-Covariance Matrix","short_definition":"A symmetric array of variances and pairwise covariances that describes the scale and joint movement of a set of random quantities or estimates.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Parameters","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Parameters","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:22.915Z"},{"slug":"variation","canonical_uri":"https://healtheconomics.wiki/concept/variation","name":"Variation","short_definition":"Variation is the spread of a measured quantity, such as cost, service use or outcome, across patients, providers, areas or time periods in a health system.","category":"NHS Productivity","category_path":"Health Systems › NHS Productivity › Healthcare Quality","level_1":"Health Systems","level_2":"NHS Productivity","level_3":"Healthcare Quality","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-29T01:19:08.546Z"},{"slug":"varimax-rotation","canonical_uri":"https://healtheconomics.wiki/concept/varimax-rotation","name":"Varimax Rotation","short_definition":"An orthogonal factor rotation maximising the variance of squared loadings within each factor, tending to make each variable load strongly on only one factor.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:12.645Z"},{"slug":"verification-bias","canonical_uri":"https://healtheconomics.wiki/concept/verification-bias","name":"Verification Bias","short_definition":"Verification bias is error in estimated sensitivity and specificity when who receives the reference standard, or which one, depends on the test result.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Bias & Validity","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Bias & Validity","evidence_level":null,"version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T20:26:38.790Z"},{"slug":"vertical-equity","canonical_uri":"https://healtheconomics.wiki/concept/vertical-equity","name":"Vertical Equity","short_definition":"Vertical equity is the principle that those in greater need should get appropriately more care, and those more able to pay should pay more.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":"high","version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-13T23:58:02.660Z"},{"slug":"visual-analogue-scale","canonical_uri":"https://healtheconomics.wiki/concept/visual-analogue-scale","name":"Visual Analogue Scale","short_definition":"A health state valuation method in which respondents mark a perceived health state on a continuous line anchored between worst and best imaginable health.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:12.773Z"},{"slug":"voi-analysis","canonical_uri":"https://healtheconomics.wiki/concept/voi-analysis","name":"VOI Analysis","short_definition":"VOI analysis (value of information analysis) takes a model's PSA through EVPI, EVPPI, EVSI and ENBS in turn to decide if more research is worth its cost.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Value of Information","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Value of Information","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:25.969Z"},{"slug":"wald-test","canonical_uri":"https://healtheconomics.wiki/concept/wald-test","name":"Wald Test","short_definition":"A statistical test assessing whether an estimated parameter differs significantly from a specified value, based on the ratio of estimate to standard error.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Model Validation","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Model Validation","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T23:54:12.919Z"},{"slug":"weak-dominance","canonical_uri":"https://healtheconomics.wiki/concept/weak-dominance","name":"Weak Dominance","short_definition":"Weak dominance is when another option costs no more and is at least as effective, and is strictly better on one, so the dominated option is dropped.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:26.026Z"},{"slug":"weibull-distribution","canonical_uri":"https://healtheconomics.wiki/concept/weibull-distribution","name":"Weibull Distribution","short_definition":"A flexible probability distribution capable of a monotonically increasing or decreasing hazard rate depending on its shape parameter.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:26.083Z"},{"slug":"weibull-model","canonical_uri":"https://healtheconomics.wiki/concept/weibull-model","name":"Weibull Model","short_definition":"A survival model based on the Weibull distribution, representing an increasing or decreasing hazard over time, though restricted to a monotonic pattern.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-21T00:55:26.140Z"},{"slug":"weighted-least-squares","canonical_uri":"https://healtheconomics.wiki/concept/weighted-least-squares","name":"Weighted Least Squares Regression","short_definition":"Weighted least squares (WLS) is regression that weights each squared residual, ideally by the inverse of its error variance, as in meta-analysis for HTA.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-14T21:48:23.857Z"},{"slug":"weighted-log-rank","canonical_uri":"https://healtheconomics.wiki/concept/weighted-log-rank","name":"Weighted Log-Rank","short_definition":"A survival-curve comparison test that weights each event-time observed-minus-expected count to emphasize a prespecified pattern of differences over follow-up.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T01:49:17.463Z"},{"slug":"welfare-economics","canonical_uri":"https://healtheconomics.wiki/concept/welfare-economics","name":"Welfare Economics","short_definition":"Welfare economics is the normative branch of economics that judges whether changes in the allocation of resources and health make society better off.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Welfare Economics","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Welfare Economics","evidence_level":null,"version":"1.0.2","status":"PUBLISHED","published_at":"2026-10-21T00:55:26.197Z"},{"slug":"wellbeing-or-capability-instrument","canonical_uri":"https://healtheconomics.wiki/concept/wellbeing-or-capability-instrument","name":"Wellbeing or Capability Instrument","short_definition":"Wellbeing or capability instruments are outcome measures, such as ICECAP, WEMWBS or EQ-HWB, that capture benefits beyond health that EQ-5D QALYs miss.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Health Utility","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Health Utility","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:29.305Z"},{"slug":"wemwbs","canonical_uri":"https://healtheconomics.wiki/concept/wemwbs","name":"WEMWBS","short_definition":"WEMWBS is the Warwick-Edinburgh Mental Wellbeing Scale, a 14-item measure of positive mental wellbeing used as an outcome in public health evaluations.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:26.720Z"},{"slug":"whoqol-bref","canonical_uri":"https://healtheconomics.wiki/concept/whoqol-bref","name":"WHOQOL-BREF","short_definition":"WHOQOL-BREF is the WHO's 26-item generic quality of life questionnaire with four domain scores, used as a trial outcome but not as a QALY utility.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.434Z"},{"slug":"wilcoxon-test","canonical_uri":"https://healtheconomics.wiki/concept/wilcoxon-test","name":"Wilcoxon Test","short_definition":"A test comparing survival distributions that gives greater weight to earlier event times than later ones, unlike the standard log-rank test.","category":"Economic Modelling","category_path":"Health Economics › Economic Modelling › Survival Modelling","level_1":"Health Economics","level_2":"Economic Modelling","level_3":"Survival Modelling","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T22:25:44.550Z"},{"slug":"willingness-to-accept","canonical_uri":"https://healtheconomics.wiki/concept/willingness-to-accept","name":"Willingness to Accept","short_definition":"The minimum compensation an individual would require to voluntarily give up a good or accept a worse outcome.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-15T00:58:43.680Z"},{"slug":"willingness-to-pay","canonical_uri":"https://healtheconomics.wiki/concept/willingness-to-pay","name":"Willingness to Pay","short_definition":"Willingness to pay (WTP) is the most money a person would give up for a health gain or other benefit, used to value outcomes in cost-benefit analysis.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.14","status":"PUBLISHED","published_at":"2026-10-15T00:58:43.699Z"},{"slug":"willingness-to-pay-estimation","canonical_uri":"https://healtheconomics.wiki/concept/willingness-to-pay-estimation","name":"Willingness-to-Pay Estimation","short_definition":"The empirical process of measuring willingness to pay, typically through stated preference methods such as contingent valuation or discrete choice experiments.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Benefit Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Benefit Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:23.389Z"},{"slug":"willingness-to-pay-threshold","canonical_uri":"https://healtheconomics.wiki/concept/willingness-to-pay-threshold","name":"Willingness-to-Pay Threshold","short_definition":"A willingness-to-pay threshold is the cost per QALY below which a treatment counts as good value; strictly, the most society would pay for one extra QALY.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Cost-Effectiveness Analysis","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Cost-Effectiveness Analysis","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:26.254Z"},{"slug":"within-subject-variation","canonical_uri":"https://healtheconomics.wiki/concept/within-subject-variation","name":"Within Subject Variation","short_definition":"The degree to which repeated measurements on the same individual fluctuate over time, unlike between-subject variation reflecting differences across individuals.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:23.469Z"},{"slug":"womac","canonical_uri":"https://healtheconomics.wiki/concept/womac","name":"WOMAC","short_definition":"WOMAC is a 24-question index of pain, stiffness and physical function in hip and knee osteoarthritis, used in trials and mapped to EQ-5D utilities.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Patient-Reported Outcomes","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Patient-Reported Outcomes","evidence_level":null,"version":"1.0.1","status":"PUBLISHED","published_at":"2026-10-17T14:48:27.874Z"},{"slug":"years-lived-with-disability","canonical_uri":"https://healtheconomics.wiki/concept/years-lived-with-disability","name":"Years Lived with Disability","short_definition":"Years lived with disability (YLDs) measure non-fatal health loss, usually as prevalence times disability weight; adding years of life lost gives the DALY.","category":"Economic Evaluation","category_path":"Health Economics › Economic Evaluation › Disability-Adjusted Life Years","level_1":"Health Economics","level_2":"Economic Evaluation","level_3":"Disability-Adjusted Life Years","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-13T23:58:04.114Z"},{"slug":"years-of-life-lost","canonical_uri":"https://healtheconomics.wiki/concept/years-of-life-lost","name":"Years of Life Lost","short_definition":"Years of life lost (YLL) measure premature mortality as deaths times standard remaining life expectancy at the age of death, the fatal part of the DALY.","category":"Health Policy","category_path":"Health Systems › Health Policy › Population Health Outcomes","level_1":"Health Systems","level_2":"Health Policy","level_3":"Population Health Outcomes","evidence_level":"high","version":"1.0.3","status":"PUBLISHED","published_at":"2026-10-21T00:55:26.310Z"},{"slug":"z-score","canonical_uri":"https://healtheconomics.wiki/concept/z-score","name":"Z-Score","short_definition":"A standardised statistic representing how many standard deviations an observation lies above or below the mean of its distribution.","category":"Evidence Synthesis","category_path":"Health Economics › Evidence Synthesis › Statistical Analysis","level_1":"Health Economics","level_2":"Evidence Synthesis","level_3":"Statistical Analysis","evidence_level":"high","version":"1.0.0","status":"PUBLISHED","published_at":"2026-10-14T23:52:23.610Z"}],"count":1351}